

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|-----------|--|
| (51) International Patent Classification ⁶ : C07K 14/00 | A2 | (11) International Publication Number: WO 99/06439 (43) International Publication Date: 11 February 1999 (11.02.99) |
| (21) International Application Number: PCT/IB98/01233 (22) International Filing Date: 31 July 1998 (31.07.98) (30) Priority Data: 08/904,468 1 August 1997 (01.08.97) US (71) Applicant (for all designated States except US): GENSET [FR/FR]; 24, rue Royale, F-75008 Paris (FR). (72) Inventors; and (73) Inventors/Applicants (for US only): DUMAS MILNE ED- WARDS, Jean-Baptiste [FR/FR]; 8, rue Grégoire de Tours, F-75006 Paris (FR). DUCLERT, Aymeric [FR/FR]; 6 ter, rue Victorine, F-94100 Saint-Maur (FR). LACROIX, Bruno [FR/FR]; 93, route de Vourles, F-69230 Saint-Genis Laval (FR). (74) Agents: MARTIN, Jean-Jacques et al.; Cabinet Regimbeau, 26, avenue Kléber, F-75116 Paris (FR). | | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i> |
| (54) Title: 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN ENDODERM (57) Abstract The sequences of 5' ESTs derived from mRNAs encoding secreted proteins are disclosed. The 5' ESTs may be to obtain cDNAs and genomic DNAs corresponding to the 5' ESTs. The 5' ESTs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. Upstream regulatory sequences may also be obtained using the 5' ESTs. The 5' ESTs may also be used to design expression vectors and secretion vectors. | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | | | TR | Turkey |
| BG | Bulgaria | HU | Hungary | ML | Mali | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MN | Mongolia | UA | Ukraine |
| BR | Brazil | IL | Israel | MR | Mauritania | UG | Uganda |
| BY | Belarus | IS | Iceland | MW | Malawi | US | United States of America |
| CA | Canada | IT | Italy | MX | Mexico | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NE | Niger | VN | Viet Nam |
| CG | Congo | KE | Kenya | NL | Netherlands | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NO | Norway | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | NZ | New Zealand | | |
| CM | Cameroon | | | PL | Poland | | |
| CN | China | KR | Republic of Korea | PT | Portugal | | |
| CU | Cuba | KZ | Kazakhstan | RO | Romania | | |
| CZ | Czech Republic | LC | Saint Lucia | RU | Russian Federation | | |
| DE | Germany | LI | Liechtenstein | SD | Sudan | | |
| DK | Denmark | LK | Sri Lanka | SE | Sweden | | |
| EE | Estonia | LR | Liberia | SG | Singapore | | |

5' ESTs FOR SECRETED PROTEINS EXPRESSED IN ENDODERM

Background of the Invention

The estimated 50,000-100,000 genes scattered along the human chromosomes offer tremendous promise for the understanding, diagnosis, and treatment of human diseases. In addition, probes capable of specifically hybridizing to loci distributed throughout the human genome find applications in the construction of high resolution chromosome maps and in the identification of individuals.

In the past, the characterization of even a single human gene was a painstaking process, requiring years of effort. Recent developments in the areas of cloning vectors, DNA sequencing, and computer technology have merged to greatly accelerate the rate at which human genes can be isolated, sequenced, mapped, and characterized. Cloning vectors such as yeast artificial chromosomes (YACs) and bacterial artificial chromosomes (BACs) are able to accept DNA inserts ranging from 300 to 1000 kilobases (kb) or 100-400 kb in length respectively, thereby facilitating the manipulation and ordering of DNA sequences distributed over great distances on the human chromosomes. Automated DNA sequencing machines permit the rapid sequencing of human genes. Bioinformatics software enables the comparison of nucleic acid and protein sequences, thereby assisting in the characterization of human gene products.

Currently, two different approaches are being pursued for identifying and characterizing the genes distributed along the human genome. In one approach, large fragments of genomic DNA are isolated, cloned, and sequenced. Potential open reading frames in these genomic sequences are identified using bioinformatics software. However, this approach entails sequencing large stretches of human DNA which do not encode proteins in order to find the protein encoding sequences scattered throughout the genome. In addition to requiring extensive sequencing, the bioinformatics software may mischaracterize the genomic sequences obtained. Thus, the software may produce false positives in which non-coding DNA is mischaracterized as coding DNA or false negatives in which coding DNA is mislabeled as non-coding DNA.

An alternative approach takes a more direct route to identifying and characterizing human genes. In this approach, complementary DNAs (cDNAs) are synthesized from isolated messenger RNAs (mRNAs) which encode human proteins. Using this approach,

sequencing is only performed on DNA which is derived from protein coding portions of the genome. Often, only short stretches of the cDNAs are sequenced to obtain sequences called expressed sequence tags (ESTs). The ESTs may then be used to isolate or purify extended cDNAs which include sequences adjacent to the EST sequences. The extended cDNAs may contain all of the sequence of the EST which was used to obtain them or only a portion of the sequence of the EST which was used to obtain them. In addition, the extended cDNAs may contain the full coding sequence of the gene from which the EST was derived or, alternatively, the extended cDNAs may include portions of the coding sequence of the gene from which the EST was derived. It will be appreciated that there may be several extended cDNAs which include the EST sequence as a result of alternate splicing or the activity of alternative promoters.

In the past, these short EST sequences were often obtained from oligo-dT primed cDNA libraries. Accordingly, they mainly corresponded to the 3' untranslated region of the mRNA. In part, the prevalence of EST sequences derived from the 3' end of the mRNA is a result of the fact that typical techniques for obtaining cDNAs are not well suited for isolating cDNA sequences derived from the 5' ends of mRNAs. (Adams *et al.*, *Nature* 377:3-174, 1996; Hillier *et al.*, *Genome Res.* 6:807-828, 1996).

In addition, in those reported instances where longer cDNA sequences have been obtained, the reported sequences typically correspond to coding sequences and do not include the full 5' untranslated region of the mRNA from which the cDNA is derived. Such incomplete sequences may not include the first exon of the mRNA, particularly in situations where the first exon is short. Furthermore, they may not include some exons, often short ones, which are located upstream of splicing sites. Thus, there is a need to obtain sequences derived from the 5' ends of mRNAs.

While many sequences derived from human chromosomes have practical applications, approaches based on the identification and characterization of those chromosomal sequences which encode a protein product are particularly relevant to diagnostic and therapeutic uses. Of the 50,000-100,000 protein coding genes, those genes encoding proteins which are secreted from the cell in which they are synthesized, as well as the secreted proteins themselves, are particularly valuable as potential therapeutic agents. Such proteins are often

involved in cell to cell communication and may be responsible for producing a clinically relevant response in their target cells.

In fact, several secretory proteins, including tissue plasminogen activator, G-CSF, GM-CSF, erythropoietin, human growth hormone, insulin, interferon- α , interferon- β , interferon- γ , and interleukin-2, are currently in clinical use. These proteins are used to treat a wide range of conditions, including acute myocardial infarction, acute ischemic stroke, anemia, diabetes, growth hormone deficiency, hepatitis, kidney carcinoma, chemotherapy induced neutropenia and multiple sclerosis. For these reasons, extended cDNAs encoding secreted proteins or portions thereof represent a particularly valuable source of therapeutic agents. Thus, there is a need for the identification and characterization of secreted proteins and the nucleic acids encoding them.

In addition to being therapeutically useful themselves, secretory proteins include short peptides, called signal peptides, at their amino termini which direct their secretion. These signal peptides are encoded by the signal sequences located at the 5' ends of the coding sequences of genes encoding secreted proteins. Because these signal peptides will direct the extracellular secretion of any protein to which they are operably linked, the signal sequences may be exploited to direct the efficient secretion of any protein by operably linking the signal sequences to a gene encoding the protein for which secretion is desired. In addition, portions of signal sequences may also be used to direct the intracellular import of a peptide or protein of interest. This may prove beneficial in gene therapy strategies in which it is desired to deliver a particular gene product to cells other than the cell in which it is produced. Signal sequences encoding signal peptides also find application in simplifying protein purification techniques. In such applications, the extracellular secretion of the desired protein greatly facilitates purification by reducing the number of undesired proteins from which the desired protein must be selected. Thus, there exists a need to identify and characterize the 5' portions of the genes for secretory proteins which encode signal peptides.

Public information on the number of human genes for which the promoters and upstream regulatory regions have been identified and characterized is quite limited. In part, this may be due to the difficulty of isolating such regulatory sequences. Upstream regulatory sequences such as transcription factor binding sites are typically too short to be utilized as probes for isolating promoters from human genomic libraries. Recently, some approaches

have been developed to isolate human promoters. One of them consists of making a CpG island library (Cross, *et al.*, *Nature Genetics* 6: 236-244, 1994). The second consists of isolating human genomic DNA sequences containing SpeI binding sites by the use of SpeI binding protein. (Mortlock *et al.*, *Genome Res.* 6:327-335, 1996). Both of these approaches
5 have their limits due to a lack of specificity or of comprehensiveness.

The present 5' ESTs may be used to efficiently identify and isolate upstream regulatory regions which control the location, developmental stage, rate, and quantity of protein synthesis, as well as the stability of the mRNA. (Theil, *BioFactors* 4:87-93, 1993). Once identified and characterized, these regulatory regions may be utilized in gene therapy or
10 protein purification schemes to obtain the desired amount and locations of protein synthesis or to inhibit, reduce, or prevent the synthesis of undesirable gene products.

In addition, ESTs containing the 5' ends of secretory protein genes may include sequences useful as probes for chromosome mapping and the identification of individuals. Thus, there is a need to identify and characterize the sequences upstream of the 5' coding
15 sequences of genes encoding secretory proteins.

Summary of the Invention

The present invention relates to purified, isolated, or recombinant ESTs which include sequences derived from the authentic 5' ends of their corresponding mRNAs. The term
20 "corresponding mRNA" refers to the mRNA which was the template for the cDNA synthesis which produced the 5' EST. These sequences will be referred to hereinafter as "5' ESTs." As used herein, the term "purified" does not require absolute purity; rather, it is intended as a relative definition. Individual 5' EST clones isolated from a cDNA library have been conventionally purified to electrophoretic homogeneity. The sequences obtained from these
25 clones could not be obtained directly either from the library or from total human DNA. The cDNA clones are not naturally occurring as such, but rather are obtained via manipulation of a partially purified naturally occurring substance (messenger RNA). The conversion of mRNA into a cDNA library involves the creation of a synthetic substance (cDNA) and pure individual cDNA clones can be isolated from the synthetic library by clonal selection. Thus,
30 creating a cDNA library from messenger RNA and subsequently isolating individual clones from that library results in an approximately 10^4 - 10^6 fold purification of the native message.

Purification of starting material or natural material to at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated.

As used herein, the term "isolated" requires that the material be removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide present in a living animal is not isolated, but the same polynucleotide, separated from some or all of the coexisting materials in the natural system, is isolated.

As used herein, the term "recombinant" means that the 5' EST is adjacent to "backbone" nucleic acid to which it is not adjacent in its natural environment. Additionally, to be "enriched" the 5' ESTs will represent 5% or more of the number of nucleic acid inserts in a population of nucleic acid backbone molecules. Backbone molecules according to the present invention include nucleic acids such as expression vectors, self-replicating nucleic acids, viruses, integrating nucleic acids, and other vectors or nucleic acids used to maintain or manipulate a nucleic acid insert of interest. Preferably, the enriched 5' ESTs represent 15% or more of the number of nucleic acid inserts in the population of recombinant backbone molecules. More preferably, the enriched 5' ESTs represent 50% or more of the number of nucleic acid inserts in the population of recombinant backbone molecules. In a highly preferred embodiment, the enriched 5' ESTs represent 90% or more of the number of nucleic acid inserts in the population of recombinant backbone molecules.

"Stringent", moderate, and "low" hybridization conditions are as defined in Example 29.

Unless otherwise indicated, a "complementary" sequence is fully complementary.

Thus, 5' ESTs in cDNA libraries in which one or more 5' ESTs make up 5% or more of the number of nucleic acid inserts in the backbone molecules are "enriched recombinant 5' ESTs" as defined herein. Likewise, 5' ESTs in a population of plasmids in which one or more 5' EST of the present invention have been inserted such that they represent 5% or more of the number of inserts in the plasmid backbone are "enriched recombinant 5' ESTs" as defined herein. However, 5' ESTs in cDNA libraries in which 5' ESTs constitute less than 5% of the number of nucleic acid inserts in the population of backbone molecules, such as libraries in

which backbone molecules having a 5' EST insert are extremely rare, are not "enriched recombinant 5' ESTs."

In particular, the present invention relates to 5' ESTs which are derived from genes encoding secreted proteins. As used herein, a "secreted" protein is one which, when
5 expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal peptides in its amino acid sequence. "Secreted" proteins include without limitation proteins secreted wholly (e.g. soluble proteins), or partially (e.g. receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.

10 Such 5' ESTs include nucleic acid sequences, called signal sequences, which encode signal peptides which direct the extracellular secretion of the proteins encoded by the genes from which the 5' ESTs are derived. Generally, the signal peptides are located at the amino termini of secreted proteins.

Secreted proteins are translated by ribosomes associated with the "rough"
15 endoplasmic reticulum. Generally, secreted proteins are co-translationally transferred to the membrane of the endoplasmic reticulum. Association of the ribosome with the endoplasmic reticulum during translation of secreted proteins is mediated by the signal peptide. The signal peptide is typically cleaved following its co-translational entry into the endoplasmic reticulum. After delivery to the endoplasmic reticulum, secreted proteins may proceed through the
20 Golgi apparatus. In the Golgi apparatus, the proteins may undergo post-translational modification before entering secretory vesicles which transport them across the cell membrane.

The 5' ESTs of the present invention have several important applications. For example, they may be used to obtain and express cDNA clones which include the full protein
25 coding sequences of the corresponding gene products, including the authentic translation start sites derived from the 5' ends of the coding sequences of the mRNAs from which the 5' ESTs are derived. These cDNAs will be referred to hereinafter as "full length cDNAs." These cDNAs may also include DNA derived from mRNA sequences upstream of the translation start site. The full length cDNA sequences may be used to express the proteins
30 corresponding to the 5' ESTs. As discussed above, secreted proteins are therapeutically important. Thus, the proteins expressed from the cDNAs may be useful in treating or

controlling a variety of human conditions. The 5' ESTs may also be used to obtain the corresponding genomic DNA. The term "corresponding genomic DNA" refers to the genomic DNA which encodes the mRNA from which the 5' EST was derived.

Alternatively, the 5' ESTs may be used to obtain and express extended cDNAs
5 encoding portions of the secreted protein. The portions may comprise the signal peptides of the secreted proteins or the mature proteins generated when the signal peptide is cleaved off. The portions may also comprise polypeptides having at least 10 consecutive amino acids encoded by the extended cDNAs or full length cDNAs. Alternatively, the portions may comprise at least 15 consecutive amino acids encoded by the extended cDNAs or full length
10 cDNAs. In some embodiments, the portions may comprise at least 25 consecutive amino acids encoded by the extended cDNAs or full length cDNAs. In other embodiments, the portions may comprise at least 40 amino acids encoded by the extended cDNAs or full length cDNAs.

Antibodies which specifically recognize the entire secreted proteins encoded by the
15 extended cDNAs, full length cDNAs, or fragments thereof having at least 10 consecutive amino acids, at least 15 consecutive amino acids, at least 25 consecutive amino acids, or at least 40 consecutive amino acids may also be obtained as described below. Antibodies which specifically recognize the mature protein generated when the signal peptide is cleaved may also be obtained as described below. Similarly, antibodies which specifically recognize the
20 signal peptides encoded by the extended cDNAs or full length cDNAs may also be obtained.

In some embodiments, the extended cDNAs obtained using the 5' ESTs include the signal sequence. In other embodiments, the extended cDNAs obtained using the 5' ESTs may include the full coding sequence for the mature protein (*i.e.* the protein generated when the signal polypeptide is cleaved off). In addition, the extended cDNAs obtained using the 5'
25 ESTs may include regulatory regions upstream of the translation start site or downstream of the stop codon which control the amount, location, or developmental stage of gene expression.

As discussed above, secreted proteins are therapeutically important. Thus, the proteins expressed from the extended cDNAs or full length cDNAs obtained using the 5'
30 ESTs may be useful in treating or controlling a variety of human conditions.

The 5' ESTs (or cDNAs or genomic DNAs obtained therefrom) may be used in forensic procedures to identify individuals or in diagnostic procedures to identify individuals having genetic diseases resulting from abnormal expression of the genes corresponding to the 5' ESTs. In addition, the present invention is useful for constructing a high resolution map of the human chromosomes.

The present invention also relates to secretion vectors capable of directing the secretion of a protein of interest. Such vectors may be used in gene therapy strategies in which it is desired to produce a gene product in one cell which is to be delivered to another location in the body. Secretion vectors may also facilitate the purification of desired proteins.

The present invention also relates to expression vectors capable of directing the expression of an inserted gene in a desired spatial or temporal manner or at a desired level. Such vectors may include sequences upstream of the 5' ESTs, such as promoters or upstream regulatory sequences.

Finally, the present invention may also be used for gene therapy to control or treat genetic diseases. Signal peptides may also be fused to heterologous proteins to direct their extracellular secretion.

Bacterial clones containing Bluescript plasmids having inserts containing the 5' ESTs of the present invention (SEQ ID NOs: 38-184 are presently stored at 80°C in 4% (v/v) glycerol in the inventor's laboratories under the designations listed next to the SEQ ID NOs in II). The inserts may be recovered from the deposited materials by growing the appropriate clones on a suitable medium. The Bluescript DNA can then be isolated using plasmid isolation procedures familiar to those skilled in the art such as alkaline lysis minipreps or large scale alkaline lysis plasmid isolation procedures. If desired the plasmid DNA may be further enriched by centrifugation on a cesium chloride gradient, size exclusion chromatography, or anion exchange chromatography. The plasmid DNA obtained using these procedures may then be manipulated using standard cloning techniques familiar to those skilled in the art. Alternatively, a PCR can be done with primers designed at both ends of the EST insertion. The PCR product which corresponds to the 5' EST can then be manipulated using standard cloning techniques familiar to those skilled in the art.

One aspect of the present invention is a purified or isolated nucleic acid having the sequence of one of SEQ ID NOs: 38-184 or having a sequence complementary thereto. In one embodiment, the nucleic acid is recombinant.

Another aspect of the present invention is a purified or isolated nucleic acid comprising at least 10 consecutive bases of the sequence of one of SEQ ID NOs: 38-184 or one of the sequences complementary thereto.

Yet another aspect of the present invention is a purified or isolated nucleic acid comprising at least 15 consecutive bases of one of the sequences of SEQ ID NOs: 38-184 or one of the sequences complementary thereto. In one embodiment, the nucleic acid is recombinant.

A further aspect of the present invention is a purified or isolated nucleic acid of at least 15 bases capable of hybridizing under stringent conditions to the sequence of one of SEQ ID NOs: 38-184 or one of the sequences complementary to the sequences of SEQ ID NOs: 38-184. In one embodiment, the nucleic acid is recombinant.

Another aspect of the present invention is a purified or isolated nucleic acid encoding a human gene product, said human gene product having a sequence partially encoded by one of the sequences of SEQ ID NO: 38-184.

Still another aspect of the present invention is a method of making a cDNA encoding a human secretory protein, said human secretory protein being partially encoded by one of SEQ ID NOs 38-184, comprising the steps of contacting a collection of mRNA molecules from human cells with a primer comprising at least 15 consecutive nucleotides of a sequence complementary to one of SEQ ID NOs: 38-184; hybridizing said primer to an mRNA in said collection that encodes said protein; reverse transcribing said hybridized primer to make a first cDNA strand from said mRNA; making a second cDNA strand complementary to said first cDNA strand; and isolating the resulting cDNA encoding said protein comprising said first cDNA strand and said second cDNA strand.

Another aspect of the invention is an isolated or purified cDNA encoding a human secretory protein, said human secretory protein comprising the protein encoded by one of SEQ ID NOs 38-184 or a fragment thereof of at least 10 amino acids, said cDNA being obtainable by the method described in the preceding paragraph. In one embodiment, the

cDNA comprises the full protein coding sequence of said protein which sequence is partially included in one of the sequences of SEQ ID NOs: 38-184.

Another aspect of the present invention is a method of making a cDNA encoding a human secretory protein that is partially encoded by one of SEQ ID NOs 38-184, comprising the steps of obtaining a cDNA comprising one of the sequences of SEQ ID NOs: 38-184; contacting said cDNA with a detectable probe comprising at least 15 consecutive nucleotides of said sequence of SEQ ID NO: 38-184 or a sequence complementary thereto under conditions which permit said probe to hybridize to said cDNA; identifying a cDNA which hybridizes to said detectable probe; and isolating said cDNA which hybridizes to said probe.

Another aspect of the present invention is an isolated or purified cDNA encoding a human secretory protein, said human secretory protein comprising the protein encoded by one of SEQ ID NOs 38-184 or a fragment thereof of at least 10 amino acids, said cDNA being obtainable by the method described in the preceding paragraph. In one embodiment, the cDNA comprises the full protein coding sequence partially included in one of the sequences of SEQ ID NOs: 38-184.

Another aspect of the present invention is a method of making a cDNA comprising one of the sequence of SEQ ID NOs: 38-184, comprising the steps of contacting a collection of mRNA molecules from human cells with a first primer capable of hybridizing to the polyA tail of said mRNA; hybridizing said first primer to said polyA tail; reverse transcribing said mRNA to make a first cDNA strand; making a second cDNA strand complementary to said first cDNA strand using at least one primer comprising at least 15 nucleotides of one of the sequences of SEQ ID NOs 38-184; and isolating the resulting cDNA comprising said first cDNA strand and said second cDNA strand.

Another aspect of the present invention is an isolated or purified cDNA encoding a human secretory protein, said human secretory protein comprising the protein encoded by one of SEQ ID NOs 38-184 or a fragment thereof of at least 10 amino acids, said cDNA being obtainable by the method described in the preceding paragraph. In one embodiment, the cDNA comprises the full protein coding sequence partially included in one of the sequences of SEQ ID NOs: 38-184.

In one embodiment of the method described in the two paragraphs above, the second cDNA strand is made by contacting said first cDNA strand with a first pair of primers, said

first pair of primers comprising a second primer comprising at least 15 consecutive nucleotides of one of the sequences of SEQ ID NOs 38-184 and a third primer having a sequence therein which is included within the sequence of said first primer, performing a first polymerase chain reaction with said first pair of nested primers to generate a first PCR product; contacting said first PCR product with a second pair of primers, said second pair of primers comprising a fourth primer, said fourth primer comprising at least 15 consecutive nucleotides of said sequence of one of SEQ ID NOs: 38-184, and a fifth primer, said fourth and fifth primers being capable of hybridizing to sequences within said first PCR product; and performing a second polymerase chain reaction, thereby generating a second PCR product.

One aspect of the present invention is an isolated or purified cDNA encoding a human secretory protein, said human secretory protein comprising the protein encoded by one of SEQ ID NOs 38-184, or a fragment thereof of at least 10 amino acids, said cDNA being obtainable by the method of the preceding paragraph. In one embodiment, the cDNA comprises the full protein coding sequence partially included in one of the sequences of SEQ ID NOs: 38-184.

Another aspect of the present invention is the method described four paragraphs above in which the second cDNA strand is made by contacting said first cDNA strand with a second primer comprising at least 15 consecutive nucleotides of the sequences of SEQ ID NOs: 38-184; hybridizing said second primer to said first strand cDNA; and extending said hybridized second primer to generate said second cDNA strand.

Another aspect of the present invention is an isolated or purified cDNA encoding a human secretory protein, said human secretory protein comprising the protein partially encoded by one of SEQ ID NOs 38-184 or comprising a fragment thereof of at least 10 amino acids, said cDNA being obtainable by the method described in the preceding paragraph. In one embodiment, the cDNA comprises the full protein coding sequence partially included in one of the sequences of SEQ ID NOs: 38-184.

Another aspect of the present invention is a method of making a protein comprising one of the sequences of SEQ ID NOs: 185-331, comprising the steps of obtaining a cDNA encoding the full protein sequence partially included in one of the sequences of sequence of SEQ ID NOs: 38-184; inserting said cDNA in an expression vector such that said cDNA is

operably linked to a promoter; introducing said expression vector into a host cell whereby said host cell produces the protein encoded by said cDNA; and isolating said protein.

Another aspect of the present invention is an isolated protein obtainable by the method described in the preceding paragraph.

5 Another aspect of the present invention is a method of obtaining a promoter DNA comprising the steps of obtaining DNAs located upstream of the nucleic acids of SEQ ID NOs: 38-184 or the sequences complementary thereto; screening said upstream DNAs to identify a promoter capable of directing transcription initiation; and isolating said DNA comprising said identified promoter. In one embodiment, the obtaining step comprises
10 chromosome walking from said nucleic acids of SEQ ID NOs: 38-184 or sequences complementary thereto. In another embodiment, the screening step comprises inserting said upstream sequences into a promoter reporter vector. In another embodiment, the screening step comprises identifying motifs in said upstream DNAs which are transcription factor binding sites or transcription start sites.

15 Another aspect of the present invention is an isolated promoter obtainable by the method described above.

Another aspect of the present invention is an isolated or purified protein comprising one of the sequences of SEQ ID NOs: 185-331.

Another aspect of the present invention is the inclusion of at least one of the
20 sequences of SEQ ID NOs: 38-184, or one of the sequences complementary to the sequences of SEQ ID NOs: 38-184, or a fragment thereof of at least 15 consecutive nucleotides in an array of discrete ESTs or fragments thereof of at least 15 nucleotides in length. In one embodiment, the array includes at least two of the sequences of SEQ ID NOs: 38-184, the sequences complementary to the sequences of SEQ ID NOs: 38-184, or fragments thereof of
25 at least 15 consecutive nucleotides. In another embodiment, the array includes at least five of the sequences of SEQ ID NOs: 38-184, the sequences complementary to the sequences of SEQ ID NOs: 38-184, or fragments thereof of at least 15 consecutive nucleotides.

Another aspect of the present invention is a promoter having a sequence selected from the group consisting of SEQ ID NOs: 31, 34, and 37.

Brief Description of the Drawings

Figure 1 is a summary of a procedure for obtaining cDNAs which have been selected to include the 5' ends of the mRNAs from which they derived.

Figure 2 shows the distribution of Von Heijne scores for 5' ESTs in each of the categories described herein and the probability that these 5' ESTs encode a signal peptide.

Figure 3 summarizes a general method used to clone and sequence extended cDNAs containing sequences adjacent to 5' ESTs.

Figure 4 (description of promoters structure isolated from SignalTag 5' ESTs) provides a schematic description of promoters isolated and the way they are assembled with the corresponding 5' tags.

Detailed Description of the Preferred Embodiment

Table IV is an analysis of the 43 amino acids located at the N terminus of all human SwissProt proteins to determine the frequency of false positives and false negatives using the techniques for signal peptide identification described herein.

Table V shows the distribution of 5' ESTs in each category described herein and the number of 5' ESTs in each category having a given minimum Von Heijne's score.

Table VI shows the distribution of 5' ESTs in each category described herein with respect to the tissue from which the 5' ESTs of the corresponding mRNA were obtained.

Table VII describes the transcription factor binding sites present in each of these promoters.

I. General Methods for Obtaining 5' ESTs derived from mRNAs with intact 5' ends

In order to obtain the 5' ESTs of the present invention, mRNAs with intact 5' ends must be obtained. Currently, there are two approaches for obtaining such mRNAs with intact 5' ends as described below: either chemical (1) or enzymatic (2).

1. Chemical Methods for Obtaining mRNAs having Intact 5' Ends

One of these approaches is a chemical modification method involving derivatization of the 5' ends of the mRNAs and selection of the derivatized mRNAs. The 5' ends of eukaryotic mRNAs possess a structure referred to as a "cap" which comprises a guanosine

5 methylated at the 7 position. The cap is joined to the first transcribed base of the mRNA by a 5', 5'-triphosphate bond. In some instances, the 5' guanosine is methylated in both the 2 and 7 positions. Rarely, the 5' guanosine is trimethylated at the 2, 7 and 7 positions. In the chemical method for obtaining mRNAs having intact 5' ends, the 5' cap is specifically derivatized and coupled to a reactive group on an immobilizing substrate. This specific derivatization is based on the fact that only the ribose linked to the methylated guanosine at the 5' end of the mRNA and the ribose linked to the base at the 3' terminus of the mRNA, possess 2', 3'-cis diols.

10 Optionally, the 2', 3'-cis diol of the 3' terminal ribose may be chemically modified, substituted, converted, or eliminated, leaving only the ribose linked to the methylated guanosine at the 5' end of the mRNA with a 2', 3'-cis diol. A variety of techniques are available for eliminating the 2', 3'-cis diol on the 3' terminal ribose. For example, controlled alkaline hydrolysis may be used to generate mRNA fragments in which the 3' terminal ribose is a 3'-phosphate, 2'-phosphate or (2', 3')-cyclophosphate. Thereafter, the fragment which includes the original 3' ribose may be eliminated from the mixture through chromatography on an oligodT column. Alternatively, a base which lacks the 2', 3'-cis diol may be added to the 3' end of the mRNA using an RNA ligase such as T4 RNA ligase. Example 1 below describes a method for ligation of a nucleoside diphosphate to the 3' end of messenger RNA.

20

EXAMPLE 1

Ligation of the Nucleoside Diphosphate pCp to the 3' End of mRNA.

One μg of RNA was incubated in a final reaction medium of 10 μl in the presence of 5 U of T₄ phage RNA ligase in the buffer provided by the manufacturer (Gibco - BRL), 40 U of the RNase inhibitor RNasin (Promega) and, 2 μl of ³²pCp (Amersham #PB 25 10208). The incubation was performed at 37°C for 2 hours or overnight at 7-8°C.

Following modification or elimination of the 2', 3'-cis diol at the 3' ribose, the 2', 3'-cis diol present at the 5' end of the mRNA may be oxidized using reagents such as NaBH₄, NaBH₃CN, or sodium periodate, thereby converting the 2', 3'-cis diol to a dialdehyde.

Example 2 describes the oxidation of the 2', 3'-cis diol at the 5' end of the mRNA with sodium periodate.

EXAMPLE 2

5 Oxidation of 2', 3'-cis diol at the 5' End of the mRNA with Sodium Periodate

0.1 OD unit of either a capped oligoribonucleotide of 47 nucleotides (including the cap) or an uncapped oligoribonucleotide of 46 nucleotides were treated as follows. The oligoribonucleotides were produced by *in vitro* transcription using the transcription kit "AmpliScribe T7" (Epicentre Technologies). As indicated below, the DNA template for the
10 RNA transcript contained a single cytosine. To synthesize the uncapped RNA, all four NTPs were included in the *in vitro* transcription reaction. To obtain the capped RNA, GTP was replaced by an analogue of the cap, m7G(5')ppp(5')G. This compound, recognized by the polymerase, was incorporated into the 5' end of the nascent transcript during the initiation of transcription but was not incorporated during the extension step. Consequently, the resulting
15 RNA contained a cap at its 5' end. The sequences of the oligoribonucleotides produced by the *in vitro* transcription reaction were:

+Cap:

5'm7GpppGCAUCCUACUCCCAUCCAAUUCCACCCUAACUCCUCCCAUCUCCAC-
3' (SEQ ID NO:1)

20 -Cap:

5'-pppGCAUCCUACUCCCAUCCAAUUCCACCCUAACUCCUCCCAUCUCCAC-3'
(SEQ ID NO:2)

The oligoribonucleotides were dissolved in 9 µl of acetate buffer (0.1 M sodium acetate, pH 5.2) and 3 µl of freshly prepared 0.1 M sodium periodate solution. The mixture
25 was incubated for 1 hour in the dark at 4°C or room temperature. Thereafter, the reaction was stopped by adding 4 µl of 10% ethylene glycol. The product was ethanol precipitated, resuspended in at least 10 µl of water or appropriate buffer and dialyzed against water.

The resulting aldehyde groups may then be coupled to molecules having a reactive
30 amine group, such as hydrazine, carbazide, thiocarbazide or semicarbazide groups, in order to facilitate enrichment of the 5' ends of the mRNAs. Molecules having reactive amine groups

which are suitable for use in selecting mRNAs having intact 5' ends include avidin, proteins, antibodies, vitamins, ligands capable of specifically binding to receptor molecules, or oligonucleotides. Example 3 below describes the coupling of the resulting dialdehyde to biotin.


5

EXAMPLE 3

Coupling of the Dialdehyde at the 5' End of Transcripts with Biotin

The oxidation product obtained in Example 2 was dissolved in 50 μ l of sodium acetate at a pH between 5 and 5.2 and 50 μ l of freshly prepared 0.02 M solution of biotin hydrazide in a methoxyethanol/water mixture (1:1) of formula:

10



EXAMPLE 4

Specificity of Biotinylation of Capped Transcripts

The specificity of the biotinylation for capped mRNAs was evaluated by gel electrophoresis of the following samples:

15

Sample 1. The 46 nucleotide uncapped *in vitro* transcript prepared as in Example 2 and labeled with 32 Pcp as described in Example 1.

Sample 2. The 46 nucleotide uncapped *in vitro* transcript prepared as in Example 2, labeled with 32 Pcp as described in Example 1, treated with the oxidation reaction of Example 2, and subjected to the biotinylation conditions of Example 3.

20

Sample 3. The 47 nucleotide capped *in vitro* transcript prepared as in Example 2 and labeled with 32 Pcp as described in Example 1.

Sample 4. The 47 nucleotide capped *in vitro* transcript prepared as in Example 2, labeled with 32 Pcp as described in Example 1, treated with the oxidation reaction of Example 2, and subjected to the biotinylation conditions of Example 3.

25

Samples 1 and 2 had identical migration rates, demonstrating that the uncapped RNAs were not oxidized and biotinylated. Sample 3 migrated more slowly than Samples 1 and 2, while Sample 4 exhibited the slowest migration. The difference in migration of the RNAs in Samples 3 and 4 demonstrates that the capped RNAs were specifically biotinylated.

5

In some cases, mRNAs having intact 5' ends may be enriched by binding the molecule containing a reactive amine group to a suitable solid phase substrate such as the inside of the vessel containing the mRNAs, magnetic beads, chromatography matrices, or nylon or nitrocellulose membranes. For example, where the molecule having a reactive amine group is biotin, the solid phase substrate may be coupled to avidin or streptavidin. Alternatively, where the molecule having the reactive amine group is an antibody or receptor ligand, the solid phase substrate may be coupled to the cognate antigen or receptor. Finally, where the molecule having a reactive amine group comprises an oligonucleotide, the solid phase substrate may comprise a complementary oligonucleotide.

10

The mRNAs having intact 5' ends may be released from the solid phase following the enrichment procedure. For example, where the dialdehyde is coupled to biotin hydrazide and the solid phase comprises streptavidin, the mRNAs may be released from the solid phase by simply heating to 95 degrees Celsius in 2% SDS. In some methods, the molecule having a reactive amine group may also be cleaved from the mRNAs having intact 5' ends following enrichment. Example 5 describes the capture of biotinylated mRNAs with streptavidin coated beads and the release of the biotinylated mRNAs from the beads following enrichment.

15

20

EXAMPLE 5

Capture and Release of Biotinylated mRNAs Using Streptavidin Coated Beads

25

The streptavidin coated magnetic beads were prepared according to the manufacturer's instructions (CPG Inc., USA). The biotinylated mRNAs were added to a hybridization buffer (1.5 M NaCl, pH 5 - 6). After incubating for 30 minutes, the unbound and nonbiotinylated material was removed. The beads were then washed several times in water with 1% SDS. The beads thus obtained were incubated for 15 minutes at 95°C in water containing 2% SDS.

30

Example 6 demonstrates the efficiency with which biotinylated mRNAs were recovered from the streptavidin coated beads.

EXAMPLE 6

5 Efficiency of Recovery of Biotinylated mRNAs

The efficiency of the recovery procedure was evaluated as follows. Capped RNAs were labeled with ^{32}pCp , oxidized, biotinylated and bound to streptavidin coated beads as described above. Subsequently, the bound RNAs were incubated for 5, 15 or 30 minutes at 95°C in the presence of 2% SDS.

10 The products of the reaction were analyzed by electrophoresis on 12% polyacrylamide gels under denaturing conditions (7 M urea). The gels were subjected to autoradiography. During this manipulation, the hydrazone bonds were not reduced.

Increasing amounts of nucleic acids were recovered as incubation times in 2% SDS increased, demonstrating that biotinylated mRNAs were efficiently recovered.

15 In an alternative method for obtaining mRNAs having intact 5' ends, an oligonucleotide which has been derivatized to contain a reactive amine group is specifically coupled to mRNAs having an intact cap. Preferably, the 3' end of the mRNA is blocked prior to the step in which the aldehyde groups are joined to the derivatized oligonucleotide, as described above, so as to prevent the derivatized oligonucleotide from being joined to the 3' end of the mRNA. For example, pCp may be attached to the 3' end of the mRNA using T4 RNA ligase as described in example 1. However, as discussed above, blocking the 3' end of the mRNA is an optional step. Derivatized oligonucleotides may be prepared as described in Example 7.

25

EXAMPLE 7

Derivatization of Oligonucleotides

An oligonucleotide phosphorylated at its 3' end was converted to a 3' hydrazide in 3' by treatment with an aqueous solution of hydrazine or of dihydrazide of the formula
30 $\text{H}_2\text{N}(\text{R}1)\text{NH}_2$ at about 1 to 3 M, and at pH 4.5 at a temperature of 8°C overnight. This

incubation was performed in the presence of a carbodiimide type agent soluble in water such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide at a final concentration of 0.3 M.

The derivatized oligonucleotide was then separated from the other agents and products using a standard technique for isolating oligonucleotides.

- 5 As discussed above, the mRNAs to be enriched may be treated to eliminate the 3' OH groups which may be present thereon. This may be accomplished by enzymatic ligation of sequences lacking a 3' OH, such as pCp, as described in Example 1. Alternatively, the 3' OH groups may be eliminated by alkaline hydrolysis as described in Example 8 below.

10

EXAMPLE 8

Elimination of 3' OH Groups of mRNA Using Alkaline Hydrolysis

In a total volume of 100 μ l of 0.1 N sodium hydroxide, 1.5 μ g mRNA is incubated for 40 to 60 minutes at 4°C. The solution is neutralized with acetic acid and precipitated with ethanol.

15

Following the optional elimination of the 3' OH groups, the diol groups at the 5' ends of the mRNAs are oxidized as described below in Example 9.

EXAMPLE 9

Oxidation of Diols of mRNA

20

Up to 1 OD unit of RNA was dissolved in 9 μ l of buffer (0.1 M sodium acetate, pH 6-7) or water and 3 μ l of freshly prepared 0.1 M sodium periodate solution. The reaction was incubated for 1 h in the dark at 4°C or room temperature. Following the incubation, the reaction was stopped by adding 4 μ l of 10% ethylene glycol. Thereafter the mixture was incubated at room temperature for 15 minutes. After ethanol precipitation, the product was

25 resuspended in at least 10 μ l of water or appropriate buffer and dialyzed against water.

Following oxidation of the diol groups at the 5' ends of the mRNAs, the derivatized oligonucleotide was joined to the resulting aldehydes as described in Example 10.

30

EXAMPLE 10**Ligature of Aldehydes of mRNA to Derivatized Oligonucleotides**

The oxidized mRNA was dissolved in an acidic medium such as 50 μ l of sodium acetate pH 4-6. Fifty μ l of a solution of the derivatized oligonucleotide were added in order to obtain an mRNA:derivatized oligonucleotide ratio of 1:20. The mixture was reduced with a borohydride and incubated for 2 h at 37°C or overnight (14 h) at 10°C. The mixture was then ethanol precipitated, resuspended in 10 μ l or more of water or appropriate buffer and dialyzed against distilled water. If desired, the resulting product may be analyzed using acrylamide gel electrophoresis, HPLC analysis, or other conventional techniques.

Following the attachment of the derivatized oligonucleotide to the mRNAs, a reverse transcription reaction may be performed as described in Example 11 below.

EXAMPLE 11**Reverse Transcription of mRNAs Ligatured to Derivatized Oligonucleotides**

An oligodeoxynucleotide was derivatized as follows. Three OD units of an oligodeoxynucleotide of sequence 5'ATCAAGAATTGCGACGAGACCATTAA3' (SEQ ID NO:3) having 5'-OH and 3'-P ends were dissolved in 70 μ l of a 1.5 M hydroxybenzotriazole solution, pH 5.3, prepared in dimethylformamide/water (75:25) containing 2 μ g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. The mixture was incubated for 2 h 30 min at 22°C and then precipitated twice in LiClO₄/acetone. The pellet was resuspended in 200 μ l of 0.25 M hydrazine and incubated at 8°C from 3 to 14 h. Following the hydrazine reaction, the mixture was precipitated twice in LiClO₄/acetone.

The messenger RNAs to be reverse transcribed were extracted from blocks of placenta having sides of 2 cm which had been stored at -80°C. The total RNA was extracted using conventional acidic phenol techniques. Oligo-dT chromatography was used to purify the mRNAs. The integrity of the mRNAs was checked by Northern-blotting.

The diol groups on 7 μ g of the placental mRNAs were oxidized as described above in Example 9. The derivatized oligonucleotide was joined to the mRNAs as described in Example 10 above except that the precipitation step was replaced by an exclusion

chromatography step to remove derivatized oligodeoxyribonucleotides which were not joined to mRNAs. Exclusion chromatography was performed as follows:

5 Ten ml of Ultrogel AcA34 (BioSeptra#230151) gel, a mix of agarose and acrylamide, were equilibrated in 50 ml of a solution of 10 mM Tris pH 8.0, 300 mM NaCl, 1 mM EDTA, and 0.05% SDS. The mixture was allowed to sediment. The supernatant was eliminated and the gel was resuspended in 50 ml of buffer. This procedure was repeated 2 or 3 times.

10 A glass bead (diameter 3 mm) was introduced into a 2 ml disposable pipette (length 25 cm). The pipette was filled with the gel suspension until the height of the gel stabilized at 1 cm from the top of the pipette. The column was then equilibrated with 20 ml of equilibration buffer (10 mM Tris HCl pH 7.4, 20 mM NaCl).

Ten μ l of the mRNA which had reacted with the derivatized oligonucleotide were mixed in 39 μ l of 10 mM urea and 2 μ l of blue-glycerol buffer, which had been prepared by dissolving 5 mg of bromophenol blue in 60% glycerol (v/v), and passing the mixture through a 0.45 μ m diameter filter.

15 The column was then loaded with the mRNAs coupled to the oligonucleotide. As soon as the sample had penetrated, equilibration buffer was added. Hundred μ l fractions were then collected. Derivatized oligonucleotide which had not been attached to mRNA appeared in fraction 16 and later fractions. Thus, fractions 3 to 15 were combined and precipitated with ethanol.

20 To determine whether the derivatized oligonucleotide was actually linked to mRNA, one tenth of the combined fractions were spotted twice on a nylon membrane and hybridized to a radioactive probe using conventional techniques. The 32 P labeled probe used in these hybridizations was an oligodeoxyribonucleotide of sequence
25 5'TAATGGTCTCGTGCGAATTCTTGAT3' (SEQ ID NO:4) anticomplementary to the derivatized oligonucleotide. A signal observed after autoradiography, indicated that the derivatized oligonucleotide had been truly joined to the mRNA.

The remaining nine tenth of the mRNAs which had reacted with the derivatized oligonucleotide was reverse transcribed as follows. A reverse transcription reaction was carried out with reverse transcriptase following the manufacturer's instructions and 50 pmol
30 of nonamers with random sequence as primers.

To ensure that reverse transcription had been carried out through the cap structure, two types of experiments were performed.

In the first approach, after elimination of RNA of the cDNA:RNA heteroduplexes obtained from the reverse transcription reaction by an alkaline hydrolysis, a portion of the resulting single stranded cDNAs was spotted on a positively charged membrane and hybridized, using conventional methods, to a ³²P labeled probe having a sequence identical to that of the derivatized oligonucleotide. Control spots containing, 1 pmol, 100 fmol, 50 fmol, 10 fmol and 1 fmol of a control oligodeoxyribonucleotide of sequence identical to that of the derivatized oligonucleotide were included. The signal observed in the spots containing the cDNA indicated that approximately 15 fmol of the derivatized oligonucleotide had been reverse transcribed. These results demonstrate that the reverse transcription can be performed through the cap and, in particular, that reverse transcriptase crosses the 5'-P-P-P-5' bond of the cap of eukaryotic messenger RNAs.

In the second type of experiment, the single stranded cDNAs obtained from the above first strand synthesis were used as template for PCR reactions. Two types of reactions were carried out. First, specific amplification of the mRNAs for alpha globin, dehydrogenase, pp15 and elongation factor E4 were carried out using the following pairs of oligodeoxyribonucleotide primers.

20 alpha-globin

GLO-S: 5'CCG ACA AGA CCA ACG TCA AGG CCG C3' (SEQ ID NO:5)

GLO-As: 5'TCA CCA GCA GGC AGT GGC TTA GGA G 3' (SEQ ID NO:6)

dehydrogenase

25 3 DH-S: 5'AGT GAT TCC TGC TAC TTT GGA TGG C3' (SEQ ID NO:7)

3 DH-As: 5'GCT TGG TCT TGT TCT GGA GTT TAG A3' (SEQ ID NO:8)

pp15

PP15-S: 5'TCC AGA ATG GGA GAC AAG CCA ATT T3' (SEQ ID NO:9)

30 PP15-As: 5'AGG GAG GAG GAA ACA GCG TGA GTC C3' (SEQ ID NO:10)

Elongation factor E4

EFA1-S: 5'ATG GGA AAG GAA AAG ACT CAT ATC A3' (SEQ ID NO:11)

EF1A-As: 5'AGC AGC AAC AAT CAG GAC AGC ACA G3' (SEQ ID NO:12)

5 Second, non specific amplifications were also carried out with the antisense oligodeoxyribonucleotides of the pairs described above and with a primer derived from the sequence of the derivatized oligodeoxyribonucleotide (5'ATCAAGAATTCGCACGAGACCATTAA3') (SEQ ID NO:13).

One twentieth of the following RT-PCR product samples were run on a 1.5%
10 agarose gel and stained with ethidium bromide.

Sample 1: The products of a PCR reaction using the globin primers of SEQ ID NOs 5 and 6 in the presence of cDNA.

Sample 2: The products of a PCR reaction using the globin primers of SEQ ID NOs 5 and 6 in the absence of added cDNA.

15 Sample 3: The products of a PCR reaction using the dehydrogenase primers of SEQ ID NOs 7 and 8 in the presence of cDNA.

Sample 4: The products of a PCR reaction using the dehydrogenase primers of SEQ ID NOs 7 and 8 in the absence of added cDNA.

Sample 5: The products of a PCR reaction using the pp15 primers of SEQ ID NOs 9
20 and 10 in the presence of cDNA.

Sample 6: The products of a PCR reaction using the pp15 primers of SEQ ID NOs 9 and 10 in the absence of added cDNA.

Sample 7: The products of a PCR reaction using the EIF4 primers of SEQ ID NOs 11 and 12 in the presence of added cDNA.

25 Sample 8: The products of a PCR reaction using the EIF4 primers of SEQ ID NOs 11 and 12 in the absence of added cDNA.

A band of the size expected for the PCR product was observed only in samples 1, 3, 5 and 7, thus indicating the presence of the corresponding sequence in the cDNA population.

30 PCR reactions were also carried out with the antisense oligonucleotides of the globin and dehydrogenase primers (SEQ ID NOs 6 and 8) and an oligonucleotide whose sequence corresponds to that of the derivatized oligonucleotide. The presence of PCR products of the

expected size in the samples equivalent to above samples 1 and 3 indicated that the derivatized oligonucleotide had been linked to mRNA.

The above examples summarize the chemical procedure for enriching mRNAs for those having intact 5' ends as illustrated in Figure 1. Further detail regarding the chemical approaches for obtaining such mRNAs are disclosed in International Application No. WO96/34981, published November 7, 1996, which is incorporated herein by reference. Strategies based on the above chemical modifications to the 5' cap structure may be utilized to generate cDNAs selected to include the 5' ends of the mRNAs from which they derived.

10 In one version of such procedures, the 5' ends of the mRNAs are modified as described above. Thereafter, a reverse transcription reaction is conducted to extend a primer complementary to the 5' end of the mRNA. Single stranded RNAs are eliminated to obtain a population of cDNA/mRNA heteroduplexes in which the mRNA includes an intact 5' end. The resulting heteroduplexes may be captured on a solid phase coated with a molecule

15 capable of interacting with the molecule used to derivatize the 5' end of the mRNA. Thereafter, the strands of the heteroduplexes are separated to recover single stranded first cDNA strands which include the 5' end of the mRNA. Second strand cDNA synthesis may then proceed using conventional techniques. For example, the procedures disclosed in WO 96/34981 or in Carninci. *et al.*, *Genomics* 37:327-336, 1996, the disclosures of which are

20 incorporated herein by reference, may be employed to select cDNAs which include the sequence derived from the 5' end of the coding sequence of the mRNA.

Following ligation of the oligonucleotide tag to the 5' cap of the mRNA, a reverse transcription reaction is conducted to extend a primer complementary to the mRNA to the 5' end of the mRNA. Following elimination of the RNA component of the

25 resulting heteroduplex using standard techniques, second strand cDNA synthesis is conducted with a primer complementary to the oligonucleotide tag.

2. Enzymatic Methods for Obtaining mRNAs having Intact 5' Ends

Other techniques for selecting cDNAs extending to the 5' end of the mRNA from

30 which they are derived are fully enzymatic. Some versions of these techniques are disclosed in Dumas Milne Edwards J.B. (Doctoral Thesis of Paris VI University, Le clonage des ADNc

complets: difficultes et perspectives nouvelles. Apports pour l'etude de la regulation de l'expression de la tryptophane hydroxylase de rat, 20 Dec. 1993), EP0 625572 and Kato *et al.*, *Gene* 150:243-250, 1994, the disclosures of which are incorporated herein by reference.

Briefly, in such approaches, isolated mRNA is treated with alkaline phosphatase to
5 remove the phosphate groups present on the 5' ends of uncapped incomplete mRNAs. Following this procedure, the cap present on full length mRNAs is enzymatically removed with a decapping enzyme such as T4 polynucleotide kinase or tobacco acid pyrophosphatase. An oligonucleotide, which may be either a DNA oligonucleotide or a DNA-RNA hybrid oligonucleotide having RNA at its 3' end, is then ligated to the phosphate present at the 5'
10 end of the decapped mRNA using T4 RNA ligase. The oligonucleotide may include a restriction site to facilitate cloning of the cDNAs following their synthesis. Example 12 below describes one enzymatic method based on the doctoral thesis of Dumas.

EXAMPLE 12

15 Enzymatic Approach for Obtaining 5' ESTs

Twenty micrograms of PolyA+ RNA were dephosphorylated using Calf Intestinal Phosphatase (Biolabs). After a phenol chloroform extraction, the cap structure of mRNA was hydrolysed using the Tobacco Acid Pyrophosphatase (purified as described by Shinshi *et al.*, *Biochemistry* 15: 2185-2190, 1976) and a hemi 5'DNA/RNA-3' oligonucleotide having
20 an unphosphorylated 5' end, a stretch of adenosine ribophosphate at the 3' end, and an EcoRI site near the 5' end was ligated to the 5'P ends of mRNA using the T4 RNA ligase (Biolabs). Oligonucleotides suitable for use in this procedure are preferably 30 to 50 bases in length. Oligonucleotides having an unphosphorylated 5' end may be synthesized by adding a fluorochrome at the 5' end. The inclusion of a stretch of adenosine ribophosphates at the 3'
25 end of the oligonucleotide increases ligation efficiency. It will be appreciated that the oligonucleotide may contain cloning sites other than EcoRI.

Following ligation of the oligonucleotide to the phosphate present at the 5' end of the decapped mRNA, first and second strand cDNA synthesis is carried out using
30 conventional methods or those specified in EP0 625,572 and Kato *et al. supra*, and Dumas Milne Edwards, *supra*, the disclosures of which are incorporated herein by

reference. The resulting cDNA may then be ligated into vectors such as those disclosed in Kato *et al.*, *supra* or other nucleic acid vectors known to those skilled in the art using techniques such as those described in Sambrook *et al.*, Molecular Cloning: A Laboratory Manual 2d Ed., Cold Spring Harbor Laboratory Press, 1989, the disclosure of which is
5 incorporated herein by reference.

II. Obtention and Characterization of the 5' ESTs of the Present Invention

The 5' ESTs of the present invention were obtained using the aforementioned chemical and enzymatic approaches for enriching mRNAs for those having intact 5' ends
10 as described below.

1. Obtention of 5' ESTS Using mRNAs with Intact 5' Ends

First, mRNAs were prepared as described in Example 13 below.

15

EXAMPLE 13

Preparation of mRNA With Intact 5' Ends

Total human RNAs or polyA⁺ RNAs derived from 29 different tissues were respectively purchased from LABIMO and CLONTECH and used to generate 44 cDNA libraries as follows. The purchased RNA had been isolated from cells or tissues using acid
20 guanidium thiocyanate-phenol-chloroform extraction (Chomczynski and Sacchi, *Analytical Biochemistry* 162:156-159, 1987). PolyA⁺ RNA was isolated from total RNA (LABIMO) by two passes of oligo dT chromatography, as described by Aviv and Leder, *Proc. Natl. Acad. Sci. USA* 69:1408-1412, 1972 in order to eliminate ribosomal RNA.

The quality and the integrity of the polyA⁺ RNAs were checked. Northern blots
25 hybridized with a globin probe were used to confirm that the mRNAs were not degraded. Contamination of the polyA⁺ mRNAs by ribosomal sequences was checked using Northern blots and a probe derived from the sequence of the 28S rRNA. Preparations of mRNAs with less than 5% of rRNAs were used in library construction. To avoid constructing libraries with RNAs contaminated by exogenous sequences (prokaryotic or fungal), the presence of
30 bacterial 16S ribosomal sequences or of two highly expressed fungal mRNAs was examined using PCR.

Following preparation of the mRNAs, the above described chemical and/or the enzymatic procedures for enriching mRNAs for those having intact 5' ends were employed to obtain 5' ESTs from various tissues. In both approaches, an oligonucleotide tag was attached to the 5' ends of the mRNAs. The oligonucleotide tag had an EcoRI site therein to facilitate later cloning procedures. To facilitate the processing of single stranded and double stranded cDNA obtained in the construction of the libraries, the same nucleotidic sequence was used to design the ligated oligonucleotide in both chemical and enzymatic approaches. Nevertheless, in the chemical procedure, the tag used was an oligodeoxyribonucleotide which was linked to the cap of the mRNA whereas in the enzymatic ligation, the tag was a chimeric hemi 5'DNA/RNA3' oligonucleotide which was ligated to the 5' end of decapped mRNA as described in example 12.

Following attachment of the oligonucleotide tag to the mRNA by either the chemical or enzymatic methods, the integrity of the mRNA was examined by performing a Northern blot with 200 to 500 ng of mRNA using a probe complementary to the oligonucleotide tag before performing the first strand synthesis as described in example 14.

EXAMPLE 14.

cDNA Synthesis Using mRNA Templates Having Intact 5' Ends

For the mRNAs joined to oligonucleotide tags using both the chemical and enzymatic methods, first strand cDNA synthesis was performed using the Superscript II (Gibco BRL) or the Rnase H Minus M-MLV (Promega) reverse transcriptase with random nonamers as primers. In order to protect internal EcoRI sites in the cDNA from digestion at later steps in the procedure, methylated dCTP was used for first strand synthesis. After removal of RNA by an alkaline hydrolysis, the first strand of cDNA was precipitated using isopropanol in order to eliminate residual primers.

For both the chemical and the enzymatic methods, the second strand of the cDNA was synthesized with a Klenow fragment using a primer corresponding to the 5' end of the ligated oligonucleotide described in Example 12. Preferably, the primer is 20-25 bases in length. Methylated dCTP was also used for second strand synthesis in order to protect internal EcoRI sites in the cDNA from digestion during the cloning process.

Following cDNA synthesis, the cDNAs were cloned into pBlueScript as described in Example 15 below.

EXAMPLE 15

5 Cloning of cDNAs derived from mRNA with intact 5' ends into BlueScript

Following second strand synthesis, the ends of the cDNA were blunted with T4 DNA polymerase (Biolabs) and the cDNA was digested with EcoRI. Since methylated dCTP was used during cDNA synthesis, the EcoRI site present in the tag was the only hemi-methylated site, hence the only site susceptible to EcoRI digestion. The cDNA was then size fractionated
10 using exclusion chromatography (AcA, Biosepra) and fractions corresponding to cDNAs of more than 150 bp were pooled and ethanol precipitated. The cDNA was directionally cloned into the SmaI and EcoRI ends of the phagemid pBlueScript vector (Stratagene). The ligation mixture was electroporated into bacteria and propagated under appropriate antibiotic selection.

15 Clones containing the oligonucleotide tag attached were then selected as described in Example 16 below.

EXAMPLE 16

20 Selection of Clones Having the Oligonucleotide Tag Attached Thereto

The plasmid DNAs containing 5' EST libraries made as described above were purified (Qiagen). A positive selection of the tagged clones was performed as follows. Briefly, in this selection procedure, the plasmid DNA was converted to single stranded DNA using gene II endonuclease of the phage F1 in combination with an exonuclease (Chang *et al.*, *Gene* 127:95-8, 1993) such as exonuclease III or T7 gene 6 exonuclease. The resulting
25 single stranded DNA was then purified using paramagnetic beads as described by Fry *et al.*, *Biotechniques*, 13: 124-131, 1992. In this procedure, the single stranded DNA was hybridized with a biotinylated oligonucleotide having a sequence corresponding to the 3' end of the oligonucleotide described in Example 13. Preferably, the primer has a length of 20-25 bases. Clones including a sequence complementary to the biotinylated oligonucleotide were
30 captured by incubation with streptavidin coated magnetic beads followed by magnetic selection. After capture of the positive clones, the plasmid DNA was released from the

magnetic beads and converted into double stranded DNA using a DNA polymerase such as the ThermoSequenase obtained from Amersham Pharmacia Biotech. Alternatively, protocols such as the one described in the Gene Trapper kit available from Gibco BRL may be used. The double stranded DNA was then electroporated into bacteria. The percentage of positive clones having the 5' tag oligonucleotide was estimated to typically rank between 90 and 98% using dot blot analysis.

Following electroporation, the libraries were ordered in 384-microtiter plates (MTP). A copy of the MTP was stored for future needs. Then the libraries were transferred into 96 MTP and sequenced as described below.

EXAMPLE 17

Sequencing of Inserts in Selected Clones

Plasmid inserts were first amplified by PCR on PE 9600 thermocyclers (Perkin-Elmer, Applied Biosystems Division, Foster City, CA), using standard SETA-A and SETA-B primers (Genset SA), AmpliTaqGold (Perkin-Elmer), dNTPs (Boehringer), buffer and cycling conditions as recommended by the Perkin-Elmer Corporation.

PCR products were then sequenced using automatic ABI Prism 377 sequencers (Perkin Elmer). Sequencing reactions were performed using PE 9600 thermocyclers with standard dye-primer chemistry and ThermoSequenase (Amersham Pharmacia Biotech). The primers used were either T7 or 21M13 (available from Genset SA) as appropriate. The primers were labeled with the JOE, FAM, ROX and TAMRA dyes. The dNTPs and ddNTPs used in the sequencing reactions were purchased from Boehringer. Sequencing buffer, reagent concentrations and cycling conditions were as recommended by Amersham.

Following the sequencing reaction, the samples were precipitated with ethanol, resuspended in formamide loading buffer, and loaded on a standard 4% acrylamide gel. Electrophoresis was performed for 2.5 hours at 3000V on an ABI 377 sequencer, and the sequence data were collected and analyzed using the ABI Prism DNA Sequencing Analysis Software, version 2.1.2.

2. Computer analysis of the Obtained 5' ESTs: Construction of NetGene and SignalTag databases

The sequence data from the 44 cDNA libraries made as described above were transferred to a proprietary database, where quality control and validation steps were performed. A proprietary base-caller, working using a Unix system, automatically flagged suspect peaks, taking into account the shape of the peaks, the inter-peak resolution, and the noise level. The proprietary base-caller also performed an automatic trimming. Any stretch of 25 or fewer bases having more than 4 suspect peaks was considered unreliable and was discarded. Sequences corresponding to cloning vector or ligation oligonucleotides were automatically removed from the EST sequences. However, the resulting EST sequences may contain 1 to 5 bases belonging to the above mentioned sequences at their 5' end. If needed, these can easily be removed on a case to case basis.

Following sequencing as described above, the sequences of the 5' ESTs were entered in NetGene™, a proprietary database called for storage and manipulation as described below. It will be appreciated by those skilled in the art that the data could be stored and manipulated on any medium which can be read and accessed by a computer. Computer readable media include magnetically, optically, or electronically readable media. For example, the computer readable media may be a hard disc, a floppy disc, a magnetic tape, CD-ROM, RAM, or ROM as well as other types of other media known to those skilled in the art.

In addition, the sequence data may be stored and manipulated in a variety of data processor programs in a diversity of formats. For instance, the sequence data may be stored as text in a word processing file, such as Microsoft WORD or WORDPERFECT or as an ASCII file in a variety of database programs familiar to those of skill in the art, such as DB2, SYBASE, or ORACLE.

The computer readable media on which the sequence information is stored may be in a personal computer, a network, a server or other computer systems known to those skilled in the art. The computer or other system preferably includes the storage media described above, and a processor for accessing and manipulating the sequence data. Once the sequence data has been stored, it may be manipulated and searched to locate those stored sequences which contain a desired nucleic acid sequence or which encode a protein having a particular functional domain. For example, the stored sequence information may be compared to other

known sequences to identify homologies, motifs implicated in biological function, or structural motifs.

Programs which may be used to search or compare the stored sequences include the MacPattern (EMBL), BLAST, and BLAST2 program series (NCBI), basic local alignment
5 search tool programs for nucleotide (BLASTN) and peptide (BLASTX) comparisons (Altschul *et al*, *J. Mol. Biol.* 215: 403, 1990) and FASTA (Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* 85: 2444, 1988). The BLAST programs then extend the alignments on the basis of defined match and mismatch criteria.

10 Motifs which may be detected using the above programs and those described in Example 28 include sequences encoding leucine zippers, helix-turn-helix motifs, glycosylation sites, ubiquitination sites, alpha helices, and beta sheets, signal sequences encoding signal peptides which direct the secretion of the encoded proteins, sequences implicated in transcription regulation such as homeoboxes, acidic stretches, enzymatic active sites, substrate binding sites, and enzymatic cleavage sites.

15 Before searching the cDNAs in the NetGene™ database for sequence motifs of interest, cDNAs derived from mRNAs which were not of interest were identified and eliminated from further consideration as described in Example 18 below.

EXAMPLE 18

20 Elimination of Undesired Sequences from Further Consideration

5' ESTs in the NetGene™ database which were derived from undesired sequences such as transfer RNAs, ribosomal RNAs, mitochondrial RNAs, prokaryotic RNAs, fungal RNAs, Alu sequences, L1 sequences, or repeat sequences were identified using the FASTA and BLASTN programs with the parameters listed in Table I.

25 To eliminate 5' ESTs encoding tRNAs from further consideration, the 5' EST sequences were compared to the sequences of 1190 known tRNAs obtained from EMBL release 38, of which 100 were human. The comparison was performed using FASTA on both strands of the 5' ESTs. Sequences having more than 80% homology over more than 60 nucleotides were identified as tRNA. Of the 144,341 sequences screened, 26 were identified
30 as tRNAs and eliminated from further consideration.

To eliminate 5' ESTs encoding rRNAs from further consideration, the 5' EST sequences were compared to the sequences of 2497 known rRNAs obtained from EMBL release 38, of which 73 were human. The comparison was performed using BLASTN on both strands of the 5' ESTs with the parameter S=108. Sequences having more than 80% homology over stretches longer than 40 nucleotides were identified as rRNAs. Of the 144,341 sequences screened, 3,312 were identified as rRNAs and eliminated from further consideration.

To eliminate 5' ESTs encoding mtRNAs from further consideration, the 5' EST sequences were compared to the sequences of the two known mitochondrial genomes for which the entire genomic sequences are available and all sequences transcribed from these mitochondrial genomes including tRNAs, rRNAs, and mRNAs for a total of 38 sequences. The comparison was performed using BLASTN on both strands of the 5' ESTs with the parameter S=108. Sequences having more than 80% homology over stretches longer than 40 nucleotides were identified as mtRNAs. Of the 144,341 sequences screened, 6,110 were identified as mtRNAs and eliminated from further consideration.

Sequences which might have resulted from exogenous contaminants were eliminated from further consideration by comparing the 5' EST sequences to release 46 of the EMBL bacterial and fungal divisions using BLASTN with the parameter S=144. All sequences having more than 90% homology over at least 40 nucleotides were identified as exogenous contaminants. Of the 42 cDNA libraries examined, the average percentages of prokaryotic and fungal sequences contained therein were 0.2% and 0.5% respectively. Among these sequences, only one could be identified as a sequence specific to fungi. The others were either fungal or prokaryotic sequences having homologies with vertebrate sequences or including repeat sequences which had not been masked during the electronic comparison.

In addition, the 5' ESTs were compared to 6093 Alu sequences and 1115 L1 sequences to mask 5' ESTs containing such repeat sequences. 5' ESTs including THE and MER repeats, SSTR sequences or satellite, micro-satellite, or telomeric repeats were also eliminated from further consideration. On average, 11.5% of the sequences in the libraries contained repeat sequences. Of this 11.5%, 7% contained Alu repeats, 3.3% contained L1 repeats and the remaining 1.2% were derived from the other screened types of repetitive sequences. These percentages are consistent with those found in cDNA libraries prepared by

other groups. For example, the cDNA libraries of Adams *et al.* contained between 0% and 7.4% Alu repeats depending on the source of the RNA which was used to prepare the cDNA library (Adams *et al.*, *Nature* 377:174, 1996).

- 5 The sequences of those 5' ESTs remaining after the elimination of undesirable sequences were compared with the sequences of known human mRNAs to determine the accuracy of the sequencing procedures described above.

EXAMPLE 19

10 Measurement of Sequencing Accuracy by Comparison to Known Sequences

To further determine the accuracy of the sequencing procedure described above, the sequences of 5' ESTs derived from known sequences were identified and compared to the original known sequences. First, a FASTA analysis with overhangs shorter than 5 bp on both ends was conducted on the 5' ESTs to identify those matching an entry in the public human mRNA database. The 6655 5' ESTs which matched a known human mRNA were then
15 realigned with their cognate mRNA and dynamic programming was used to include substitutions, insertions, and deletions in the list of "errors" which would be recognized. Errors occurring in the last 10 bases of the 5' EST sequences were ignored to avoid the inclusion of spurious cloning sites in the analysis of sequencing accuracy.

- 20 This analysis revealed that the sequences incorporated in the NetGene™ database had an accuracy of more than 99.5%.

To determine the efficiency with which the above selection procedures select cDNAs which include the 5' ends of their corresponding mRNAs, the following analysis was
25 performed.

EXAMPLE 20

Determination of Efficiency of 5' EST Selection

- To determine the efficiency at which the above selection procedures isolated 5' ESTs
30 which included sequences close to the 5' end of the mRNAs from which they derived, the sequences of the ends of the 5' ESTs derived from the elongation factor 1 subunit α and

ferritin heavy chain genes were compared to the known cDNA sequences of these genes. Since the transcription start sites of both genes are well characterized, they may be used to determine the percentage of derived 5' ESTs which included the authentic transcription start sites.

5 For both genes, more than 95% of the obtained 5' ESTs actually included sequences close to or upstream of the 5' end of the corresponding mRNAs.

To extend the analysis of the reliability of the procedures for isolating 5' ESTs from ESTs in the NetGene™ database, a similar analysis was conducted using a database composed of human mRNA sequences extracted from GenBank database release 97 for
10 comparison. The 5' ends of more than 85% of 5' ESTs derived from mRNAs included in the GeneBank database were located close to the 5' ends of the known sequence. As some of the mRNA sequences available in the GenBank database are deduced from genomic sequences, a 5' end matching with these sequences will be counted as an internal match. Thus, the method used here underestimates the yield of ESTs including the authentic 5' ends
15 of their corresponding mRNAs.

The EST libraries made above included multiple 5' ESTs derived from the same mRNA. The sequences of such 5' ESTs were compared to one another and the longest 5' ESTs for each mRNA were identified. Overlapping cDNAs were assembled into continuous
20 sequences (contigs). The resulting continuous sequences were then compared to public databases to gauge their similarity to known sequences, as described in Example 21 below.

EXAMPLE 21

Clustering of the 5' ESTs and Calculation of Novelty Indices for cDNA Libraries

25 For each sequenced EST library, the sequences were clustered by the 5' end. Each sequence in the library was compared to the others with BLASTN2 (direct strand, parameters S=107). ESTs with High Scoring Segment Pairs (HSPs) at least 25 bp long, having 95% identical bases and beginning closer than 10 bp from each EST 5' end were grouped. The longest sequence found in the cluster was used as representative of the group. A global
30 clustering between libraries was then performed leading to the definition of super-contigs.

To assess the yield of new sequences within the EST libraries, a novelty rate (NR) was defined as: $NR = 100 \times (\text{Number of new unique sequences found in the library} / \text{Total number of sequences from the library})$. Typically, novelty rating ranged between 10% and 41% depending on the tissue from which the EST library was obtained. For most of the
5 libraries, the random sequencing of 5' EST libraries was pursued until the novelty rate reached 20%.

Following characterization as described above, the collection of 5' ESTs in NetGene™ was screened to identify those 5' ESTs bearing potential signal sequences as
10 described in Example 22 below.

EXAMPLE 22

Identification of Potential Signal Sequences in 5' ESTs

The 5' ESTs in the NetGene™ database were screened to identify those having an
15 uninterrupted open reading frame (ORF) longer than 45 nucleotides beginning with an ATG codon and extending to the end of the EST. Approximately half of the cDNA sequences in NetGene™ contained such an ORF. The ORFs of these 5' ESTs were then searched to identify potential signal motifs using slight modifications of the procedures disclosed in Von Heijne, *Nucleic Acids Res.* 14:4683-4690, 1986, the disclosure of which is incorporated
20 herein by reference. Those 5' EST sequences encoding a stretch of at least 15 amino acid long with a score of at least 3.5 in the Von Heijne signal peptide identification matrix were considered to possess a signal sequence. Those 5' ESTs which matched a known human mRNA or EST sequence and had a 5' end more than 20 nucleotides downstream of the known 5' end were excluded from further analysis. The remaining cDNAs having signal
25 sequences therein were included in a database called SignalTag™.

To confirm the accuracy of the above method for identifying signal sequences, the analysis of Example 23 was performed.

EXAMPLE 23**Confirmation of Accuracy of Identification of Potential Signal Sequences in 5' ESTs**

The accuracy of the above procedure for identifying signal sequences encoding signal peptides was evaluated by applying the method to the 43 amino acids located at the N terminus of all human SwissProt proteins. The computed Von Heijne score for each protein was compared with the known characterization of the protein as being a secreted protein or a non-secreted protein. In this manner, the number of non-secreted proteins having a score higher than 3.5 (false positives) and the number of secreted proteins having a score lower than 3.5 (false negatives) could be calculated.

Using the results of the above analysis, the probability that a peptide encoded by the 5' region of the mRNA is in fact a genuine signal peptide based on its Von Heijne's score was calculated based on either the assumption that 10% of human proteins are secreted or the assumption that 20% of human proteins are secreted. The results of this analysis are shown in Figure 2 and table IV.

Using the above method of identification of secretory proteins, 5' ESTs of the following polypeptides known to be secreted were obtained: human glucagon, gamma interferon induced monokine precursor, secreted cyclophilin-like protein, human pleiotropin, and human biotinidase precursor. Thus, the above method successfully identified those 5' ESTs which encode a signal peptide.

To confirm that the signal peptide encoded by the 5' ESTs actually functions as a signal peptide, the signal sequences from the 5' ESTs may be cloned into a vector designed for the identification of signal peptides. Such vectors are designed to confer the ability to grow in selective medium only to host cells containing a vector with an operably linked signal sequence. For example, to confirm that a 5' EST encodes a genuine signal peptide, the signal sequence of the 5' EST may be inserted upstream and in frame with a non-secreted form of the yeast invertase gene in signal peptide selection vectors such as those described in U.S. Patent No. 5,536,637, the disclosure of which is incorporated herein by reference. Growth of host cells containing signal sequence selection vectors with the correctly inserted 5' EST signal sequence confirms that the 5' EST encodes a genuine signal peptide.

Alternatively, the presence of a signal peptide may be confirmed by cloning the extended cDNAs obtained using the ESTs into expression vectors such as pXT1 (as described below in example 30), or by constructing promoter-signal sequence-reporter gene vectors which encode fusion proteins between the signal peptide and an assayable reporter protein. After introduction of these vectors into a suitable host cell, such as COS cells or NIH 3T3 cells, the growth medium may be harvested and analyzed for the presence of the secreted protein. The medium from these cells is compared to the medium from control cells containing vectors lacking the signal sequence or extended cDNA insert to identify vectors which encode a functional signal peptide or an authentic secreted protein.

Those 5' ESTs which encoded a signal peptide, as determined by the method of Example 22 above, were further grouped into four categories based on their homology to known sequences as described in Example 24 below.

EXAMPLE 24

Categorization of 5' ESTs Encoding a Signal Peptide

Those 5' ESTs having a sequence not matching any known vertebrate sequence nor any publicly available EST sequence were designated "new." Of the sequences in the SignalTag™ database, 947 of the 5' ESTs having a Von Heijne's score of at least 3.5 fell into this category.

Those 5' ESTs having a sequence not matching any vertebrate sequence but matching a publicly known EST were designated "EST-ext", provided that the known EST sequence was extended by at least 40 nucleotides in the 5' direction. Of the sequences in the SignalTag™ database, 150 of the 5' ESTs having a Von Heijne's score of at least 3.5 fell into this category.

Those ESTs not matching any vertebrate sequence but matching a publicly known EST without extending the known EST by at least 40 nucleotides in the 5' direction were designated "EST." Of the sequences in the SignalTag™ database, 599 of the 5' ESTs having a Von Heijne's score of at least 3.5 fell into this category.

Those 5' ESTs matching a human mRNA sequence but extending the known sequence by at least 40 nucleotides in the 5' direction were designated "VERT-ext." Of the sequences in the SignalTag™ database, 23 of the 5' ESTs having a Von Heijne's score of at

least 3.5 fell into this category. Included in this category was a 5' EST which extended the known sequence of the human translocase mRNA by more than 200 bases in the 5' direction. A 5' EST which extended the sequence of a human tumor suppressor gene in the 5' direction was also identified.

5 Table V shows the distribution of 5' ESTs in each category and the number of 5' ESTs in each category having a given minimum von Heijne's score.

3. Evaluation of Spatial and Temporal Expression of mRNAs Corresponding to the 5'ESTs or Extended cDNAs

10

Each of the 5' ESTs was also categorized based on the tissue from which its corresponding mRNA was obtained, as described below in Example 25.

EXAMPLE 25

15

Categorization of Expression Patterns

Table VI shows the distribution of 5' ESTs in each of the above defined category with respect to the tissue from which the 5'ESTs of the corresponding mRNA were obtained.

20 Table II provides the sequence identification numbers of 5' EST sequences derived from endoderm, the categories in which these sequences fall, and the von Heijne's score of the signal peptides which they encode. The 5' EST sequences and the amino acid sequences they encode are provided in the appended sequence listings. Table III provides the sequence ID numbers of the 5' ESTs and the sequences of the signal peptides which they encode. The sequences of the 5' ESTs and the polypeptides they encode are provided in the sequence listing appended hereto.

25 The sequences of DNA SEQ ID NOs: 38-184 can readily be screened for any errors therein and any sequence ambiguities can be resolved by resequencing a fragment containing such errors or ambiguities on both strands. Such fragments may be obtained from the plasmids stored in the inventors' laboratory or can be isolated using the techniques described herein. Resolution of any such ambiguities or errors may be facilitated by using primers
30 which hybridize to sequences located close to the ambiguous or erroneous sequences. For example, the primers may hybridize to sequences within 50-75 bases of the ambiguity or

error. Upon resolution of an error or ambiguity, the corresponding corrections can be made in the protein sequences encoded by the DNA containing the error or ambiguity.

In addition to categorizing the 5' ESTs with respect to their tissue of origin, the spatial and temporal expression patterns of the mRNAs corresponding to the 5' ESTs, as well as their expression levels, may be determined as described in Example 26 below. Characterization of the spatial and temporal expression patterns and expression levels of these mRNAs is useful for constructing expression vectors capable of producing a desired level of gene product in a desired spatial or temporal manner, as will be discussed in more detail below.

Furthermore, 5' ESTs whose corresponding mRNAs are associated with disease states may also be identified. For example, a particular disease may result from the lack of expression, over expression, or under expression of an mRNA corresponding to a 5' EST. By comparing mRNA expression patterns and quantities in samples taken from healthy individuals with those from individuals suffering from a particular disease, 5' ESTs responsible for the disease may be identified.

It will be appreciated that the results of the above characterization procedures for 5' ESTs also apply to extended cDNAs (obtainable as described below) which contain sequences adjacent to the 5' ESTs. It will also be appreciated that if desired, characterization may be delayed until extended cDNAs have been obtained rather than characterizing the ESTs themselves.

EXAMPLE 26

Evaluation of Expression Levels and Patterns of mRNAs

Corresponding to 5' ESTs or Extended cDNAs

Expression levels and patterns of mRNAs corresponding to 5' ESTs or extended cDNAs (obtainable as described below in example 27) may be analyzed by solution hybridization with long probes as described in International Patent Application No. WO 97/05277, the entire contents of which are hereby incorporated by reference. Briefly, a 5' EST, extended cDNA, or fragment thereof corresponding to the gene encoding the mRNA to be characterized is inserted at a cloning site immediately downstream of a bacteriophage (T3,

T7 or SP6) RNA polymerase promoter to produce antisense RNA. Preferably, the 5' EST or extended cDNA has 100 or more nucleotides. The plasmid is linearized and transcribed in the presence of ribonucleotides comprising modified ribonucleotides (*i.e.* biotin-UTP and DIG-UTP). An excess of this doubly labeled RNA is hybridized in solution with mRNA isolated from cells or tissues of interest. The hybridizations are performed under standard stringent conditions (40-50°C for 16 hours in an 80% formamide, 0.4 M NaCl buffer, pH 7-8). The unhybridized probe is removed by digestion with ribonucleases specific for single-stranded RNA (*i.e.* RNases CL3, T1, Phy M, U2 or A). The presence of the biotin-UTP modification enables capture of the hybrid on a microtitration plate coated with streptavidin. The presence of the DIG modification enables the hybrid to be detected and quantified by ELISA using an anti-DIG antibody coupled to alkaline phosphatase.

The 5' ESTs, extended cDNAs, or fragments thereof may also be tagged with nucleotide sequences for the serial analysis of gene expression (SAGE) as disclosed in UK Patent Application No. 2 305 241 A, the entire contents of which are incorporated by reference. In this method, cDNAs are prepared from a cell, tissue, organism or other source of nucleic acid for which gene expression patterns must be determined. The resulting cDNAs are separated into two pools. The cDNAs in each pool are cleaved with a first restriction endonuclease, called an anchoring enzyme, having a recognition site which is likely to be present at least once in most cDNAs. The fragments which contain the 5' or 3' most region of the cleaved cDNA are isolated by binding to a capture medium such as streptavidin coated beads. A first oligonucleotide linker having a first sequence for hybridization of an amplification primer and an internal restriction site for a so-called tagging endonuclease is ligated to the digested cDNAs in the first pool. Digestion with the second endonuclease produces short tag fragments from the cDNAs.

A second oligonucleotide having a second sequence for hybridization of an amplification primer and an internal restriction site is ligated to the digested cDNAs in the second pool. The cDNA fragments in the second pool are also digested with the tagging endonuclease to generate short tag fragments derived from the cDNAs in the second pool. The tags resulting from digestion of the first and second pools with the anchoring enzyme and the tagging endonuclease are ligated to one another to produce so-called ditags. In some embodiments, the ditags are concatamerized to produce ligation products containing from 2

to 200 ditags. The tag sequences are then determined and compared to the sequences of the 5' ESTs or extended cDNAs to determine which 5' ESTs or extended cDNAs are expressed in the cell, tissue, organism, or other source of nucleic acids from which the tags were derived. In this way, the expression pattern of the 5' ESTs or extended cDNAs in the cell,
5 tissue, organism, or other source of nucleic acids is obtained.

Quantitative analysis of gene expression may also be performed using arrays. As used herein, the term array means a one dimensional, two dimensional, or multidimensional arrangement of full length cDNAs (*i.e.* extended cDNAs which include the coding sequence for the signal peptide, the coding sequence for the mature protein, and a stop codon),
10 extended cDNAs, 5' ESTs or fragments thereof of sufficient length to permit specific detection of gene expression. Preferably, the fragments are at least 15 nucleotides in length. More preferably, the fragments are at least 100 nucleotide long. More preferably, the fragments are more than 100 nucleotides in length. In some embodiments, the fragments may be more than 500 nucleotide long.

For example, quantitative analysis of gene expression may be performed with full
15 length cDNAs as defined below, extended cDNAs, 5' ESTs, or fragments thereof in a complementary DNA microarray as described by Schena *et al.* (*Science* 270:467-470, 1995; *Proc. Natl. Acad. Sci. U.S.A.* 93:10614-10619, 1996). Full length cDNAs, extended cDNAs, 5' ESTs or fragments thereof are amplified by PCR and arrayed from 96-well microtiter
20 plates onto silylated microscope slides using high-speed robotics. Printed arrays are incubated in a humid chamber to allow rehydration of the array elements and rinsed, once in 0.2% SDS for 1 min, twice in water for 1 min and once for 5 min in sodium borohydride solution. The arrays are submerged in water for 2 min at 95°C, transferred into 0.2% SDS for 1 min, rinsed twice with water, air dried and stored in the dark at 25°C.

Cell or tissue mRNA is isolated or commercially obtained and probes are prepared by
25 a single round of reverse transcription. Probes are hybridized to 1 cm² microarrays under a 14 x 14 mm glass coverslip for 6-12 hours at 60°C. Arrays are washed for 5 min at 25°C in low stringency wash buffer (1 x SSC/0.2% SDS), then for 10 min at room temperature in high stringency wash buffer (0.1 x SSC/0.2% SDS). Arrays are scanned in 0.1 x SSC using a
30 fluorescence laser scanning device fitted with a custom filter set. Accurate differential

expression measurements are obtained by taking the average of the ratios of two independent hybridizations.

Quantitative analysis of the expression of genes may also be performed with full length cDNAs, extended cDNAs, 5' ESTs, or fragments thereof in complementary DNA arrays as described by Pietu *et al.* (*Genome Research* 6:492-503, 1996). The full length
5 cDNAs, extended cDNAs, 5' ESTs or fragments thereof are PCR amplified and spotted on membranes. Then, mRNAs originating from various tissues or cells are labeled with radioactive nucleotides. After hybridization and washing in controlled conditions, the hybridized mRNAs are detected by phospho-imaging or autoradiography. Duplicate
10 experiments are performed and a quantitative analysis of differentially expressed mRNAs is then performed.

Alternatively, expression analysis of the 5' ESTs or extended cDNAs can be done through high density nucleotide arrays as described by Lockhart *et al.* (*Nature Biotechnology* 14: 1675-1680, 1996) and Sosnowsky *et al.* (*Proc. Natl. Acad. Sci.* 94:1119-1123, 1997).
15 Oligonucleotides of 15-50 nucleotides corresponding to sequences of the 5' ESTs or extended cDNAs are synthesized directly on the chip (Lockhart *et al.*, *supra*) or synthesized and then addressed to the chip (Sosnowsky *et al.*, *supra*). Preferably, the oligonucleotides are about 20 nucleotides in length.

cDNA probes labeled with an appropriate compound, such as biotin, digoxigenin
20 or fluorescent dye, are synthesized from the appropriate mRNA population and then randomly fragmented to an average size of 50 to 100 nucleotides. The said probes are then hybridized to the chip. After washing as described in Lockhart *et al.*, *supra* and application of different electric fields (Sonowsky *et al.*, *supra.*), the dyes or labeling compounds are detected and quantified. Duplicate hybridizations are performed.
25 Comparative analysis of the intensity of the signal originating from cDNA probes on the same target oligonucleotide in different cDNA samples indicates a differential expression of the mRNA corresponding to the 5' EST or extended cDNA from which the oligonucleotide sequence has been designed.

III. Use of 5' ESTs to Clone Extended cDNAs and to Clone the Corresponding Genomic DNAs

Once 5' ESTs which include the 5' end of the corresponding mRNAs have been selected using the procedures described above, they can be utilized to isolate extended cDNAs which contain sequences adjacent to the 5' ESTs. The extended cDNAs may include the entire coding sequence of the protein encoded by the corresponding mRNA, including the authentic translation start site, the signal sequence, and the sequence encoding the mature protein remaining after cleavage of the signal peptide. Such extended cDNAs are referred to herein as "full length cDNAs." Alternatively, the extended cDNAs may include only the sequence encoding the mature protein remaining after cleavage of the signal peptide, or only the sequence encoding the signal peptide.

Example 27 below describes a general method for obtaining extended cDNAs using 5' ESTs. Example 28 below provides experimental results, using the method explained in example 27, describing several extended cDNAs including the entire coding sequence and authentic 5' end of the corresponding mRNA for several secreted proteins.

The methods of Examples 27, 28, and 29 can also be used to obtain extended cDNAs which encode less than the entire coding sequence of the secreted proteins encoded by the genes corresponding to the 5' ESTs. In some embodiments, the extended cDNAs isolated using these methods encode at least 10 amino acids of one of the proteins encoded by the sequences of SEQ ID NOs: 38-184. In further embodiments, the extended cDNAs encode at least 20 amino acids of the proteins encoded by the sequences of SEQ ID NOs: 38-184. In further embodiments, the extended cDNAs encode at least 30 amino acids of the sequences of SEQ ID NOs: 38-184. In a preferred embodiment, the extended cDNAs encode a full length protein sequence, which includes the protein coding sequences of SEQ ID NOs: 38-184.

EXAMPLE 27

General Method for Using 5' ESTs to Clone and Sequence cDNAs which Include the Entire Coding Region and the Authentic 5' End of the Corresponding mRNA

The following general method has been used to quickly and efficiently isolate extended cDNAs having the authentic 5' ends of their corresponding mRNAs as well as

the full protein coding sequence and including sequence adjacent to the sequences of the 5' ESTs used to obtain them. This method may be applied to obtain extended cDNAs for any 5' EST in the NetGene™ database, including those 5' ESTs encoding polypeptides belonging to secreted proteins. The method is summarized in figure 3.

5

1. Obtention of Extended cDNAs

a) First strand synthesis

The method takes advantage of the known 5' sequence of the mRNA. A reverse transcription reaction is conducted on purified mRNA with a poly 14dT primer containing a 49 nucleotide sequence at its 5' end allowing the addition of a known sequence at the end of the cDNA which corresponds to the 3' end of the mRNA. For example, the primer may have the following sequence: 5'-ATC GTT GAG ACT CGT ACC AGC AGA GTC ACG AGA GAG ACT ACA CGG TAC TGG TTT TTT TTT TTT TTVN -3' (SEQ ID NO:14). Those skilled in the art will appreciate that other sequences may also be added to the poly dT sequence and used to prime the first strand synthesis. Using this primer and a reverse transcriptase such as the Superscript II (Gibco BRL) or Rnase H Minus M-MLV (Promega) enzyme, a reverse transcript anchored at the 3' polyA site of the RNAs is generated.

10

15

20

After removal of the mRNA hybridized to the first cDNA strand by alkaline hydrolysis, the products of the alkaline hydrolysis and the residual poly dT primer are eliminated with an exclusion column such as an Aca34 (Biosepra) matrix as explained in Example 11.

b) Second strand synthesis

25

A pair of nested primers on each end is designed based on the known 5' sequence from the 5' EST and the known 3' end added by the poly dT primer used in the first strand synthesis. Softwares used to design primers are either based on GC content and melting temperatures of oligonucleotides, such as OSP (Illier and Green, *PCR Meth. Appl.* 1:124-128, 1991), or based on the octamer frequency disparity method (Griffais *et al.*, *Nucleic Acids Res.* 19: 3887-3891, 1991) such as PC-Rare (<http://bioinformatics.weizmann.ac.il/software/PC-Rare/doc/manuel.html>).

Preferably, the nested primers at the 5' end are separated from one another by four to nine bases. The 5' primer sequences may be selected to have melting temperatures and specificities suitable for use in PCR.

Preferably, the nested primers at the 3' end are separated from one another by four to nine bases. For example, the nested 3' primers may have the following sequences: (5'- CCA GCA GAG TCA CGA GAG AGA CTA CAC GG -3'(SEQ ID NO:15), and 5'- CAC GAG AGA GAC TAC ACG GTA CTG G -3' (SEQ ID NO:16). These primers were selected because they have melting temperatures and specificities compatible with their use in PCR. However, those skilled in the art will appreciate that other sequences may also be used as primers.

The first PCR run of 25 cycles is performed using the Advantage Tth Polymerase Mix (Clontech) and the outer primer from each of the nested pairs. A second 20 cycle PCR using the same enzyme and the inner primer from each of the nested pairs is then performed on 1/2500 of the first PCR product. Thereafter, the primers and nucleotides are removed.

2. Sequencing of Full Length Extended cDNAs or Fragments Thereof

Due to the lack of position constraints on the design of 5' nested primers compatible for PCR use using the OSP software, amplicons of two types are obtained. Preferably, the second 5' primer is located upstream of the translation initiation codon thus yielding a nested PCR product containing the whole coding sequence. Such a full length extended cDNA undergoes a direct cloning procedure as described in section a. However, in some cases, the second 5' primer is located downstream of the translation initiation codon, thereby yielding a PCR product containing only part of the ORF. Such incomplete PCR products are submitted to a modified procedure described in section b.

a) Nested PCR products containing complete ORFs

When the resulting nested PCR product contains the complete coding sequence, as predicted from the 5'EST sequence, it is cloned in an appropriate vector such as pED6dpc2, as described in section 3.

b) Nested PCR products containing incomplete ORFs

When the amplicon does not contain the complete coding sequence, intermediate steps are necessary to obtain both the complete coding sequence and a PCR product containing the full coding sequence. The complete coding sequence can be assembled from several partial sequences determined directly from different PCR products as described in the following section.

Once the full coding sequence has been completely determined, new primers compatible for PCR use are designed to obtain amplicons containing the whole coding region. However, in such cases, 3' primers compatible for PCR use are located inside the 3' UTR of the corresponding mRNA, thus yielding amplicons which lack part of this region, *i.e.* the polyA tract and sometimes the polyadenylation signal, as illustrated in figure 3. Such full length extended cDNAs are then cloned into an appropriate vector as described in section 3.

c) Sequencing extended cDNAs

Sequencing of extended cDNAs is performed using a Die Terminator approach with the AmpliTaq DNA polymerase FS kit available from Perkin Elmer.

In order to sequence PCR fragments, primer walking is performed using software such as OSP to choose primers and automated computer software such as ASMG (Sutton *et al.*, *Genome Science Technol.* 1: 9-19, 1995) to construct contigs of walking sequences including the initial 5' tag using minimum overlaps of 32 nucleotides. Preferably, primer walking is performed until the sequences of full length cDNAs are obtained.

Completion of the sequencing of a given extended cDNA fragment is assessed as follows. Since sequences located after a polyA tract are difficult to determine precisely in the case of uncloned products, sequencing and primer walking processes for PCR products are interrupted when a polyA tract is identified in extended cDNAs obtained as described in case b. The sequence length is compared to the size of the nested PCR product obtained as described above. Due to the limited accuracy of the determination of the PCR product size by gel electrophoresis, a sequence is considered complete if the size of the obtained sequence is at least 70 % the size of the first nested PCR product. If the length of the sequence determined from the computer analysis is not at least 70% of the length of the nested PCR product, these PCR products are cloned and the sequence of the insertion is determined. When Northern blot data are available, the size of the mRNA detected for a given PCR

product is used to finally assess that the sequence is complete. Sequences which do not fulfill the above criteria are discarded and will undergo a new isolation procedure.

Sequence data of all extended cDNAs are then transferred to a proprietary database, where quality controls and validation steps are carried out as described in
5 example 15.

3. Cloning of Full Length Extended cDNAs

The PCR product containing the full coding sequence is then cloned in an appropriate vector. For example, the extended cDNAs can be cloned into the expression vector
10 pED6dpc2 (DiscoverEase, Genetics Institute, Cambridge, MA) as follows. pED6dpc2 vector DNA is prepared with blunt ends by performing an EcoRI digestion followed by a fill in reaction. The blunt ended vector is dephosphorylated. After removal of PCR primers and ethanol precipitation, the PCR product containing the full coding sequence or the extended
15 cDNA obtained as described above is phosphorylated with a kinase subsequently removed by phenol-Sevag extraction and precipitation. The double stranded extended cDNA is then ligated to the vector and the resulting expression plasmid introduced into appropriate host cells.

Since the PCR products obtained as described above are blunt ended molecules that can be cloned in either direction, the orientation of several clones for each PCR product is
20 determined. Then, 4 to 10 clones are ordered in microtiter plates and subjected to a PCR reaction using a first primer located in the vector close to the cloning site and a second primer located in the portion of the extended cDNA corresponding to the 3' end of the mRNA. This second primer may be the antisense primer used in anchored PCR in the case of direct cloning (case a) or the antisense primer located inside the 3'UTR in the case of indirect cloning (case
25 b). Clones in which the start codon of the extended cDNA is operably linked to the promoter in the vector so as to permit expression of the protein encoded by the extended cDNA are conserved and sequenced. In addition to the ends of cDNA inserts, approximately 50 bp of vector DNA on each side of the cDNA insert are also sequenced.

The cloned PCR products are then entirely sequenced according to the
30 aforementioned procedure. In this case, contiguation of long fragments is then performed on walking sequences that have already contiguated for uncloned PCR products during

primer walking. Sequencing of cloned amplicons is complete when the resulting contigs include the whole coding region as well as overlapping sequences with vector DNA on both ends.

5 4. Computer analysis of Full Length Extended cDNA

Sequences of all full length extended cDNAs are then submitted to further analysis as described below. Before searching the extended full length cDNAs for sequences of interest, extended cDNAs which are not of interest (vector RNAs, transfer RNAs, ribosomal RNAs, mitochondrial RNAs, prokaryotic RNAs and fungal RNAs) are discarded using methods essentially similar to those described for 5'ESTs in Example 18.

10 *a) Identification of structural features*

Structural features, e.g. polyA tail and polyadenylation signal, of the sequences of full length extended cDNAs are subsequently determined as follows.

15 A polyA tail is defined as a homopolymeric stretch of at least 11 A with at most one alternative base within it. The polyA tail search is restricted to the last 100 nt of the sequence and limited to stretches of 11 consecutive A's because sequencing reactions are often not readable after such a polyA stretch. Stretches having more than 90% homology over 8 nucleotides are identified as polyA tails using BLAST2N.

20 To search for a polyadenylation signal, the polyA tail is clipped from the full-length sequence. The 50 bp preceding the polyA tail are first searched for the canonic polyadenylation AAUAAA signal and, if the canonic signal is not detected, for the alternative AUUAAA signal (Sheets *et al.*, *Nuc. Acids Res.* 18: 5799-5805, 1990). If neither of these consensus polyadenylation signals is found, the canonic motif is searched again allowing one mismatch to account for possible sequencing errors. More than 85 %
25 of identified polyadenylation signals of either type actually ends 10 to 30 bp from the polyA tail. Alternative AUUAAA signals represents approximately 15 % of the total number of identified polyadenylation signals.

30 *b) Identification of functional features*

Functional features, e.g. ORFs and signal sequences, of the sequences of full length extended cDNAs were subsequently determined as follows.

The 3 upper strand frames of extended cDNAs are searched for ORFs defined as the maximum length fragments beginning with a translation initiation codon and ending with a stop codon. ORFs encoding at least 20 amino acids are preferred.

Each found ORF is then scanned for the presence of a signal peptide in the first
5 50 amino-acids or, where appropriate, within shorter regions down to 20 amino acids or less in the ORF, using the matrix method of von Heijne (*Nuc. Acids Res.* 14: 4683-4690, 1986), the disclosure of which is incorporated herein by reference as described in Example 22.

c) Homology to either nucleotidic or proteic sequences

10 Categorization of full-length sequences may be achieved using procedures essentially similar to those described for 5'ESTs in Example 24.

Extended cDNAs prepared as described above may be subsequently engineered to obtain nucleic acids which include desired portions of the extended cDNA using conventional
15 techniques such as subcloning, PCR, or *in vitro* oligonucleotide synthesis. For example, nucleic acids which include only the full coding sequences (*i.e.* the sequences encoding the signal peptide and the mature protein remaining after the signal peptide is cleaved off) may be obtained using techniques known to those skilled in the art. Alternatively, conventional techniques may be applied to obtain nucleic acids which contain only the coding sequences
20 for the mature protein remaining after the signal peptide is cleaved off or nucleic acids which contain only the coding sequences for the signal peptides.

Similarly, nucleic acids containing any other desired portion of the coding sequences for the secreted protein may be obtained. For example, the nucleic acid may contain at least 10 consecutive bases of an extended cDNA such as one of the extended cDNAs described
25 below. In another embodiment, the nucleic acid may contain at least 15 consecutive bases of an extended cDNA such as one of the extended cDNAs described below. Alternatively, the nucleic acid may contain at least 20 consecutive bases of an extended cDNA such as one of the extended cDNAs described below. In another embodiment, the nucleic acid may contain at least 25 consecutive bases of an extended cDNA such as one of the extended cDNAs
30 described below. In yet another embodiment, the nucleic acid may contain at least 40

consecutive bases of an extended cDNA such as one of the extended cDNAs described below.

Once an extended cDNA has been obtained, it can be sequenced to determine the amino acid sequence it encodes. Once the encoded amino acid sequence has been
5 determined, one can create and identify any of the many conceivable cDNAs that will encode that protein by simply using the degeneracy of the genetic code. For example, allelic variants or other homologous nucleic acids can be identified as described below. Alternatively, nucleic acids encoding the desired amino acid sequence can be synthesized *in vitro*.

In a preferred embodiment, the coding sequence may be selected using the known
10 codon or codon pair preferences for the host organism in which the cDNA is to be expressed.

The extended cDNAs derived from the 5' ESTS of the present invention were obtained as described in Example 28 below.

EXAMPLE 28

15 Characterization of cloned extended cDNAs obtained using 5' ESTs

The procedure described in Example 27 above was used to obtain the extended cDNAs derived from the 5' ESTs of the present invention in a variety of tissues. The following list provides a few examples of thus obtained extended cDNAs.

Using this approach, the full length cDNA of SEQ ID NO:17 (internal identification
20 number 48-19-3-G1-FL1) was obtained. This cDNA falls into the "EST-ext" category described above and encodes the signal peptide MKKVLLLITAILAVAVG (SEQ ID NO: 18) having a von Heijne score of 8.2.

The full length cDNA of SEQ ID NO:19 (internal identification number 58-34-2-E7-
25 FL2) was also obtained using this procedure. This cDNA falls into the "EST-ext" category described above and encodes the signal peptide MWWFQQGLSFLPSALVIWTS (SEQ ID NO:20) having a von Heijne score of 5.5.

Another full length cDNA obtained using the procedure described above has the sequence of SEQ ID NO:21 (internal identification number 51-27-1-E8-FL1). This cDNA, falls into the "EST-ext" category described above and encodes the signal peptide
30 MVLTTLP SANSANSPVNMPTTGPNLSYASSALSPCLT (SEQ ID NO:22) having a von Heijne score of 5.9.

The above procedure was also used to obtain a full length cDNA having the sequence of SEQ ID NO:23 (internal identification number 76-4-1-G5-FL1). This cDNA falls into the "EST-ext" category described above and encodes the signal peptide ILSTVTALTFAXA (SEQ ID NO:24) having a von Heijne score of 5.5.

5 The full length cDNA of SEQ ID NO:25 (internal identification number 51-3-3-B10-FL3) was also obtained using this procedure. This cDNA falls into the "new" category described above and encodes a signal peptide LVLTLCTLPLAVA (SEQ ID NO:26) having a von Heijne score of 10.1.

10 The full length cDNA of SEQ ID NO:27 (internal identification number 58-35-2-F10-FL2) was also obtained using this procedure. This cDNA falls into the "new" category described above and encodes a signal peptide LWLLFFLVTAIHA (SEQ ID NO:28) having a von Heijne score of 10.7.

15 Bacterial clones containing plasmids containing the full length cDNAs described above are presently stored in the inventor's laboratories under the internal identification numbers provided above. The inserts may be recovered from the stored materials by growing an aliquot of the appropriate bacterial clone in the appropriate medium. The plasmid DNA can then be isolated using plasmid isolation procedures familiar to those skilled in the art such as alkaline lysis minipreps or large scale alkaline lysis plasmid isolation procedures. If desired the plasmid DNA may be further enriched by centrifugation on a cesium chloride gradient, size exclusion chromatography, or anion exchange chromatography. The plasmid DNA obtained using these procedures may then be manipulated using standard cloning techniques familiar to those skilled in the art. Alternatively, a PCR can be done with primers designed at both ends of the cDNA insertion. The PCR product which corresponds to the cDNA can then be manipulated using standard cloning techniques familiar to those skilled in the art.

25 The polypeptides encoded by the extended cDNAs may be screened for the presence of known structural or functional motifs or for the presence of signatures, small amino acid sequences which are well conserved amongst the members of a protein family. The conserved regions have been used to derive consensus patterns or matrices included in the PROSITE data bank, in particular in the file prosite.dat (Release 13.0 of November 1995, located at <http://expasy.hcuge.ch/sprot/prosite.html>. Prosite_convert and prosite_scan

30

programs (http://ulrec3.unil.ch/ftpserveur/prosite_scan) may be used to find signatures on the extended cDNAs.

For each pattern obtained with the `prosite_convert` program from the `prosite.dat` file, the accuracy of the detection on a new protein sequence may be assessed by evaluating the frequency of irrelevant hits on the population of human secreted proteins included in the data bank SWISSPROT. The ratio between the number of hits on shuffled proteins (with a window size of 20 amino acids) and the number of hits on native (unshuffled) proteins may be used as an index. Every pattern for which the ratio is greater than 20% (one hit on shuffled proteins for 5 hits on native proteins) may be skipped during the search with `prosite_scan`. The program used to shuffle protein sequences (`db_shuffled`) and the program used to determine the statistics for each pattern in the protein data banks (`prosite_statistics`) are available on the ftp site http://ulrec3.unil.ch/ftpserveur/prosite_scan.

In addition to PCR based methods for obtaining extended cDNAs, traditional hybridization based methods may also be employed. These methods may also be used to obtain the genomic DNAs which encode the mRNAs from which the 5' ESTs were derived, mRNAs corresponding to the extended cDNAs, or nucleic acids which are homologous to extended cDNAs or 5' ESTs. Example 29 below provides examples of such methods.

20

EXAMPLE 29

Methods for Obtaining cDNAs which include the Entire Coding Region and the Authentic 5'End of the Corresponding mRNA

A full length cDNA library can be made using the strategies described in Examples 13, 14, 15, and 16 above by replacing the random nonamer used in Example 14 with an oligo-dT primer. For instance, the oligonucleotide of SEQ ID NO:14 may be used.

Alternatively, a cDNA library or genomic DNA library may be obtained from a commercial source or made using techniques familiar to those skilled in the art. Such cDNA or genomic DNA libraries may be used to isolate extended cDNAs obtained from 5' EST or nucleic acids homologous to extended cDNAs or 5' EST as follows. The cDNA library or genomic DNA library is hybridized to a detectable probe comprising at least 10 consecutive nucleotides from the 5' EST or extended cDNA using conventional techniques. Preferably,

the probe comprises at least 12, 15, or 17 consecutive nucleotides from the 5' EST or extended cDNA. More preferably, the probe comprises at least 20 to 30 consecutive nucleotides from the 5' EST or extended cDNA. In some embodiments, the probe comprises more than 30 nucleotides from the 5' EST or extended cDNA.

5 Techniques for identifying cDNA clones in a cDNA library which hybridize to a given probe sequence are disclosed in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual 2d Ed.*, Cold Spring Harbor Laboratory Press, 1989, the disclosure of which is incorporated herein by reference. The same techniques may be used to isolate genomic DNAs.

10 Briefly, cDNA or genomic DNA clones which hybridize to the detectable probe are identified and isolated for further manipulation as follows. A probe comprising at least 10 consecutive nucleotides from the 5' EST or extended cDNA is labeled with a detectable label such as a radioisotope or a fluorescent molecule. Preferably, the probe comprises at least 12, 15, or 17 consecutive nucleotides from the 5' EST or extended cDNA. More preferably, the probe comprises 20 to 30 consecutive nucleotides from the 5' EST or extended cDNA. In
15 some embodiments, the probe comprises more than 30 nucleotides from the 5' EST or extended cDNA.

Techniques for labeling the probe are well known and include phosphorylation with polynucleotide kinase, nick translation, *in vitro* transcription, and non radioactive techniques.

20 The cDNAs or genomic DNAs in the library are transferred to a nitrocellulose or nylon filter and denatured. After blocking of non specific sites, the filter is incubated with the labeled probe for an amount of time sufficient to allow binding of the probe to cDNAs or genomic DNAs containing a sequence capable of hybridizing thereto.

25 By varying the stringency of the hybridization conditions used to identify extended cDNAs or genomic DNAs which hybridize to the detectable probe, extended cDNAs having different levels of homology to the probe can be identified and isolated as described below.

1. Identification of Extended cDNA or Genomic cDNA Sequences Having a High Degree of Homology to the Labeled Probe

To identify extended cDNAs or genomic DNAs having a high degree of homology to the probe sequence, the melting temperature of the probe may be calculated using the following formulas:

For probes between 14 and 70 nucleotides in length the melting temperature (T_m) is calculated using the formula: $T_m = 81.5 + 16.6(\log [Na+]) + 0.41(\text{fraction G+C}) - (600/N)$ where N is the length of the probe.

If the hybridization is carried out in a solution containing formamide, the melting temperature may be calculated using the equation $T_m = 81.5 + 16.6(\log [Na+]) + 0.41(\text{fraction G+C}) - (0.63\% \text{ formamide}) - (600/N)$ where N is the length of the probe.

Prehybridization may be carried out in 6X SSC, 5X Denhardt's reagent, 0.5% SDS, 100 μ g denatured fragmented salmon sperm DNA or 6X SSC, 5X Denhardt's reagent, 0.5% SDS, 100 μ g denatured fragmented salmon sperm DNA, 50% formamide. The formulas for SSC and Denhardt's solutions are listed in Sambrook *et al.*, *supra*.

Hybridization is conducted by adding the detectable probe to the prehybridization solutions listed above. Where the probe comprises double stranded DNA, it is denatured before addition to the hybridization solution. The filter is contacted with the hybridization solution for a sufficient period of time to allow the probe to hybridize to extended cDNAs or genomic DNAs containing sequences complementary thereto or homologous thereto. For probes over 200 nucleotides in length, the hybridization may be carried out at 15-25°C below the T_m . For shorter probes, such as oligonucleotide probes, the hybridization may be conducted at 15-25°C below the T_m . Preferably, for hybridizations in 6X SSC, the hybridization is conducted at approximately 68°C. Preferably, for hybridizations in 50% formamide containing solutions, the hybridization is conducted at approximately 42°C.

All of the foregoing hybridizations would be considered to be under "stringent" conditions.

Following hybridization, the filter is washed in 2X SSC, 0.1% SDS at room temperature for 15 minutes. The filter is then washed with 0.1X SSC, 0.5% SDS at room temperature for 30 minutes to 1 hour. Thereafter, the solution is washed at the hybridization temperature in 0.1X SSC, 0.5% SDS. A final wash is conducted in 0.1X SSC at room temperature.

Extended cDNAs, nucleic acids homologous to extended cDNAs or 5' ESTs, or genomic DNAs which have hybridized to the probe are identified by autoradiography or other conventional techniques.

5 2. Obtention of Extended cDNA or Genomic cDNA Sequences Having Lower Degrees of Homology to the Labeled Probe

10 The above procedure may be modified to identify extended cDNAs, nucleic acids homologous to extended cDNAs, or genomic DNAs having decreasing levels of homology to the probe sequence. For example, to obtain extended cDNAs, nucleic acids homologous to extended cDNAs, or genomic DNAs of decreasing homology to the detectable probe, less stringent conditions may be used. For example, the hybridization temperature may be decreased in increments of 5°C from 68°C to 42°C in a hybridization buffer having a sodium concentration of approximately 1M. Following hybridization, the filter may be washed with 2X SSC, 0.5% SDS at the temperature of hybridization. These conditions are considered to be "moderate" conditions above 50°C and "low" conditions below 50°C.

15 Alternatively, the hybridization may be carried out in buffers, such as 6X SSC, containing formamide at a temperature of 42°C. In this case, the concentration of formamide in the hybridization buffer may be reduced in 5% increments from 50% to 0% to identify clones having decreasing levels of homology to the probe. Following hybridization, the filter may be washed with 6X SSC, 0.5% SDS at 50°C. These conditions are considered to be "moderate" conditions above 25% formamide and "low" conditions below 25% formamide.

20 Extended cDNAs, nucleic acids homologous to extended cDNAs, or genomic DNAs which have hybridized to the probe are identified by autoradiography.

25 3. Determination of the Degree of Homology Between the Obtained Extended cDNAs and the Labeled Probe

30 If it is desired to obtain nucleic acids homologous to extended cDNAs, such as allelic variants thereof or nucleic acids encoding proteins related to the proteins encoded by the extended cDNAs, the level of homology between the hybridized nucleic acid and the extended cDNA or 5' EST used as the probe may be further determined using BLAST2N; parameters may be adapted depending on the sequence length and degree of homology

studied. To determine the level of homology between the hybridized nucleic acid and the extended cDNA or 5'EST from which the probe was derived, the nucleotide sequences of the hybridized nucleic acid and the extended cDNA or 5'EST from which the probe was derived are compared. For example, using the above methods, nucleic acids having at least 95%
5 nucleic acid homology to the extended cDNA or 5'EST from which the probe was derived may be obtained and identified. Similarly, by using progressively less stringent hybridization conditions one can obtain and identify nucleic acids having at least 90%, at least 85%, at least 80% or at least 75% homology to the extended cDNA or 5'EST from which the probe was derived.

10 To determine whether a clone encodes a protein having a given amount of homology to the protein encoded by the extended cDNA or 5' EST, the amino acid sequence encoded by the extended cDNA or 5' EST is compared to the amino acid sequence encoded by the hybridizing nucleic acid. Homology is determined to exist when an amino acid sequence in the extended cDNA or 5' EST is closely related to an amino acid sequence in the hybridizing
15 nucleic acid. A sequence is closely related when it is identical to that of the extended cDNA or 5' EST or when it contains one or more amino acid substitutions therein in which amino acids having similar characteristics have been substituted for one another. Using the above methods and algorithms such as FASTA with parameters depending on the sequence length and degree of homology studied, one can obtain nucleic acids encoding proteins having at
20 least 95%, at least 90%, at least 85%, at least 80% or at least 75% homology to the proteins encoded by the extended cDNA or 5'EST from which the probe was derived.

In addition to the above described methods, other protocols are available to obtain extended cDNAs using 5' ESTs as outlined in the following paragraphs.

25 Extended cDNAs may be prepared by obtaining mRNA from the tissue, cell, or organism of interest using mRNA preparation procedures utilizing polyA selection procedures or other techniques known to those skilled in the art. A first primer capable of hybridizing to the polyA tail of the mRNA is hybridized to the mRNA and a reverse transcription reaction is performed to generate a first cDNA strand.

30 The first cDNA strand is hybridized to a second primer containing at least 10 consecutive nucleotides of the sequences of SEQ ID NOs 38-184. Preferably, the primer

comprises at least 12, 15, or 17 consecutive nucleotides from the sequences of SEQ ID NOs 38-184. More preferably, the primer comprises 20 to 30 consecutive nucleotides from the sequences of SEQ ID NOs 38-184. In some embodiments, the primer comprises more than 30 nucleotides from the sequences of SEQ ID NOs 38-184. If it is desired to obtain extended
5 cDNAs containing the full protein coding sequence, including the authentic translation initiation site, the second primer used contains sequences located upstream of the translation initiation site. The second primer is extended to generate a second cDNA strand complementary to the first cDNA strand. Alternatively, RT-PCR may be performed as described above using primers from both ends of the cDNA to be obtained.

10 Extended cDNAs containing 5' fragments of the mRNA may be prepared by hybridizing an mRNA comprising the sequence of the 5'EST for which an extended cDNA is desired with a primer comprising at least 10 consecutive nucleotides of the sequences complementary to the 5'EST and reverse transcribing the hybridized primer to make a first
15 cDNA strand from the mRNAs. Preferably, the primer comprises at least 12, 15, or 17 consecutive nucleotides from the 5'EST. More preferably, the primer comprises 20 to 30 consecutive nucleotides from the 5'EST.

Thereafter, a second cDNA strand complementary to the first cDNA strand is synthesized. The second cDNA strand may be made by hybridizing a primer complementary to sequences in the first cDNA strand to the first cDNA strand and extending the primer to
20 generate the second cDNA strand.

The double stranded extended cDNAs made using the methods described above are isolated and cloned. The extended cDNAs may be cloned into vectors such as plasmids or viral vectors capable of replicating in an appropriate host cell. For example, the host cell may be a bacterial, mammalian, avian, or insect cell.

25 Techniques for isolating mRNA, reverse transcribing a primer hybridized to mRNA to generate a first cDNA strand, extending a primer to make a second cDNA strand complementary to the first cDNA strand, isolating the double stranded cDNA and cloning the double stranded cDNA are well known to those skilled in the art and are described in *Current Protocols in Molecular Biology*, John Wiley and Sons, Inc. 1997 and Sambrook *et al.*,
30 *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989, the entire disclosures of which are incorporated herein by reference.

Alternatively, procedures such as the one described in Example 29 may be used for obtaining full length cDNAs or extended cDNAs. In this approach, full length or extended cDNAs are prepared from mRNA and cloned into double stranded phagemids as follows. The cDNA library in the double stranded phagemids is then rendered single stranded by
5 treatment with an endonuclease, such as the Gene II product of the phage F1, and an exonuclease (Chang *et al.*, *Gene* 127:95-8, 1993). A biotinylated oligonucleotide comprising the sequence of a 5' EST, or a fragment containing at least 10 nucleotides thereof, is hybridized to the single stranded phagemids. Preferably, the fragment comprises at least 12, 15, or 17 consecutive nucleotides from the 5' EST. More preferably, the fragment comprises
10 20-30 consecutive nucleotides from the 5' EST. In some procedures, the fragment may comprise more than 30 consecutive nucleotides from the 5' EST.

Hybrids between the biotinylated oligonucleotide and phagemids having inserts containing the 5' EST sequence are isolated by incubating the hybrids with streptavidin coated paramagnetic beads and retrieving the beads with a magnet (Fry *et al.*, *Biotechniques*,
15 13: 124-131, 1992). Thereafter, the resulting phagemids containing the 5' EST sequence are released from the beads and converted into double stranded DNA using a primer specific for the 5' EST sequence. Alternatively, protocols such as the Gene Trapper kit (Gibco BRL) may be used. The resulting double stranded DNA is transformed into bacteria. Extended cDNAs containing the 5' EST sequence are identified by colony PCR or colony hybridization.

20

Using any of the above described methods in section III, a plurality of extended cDNAs containing full length protein coding sequences or sequences encoding only the mature protein remaining after the signal peptide is cleaved off may be provided as cDNA libraries for subsequent evaluation of the encoded proteins or use in diagnostic
25 assays as described below.

IV. Expression of Proteins Encoded by Extended cDNAs Isolated Using 5' ESTs

Extended cDNAs containing the full protein coding sequences of their corresponding mRNAs or portions thereof, such as cDNAs encoding the mature protein, may be used to
30 express the encoded secreted proteins or portions thereof as described in Example 30 below. If desired, the extended cDNAs may contain the sequences encoding the signal peptide to

facilitate secretion of the expressed protein. It will be appreciated that a plurality of extended cDNAs containing the full protein coding sequences or portions thereof may be simultaneously cloned into expression vectors to create an expression library for analysis of the encoded proteins as described below.

5

EXAMPLE 30

Expression of the Proteins Encoded by the Genes Corresponding to 5'ESTS or Portions Thereof

To express the proteins encoded by the genes corresponding to 5' ESTs (or portions thereof), full length cDNAs containing the entire protein coding region or extended cDNAs containing sequences adjacent to the 5' ESTs (or portions thereof) are obtained as described in Examples 27-29 and cloned into a suitable expression vector. If desired, the nucleic acids may contain the sequences encoding the signal peptide to facilitate secretion of the expressed protein. The nucleic acids inserted into the expression vectors may also contain sequences upstream of the sequences encoding the signal peptide, such as sequences which regulate expression levels or sequences which confer tissue specific expression.

The nucleic acid encoding the protein or polypeptide to be expressed is operably linked to a promoter in an expression vector using conventional cloning technology. The expression vector may be any of the mammalian, yeast, insect or bacterial expression systems known in the art. Commercially available vectors and expression systems are available from a variety of suppliers including Genetics Institute (Cambridge, MA), Stratagene (La Jolla, California), Promega (Madison, Wisconsin), and Invitrogen (San Diego, California). If desired, to enhance expression and facilitate proper protein folding, the codon context and codon pairing of the sequence may be optimized for the particular expression organism in which the expression vector is introduced, as explained by Hatfield, *et al.*, U.S. Patent No. 5,082,767, incorporated herein by this reference.

The cDNA cloned into the expression vector may encode the entire protein (*i.e.* the signal peptide and the mature protein), the mature protein (*i.e.* the protein created by cleaving the signal peptide off), only the signal peptide or any other portion thereof.

The following is provided as one exemplary method to express the proteins encoded by the extended cDNAs corresponding to the 5' ESTs or the nucleic acids described above.

First, the methionine initiation codon for the gene and the polyA signal of the gene are identified. If the nucleic acid encoding the polypeptide to be expressed lacks a methionine to serve as the initiation site, an initiating methionine can be introduced next to the first codon of the nucleic acid using conventional techniques. Similarly, if the extended cDNA lacks a polyA signal, this sequence can be added to the construct by, for example, splicing out the polyA signal from pSG5 (Stratagene) using BglII and SalI restriction endonuclease enzymes and incorporating it into the mammalian expression vector pXT1 (Stratagene). pXT1 contains the LTRs and a portion of the *gag* gene from Moloney Murine Leukemia Virus. The position of the LTRs in the construct allow efficient stable transfection. The vector includes the Herpes Simplex thymidine kinase promoter and the selectable neomycin gene. The extended cDNA or portion thereof encoding the polypeptide to be expressed is obtained by PCR from the bacterial vector using oligonucleotide primers complementary to the extended cDNA or portion thereof and containing restriction endonuclease sequences for PstI incorporated into the 5' primer and BglII at the 5' end of the corresponding cDNA 3' primer, taking care to ensure that the extended cDNA is positioned with the poly A signal. The purified fragment obtained from the resulting PCR reaction is digested with PstI, blunt ended with an exonuclease, digested with Bgl II, purified and ligated to pXT1 containing a poly A signal and prepared for this ligation (blunt/BglII).

The ligated product is transfected into mouse NIH 3T3 cells using Lipofectin (Life Technologies, Inc., Grand Island, New York) under conditions outlined in the product specification. Positive transfectants are selected after growing the transfected cells in 600 µg/ml G418 (Sigma, St. Louis, Missouri). Preferably the expressed protein is released into the culture medium, thereby facilitating purification.

Alternatively, the extended cDNAs may be cloned into pED6dpc2 as described above. The resulting pED6dpc2 constructs may be transfected into a suitable host cell, such as COS 1 cells. Methotrexate resistant cells are selected and expanded. Preferably, the protein expressed from the extended cDNA is released into the culture medium thereby facilitating purification.

Proteins in the culture medium are separated by gel electrophoresis. If desired, the proteins may be ammonium sulfate precipitated or separated based on size or charge prior to electrophoresis.

As a control, the expression vector lacking a cDNA insert is introduced into host cells or organisms and the proteins in the medium are harvested. The secreted proteins present in the medium are detected using techniques familiar to those skilled in the art such as Coomassie blue or silver staining or using antibodies against the protein encoded by the extended cDNA.

Antibodies capable of specifically recognizing the protein of interest may be generated using synthetic 15-mer peptides having a sequence encoded by the appropriate 5' EST, extended cDNA, or portion thereof. The synthetic peptides are injected into mice to generate antibody to the polypeptide encoded by the 5' EST, extended cDNA, or portion thereof.

Secreted proteins from the host cells or organisms containing an expression vector which contains the extended cDNA derived from a 5' EST or a portion thereof are compared to those from the control cells or organism. The presence of a band in the medium from the cells containing the expression vector which is absent in the medium from the control cells indicates that the extended cDNA encodes a secreted protein. Generally, the band corresponding to the protein encoded by the extended cDNA will have a mobility near that expected based on the number of amino acids in the open reading frame of the extended cDNA. However, the band may have a mobility different than that expected as a result of modifications such as glycosylation, ubiquitination, or enzymatic cleavage.

Alternatively, if the protein expressed from the above expression vectors does not contain sequences directing its secretion, the proteins expressed from host cells containing an expression vector with an insert encoding a secreted protein or portion thereof can be compared to the proteins expressed in control host cells containing the expression vector without an insert. The presence of a band in samples from cells containing the expression vector with an insert which is absent in samples from cells containing the expression vector without an insert indicates that the desired protein or portion thereof is being expressed. Generally, the band will have the mobility expected for the secreted protein or portion thereof. However, the band may have a mobility different than that expected as a result of modifications such as glycosylation, ubiquitination, or enzymatic cleavage.

The protein encoded by the extended cDNA may be purified using standard immunochromatography techniques. In such procedures, a solution containing the secreted protein, such as the culture medium or a cell extract, is applied to a column having antibodies against the secreted protein attached to the chromatography matrix. The secreted protein is
5 allowed to bind the immunochromatography column. Thereafter, the column is washed to remove non-specifically bound proteins. The specifically bound secreted protein is then released from the column and recovered using standard techniques.

If antibody production is not possible, the extended cDNA sequence or portion thereof may be incorporated into expression vectors designed for use in purification schemes
10 employing chimeric polypeptides. In such strategies, the coding sequence of the extended cDNA or portion thereof is inserted in frame with the gene encoding the other half of the chimera. The other half of the chimera may be β -globin or a nickel binding polypeptide. A chromatography matrix having antibody to β -globin or nickel attached thereto is then used to purify the chimeric protein. Protease cleavage sites may be engineered between the β -globin
15 gene or the nickel binding polypeptide and the extended cDNA or portion thereof. Thus, the two polypeptides of the chimera may be separated from one another by protease digestion.

One useful expression vector for generating β -globin chimerics is pSG5 (Stratagene), which encodes rabbit β -globin. Intron II of the rabbit β -globin gene facilitates splicing of the expressed transcript, and the polyadenylation signal incorporated into the construct increases
20 the level of expression. These techniques as described are well known to those skilled in the art of molecular biology. Standard methods are published in methods texts such as Davis *et al.*, (*Basic Methods in Molecular Biology*, Davis, Dibner, and Battey, ed., Elsevier Press, NY, 1986) and many of the methods are available from Stratagene, Life Technologies, Inc., or Promega. Polypeptide may additionally be produced from the construct using *in vitro*
25 translation systems such as the *In vitro* ExpressTM Translation Kit (Stratagene).

Following expression and purification of the secreted proteins encoded by the 5' ESTs, extended cDNAs, or fragments thereof, the purified proteins may be tested for the ability to bind to the surface of various cell types as described in Example 31 below. It will be
30 appreciated that a plurality of proteins expressed from these cDNAs may be included in a

panel of proteins to be simultaneously evaluated for the activities specifically described below, as well as other biological roles for which assays for determining activity are available.

EXAMPLE 31

5 Analysis of Secreted Proteins to Determine Whether they Bind to the Cell Surface

10 The proteins encoded by the 5' ESTs, extended cDNAs, or fragments thereof are cloned into expression vectors such as those described in Example 30. The proteins are purified by size, charge, immunochromatography or other techniques familiar to those skilled in the art. Following purification, the proteins are labeled using techniques known to those skilled in the art. The labeled proteins are incubated with cells or cell lines derived from a variety of organs or tissues to allow the proteins to bind to any receptor present on the cell surface. Following the incubation, the cells are washed to remove non-specifically bound protein. The labeled proteins are detected by autoradiography. Alternatively, unlabeled proteins may be incubated with the cells and detected with antibodies having a detectable label, such as a fluorescent molecule, attached thereto.

15 Specificity of cell surface binding may be analyzed by conducting a competition analysis in which various amounts of unlabeled protein are incubated along with the labeled protein. The amount of labeled protein bound to the cell surface decreases as the amount of competitive unlabeled protein increases. As a control, various amounts of an unlabeled protein unrelated to the labeled protein is included in some binding reactions. The amount of labeled protein bound to the cell surface does not decrease in binding reactions containing increasing amounts of unrelated unlabeled protein, indicating that the protein encoded by the cDNA binds specifically to the cell surface.

25 As discussed above, secreted proteins have been shown to have a number of important physiological effects and, consequently, represent a valuable therapeutic resource. The secreted proteins encoded by the extended cDNAs or portions thereof made according to Examples 27-29 may be evaluated to determine their physiological activities as described below.

EXAMPLE 32

Assaying the Proteins Expressed from Extended cDNAs or Portions Thereof for
Cytokine, Cell Proliferation or Cell Differentiation Activity

As discussed above, secreted proteins may act as cytokines or may affect cellular proliferation or differentiation. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein encoded by the extended cDNAs is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M^c (preB M^c), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7c and CMK. The proteins encoded by the above extended cDNAs or portions thereof may be evaluated for their ability to regulate T cell or thymocyte proliferation in assays such as those described above or in the following references, which are incorporated herein by reference: *Current Protocols in Immunology*, Ed. by Coligan *et al.*, Greene Publishing Associates and Wiley-Interscience; Takai *et al. J. Immunol.* 137:3494-3500, 1986.; Bertagnolli *et al., J. Immunol.* 145:1706-1712, 1990.; Bertagnolli *et al., Cell. Immunol.* 133:327-341, 1991; Bertagnolli, *et al., J. Immunol.* 149:3778-3783, 1992; Bowman *et al., J. Immunol.* 152:1756-1761, 1994.

In addition, numerous assays for cytokine production and/or the proliferation of spleen cells, lymph node cells and thymocytes are known. These include the techniques disclosed in *Current Protocols in Immunology*, *supra* 1:3.12.1-3.12.14; and Schreiber In *Current Protocols in Immunology*, *supra* 1 : 6.8.1-6.8.8.

The proteins encoded by the cDNAs may also be assayed for the ability to regulate the proliferation and differentiation of hematopoietic or lymphopoietic cells. Many assays for such activity are familiar to those skilled in the art, including the assays in the following references, which are incorporated herein by reference: Bottomly *et al.*, In *Current Protocols in Immunology*, *supra* 1 : 6.3.1-6.3.12.; deVries *et al., J. Exp. Med.* 173:1205-1211, 1991; Moreau *et al., Nature* 36:690-692, 1988; Greenberger *et al., Proc. Natl. Acad. Sci. U.S.A.* 80:2931-2938, 1983; Nordan, R., In *Current Protocols in Immunology*, *supra* 1 : 6.6.1-6.6.5; Smith *et al., Proc. Natl. Acad. Sci. U.S.A.* 83:1857-1861, 1986; Bennett *et al.*, in

Current Protocols in Immunology supra 1 : 6.15.1; Ciarletta *et al.*, In *Current Protocols in Immunology. supra* 1 : 6.13.1.

The proteins encoded by the cDNAs may also be assayed for their ability to regulate T-cell responses to antigens. Many assays for such activity are familiar to those skilled in the art, including the assays described in the following references, which are incorporated herein by reference: Chapter 3 (*In Vitro* Assays for Mouse Lymphocyte Function), Chapter 6 (Cytokines and Their Cellular Receptors) and Chapter 7, (Immunologic Studies in Humans) in *Current Protocols in Immunology supra*; Weinberger *et al.*, *Proc. Natl. Acad. Sci. USA* 77:6091-6095, 1980; Weinberger *et al.*, *Eur. J. Immunol.* 11:405-411, 1981; Takai *et al.*, *J. Immunol.* 137:3494-3500, 1986; Takai *et al.*, *J. Immunol.* 140:508-512, 1988.

Those proteins which exhibit cytokine, cell proliferation, or cell differentiation activity may then be formulated as pharmaceuticals and used to treat clinical conditions in which induction of cell proliferation or differentiation is beneficial. Alternatively, as described in more detail below, genes encoding these proteins or nucleic acids regulating the expression of these proteins may be introduced into appropriate host cells to increase or decrease the expression of the proteins as desired.

EXAMPLE 33

Assaying the Proteins Expressed from Extended cDNAs or Portions

Thereof for Activity as Immune System Regulators

The proteins encoded by the cDNAs may also be evaluated for their effects as immune regulators. For example, the proteins may be evaluated for their activity to influence thymocyte or splenocyte cytotoxicity. Numerous assays for such activity are familiar to those skilled in the art including the assays described in the following references, which are incorporated herein by reference: Chapter 3 (*In Vitro* Assays for Mouse Lymphocyte Function 3.1-3.19) and Chapter 7 (Immunologic studies in Humans) in *Current Protocols in Immunology*, Coligan *et al.*, Eds, Greene Publishing Associates and Wiley-Interscience; Herrmann *et al.*, *Proc. Natl. Acad. Sci. USA* 78:2488-2492, 1981; Herrmann *et al.*, *J. Immunol.* 128:1968-1974, 1982; Handa *et al.*, *J. Immunol.* 135:1564-1572, 1985; Takai *et al.*, *J. Immunol.* 137:3494-3500, 1986; Takai *et al.*, *J. Immunol.* 140:508-512, 1988;

Bowman *et al.*, *J. Virology* 61:1992-1998; Bertagnolli *et al.*, *Cell. Immunol.* 133:327-341, 1991; Brown *et al.*, *J. Immunol.* 153:3079-3092, 1994.

5 The proteins encoded by the cDNAs may also be evaluated for their effects on T-cell dependent immunoglobulin responses and isotype switching. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references, which are incorporated herein by reference: Maliszewski, *J. Immunol.* 144:3028-3033, 1990; Mond *et al.* in *Current Protocols in Immunology*, 1 : 3.8.1-3.8.16, *supra*.

10 The proteins encoded by the cDNAs may also be evaluated for their effect on immune effector cells, including their effect on Th1 cells and cytotoxic lymphocytes. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references, which are incorporated herein by reference: Chapter 3 (*In Vitro* Assays for Mouse Lymphocyte Function 3.1-3.19) and Chapter 7 (Immunologic Studies in Humans) in *Current Protocols in Immunology*, *supra*; Takai *et al.*, *J. Immunol.* 137:3494-3500, 1986; Takai *et al.*, *J. Immunol.* 140:508-512, 1988; Bertagnolli *et al.*, *J. Immunol.* 149:3778-3783, 15 1992.

The proteins encoded by the cDNAs may also be evaluated for their effect on dendritic cell mediated activation of naive T-cells. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references, which are incorporated herein by reference: Guery *et al.*, *J. Immunol.* 134:536-544, 1995; Inaba *et al.*, *J. Exp. Med.* 173:549-559, 1991; Macatonia *et al.*, *J. Immunol.* 154:5071-5079, 1995; Porgador *et al.*, *J. Exp. Med.* 182:255-260, 1995; Nair *et al.*, *J. Virol.* 67:4062-4069, 1993; Huang *et al.*, *Science* 264:961-965, 1994; Macatonia *et al.*, *J. Exp. Med.* 169:1255-1264, 1989; Bhardwaj *et al.*, *Journal of Clinical Investigation* 94:797-807, 1994; and Inaba *et al.*, *J. Exp. Med.* 172:631-640, 1990.

25 The proteins encoded by the cDNAs may also be evaluated for their influence on the lifetime of lymphocytes. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references, which are incorporated herein by reference: Darzynkiewicz *et al.*, *Cytometry* 13:795-808, 1992; Gorczyca *et al.*, *Leukemia* 7:659-670, 1993; Gorczyca *et al.*, *Cancer Res.* 53:1945-1951, 1993; Itoh *et al.*, *Cell* 66:233-243, 1991; Zacharchuk, *J. Immunol.* 145:4037-4045, 1990; Zamai *et al.*, *Cytometry* 14:891-30 897, 1993; Gorczyca *et al.*, *Int. J. Oncol.* 1:639-648, 1992.

The proteins encoded by the cDNAs may also be evaluated for their influence on early steps of T-cell commitment and development. Numerous assays for such activity are familiar to those skilled in the art, including without limitation the assays disclosed in the following references, which are incorporated herein by references: Antica *et al.*, *Blood* 84:111-117, 1994; Fine *et al.*, *Cell. Immunol.* 155:111-122, 1994; Galy *et al.*, *Blood* 85:2770-2778, 1995; Toki *et al.*, *Proc. Nat. Acad. Sci. USA* 88:7548-7551, 1991.

Those proteins which exhibit activity as immune system regulators activity may then be formulated as pharmaceuticals and used to treat clinical conditions in which regulation of immune activity is beneficial. For example, the protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as affecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases caused by viral, bacterial, fungal or other infection may be treatable using a protein encoded by extended cDNAs derived from the 5' ESTs of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, *Leishmania* spp., *Plasmodium* and various fungal infections such as candidiasis. Of course, in this regard, a protein encoded by extended cDNAs derived from the 5' ESTs of the present invention may also be useful where a boost to the immune system generally may be desirable, *i.e.*, in the treatment of cancer.

Alternatively, proteins encoded by extended cDNAs derived from the 5' ESTs of the present invention may be used in treatment of autoimmune disorders including, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein encoded by extended cDNAs derived from the 5' ESTs of the present invention may also be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein encoded by extended cDNAs derived from the 5' ESTs of the present invention.

Using the proteins of the invention it may also be possible to regulate immune responses either up or down.

Down regulation may involve inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of
5 activated T-cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active non-antigen-specific process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T
10 cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after the end of exposure to the tolerizing agent. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions, such as, for example, B7 costimulation), e.g.,
15 preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the
20 transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (e.g., B7-1, B7-3) or blocking antibody), prior to transplantation, can lead to the binding of the molecule to the natural
25 ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may
30 avoid the necessity of repeated administration of these blocking reagents. To achieve

sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.

The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans.

- 5 Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins *in vivo* as described in Lenschow *et al.*, *Science* **257**:789-792, 1992 and Turka *et al.*, *Proc. Natl. Acad. Sci USA*, **89**:11102-11105, 1992. In addition, murine models of GVHD (see Paul ed., *Fundamental*
10 *Immunology*, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function *in vivo* on the development of that disease.

- Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and
15 autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block costimulation of T cells by disrupting receptor/ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which potentially involved in the disease process.
20 Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythematosus in MRL/pr/pr mice or
25 NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in OD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., *supra*, pp. 840-856).

- Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may involve either enhancing an existing immune response or eliciting an
30 initial immune response as shown by the following examples. For instance, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases

of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory form of B lymphocyte antigens systemically.

Alternatively, antiviral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells *in vitro* with viral antigen-pulsed APCs either expressing a peptide encoded by extended cDNAs derived from the 5' ESTs of the present invention or together with a stimulatory form of a soluble peptide encoded by extended cDNAs derived from the 5' ESTs of the present invention and reintroducing the *in vitro* primed T cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to T cells *in vivo*, thereby activating the T cells.

In another application, upregulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (e.g., sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide encoded by extended cDNAs derived from the 5' ESTs of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected *ex vivo* with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection *in vivo*.

The presence of the peptide encoded by extended cDNAs derived from the 5' ESTs of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules can be transfected with nucleic acids encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I α chain and β_2 microglobulin or an MHC class II α chain and an MHC class II β chain to thereby express MHC class I or MHC class II proteins on the cell surface, respectively. Expression of the appropriate MHC class I or class II

molecules in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA
5 encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject. Alternatively, as described in more detail below, genes encoding these immune system regulator proteins or nucleic acids regulating the expression of
10 such proteins may be introduced into appropriate host cells to increase or decrease the expression of the proteins as desired.

EXAMPLE 34

Assaying the Proteins Expressed from Extended cDNAs 15 or Portions Thereof for Hematopoiesis Regulating Activity

The proteins encoded by the extended cDNAs or portions thereof may also be evaluated for their hematopoiesis regulating activity. For example, the effect of the proteins on embryonic stem cell differentiation may be evaluated. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following
20 references, which are incorporated herein by reference: Johansson *et al. Cell. Biol.* 15:141-151, 1995; Keller *et al., Mol. Cell. Biol.* 13:473-486, 1993; McClanahan *et al., Blood* 81:2903-2915, 1993.

The proteins encoded by the extended cDNAs or portions thereof may also be evaluated for their influence on the lifetime of stem cells and stem cell differentiation.
25 Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references, which are incorporated herein by reference: Freshney, Methylcellulose Colony Forming Assays, in *Culture of Hematopoietic Cells*, Freshney, *et al.*, Eds. pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994; Hirayama *et al., Proc. Natl. Acad. Sci. USA* 89:5907-5911, 1992; McNiece and Briddell, in *Culture of Hematopoietic Cells*,
30 *supra*; Neben *et al., Exp. Hematol.* 22:353-359, 1994; Ploemacher and Cobblestone In

Culture of Hematopoietic Cells, supra 1-21, Spooncer *et al*, in *Culture of Hematopoietic Cells, supra* 163-179 and Sutherland in *Culture of Hematopoietic Cells, supra*, 139-162.

Those proteins which exhibit hematopoiesis regulatory activity may then be formulated as pharmaceuticals and used to treat clinical conditions in which regulation of hematopoiesis is beneficial, such as in the treatment of myeloid or lymphoid cell deficiencies. Involvement in regulating hematopoiesis is indicated even by marginal biological activity in support of colony forming cells or of factor-dependent cell lines. For example, proteins supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, indicates utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells. Proteins supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (*i.e.*, traditional CSF activity) may be useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelosuppression. Proteins supporting the growth and proliferation of megakaryocytes and consequently of platelets allows prevention or treatment of various platelet disorders such as thrombocytopenia, and generally may be used in place of or complementary to platelet transfusions. Proteins supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells may therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either *in vivo* or *ex vivo* (*i.e.*, in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy. Alternatively, as described in more detail below, genes encoding hematopoiesis regulating activity proteins or nucleic acids regulating the expression of such proteins may be introduced into appropriate host cells to increase or decrease the expression of the proteins as desired.

EXAMPLE 35

Assaying the Proteins Expressed from Extended cDNAs or Portions Thereof
for Regulation of Tissue Growth

5 The proteins encoded by the extended cDNAs or portions thereof may also be evaluated for their effect on tissue growth. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in International Patent Publication No. WO95/16035, International Patent Publication No. WO95/05846 and International Patent Publication No. WO91/07491, which are incorporated herein by reference.

10 Assays for wound healing activity include, without limitation, those described in: Winter, *Epidermal Wound Healing*, pps. 71-112, Maibach and Rovee, eds., Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, *J. Invest. Dermatol.* 71:382-84, 1978, which are incorporated herein by reference.

15 Those proteins which are involved in the regulation of tissue growth may then be formulated as pharmaceuticals and used to treat clinical conditions in which regulation of tissue growth is beneficial. For example, a protein encoded by extended cDNAs derived from the 5' ESTs of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.

20 A protein encoded by extended cDNAs derived from the 5' ESTs of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. *De novo* bone synthesis induced by an osteogenic agent
25 contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of bone-forming cell progenitors. A protein of the invention may also be useful in the treatment of
30 osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or

by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

Another category of tissue regeneration activity that may be attributable to the protein encoded by extended cDNAs derived from the 5' ESTs of the present invention is tendon/ligament formation. A protein encoded by extended cDNAs derived from the 5' ESTs of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. *De novo* tendon/ligament-like tissue formation induced by a composition encoded by extended cDNAs derived from the 5' ESTs of the present invention contributes to the repair of tendon or ligaments defects of congenital, traumatic or other origin and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions encoded by extended cDNAs derived from the 5' ESTs of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors *ex vivo* for return *in vivo* to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

The protein encoded by extended cDNAs derived from the 5' ESTs of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, *i.e.*, for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and

Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.

Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

It is expected that a protein encoded by extended cDNAs derived from the 5' ESTs of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium) muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring to allow normal tissue to generate. A protein of the invention may also exhibit angiogenic activity.

A protein encoded by extended cDNAs derived from the 5' ESTs of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

A protein encoded by extended cDNAs derived from the 5' ESTs of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.

Alternatively, as described in more detail below, genes encoding tissue growth regulating activity proteins or nucleic acids regulating the expression of such proteins may be introduced into appropriate host cells to increase or decrease the expression of the proteins as desired.

EXAMPLE 36Assaying the Proteins Expressed from Extended cDNAs or PortionsThereof for Regulation of Reproductive Hormones

5 The proteins encoded by the extended cDNAs or portions thereof may also be evaluated for their ability to regulate reproductive hormones, such as follicle stimulating hormone. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references, which are incorporated herein by reference: Vale *et al.*, *Endocrinol.* **91**:562-572, 1972; Ling *et al.*, *Nature* **321**:779-782, 1986; Vale *et al.*, *Nature* **321**:776-779, 1986; Mason *et al.*, *Nature* **318**:659-663, 1985; Forage *et al.*,
10 *Proc. Natl. Acad. Sci. USA* **83**:3091-3095, 1986, Chapter 6.12 in *Current Protocols in Immunology*, Coligan *et al.* Eds. Greene Publishing Associates and Wiley-Interscience; Taub *et al.*, *J. Clin. Invest.* **95**:1370-1376, 1995; Lind *et al.*, *APMIS* **103**:140-146, 1995; Muller *et al.*, *Eur. J. Immunol.* **25**:1744-1748; Gruber *et al.*, *J. Immunol.* **152**:5860-5867, 1994; Johnston *et al.*, *J Immunol.* **153**:1762-1768, 1994.

15 Those proteins which exhibit activity as reproductive hormones or regulators of cell movement may then be formulated as pharmaceuticals and used to treat clinical conditions in which regulation of reproductive hormones are beneficial. For example, a protein encoded by extended cDNAs derived from the 5' ESTs of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of
20 follicle stimulating hormone (FSH), while activins are characterized by their ability to stimulate the release of FSH. Thus, a protein encoded by extended cDNAs derived from the 5' ESTs of the present invention, alone or in heterodimers with a member of the inhibin α family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of
25 sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin-B group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, United States Patent 4,798,885, the disclosure of which is incorporated herein by
30 reference. A protein of the invention may also be useful for advancement of the onset of

fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

Alternatively, as described in more detail below, genes encoding reproductive hormone regulating activity proteins or nucleic acids regulating the expression of such proteins may be introduced into appropriate host cells to increase or decrease the expression of the proteins as desired.

EXAMPLE 37

Assaying the Proteins Expressed from Extended cDNAs or Portions Thereof for Chemotactic/Chemokinetic Activity

The proteins encoded by the extended cDNAs or portions thereof may also be evaluated for chemotactic/chemokinetic activity. For example, a protein encoded by extended cDNAs derived from the 5' ESTs of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.

A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of

cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: *Current Protocols in Immunology*, Ed by Coligan, Kruisbeek, Margulies, Shevach and Strober, Pub. Greene Publishing Associates and Wiley-Interscience, Chapter 6.12: 6.12.1-6.12.28; Taub *et al.*, *J. Clin. Invest.* 95:1370-1376, 1995; Lind *et al.*, *APMIS* 103:140-146, 1995; Mueller *et al.*, *Eur. J. Immunol.* 25:1744-1748; Gruber *et al.*, *J. Immunol.* 152:5860-5867, 1994; Johnston *et al.* *J. Immunol.*, 153:1762-1768, 1994.

EXAMPLE 38

Assaying the Proteins Expressed from Extended cDNAs or Portions Thereof for Regulation of Blood Clotting

The proteins encoded by the extended cDNAs or portions thereof may also be evaluated for their effects on blood clotting. Numerous assays for such activity are familiar to those skilled in the art, including the assays disclosed in the following references, which are incorporated herein by reference: Linet *et al.*, *J. Clin. Pharmacol.* 26:131-140, 1986; Burdick *et al.*, *Thrombosis Res.* 45:413-419, 1987; Humphrey *et al.*, *Fibrinolysis* 5:71-79, 1991; Schaub, *Prostaglandins* 35:467-474, 1988.

Those proteins which are involved in the regulation of blood clotting may then be formulated as pharmaceuticals and used to treat clinical conditions in which regulation of blood clotting is beneficial. For example, a protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulations disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as infarction of cardiac and central nervous system vessels (e.g., stroke)). Alternatively, as described in more detail below, genes encoding blood clotting activity proteins or nucleic acids regulating the expression of such proteins may be introduced into appropriate host cells to increase or decrease the expression of the proteins as desired.

EXAMPLE 39

Assaying the Proteins Expressed from Extended cDNAs or
Portions Thereof for Involvement in Receptor/Ligand Interactions

The proteins encoded by the extended cDNAs or a portion thereof may also be
5 evaluated for their involvement in receptor/ligand interactions. Numerous assays for such
involvement are familiar to those skilled in the art, including the assays disclosed in the
following references, which are incorporated herein by reference: Chapter 7. 7.28.1-7.28.22
in *Current Protocols in Immunology*, Coligan *et al.* Eds. Greene Publishing Associates and
Wiley-Interscience; Takai *et al.*, *Proc. Natl. Acad. Sci. USA* 84:6864-6868, 1987; Bierer *et*
10 *al.*, *J. Exp. Med.* 168:1145-1156, 1988; Rosenstein *et al.*, *J. Exp. Med.* 169:149-160, 1989;
Stoltenborg *et al.*, *J. Immunol. Methods* 175:59-68, 1994; Stitt *et al.*, *Cell* 80:661-670, 1995;
Gyuris *et al.*, *Cell* 75:791-803, 1993.

For example, the proteins encoded by extended cDNAs derived from the 5' ESTs
of the present invention may also demonstrate activity as receptors, receptor ligands or
15 inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and
ligands include, without limitation, cytokine receptors and their ligands, receptor kinases
and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell
interactions and their ligands (including without limitation, cellular adhesion molecules
(such as selectins, integrins and their ligands) and receptor/ligand pairs involved in
20 antigen presentation, antigen recognition and development of cellular and humoral
immune responses). Receptors and ligands are also useful for screening of potential
peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein
encoded by extended cDNAs derived from the 5' ESTs of the present invention
(including, without limitation, fragments of receptors and ligands) may themselves be
25 useful as inhibitors of receptor/ligand interactions. Alternatively, as described in more
detail below, genes encoding proteins involved in receptor/ligand interactions or nucleic
acids regulating the expression of such proteins may be introduced into appropriate host
cells to increase or decrease the expression of the proteins as desired.

EXAMPLE 40**Assaying the Proteins Expressed from Extended cDNAs or Portions Thereof
for Anti-Inflammatory Activity**

5 The proteins encoded by the extended cDNAs or a portion thereof may also be
evaluated for anti-inflammatory activity. The anti-inflammatory activity may be achieved by
providing a stimulus to cells involved in the inflammatory response, by inhibiting or
promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or
promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting
10 cell extravasation, or by stimulating or suppressing production of other factors which more
directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can
be used to treat inflammatory conditions including chronic or acute conditions, including
without limitation inflammation associated with infection (such as septic shock, sepsis or
systemic inflammatory response syndrome), ischemia-reperfusion injury, endotoxin lethality,
arthritis, complement-mediated hyperacute rejection, nephritis, cytokine- or chemokine-
15 induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over
production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to
treat anaphylaxis and hypersensitivity to an antigenic substance or material. Alternatively, as
described in more detail below, genes encoding anti-inflammatory activity proteins or nucleic
acids regulating the expression of such proteins may be introduced into appropriate host cells
20 to increase or decrease the expression of the proteins as desired.

EXAMPLE 41**Assaying the Proteins Expressed from Extended cDNAs or
Portions Thereof for Tumor Inhibition Activity**

25 The proteins encoded by the extended cDNAs or a portion thereof may also be
evaluated for tumor inhibition activity. In addition to the activities described above for
immunological treatment or prevention of tumors, a protein of the invention may exhibit other
anti-tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for
example, via ADCC). A protein may exhibit its tumor inhibitory activity by acting on tumor
30 tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor
growth (such as, for example, by inhibiting angiogenesis), by causing production of other

factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth. Alternatively, as described in more detail below, genes tumor inhibition activity proteins or nucleic acids regulating the expression of such proteins may be introduced into appropriate host cells to
5 increase or decrease the expression of the proteins as desired.

A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting
10 (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or circadian cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism,
15 processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and
20 growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune
25 response against such protein or another material or entity which is cross-reactive with such protein. Alternatively, as described in more detail below, genes encoding proteins involved in any of the above mentioned activities or nucleic acids regulating the expression of such proteins may be introduced into appropriate host cells to increase or decrease the expression of the proteins as desired.

EXAMPLE 42Identification of Proteins which Interact with Polypeptides Encoded by Extended cDNAs

Proteins which interact with the polypeptides encoded by cDNAs derived from the 5' ESTs or fragments thereof, such as receptor proteins, may be identified using two hybrid systems such as the Matchmaker Two Hybrid System 2 (Catalog No. K1604-1, Clontech). As described in the manual accompanying the kit which is incorporated herein by reference, the the cDNAs derived from 5' ESTs, or fragments thereof, are inserted into an expression vector such that they are in frame with DNA encoding the DNA binding domain of the yeast transcriptional activator GAL4. cDNAs in a cDNA library which encode proteins which might interact with the polypeptides encoded by the extended cDNAs or portions thereof are inserted into a second expression vector such that they are in frame with DNA encoding the activation domain of GAL4. The two expression plasmids are transformed into yeast and the yeast are plated on selection medium which selects for expression of selectable markers on each of the expression vectors as well as GAL4 dependent expression of the HIS3 gene. Transformants capable of growing on medium lacking histidine are screened for GAL4 dependent lacZ expression. Those cells which are positive in both the histidine selection and the lacZ assay contain plasmids encoding proteins which interact with the polypeptide encoded by the extended cDNAs or portions thereof.

Alternatively, the system described in Lustig *et al.*, *Methods in Enzymology* 283: 83-99, 1997, and in U.S. Patent No. 5,654,150, the disclosure of which is incorporated herein by reference, may be used for identifying molecules which interact with the polypeptides encoded by extended cDNAs. In such systems, *in vitro* transcription reactions are performed on a pool of vectors containing extended cDNA inserts cloned downstream of a promoter which drives *in vitro* transcription. The resulting pools of mRNAs are introduced into *Xenopus laevis* oocytes. The oocytes are then assayed for a desired activity.

Alternatively, the pooled *in vitro* transcription products produced as described above may be translated *in vitro*. The pooled *in vitro* translation products can be assayed for a desired activity or for interaction with a known polypeptide.

Proteins or other molecules interacting with polypeptides encoded by extended cDNAs can be found by a variety of additional techniques. In one method, affinity columns containing the polypeptide encoded by the extended cDNA or a portion thereof

can be constructed. In some versions, of this method the affinity column contains chimeric proteins in which the protein encoded by the extended cDNA or a portion thereof is fused to glutathione S-transferase. A mixture of cellular proteins or pool of expressed proteins as described above and is applied to the affinity column. Proteins
5 interacting with the polypeptide attached to the column can then be isolated and analyzed on 2-D electrophoresis gel as described in Ramunsen *et al.*, *Electrophoresis* 18:588-598, 1997, the disclosure of which is incorporated herein by reference. Alternatively, the proteins retained on the affinity column can be purified by electrophoresis based methods and sequenced. The same method can be used to isolate antibodies, to screen phage
10 display products, or to screen phage display human antibodies.

Proteins interacting with polypeptides encoded by extended cDNAs or portions thereof can also be screened by using an Optical Biosensor as described in Edwards and Leatherbarrow, *Analytical Biochemistry* 246:1-6, 1997, the disclosure of which is incorporated herein by reference. The main advantage of the method is that it allows the
15 determination of the association rate between the protein and other interacting molecules. Thus, it is possible to specifically select interacting molecules with a high or low association rate. Typically a target molecule is linked to the sensor surface (through a carboxymethyl dextran matrix) and a sample of test molecules is placed in contact with the target molecules. The binding of a test molecule to the target molecule causes a
20 change in the refractive index and/ or thickness. This change is detected by the Biosensor provided it occurs in the evanescent field (which extend a few hundred nanometers from the sensor surface). In these screening assays, the target molecule can be one of the polypeptides encoded by extended cDNAs or a portion thereof and the test sample can be a collection of proteins extracted from tissues or cells, a pool of expressed
25 proteins, combinatorial peptide and/ or chemical libraries, or phage displayed peptides. The tissues or cells from which the test proteins are extracted can originate from any species.

In other methods, a target protein is immobilized and the test population is a collection of unique polypeptides encoded by the extended cDNAs or portions thereof.

30 To study the interaction of the proteins encoded by the extended cDNAs or portions thereof with drugs, the microdialysis coupled to HPLC method described by

Wang *et al.*, *Chromatographia* 44:205-208, 1997 or the affinity capillary electrophoresis method described by Busch *et al.*, *J. Chromatogr.* 777:311-328, 1997, the disclosures of which are incorporated herein by reference can be used.

5 It will be appreciated by those skilled in the art that the proteins expressed from the extended cDNAs or portions may be assayed for numerous activities in addition to those specifically enumerated above. For example, the expressed proteins may be evaluated for applications involving control and regulation of inflammation, tumor proliferation or metastasis, infection, or other clinical conditions. In addition, the proteins expressed from the
10 extended cDNAs or portions thereof may be useful as nutritional agents or cosmetic agents.

 The proteins expressed from the cDNAs or portions thereof may be used to generate antibodies capable of specifically binding to the expressed protein or fragments thereof as described in Example 40 below. The antibodies may be capable of binding a full length protein encoded by a cDNA derived from a 5' EST, a mature protein (*i.e.* the protein generated by
15 cleavage of the signal peptide) encoded by a cDNA derived from a 5' EST, or a signal peptide encoded by a cDNA derived from a 5' EST. Alternatively, the antibodies may be capable of binding fragments of at least 10 amino acids of the proteins encoded by the above cDNAs. In some embodiments, the antibodies may be capable of binding fragments of at least 15 amino acids of the proteins encoded by the above cDNAs. In other embodiments,
20 the antibodies may be capable of binding fragments of at least 25 amino acids of the proteins expressed from the extended cDNAs which comprise at least 25 amino acids of the proteins encoded by the above cDNAs. In further embodiments, the antibodies may be capable of binding fragments of at least 40 amino acids of the proteins encoded by the above cDNAs.

25

EXAMPLE 43

Production of an Antibody to a Human Protein

 Substantially pure protein or polypeptide is isolated from the transfected or transformed cells as described in Example 30. The concentration of protein in the final preparation is adjusted, for example, by concentration on an Amicon filter device, to the
30 level of a few µg/ml. Monoclonal or polyclonal antibody to the protein can then be prepared as follows:

1. Monoclonal Antibody Production by Hybridoma Fusion

Monoclonal antibody to epitopes of any of the peptides identified and isolated as described can be prepared from murine hybridomas according to the classical method of Kohler, and Milstein, *Nature* 256:495, 1975 or derivative methods thereof. Briefly, a
5 mouse is repetitively inoculated with a few micrograms of the selected protein or peptides derived therefrom over a period of a few weeks. The mouse is then sacrificed, and the antibody producing cells of the spleen isolated. The spleen cells are fused by means of polyethylene glycol with mouse myeloma cells, and the excess unfused cells destroyed by growth of the system on selective media comprising aminopterin (HAT
10 media). The successfully fused cells are diluted and aliquots of the dilution placed in wells of a microtiter plate where growth of the culture is continued. Antibody-producing clones are identified by detection of antibody in the supernatant fluid of the wells by immunoassay procedures, such as ELISA, as originally described by Engvall, *Meth. Enzymol.* 70:419, 1980, the disclosure of which is incorporated herein by reference and
15 derivative methods thereof. Selected positive clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody production are described in Davis *et al.* in *Basic Methods in Molecular Biology* Elsevier, New York. Section 21-2, the disclosure of which is incorporated herein by reference.

20

2. Polyclonal Antibody Production by Immunization

Polyclonal antiserum containing antibodies to heterogenous epitopes of a single protein can be prepared by immunizing suitable animals with the expressed protein or peptides derived therefrom, which can be unmodified or modified to enhance
25 immunogenicity. Effective polyclonal antibody production is affected by many factors related both to the antigen and the host species. For example, small molecules tend to be less immunogenic than others and may require the use of carriers and adjuvant. Also, host animals response vary depending on site of inoculations and doses, with both inadequate or excessive doses of antigen resulting in low titer antisera. Small doses (ng level) of antigen
30 administered at multiple intradermal sites appears to be most reliable. An effective

immunization protocol for rabbits can be found in Vaitukaitis. *et al*, *J. Clin. Endocrinol. Metab.* 33:988-991 (1971), the disclosure of which is incorporated herein by reference..

Booster injections can be given at regular intervals, and antiserum harvested when antibody titer thereof, as determined semi-quantitatively, for example, by double immunodiffusion in agar against known concentrations of the antigen, begins to fall. See, for example, Ouchterlony, *et al.*, Chap. 19 in: *Handbook of Experimental Immunology* D. Wier (ed) Blackwell (1973), the disclosure of which is incorporated herein by reference. Plateau concentration of antibody is usually in the range of 0.1 to 0.2 mg/ml of serum (about 12 μ M). Affinity of the antisera for the antigen is determined by preparing competitive binding curves, as described, for example, by Fisher, D., Chap. 42 in: *Manual of Clinical Immunology*, 2d Ed. (Rose and Friedman, Eds.) Amer. Soc. For Microbiol., Washington, D.C. (1980), the disclosure of which is incorporated herein by reference..

Antibody preparations prepared according to either protocol are useful in quantitative immunoassays which determine concentrations of antigen-bearing substances in biological samples; they are also used semi-quantitatively or qualitatively to identify the presence of antigen in a biological sample. The antibodies may also be used in therapeutic compositions for killing cells expressing the protein or reducing the levels of the protein in the body.

V. Use of 5' ESTs or Sequences Obtainable Therefrom or Portions Thereof as Reagents

The 5' ESTs of the present invention (or cDNAs or genomic DNAs obtainable therefrom) may be used as reagents in isolation procedures, diagnostic assays, and forensic procedures. For example, sequences from the 5' ESTs (or cDNAs or genomic DNAs obtainable therefrom) may be detectably labeled and used as probes to isolate other sequences capable of hybridizing to them. In addition, sequences from 5' ESTs (or cDNAs or genomic DNAs obtainable therefrom) may be used to design PCR primers to be used in isolation, diagnostic, or forensic procedures.

1. Use of 5' ESTs or Sequences Obtainable Therefrom or Portions Thereof in Isolation
Diagnostic and Forensic Procedures

EXAMPLE 44

5 Preparation of PCR Primers and Amplification of DNA

The 5' EST sequences (or cDNAs or genomic DNAs obtainable therefrom) may be used to prepare PCR primers for a variety of applications, including isolation procedures for cloning nucleic acids capable of hybridizing to such sequences, diagnostic techniques and forensic techniques. The PCR primers are at least 10 bases, and preferably at least 12, 15, or 10 17 bases in length. More preferably, the PCR primers are at least 20-30 bases in length. In some embodiments, the PCR primers may be more than 30 bases in length. It is preferred that the primer pairs have approximately the same G/C ratio, so that melting temperatures are approximately the same. A variety of PCR techniques are familiar to those skilled in the art. For a review of PCR technology, see Molecular Cloning to Genetic Engineering, White Ed. 15 *in Methods in Molecular Biology* 67: Humana Press, Totowa 1997, the disclosure of which is incorporated herein by reference. In each of these PCR procedures, PCR primers on either side of the nucleic acid sequences to be amplified are added to a suitably prepared nucleic acid sample along with dNTPs and a thermostable polymerase such as Taq polymerase, Pfu polymerase, or Vent polymerase. The nucleic acid in the sample is denatured and the PCR 20 primers are specifically hybridized to complementary nucleic acid sequences in the sample. The hybridized primers are extended. Thereafter, another cycle of denaturation, hybridization, and extension is initiated. The cycles are repeated multiple times to produce an amplified fragment containing the nucleic acid sequence between the primer sites.

25 **EXAMPLE 45**

Use of 5'ESTs as Probes

Probes derived from 5' ESTs (or cDNAs or genomic DNAs obtainable therefrom), including full length cDNAs or genomic sequences, may be labeled with detectable labels familiar to those skilled in the art, including radioisotopes and non-radioactive labels, to 30 provide a detectable probe. The detectable probe may be single stranded or double stranded and may be made using techniques known in the art, including *in vitro* transcription, nick

translation, or kinase reactions. A nucleic acid sample containing a sequence capable of hybridizing to the labeled probe is contacted with the labeled probe. If the nucleic acid in the sample is double stranded, it may be denatured prior to contacting the probe. In some applications, the nucleic acid sample may be immobilized on a surface such as a nitrocellulose or nylon membrane. The nucleic acid sample may comprise nucleic acids obtained from a variety of sources, including genomic DNA, cDNA libraries, RNA, or tissue samples.

Procedures used to detect the presence of nucleic acids capable of hybridizing to the detectable probe include well known techniques such as Southern blotting, Northern blotting, dot blotting, colony hybridization, and plaque hybridization. In some applications, the nucleic acid capable of hybridizing to the labeled probe may be cloned into vectors such as expression vectors, sequencing vectors, or *in vitro* transcription vectors to facilitate the characterization and expression of the hybridizing nucleic acids in the sample. For example, such techniques may be used to isolate and clone sequences in a genomic library or cDNA library which are capable of hybridizing to the detectable probe as described in Example 30 above.

PCR primers made as described in Example 44 above may be used in forensic analyses, such as the DNA fingerprinting techniques described in Examples 46-50 below. Such analyses may utilize detectable probes or primers based on the sequences of the the 5' ESTs or of cDNAs or genomic DNAs isolated using the 5' ESTs.

20

EXAMPLE 46

Forensic Matching by DNA Sequencing

In one exemplary method, DNA samples are isolated from forensic specimens of, for example, hair, semen, blood or skin cells by conventional methods. A panel of PCR primers based on a number of the 5' ESTs of Example 25, or cDNAs or genomic DNAs isolated therefrom as described above, is then utilized in accordance with Example 44 to amplify DNA of approximately 100-200 bases in length from the forensic specimen. Corresponding sequences are obtained from a test subject. Each of these identification DNAs is then sequenced using standard techniques, and a simple database comparison determines the differences, if any, between the sequences from the subject and those from the sample. Statistically significant differences between the suspect's DNA sequences and those from the sample conclusively prove a lack of identity. This lack of identity can be proven, for example,

with only one sequence. Identity, on the other hand, should be demonstrated with a large number of sequences, all matching. Preferably, a minimum of 50 statistically identical sequences of 100 bases in length are used to prove identity between the suspect and the sample.

5

EXAMPLE 47

Positive Identification by DNA Sequencing

The technique outlined in the previous example may also be used on a larger scale to provide a unique fingerprint-type identification of any individual. In this technique, primers are prepared from a large number of 5'EST sequences from Example 25, or cDNA or genomic DNA sequences obtainable therefrom. Preferably, 20 to 50 different primers are used. These primers are used to obtain a corresponding number of PCR-generated DNA segments from the individual in question in accordance with Example 44. Each of these DNA segments is sequenced, using the methods set forth in Example 46. The database of sequences generated through this procedure uniquely identifies the individual from whom the sequences were obtained. The same panel of primers may then be used at any later time to absolutely correlate tissue or other biological specimen with that individual.

15

EXAMPLE 48

Southern Blot Forensic Identification

20

The procedure of Example 47 is repeated to obtain a panel of at least 10 amplified sequences from an individual and a specimen. Preferably, the panel contains at least 50 amplified sequences. More preferably, the panel contains 100 amplified sequences. In some embodiments, the panel contains 200 amplified sequences. This PCR-generated DNA is then digested with one or a combination of, preferably, four base specific restriction enzymes. Such enzymes are commercially available and known to those of skill in the art. After digestion, the resultant gene fragments are size separated in multiple duplicate wells on an agarose gel and transferred to nitrocellulose using Southern blotting techniques well known to those with skill in the art. For a review of Southern blotting see Davis *et al.* (Basic Methods in Molecular Biology, 1986, Elsevier Press. pp 62-65), the disclosure of which is incorporated herein by reference.

25

30

A panel of probes based on the sequences of 5' ESTs (or cDNAs or genomic DNAs obtainable therefrom), or fragments thereof of at least 10 bases, are radioactively or colorimetrically labeled using methods known in the art, such as nick translation or end labeling, and hybridized to the Southern blot using techniques known in the art (Davis *et al.*,
5 supra). Preferably, the probe comprises at least 12, 15, or 17 consecutive nucleotides from the 5' EST (or cDNAs or genomic DNAs obtainable therefrom). More preferably, the probe comprises at least 20-30 consecutive nucleotides from the 5' EST (or cDNAs or genomic DNAs obtainable therefrom). In some embodiments, the probe comprises more than 30 nucleotides from the 5' EST (or cDNAs or genomic DNAs obtainable therefrom).

10 Preferably, at least 5 to 10 of these labeled probes are used, and more preferably at least about 20 or 30 are used to provide a unique pattern. The resultant bands appearing from the hybridization of a large sample of 5' EST (or cDNAs or genomic DNAs obtainable therefrom) will be a unique identifier. Since the restriction enzyme cleavage will be different for every individual, the band pattern on the Southern blot will also be unique. Increasing the
15 number of 5' EST (or cDNAs or genomic DNAs obtainable therefrom) probes will provide a statistically higher level of confidence in the identification since there will be an increased number of sets of bands used for identification.

EXAMPLE 49

20 Dot Blot Identification Procedure

Another technique for identifying individuals using the 5' EST sequences disclosed herein utilizes a dot blot hybridization technique.

Genomic DNA is isolated from nuclei of subject to be identified. Oligonucleotide probes of approximately 30 bp in length are synthesized that correspond to at least 10,
25 preferably 50 sequences from the 5' ESTs or cDNAs or genomic DNAs obtainable therefrom. The probes are used to hybridize to the genomic DNA through conditions known to those in the art. The oligonucleotides are end labeled with P^{32} using polynucleotide kinase (Pharmacia). Dot Blots are created by spotting the genomic DNA onto nitrocellulose or the like using a vacuum dot blot manifold (BioRad, Richmond California). The nitrocellulose
30 filter containing the genomic sequences is baked or UV linked to the filter, prehybridized and hybridized with labeled probe using techniques known in the art (Davis *et al.*, *supra*). The ^{32}P

labeled DNA fragments are sequentially hybridized with successively stringent conditions to detect minimal differences between the 30 bp sequence and the DNA. Tetramethylammonium chloride is useful for identifying clones containing small numbers of nucleotide mismatches (Wood *et al.*, *Proc. Natl. Acad. Sci. USA* 82(6):1585-1588, 1985) which is hereby incorporated by reference. A unique pattern of dots distinguishes one individual from another individual.

5' EST sequences (or cDNAs or genomic DNAs obtainable therefrom) or oligonucleotides containing at least 10 consecutive bases from these sequences can be used as probes in the following alternative fingerprinting technique. Preferably, the probe comprises at least 12, 15, or 17 consecutive nucleotides from the 5' EST sequences (or cDNAs or genomic DNAs obtainable therefrom). More preferably, the probe comprises at least 20-30 consecutive nucleotides from the 5' EST sequences (or cDNAs or genomic DNAs obtainable therefrom). In some embodiments, the probe comprises more than 30 nucleotides from the 5' EST sequences (or cDNAs or genomic DNAs obtainable therefrom).

Preferably, a plurality of probes having sequences from different genes are used in the alternative fingerprinting technique. Example 50 below provides a representative alternative fingerprinting procedure in which the probes are derived from 5'EST.

EXAMPLE 50

Alternative "Fingerprint" Identification Technique

20-mer oligonucleotides are prepared from a large number, e.g. 50, 100, or 200, of 5'EST using commercially available oligonucleotide services such as Genset, Paris, France. Cell samples from the test subject are processed for DNA using techniques well known to those with skill in the art. The nucleic acid is digested with restriction enzymes such as EcoRI and XbaI. Following digestion, samples are applied to wells for electrophoresis. The procedure, as known in the art, may be modified to accommodate polyacrylamide electrophoresis, however in this example, samples containing 5 ug of DNA are loaded into wells and separated on 0.8% agarose gels. The gels are transferred onto nitrocellulose using standard Southern blotting techniques.

10 ng of each of the oligonucleotides are pooled and end-labeled with ^{32}P . The nitrocellulose is prehybridized with blocking solution and hybridized with the labeled probes.

Following hybridization and washing, the nitrocellulose filter is exposed to X-Omat AR X-ray film. The resulting hybridization pattern will be unique for each individual.

It is additionally contemplated within this example that the number of probe sequences used can be varied for additional accuracy or clarity.

5

The proteins encoded by the extended cDNAs may also be used to generate antibodies as explained in Examples 30 and 43 in order to identify the tissue type or cell species from which a sample is derived as described in example 51.

10

EXAMPLE 51

Identification of Tissue Types or Cell Species by Means of Labeled Tissue Specific Antibodies

Identification of specific tissues is accomplished by the visualization of tissue specific antigens by means of antibody preparations according to Examples 30 and 43 which are
15 conjugated, directly or indirectly to a detectable marker. Selected labeled antibody species bind to their specific antigen binding partner in tissue sections, cell suspensions, or in extracts of soluble proteins from a tissue sample to provide a pattern for qualitative or semi-qualitative interpretation.

Antisera for these procedures must have a potency exceeding that of the native
20 preparation, and for that reason, antibodies are concentrated to a mg/ml level by isolation of the gamma globulin fraction, for example, by ion-exchange chromatography or by ammonium sulfate fractionation. Also, to provide the most specific antisera, unwanted antibodies, for example to common proteins, must be removed from the gamma globulin fraction, for example by means of insoluble immunoabsorbents, before the antibodies are
25 labeled with the marker. Either monoclonal or heterologous antisera is suitable for either procedure.

A. Immunohistochemical techniques

Purified, high-titer antibodies, prepared as described above, are conjugated to a detectable marker, as described, for example, by Fudenberg, Chap. 26 in: *Basic and Clinical*
30 *Immunology*, 3rd Ed. Lange, Los Altos, California, 1980, or Rose, *et al.*, Chap. 12 in:

Methods in Immunodiagnosis, 2d Ed. John Wiley and Sons, New York (1980), the disclosures of which are incorporated herein by reference.

A fluorescent marker, either fluorescein or rhodamine, is preferred, but antibodies can also be labeled with an enzyme that supports a color producing reaction with a substrate, such as horseradish peroxidase. Markers can be added to tissue-bound antibody in a second step, as described below. Alternatively, the specific antitissue antibodies can be labeled with ferritin or other electron dense particles, and localization of the ferritin coupled antigen-antibody complexes achieved by means of an electron microscope. In yet another approach, the antibodies are radiolabeled, with, for example ^{125}I , and detected by overlaying the antibody treated preparation with photographic emulsion.

Preparations to carry out the procedures can comprise monoclonal or polyclonal antibodies to a single protein or peptide identified as specific to a tissue type, for example, brain tissue, or antibody preparations to several antigenically distinct tissue specific antigens can be used in panels, independently or in mixtures, as required.

Tissue sections and cell suspensions are prepared for immunohistochemical examination according to common histological techniques. Multiple cryostat sections (about 4 μm , unfixed) of the unknown tissue and known control, are mounted and each slide covered with different dilutions of the antibody preparation. Sections of known and unknown tissues should also be treated with preparations to provide a positive control, a negative control, for example, pre-immune sera, and a control for non-specific staining, for example, buffer.

Treated sections are incubated in a humid chamber for 30 min at room temperature, rinsed, then washed in buffer for 30-45 min. Excess fluid is blotted away, and the marker developed.

If the tissue specific antibody was not labeled in the first incubation, it can be labeled at this time in a second antibody-antibody reaction, for example, by adding fluorescein- or enzyme-conjugated antibody against the immunoglobulin class of the antiserum-producing species, for example, fluorescein labeled antibody to mouse IgG. Such labeled sera are commercially available.

The antigen found in the tissues by the above procedure can be quantified by measuring the intensity of color or fluorescence on the tissue section, and calibrating that signal using appropriate standards.

B. Identification of tissue specific soluble proteins

5 The visualization of tissue specific proteins and identification of unknown tissues from that procedure is carried out using the labeled antibody reagents and detection strategy as described for immunohistochemistry; however the sample is prepared according to an electrophoretic technique to distribute the proteins extracted from the tissue in an orderly array on the basis of molecular weight for detection.

10 A tissue sample is homogenized using a Virtis apparatus; cell suspensions are disrupted by Dounce homogenization or osmotic lysis, using detergents in either case as required to disrupt cell membranes, as is the practice in the art. Insoluble cell components such as nuclei, microsomes, and membrane fragments are removed by ultracentrifugation, and the soluble protein-containing fraction concentrated if necessary and reserved for analysis.

15 A sample of the soluble protein solution is resolved into individual protein species by conventional SDS polyacrylamide electrophoresis as described, for example, by Davis, *et al.*, Section 19-2 in: *Basic Methods in Molecular Biology*, Leder ed., Elsevier, New York, 1986, the disclosure of which is incorporated herein by reference, using a range of amounts of polyacrylamide in a set of gels to resolve the entire molecular weight range of proteins to be
20 detected in the sample. A size marker is run in parallel for purposes of estimating molecular weights of the constituent proteins. Sample size for analysis is a convenient volume of from 5 to 55 μ l, and containing from about 1 to 100 μ g protein. An aliquot of each of the resolved proteins is transferred by blotting to a nitrocellulose filter paper, a process that maintains the pattern of resolution. Multiple copies are prepared. The procedure, known as Western Blot
25 Analysis, is well described in Davis, L. *et al.*, *supra* Section 19-3. One set of nitrocellulose blots is stained with Coomassie blue dye to visualize the entire set of proteins for comparison with the antibody bound proteins. The remaining nitrocellulose filters are then incubated with a solution of one or more specific antisera to tissue specific proteins prepared as described in Examples 30 and 43. In this procedure, as in procedure A above, appropriate positive and
30 negative sample and reagent controls are run.

In either procedure A or B, a detectable label can be attached to the primary tissue antigen-primary antibody complex according to various strategies and permutations thereof. In a straightforward approach, the primary specific antibody can be labeled; alternatively, the unlabeled complex can be bound by a labeled secondary anti-IgG antibody. In other
5 approaches, either the primary or secondary antibody is conjugated to a biotin molecule, which can, in a subsequent step, bind an avidin conjugated marker. According to yet another strategy, enzyme labeled or radioactive protein A, which has the property of binding to any IgG, is bound in a final step to either the primary or secondary antibody.

The visualization of tissue specific antigen binding at levels above those seen in
10 control tissues to one or more tissue specific antibodies, prepared from the gene sequences identified from extended cDNA sequences, can identify tissues of unknown origin, for example, forensic samples, or differentiated tumor tissue that has metastasized to foreign bodily sites.

In addition to their applications in forensics and identification, 5' ESTs (or
15 cDNAs or genomic DNAs obtainable therefrom) may be mapped to their chromosomal locations. Example 52 below describes radiation hybrid (RH) mapping of human chromosomal regions using 5'ESTs. Example 53 below describes a representative procedure for mapping an 5' EST to its location on a human chromosome. Example 54
20 below describes mapping of 5' ESTs on metaphase chromosomes by Fluorescence In Situ Hybridization (FISH). Those skilled in the art will appreciate that the method of Examples 52-54 may also be used to map cDNAs or genomic DNAs obtainable from the 5' ESTs to their chromosomal locations.

2. Use of 5' ESTs or Sequences Obtainable Therefrom or Portions Thereof in 25 Chromosome Mapping

EXAMPLE 52

Radiation hybrid mapping of 5'ESTs to the human genome

Radiation hybrid (RH) mapping is a somatic cell genetic approach that can be used for high resolution mapping of the human genome. In this approach, cell lines containing one
30 or more human chromosomes are lethally irradiated, breaking each chromosome into fragments whose size depends on the radiation dose. These fragments are rescued by fusion

with cultured rodent cells, yielding subclones containing different portions of the human genome. This technique is described by Benham *et al.*, *Genomics* 4:509-517, 1989; and Cox *et al.*, *Science* 250:245-250, 1990, the entire contents of which are hereby incorporated by reference. The random and independent nature of the subclones permits efficient mapping of
5 any human genome marker. Human DNA isolated from a panel of 80-100 cell lines provides a mapping reagent for ordering 5'EST. In this approach, the frequency of breakage between markers is used to measure distance, allowing construction of fine resolution maps as has been done using conventional ESTs (Schuler *et al.*, *Science* 274:540-546, 1996, hereby incorporated by reference).

10 RH mapping has been used to generate a high-resolution whole genome radiation hybrid map of human chromosome 17q22-q25.3 across the genes for growth hormone (GH) and thymidine kinase (TK) (Foster *et al.*, *Genomics* 33:185-192, 1996), the region surrounding the Gorlin syndrome gene (Obermayr *et al.*, *Eur. J. Hum. Genet.* 4:242-245, 1996), 60 loci covering the entire short arm of chromosome 12 (Raeymaekers *et al.*,
15 *Genomics* 29:170-178, 1995), the region of human chromosome 22 containing the neurofibromatosis type 2 locus (Frazer *et al.*, *Genomics* 14:574-584, 1992) and 13 loci on the long arm of chromosome 5 (Warrington *et al.*, *Genomics* 11:701-708, 1991).

EXAMPLE 53

20 Mapping of 5'ESTs to Human Chromosomes using PCR techniques

5' ESTs (or cDNAs or genomic DNAs obtainable therefrom) may be assigned to human chromosomes using PCR based methodologies. In such approaches, oligonucleotide primer pairs are designed from the 5' ESTs (or cDNAs or genomic DNAs obtainable therefrom) to minimize the chance of amplifying through an intron. Preferably, the
25 oligonucleotide primers are 18-23 bp in length and are designed for PCR amplification. The creation of PCR primers from known sequences is well known to those with skill in the art. For a review of PCR technology see Erlich in *PCR Technology, Principles and Applications for DNA Amplification*, Freeman and Co., New York, 1992, the disclosure of which is incorporated herein by reference.

30 The primers are used in polymerase chain reactions (PCR) to amplify templates from total human genomic DNA. PCR conditions are as follows: 60 ng of genomic DNA is used

as a template for PCR with 80 ng of each oligonucleotide primer, 0.6 unit of Taq polymerase, and 1 μ Ci of a 32 P-labeled deoxycytidine triphosphate. The PCR is performed in a microplate thermocycler (Techne) under the following conditions: 30 cycles of 94°C, 1.4 min; 55°C, 2 min; and 72°C, 2 min; with a final extension at 72°C for 10 min. The amplified products are analyzed on a 6% polyacrylamide sequencing gel and visualized by autoradiography. If the length of the resulting PCR product is identical to the distance between the ends of the primer sequences in the extended cDNA from which the primers are derived, then the PCR reaction is repeated with DNA templates from two panels of human-rodent somatic cell hybrids, BIOS PCRable DNA (BIOS Corporation) and NIGMS Human-Rodent Somatic Cell Hybrid Mapping Panel Number 1 (NIGMS, Camden, NJ).

PCR is used to screen a series of somatic cell hybrid cell lines containing defined sets of human chromosomes for the presence of a given 5' EST (or cDNA or genomic DNA obtainable therefrom). DNA is isolated from the somatic hybrids and used as starting templates for PCR reactions using the primer pairs from the 5' EST (or cDNA or genomic DNA obtainable therefrom). Only those somatic cell hybrids with chromosomes containing the human gene corresponding to the 5' EST (or cDNA or genomic DNA obtainable therefrom) will yield an amplified fragment. The 5' EST (or cDNA or genomic DNA obtainable therefrom) are assigned to a chromosome by analysis of the segregation pattern of PCR products from the somatic hybrid DNA templates. The single human chromosome present in all cell hybrids that give rise to an amplified fragment is the chromosome containing that 5'EST (or cDNA or genomic DNA obtainable therefrom). For a review of techniques and analysis of results from somatic cell gene mapping experiments, see Ledbetter *et al.*, *Genomics* 6:475-481, 1990, the disclosure of which is incorporated herein by reference.

EXAMPLE 54

Mapping of Extended 5' ESTs to Chromosomes Using Fluorescence *In Situ*

Hybridization

Fluorescence in situ hybridization allows the 5'EST (or cDNA or genomic DNA obtainable therefrom) to be mapped to a particular location on a given chromosome. The chromosomes to be used for fluorescence in situ hybridization techniques may be obtained from a variety of sources including cell cultures, tissues, or whole blood.

In a preferred embodiment, chromosomal localization of an 5'EST (or cDNA or genomic DNA obtainable therefrom) is obtained by FISH as described by Cherif *et al.* (*Proc. Natl. Acad. Sci. U.S.A.*, 87:6639-6643, 1990), the disclosure of which is incorporated herein by reference. Metaphase chromosomes are prepared from phytohemagglutinin (PHA)-stimulated blood cell donors. PHA-stimulated lymphocytes from healthy males are cultured for 72 h in RPMI-1640 medium. For synchronization, methotrexate (10 μ M) is added for 17 h, followed by addition of 5-bromodeoxyuridine (5-BrdU, 0.1 mM) for 6 h. Colcemid (1 μ g/ml) is added for the last 15 min before harvesting the cells. Cells are collected, washed in RPMI, incubated with a hypotonic solution of KCl (75 mM) at 37°C for 15 min and fixed in three changes of methanol:acetic acid (3:1). The cell suspension is dropped onto a glass slide and air dried. The 5'EST (or cDNA or genomic DNA obtainable therefrom) is labeled with biotin-16 dUTP by nick translation according to the manufacturer's instructions (Bethesda Research Laboratories, Bethesda, MD), purified using a Sephadex G-50 column (Pharmacia, Upsala, Sweden) and precipitated. Just prior to hybridization, the DNA pellet is dissolved in hybridization buffer (50% formamide, 2 X SSC, 10% dextran sulfate, 1 mg/ml sonicated salmon sperm DNA, pH 7) and the probe is denatured at 70°C for 5-10 min.

Slides kept at -20°C are treated for 1 h at 37°C with RNase A (100 μ g/ml), rinsed three times in 2 X SSC and dehydrated in an ethanol series. Chromosome preparations are denatured in 70% formamide, 2 X SSC for 2 min at 70°C, then dehydrated at 4°C. The slides are treated with proteinase K (10 μ g/100 ml in 20 mM Tris-HCl, 2 mM CaCl₂) at 37°C for 8 min and dehydrated. The hybridization mixture containing the probe is placed on the slide, covered with a coverslip, sealed with rubber cement and incubated overnight in a humid chamber at 37°C. After hybridization and post-hybridization washes, the biotinylated probe is detected by avidin-FITC and amplified with additional layers of biotinylated goat anti-avidin and avidin-FITC. For chromosomal localization, fluorescent R-bands are obtained as previously described (Cherif *et al.*, *supra.*). The slides are observed under a LEICA fluorescence microscope (DMRXA). Chromosomes are counterstained with propidium iodide and the fluorescent signal of the probe appears as two symmetrical yellow-green spots on both chromatids of the fluorescent R-band chromosome (red). Thus, a particular 5'EST (or cDNA or genomic DNA obtainable therefrom) may be localized to a particular cytogenetic R-band on a given chromosome.

Once the 5'EST (or cDNA or genomic DNA obtainable therefrom) have been assigned to particular chromosomes using the techniques described in Examples 52-54 above, they may be utilized to construct a high resolution map of the chromosomes on which they are located or to identify the chromosomes in a sample.

5

EXAMPLE 55

Use of 5'EST to Construct or Expand Chromosome Maps

Chromosome mapping involves assigning a given unique sequence to a particular chromosome as described above. Once the unique sequence has been mapped to a given chromosome, it is ordered relative to other unique sequences located on the same chromosome. One approach to chromosome mapping utilizes a series of yeast artificial chromosomes (YACs) bearing several thousand long inserts derived from the chromosomes of the organism from which the extended cDNAs (or genomic DNAs obtainable therefrom) are obtained. This approach is described in Nagaraja *et al.*, *Genome Research* 7:210-222, 1997, the disclosure of which is incorporated herein by reference. Briefly, in this approach each chromosome is broken into overlapping pieces which are inserted into the YAC vector. The YAC inserts are screened using PCR or other methods to determine whether they include the 5'EST (or cDNA or genomic DNA obtainable therefrom) whose position is to be determined. Once an insert has been found which includes the 5'EST (or cDNA or genomic DNA obtainable therefrom), the insert can be analyzed by PCR or other methods to determine whether the insert also contains other sequences known to be on the chromosome or in the region from which the 5'EST (or cDNA or genomic DNA obtainable therefrom) was derived. This process can be repeated for each insert in the YAC library to determine the location of each of the extended cDNAs (or genomic DNAs obtainable therefrom) relative to one another and to other known chromosomal markers. In this way, a high resolution map of the distribution of numerous unique markers along each of the organisms chromosomes may be obtained.

As described in Example 56 below extended cDNAs (or genomic DNAs obtainable therefrom) may also be used to identify genes associated with a particular phenotype, such as hereditary disease or drug response.

3. Use of 5'ESTs or Sequences Obtained Therefrom or Fragments Thereof in Gene Identification

EXAMPLE 56

Identification of genes associated with hereditary diseases or drug response

5 This example illustrates an approach useful for the association of 5'ESTs (or cDNA or genomic DNA obtainable therefrom) with particular phenotypic characteristics. In this example, a particular 5'EST (or cDNA or genomic DNA obtainable therefrom) is used as a test probe to associate that 5'EST (or cDNA or genomic DNA obtainable therefrom) with a particular phenotypic characteristic.

10 5'ESTs (or cDNA or genomic DNA obtainable therefrom) are mapped to a particular location on a human chromosome using techniques such as those described in Examples 52 and 53 or other techniques known in the art. A search of Mendelian Inheritance in Man (McKusick in *Mendelian Inheritance in Man* (available on line through Johns Hopkins University Welch Medical Library) reveals the region of the human chromosome which
15 contains the 5'EST (or cDNA or genomic DNA obtainable therefrom) to be a very gene rich region containing several known genes and several diseases or phenotypes for which genes have not been identified. The gene corresponding to this 5'EST (or cDNA or genomic DNA obtainable therefrom) thus becomes an immediate candidate for each of these genetic diseases.

20 Cells from patients with these diseases or phenotypes are isolated and expanded in culture. PCR primers from the 5'EST (or cDNA or genomic DNA obtainable therefrom) are used to screen genomic DNA, mRNA or cDNA obtained from the patients. 5'ESTs (or cDNA or genomic DNA obtainable therefrom) that are not amplified in the patients can be positively associated with a particular disease by further
25 analysis. Alternatively, the PCR analysis may yield fragments of different lengths when the samples are derived from an individual having the phenotype associated with the disease than when the sample is derived from a healthy individual, indicating that the gene containing the 5'EST may be responsible for the genetic disease.

VI. Use of 5'EST (or cDNA or Genomic DNA Obtainable Therefrom) to Construct Vectors

The present 5'ESTs (or cDNA or genomic DNA obtainable therefrom) may also be used to construct secretion vectors capable of directing the secretion of the proteins encoded by genes therein. Such secretion vectors may facilitate the purification or enrichment of the proteins encoded by genes inserted therein by reducing the number of background proteins from which the desired protein must be purified or enriched. Exemplary secretion vectors are described in Example 57 below.

1. Construction of Secretion Vectors

EXAMPLE 57

Construction of Secretion Vectors

The secretion vectors include a promoter capable of directing gene expression in the host cell, tissue, or organism of interest. Such promoters include the Rous Sarcoma Virus promoter, the SV40 promoter, the human cytomegalovirus promoter, and other promoters familiar to those skilled in the art.

A signal sequence from a 5' EST (or cDNAs or genomic DNAs obtainable therefrom) is operably linked to the promoter such that the mRNA transcribed from the promoter will direct the translation of the signal peptide. The host cell, tissue, or organism may be any cell, tissue, or organism which recognizes the signal peptide encoded by the signal sequence in the 5' EST (or cDNA or genomic DNA obtainable therefrom). Suitable hosts include mammalian cells, tissues or organisms, avian cells, tissues, or organisms, insect cells, tissues or organisms, or yeast.

In addition, the secretion vector contains cloning sites for inserting genes encoding the proteins which are to be secreted. The cloning sites facilitate the cloning of the insert gene in frame with the signal sequence such that a fusion protein in which the signal peptide is fused to the protein encoded by the inserted gene is expressed from the mRNA transcribed from the promoter. The signal peptide directs the extracellular secretion of the fusion protein.

The secretion vector may be DNA or RNA and may integrate into the chromosome of the host, be stably maintained as an extrachromosomal replicon in the host, be an artificial chromosome, or be transiently present in the host. Many nucleic acid backbones suitable for

use as secretion vectors are known to those skilled in the art, including retroviral vectors, SV40 vectors, Bovine Papilloma Virus vectors, yeast integrating plasmids, yeast episomal plasmids, yeast artificial chromosomes, human artificial chromosomes, P element vectors, baculovirus vectors, or bacterial plasmids capable of being transiently introduced into the host.

The secretion vector may also contain a polyA signal such that the polyA signal is located downstream of the gene inserted into the secretion vector.

After the gene encoding the protein for which secretion is desired is inserted into the secretion vector, the secretion vector is introduced into the host cell, tissue, or organism using calcium phosphate precipitation, DEAE-Dextran, electroporation, liposome-mediated transfection, viral particles or as naked DNA. The protein encoded by the inserted gene is then purified or enriched from the supernatant using conventional techniques such as ammonium sulfate precipitation, immunoprecipitation, immunochromatography, size exclusion chromatography, ion exchange chromatography, and HPLC. Alternatively, the secreted protein may be in a sufficiently enriched or pure state in the supernatant or growth media of the host to permit it to be used for its intended purpose without further enrichment.

The signal sequences may also be inserted into vectors designed for gene therapy. In such vectors, the signal sequence is operably linked to a promoter such that mRNA transcribed from the promoter encodes the signal peptide. A cloning site is located downstream of the signal sequence such that a gene encoding a protein whose secretion is desired may readily be inserted into the vector and fused to the signal sequence. The vector is introduced into an appropriate host cell. The protein expressed from the promoter is secreted extracellularly, thereby producing a therapeutic effect.

The 5' ESTs may also be used to clone sequences located upstream of the 5' ESTs which are capable of regulating gene expression, including promoter sequences, enhancer sequences, and other upstream sequences which influence transcription or translation levels. Once identified and cloned, these upstream regulatory sequences may be used in expression vectors designed to direct the expression of an inserted gene in a desired spatial, temporal, developmental, or quantitative fashion. Example 58 describes a method for cloning sequences upstream of the extended cDNAs or 5' ESTs.

2. Identification of Upstream Sequences With Promoting or Regulatory Activities

EXAMPLE 58

Use of Extended cDNAs or 5' ESTs to Clone Upstream Sequences from Genomic DNA

Sequences derived from extended cDNAs or 5' ESTs may be used to isolate the
5 promoters of the corresponding genes using chromosome walking techniques. In one
chromosome walking technique, which utilizes the GenomeWalker™ kit available from
Clontech, five complete genomic DNA samples are each digested with a different restriction
enzyme which has a 6 base recognition site and leaves a blunt end. Following digestion,
oligonucleotide adapters are ligated to each end of the resulting genomic DNA fragments.

10 For each of the five genomic DNA libraries, a first PCR reaction is performed
according to the manufacturer's instructions (which are incorporated herein by reference)
using an outer adaptor primer provided in the kit and an outer gene specific primer. The gene
specific primer should be selected to be specific for the extended cDNA or 5' EST of interest
and should have a melting temperature, length, and location in the extended cDNA or 5' EST
15 which is consistent with its use in PCR reactions. Each first PCR reaction contains 5 ng of
genomic DNA, 5 µl of 10X Tth reaction buffer, 0.2 mM of each dNTP, 0.2 µM each of outer
adaptor primer and outer gene specific primer, 1.1 mM of Mg(OAc)₂, and 1 µl of the Tth
polymerase 50X mix in a total volume of 50 µl. The reaction cycle for the first PCR reaction
is as follows: 1 min - 94°C / 2 sec - 94°C, 3 min - 72°C (7 cycles) / 2 sec - 94°C, 3 min -
20 67°C (32 cycles) / 5 min - 67°C.

The product of the first PCR reaction is diluted and used as a template for a
second PCR reaction according to the manufacturer's instructions using a pair of nested
primers which are located internally on the amplicon resulting from the first PCR
reaction. For example, 5 µl of the reaction product of the first PCR reaction mixture
25 may be diluted 180 times. Reactions are made in a 50 µl volume having a composition
identical to that of the first PCR reaction except the nested primers are used. The first
nested primer is specific for the adaptor, and is provided with the GenomeWalker™ kit.
The second nested primer is specific for the particular extended cDNA or 5' EST for
which the promoter is to be cloned and should have a melting temperature, length, and
30 location in the extended cDNA or 5' EST which is consistent with its use in PCR
reactions. The reaction parameters of the second PCR reaction are as follows: 1 min -

94°C / 2 sec - 94°C, 3 min - 72°C (6 cycles) / 2 sec - 94°C, 3 min - 67°C (25 cycles) / 5 min - 67°C. The product of the second PCR reaction is purified, cloned, and sequenced using standard techniques.

Alternatively, two or more human genomic DNA libraries can be constructed by using two or more restriction enzymes. The digested genomic DNA is cloned into vectors which can be converted into single stranded, circular, or linear DNA. A biotinylated oligonucleotide comprising at least 15 nucleotides from the extended cDNA or 5' EST sequence is hybridized to the single stranded DNA. Hybrids between the biotinylated oligonucleotide and the single stranded DNA containing the extended cDNA or EST sequence are isolated as described in Example 29 above. Thereafter, the single stranded DNA containing the extended cDNA or EST sequence is released from the beads and converted into double stranded DNA using a primer specific for the extended cDNA or 5' EST sequence or a primer corresponding to a sequence included in the cloning vector. The resulting double stranded DNA is transformed into bacteria. DNAs containing the 5' EST or extended cDNA sequences are identified by colony PCR or colony hybridization.

Once the upstream genomic sequences have been cloned and sequenced as described above, prospective promoters and transcription start sites within the upstream sequences may be identified by comparing the sequences upstream of the extended cDNAs or 5' ESTs with databases containing known transcription start sites, transcription factor binding sites, or promoter sequences.

In addition, promoters in the upstream sequences may be identified using promoter reporter vectors as described in Example .

25

EXAMPLE 59

Identification of Promoters in Cloned Upstream Sequences

The genomic sequences upstream of the extended cDNAs or 5' ESTs are cloned into a suitable promoter reporter vector, such as the pSEAP-Basic, pSEAP-Enhancer, p β gal-Basic, p β gal-Enhancer, or pEGFP-1 Promoter Reporter vectors available from Clontech. Briefly, each of these promoter reporter vectors include multiple cloning sites positioned upstream of a reporter gene encoding a readily assayable protein such as secreted alkaline

30

phosphatase, β galactosidase, or green fluorescent protein. The sequences upstream of the extended cDNAs or 5' ESTs are inserted into the cloning sites upstream of the reporter gene in both orientations and introduced into an appropriate host cell. The level of reporter protein is assayed and compared to the level obtained from a vector which lacks an insert in the cloning site. The presence of an elevated expression level in the vector containing the insert with respect to the control vector indicates the presence of a promoter in the insert. If necessary, the upstream sequences can be cloned into vectors which contain an enhancer for augmenting transcription levels from weak promoter sequences. A significant level of expression above that observed with the vector lacking an insert indicates that a promoter sequence is present in the inserted upstream sequence.

Appropriate host cells for the promoter reporter vectors may be chosen based on the results of the above described determination of expression patterns of the extended cDNAs and ESTs. For example, if the expression pattern analysis indicates that the mRNA corresponding to a particular extended cDNA or 5' EST is expressed in fibroblasts, the promoter reporter vector may be introduced into a human fibroblast cell line.

Promoter sequences within the upstream genomic DNA may be further defined by constructing nested deletions in the upstream DNA using conventional techniques such as Exonuclease III digestion. The resulting deletion fragments can be inserted into the promoter reporter vector to determine whether the deletion has reduced or obliterated promoter activity. In this way, the boundaries of the promoters may be defined. If desired, potential individual regulatory sites within the promoter may be identified using site directed mutagenesis or linker scanning to obliterate potential transcription factor binding sites within the promoter individually or in combination. The effects of these mutations on transcription levels may be determined by inserting the mutations into the cloning sites in the promoter reporter vectors.

EXAMPLE 60

Cloning and Identification of Promoters

Using the method described in Example 58 above with 5' ESTs, sequences upstream of several genes were obtained. Using the primer pairs GGG AAG ATG GAG ATA GTA TTG CCT G (SEQ ID NO:29) and CTG CCA TGT ACA TGA TAG AGA GAT TC (SEQ

ID NO:30), the promoter having the internal designation P13H2 (SEQ ID NO:31) was obtained.

Using the primer pairs GTA CCA GGGG ACT GTG ACC ATT GC (SEQ ID NO:32) and CTG TGA CCA TTG CTC CCA AGA GAG (SEQ ID NO:33), the promoter
5 having the internal designation P15B4 (SEQ ID NO:34) was obtained.

Using the primer pairs CTG GGA TGG AAG GCA CGG TA (SEQ ID NO:35) and GAG ACC ACA CAG CTA GAC AA (SEQ ID NO:36), the promoter having the internal designation P29B6 (SEQ ID NO:37) was obtained.

Figure 4 provides a schematic description of the promoters isolated and the way they
10 are assembled with the corresponding 5' tags. The upstream sequences were screened for the presence of motifs resembling transcription factor binding sites or known transcription start sites using the computer program MatInspector release 2.0, August 1996.

Table VII describes the transcription factor binding sites present in each of these promoters. The columns labeled matrix provides the name of the MatInspector matrix used.
15 The column labeled position provides the 5' position of the promoter site. Numeration of the sequence starts from the transcription site as determined by matching the genomic sequence with the 5' EST sequence. The column labeled "orientation" indicates the DNA strand on which the site is found, with the + strand being the coding strand as determined by matching the genomic sequence with the sequence of the 5' EST. The column labeled "score" provides
20 the MatInspector score found for this site. The column labeled "length" provides the length of the site in nucleotides. The column labeled "sequence" provides the sequence of the site found.

Bacterial clones containing plasmids containing the promoter sequences described above described above are presently stored in the inventor's laboratories under the internal
25 identification numbers provided above. The inserts may be recovered from the deposited materials by growing an aliquot of the appropriate bacterial clone in the appropriate medium.

The plasmid DNA can then be isolated using plasmid isolation procedures familiar to those skilled in the art such as alkaline lysis minipreps or large scale alkaline lysis plasmid isolation procedures. If desired the plasmid DNA may be further enriched by centrifugation on a
30 cesium chloride gradient, size exclusion chromatography, or anion exchange chromatography.

The plasmid DNA obtained using these procedures may then be manipulated using standard

cloning techniques familiar to those skilled in the art. Alternatively, a PCR can be done with primers designed at both ends of the EST insertion. The PCR product which corresponds to the 5' EST can then be manipulated using standard cloning techniques familiar to those skilled in the art.

5 The promoters and other regulatory sequences located upstream of the extended cDNAs or 5' ESTs may be used to design expression vectors capable of directing the expression of an inserted gene in a desired spatial, temporal, developmental, or quantitative manner. A promoter capable of directing the desired spatial, temporal, developmental, and quantitative patterns may be selected using the results of the expression analysis described in
10 Example 26 above. For example, if a promoter which confers a high level of expression in muscle is desired, the promoter sequence upstream of an extended cDNA or 5' EST derived from an mRNA which is expressed at a high level in muscle, as determined by the method of Example 26, may be used in the expression vector.

 Preferably, the desired promoter is placed near multiple restriction sites to facilitate
15 the cloning of the desired insert downstream of the promoter, such that the promoter is able to drive expression of the inserted gene. The promoter may be inserted in conventional nucleic acid backbones designed for extrachromosomal replication, integration into the host chromosomes or transient expression. Suitable backbones for the present expression vectors include retroviral backbones, backbones from eukaryotic episomes such as SV40 or Bovine
20 Papilloma Virus, backbones from bacterial episomes, or artificial chromosomes.

 Preferably, the expression vectors also include a polyA signal downstream of the multiple restriction sites for directing the polyadenylation of mRNA transcribed from the gene inserted into the expression vector.

 Following the identification of promoter sequences using the procedures of Examples
25 58-60, proteins which interact with the promoter may be identified as described in Example 61 below.

EXAMPLE 61**Identification of Proteins Which Interact with Promoter Sequences, Upstream****Regulatory Sequences, or mRNA**

Sequences within the promoter region which are likely to bind transcription factors
5 may be identified by homology to known transcription factor binding sites or through
conventional mutagenesis or deletion analyses of reporter plasmids containing the promoter
sequence. For example, deletions may be made in a reporter plasmid containing the promoter
sequence of interest operably linked to an assayable reporter gene. The reporter plasmids
carrying various deletions within the promoter region are transfected into an appropriate host
10 cell and the effects of the deletions on expression levels is assessed. Transcription factor
binding sites within the regions in which deletions reduce expression levels may be further
localized using site directed mutagenesis, linker scanning analysis, or other techniques familiar
to those skilled in the art.

Nucleic acids encoding proteins which interact with sequences in the promoter
15 may be identified using one-hybrid systems such as those described in the manual
accompanying the Matchmaker One-Hybrid System kit available from Clontech (Catalog
No. K1603-1), the disclosure of which is incorporated herein by reference. Briefly, the
Matchmaker One-hybrid system is used as follows. The target sequence for which it is
desired to identify binding proteins is cloned upstream of a selectable reporter gene and
20 integrated into the yeast genome. Preferably, multiple copies of the target sequences are
inserted into the reporter plasmid in tandem. A library comprised of fusions between
cDNAs to be evaluated for the ability to bind to the promoter and the activation domain
of a yeast transcription factor, such as GAL4, is transformed into the yeast strain
containing the integrated reporter sequence. The yeast are plated on selective media to
25 select cells expressing the selectable marker linked to the promoter sequence. The
colonies which grow on the selective media contain genes encoding proteins which bind
the target sequence. The inserts in the genes encoding the fusion proteins are further
characterized by sequencing. In addition, the inserts may be inserted into expression
vectors or *in vitro* transcription vectors. Binding of the polypeptides encoded by the
30 inserts to the promoter DNA may be confirmed by techniques familiar to those skilled in
the art, such as gel shift analysis or DNase protection analysis.

VII. Use of 5' ESTs (or cDNAs or Genomic DNAs Obtainable Therefrom) in Gene Therapy

The present invention also comprises the use of 5'ESTs (or cDNA or genomic DNA obtainable therefrom) in gene therapy strategies, including antisense and triple helix strategies as described in Examples 62 and 63 below. In antisense approaches, nucleic acid sequences complementary to an mRNA are hybridized to the mRNA intracellularly, thereby blocking the expression of the protein encoded by the mRNA. The antisense sequences may prevent gene expression through a variety of mechanisms. For example, the antisense sequences may inhibit the ability of ribosomes to translate the mRNA. Alternatively, the antisense sequences may block transport of the mRNA from the nucleus to the cytoplasm, thereby limiting the amount of mRNA available for translation. Another mechanism through which antisense sequences may inhibit gene expression is by interfering with mRNA splicing. In yet another strategy, the antisense nucleic acid may be incorporated in a ribozyme capable of specifically cleaving the target mRNA.

EXAMPLE 62

Preparation and Use of Antisense Oligonucleotides

The antisense nucleic acid molecules to be used in gene therapy may be either DNA or RNA sequences. They may comprise a sequence complementary to the sequence of the 5'EST (or cDNA or genomic DNA obtainable therefrom). The antisense nucleic acids should have a length and melting temperature sufficient to permit formation of an intracellular duplex with sufficient stability to inhibit the expression of the mRNA in the duplex. Strategies for designing antisense nucleic acids suitable for use in gene therapy are disclosed in Green *et al.*, *Ann. Rev. Biochem.* 55:569-597, 1986; and Izant and Weintraub, *Cell* 36:1007-1015, 1984, which are hereby incorporated by reference.

In some strategies, antisense molecules are obtained from a nucleotide sequence encoding a protein by reversing the orientation of the coding region with respect to a promoter so as to transcribe the opposite strand from that which is normally transcribed in the cell. The antisense molecules may be transcribed using *in vitro* transcription systems such as those which employ T7 or SP6 polymerase to generate the transcript. Another approach

involves transcription of the antisense nucleic acids *in vivo* by operably linking DNA containing the antisense sequence to a promoter in an expression vector.

Alternatively, oligonucleotides which are complementary to the strand normally transcribed in the cell may be synthesized *in vitro*. Thus, the antisense nucleic acids are complementary to the corresponding mRNA and are capable of hybridizing to the mRNA to create a duplex. In some embodiments, the antisense sequences may contain modified sugar phosphate backbones to increase stability and make them less sensitive to RNase activity. Examples of modifications suitable for use in antisense strategies are described by Rossi *et al.*, *Pharmacol. Ther.* 50(2):245-254, 1991, which is hereby incorporated by reference.

Various types of antisense oligonucleotides complementary to the sequence of the 5'EST (or cDNA or genomic DNA obtainable therefrom) may be used. In one preferred embodiment, stable and semi-stable antisense oligonucleotides described in International Application No. PCT WO94/23026, hereby incorporated by reference, are used. In these molecules, the 3' end or both the 3' and 5' ends are engaged in intramolecular hydrogen bonding between complementary base pairs. These molecules are better able to withstand exonuclease attacks and exhibit increased stability compared to conventional antisense oligonucleotides.

In another preferred embodiment, the antisense oligodeoxynucleotides against herpes simplex virus types 1 and 2 described in International Application No. WO 95/04141, hereby incorporated by reference, are used.

In yet another preferred embodiment, the covalently cross-linked antisense oligonucleotides described in International Application No. WO 96/31523, hereby incorporated by reference, are used. These double- or single-stranded oligonucleotides comprise one or more, respectively, inter- or intra-oligonucleotide covalent cross-linkages, wherein the linkage consists of an amide bond between a primary amine group of one strand and a carboxyl group of the other strand or of the same strand, respectively, the primary amine group being directly substituted in the 2' position of the strand nucleotide monosaccharide ring, and the carboxyl group being carried by an aliphatic spacer group substituted on a nucleotide or nucleotide analog of the other strand or the same strand, respectively.

The antisense oligodeoxynucleotides and oligonucleotides disclosed in International Application No. WO 92/18522, incorporated by reference, may also be used. These molecules are stable to degradation and contain at least one transcription control recognition sequence which binds to control proteins and are effective as decoys therefore. These
5 molecules may contain "hairpin" structures, "dumbbell" structures, "modified dumbbell" structures, "cross-linked" decoy structures and "loop" structures.

In another preferred embodiment, the cyclic double-stranded oligonucleotides described in European Patent Application No. 0 572 287 A2, hereby incorporated by reference are used. These ligated oligonucleotide "dumbbells" contain the binding site for a
10 transcription factor and inhibit expression of the gene under control of the transcription factor by sequestering the factor.

Use of the closed antisense oligonucleotides disclosed in International Application No. WO 92/19732, hereby incorporated by reference, is also contemplated. Because these molecules have no free ends, they are more resistant to degradation by exonucleases than are
15 conventional oligonucleotides. These oligonucleotides may be multifunctional, interacting with several regions which are not adjacent to the target mRNA.

The appropriate level of antisense nucleic acids required to inhibit gene expression may be determined using *in vitro* expression analysis. The antisense molecule may be introduced into the cells by diffusion, injection, infection, transfection or h-region-mediated
20 import using procedures known in the art. For example, the antisense nucleic acids can be introduced into the body as a bare or naked oligonucleotide, oligonucleotide encapsulated in lipid, oligonucleotide sequence encapsidated by viral protein, or as an oligonucleotide operably linked to a promoter contained in an expression vector. The expression vector may be any of a variety of expression vectors known in the art, including retroviral or viral vectors,
25 vectors capable of extrachromosomal replication, or integrating vectors. The vectors may be DNA or RNA.

The antisense molecules are introduced onto cell samples at a number of different concentrations preferably between $1 \times 10^{-10} \text{M}$ to $1 \times 10^{-4} \text{M}$. Once the minimum concentration that can adequately control gene expression is identified, the optimized dose is translated into
30 a dosage suitable for use *in vivo*. For example, an inhibiting concentration in culture of 1×10^{-7} translates into a dose of approximately 0.6 mg/kg bodyweight. Levels of oligonucleotide

approaching 100 mg/kg bodyweight or higher may be possible after testing the toxicity of the oligonucleotide in laboratory animals. It is additionally contemplated that cells from the vertebrate are removed, treated with the antisense oligonucleotide, and reintroduced into the vertebrate.

5 It is further contemplated that the antisense oligonucleotide sequence is incorporated into a ribozyme sequence to enable the antisense to specifically bind and cleave its target mRNA. For technical applications of ribozyme and antisense oligonucleotides see Rossi *et al.*, *supra*.

10 In a preferred application of this invention, the polypeptide encoded by the gene is first identified, so that the effectiveness of antisense inhibition on translation can be monitored using techniques that include but are not limited to antibody-mediated tests such as RIAs and ELISA, functional assays, or radiolabeling.

15 The 5' ESTs of the present invention (or cDNAs or genomic DNAs obtainable therefrom) may also be used in gene therapy approaches based on intracellular triple helix formation. Triple helix oligonucleotides are used to inhibit transcription from a genome. They are particularly useful for studying alterations in cell activity as it is associated with a particular gene. The 5' EST sequences (or cDNAs or genomic DNAs obtainable therefrom) of the present invention or, more preferably, a portion of those sequences, can be used to inhibit gene expression in individuals having diseases associated with expression of a particular gene. Similarly, a portion of 5' EST sequences (or cDNAs or genomic DNAs obtainable therefrom) can be used to study the effect of inhibiting transcription of a particular gene within a cell. Traditionally, homopurine sequences were considered the most useful for triple helix strategies. However, homopyrimidine sequences can also inhibit gene expression. Such homopyrimidine oligonucleotides bind to the major groove at
25 homopurine:homopyrimidine sequences. Thus, both types of sequences from the 5'EST or from the gene corresponding to the 5'EST are contemplated within the scope of this invention.

EXAMPLE 63

30 Preparation and Use of Triple Helix Probes

The sequences of the 5' ESTs (or cDNAs or genomic DNAs obtainable therefrom) are scanned to identify 10-mer to 20-mer homopyrimidine or homopurine stretches which could be used in triple-helix based strategies for inhibiting gene expression. Following identification of candidate homopyrimidine or homopurine stretches, their efficiency in inhibiting gene expression is assessed by introducing varying amounts of oligonucleotides containing the candidate sequences into tissue culture cells which normally express the target gene. The oligonucleotides may be prepared on an oligonucleotide synthesizer or they may be purchased commercially from a company specializing in custom oligonucleotide synthesis, such as GENSET, Paris, France.

The oligonucleotides may be introduced into the cells using a variety of methods known to those skilled in the art, including but not limited to calcium phosphate precipitation, DEAE-Dextran, electroporation, liposome-mediated transfection or native uptake.

Treated cells are monitored for altered cell function or reduced gene expression using techniques such as Northern blotting, RNase protection assays, or PCR based strategies to monitor the transcription levels of the target gene in cells which have been treated with the oligonucleotide. The cell functions to be monitored are predicted based upon the homologies of the target gene corresponding to the extended cDNA from which the oligonucleotide was derived with known gene sequences that have been associated with a particular function. The cell functions can also be predicted based on the presence of abnormal physiologies within cells derived from individuals with a particular inherited disease, particularly when the extended cDNA is associated with the disease using techniques described in Example 56.

The oligonucleotides which are effective in inhibiting gene expression in tissue culture cells may then be introduced *in vivo* using the techniques described above and in Example 62 at a dosage calculated based on the *in vitro* results, as described in Example 62.

In some embodiments, the natural (beta) anomers of the oligonucleotide units can be replaced with alpha anomers to render the oligonucleotide more resistant to nucleases. Further, an intercalating agent such as ethidium bromide, or the like, can be attached to the 3' end of the alpha oligonucleotide to stabilize the triple helix. For information on the generation of oligonucleotides suitable for triple helix formation see Griffin *et al.*, *Science* 245:967-971, 1989, which is hereby incorporated by this reference.

EXAMPLE 64

Use of cDNAs Obtained Using the 5' ESTs to Express an Encoded Protein in a Host
Organism

The cDNAs obtained as described above using the 5' ESTs of the present invention
5 may also be used to express an encoded protein in a host organism to produce a beneficial
effect. In such procedures, the encoded protein may be transiently expressed in the host
organism or stably expressed in the host organism. The encoded protein may have any of the
activities described above. The encoded protein may be a protein which the host organism
lacks or, alternatively, the encoded protein may augment the existing levels of the protein in
10 the host organism.

A full length extended cDNA encoding the signal peptide and the mature protein, or
an extended cDNA encoding only the mature protein is introduced into the host organism.
The extended cDNA may be introduced into the host organism using a variety of techniques
known to those of skill in the art. For example, the extended cDNA may be injected into the
15 host organism as naked DNA such that the encoded protein is expressed in the host organism,
thereby producing a beneficial effect.

Alternatively, the extended cDNA may be cloned into an expression vector
downstream of a promoter which is active in the host organism. The expression vector may
be any of the expression vectors designed for use in gene therapy, including viral or retroviral
20 vectors. The expression vector may be directly introduced into the host organism such that
the encoded protein is expressed in the host organism to produce a beneficial effect. In
another approach, the expression vector may be introduced into cells *in vitro*. Cells
containing the expression vector are thereafter selected and introduced into the host
organism, where they express the encoded protein to produce a beneficial effect.

25

EXAMPLE 65

Use of Signal Peptides Encoded by 5' ESTs or Sequences obtained Therefrom
to Import Proteins Into Cells

The short core hydrophobic region (h) of signal peptides encoded by the 5'ESTS or
30 extended cDNAs derived from SEQ ID NOs: 38-184 may also be used as a carrier to import
a peptide or a protein of interest, so-called cargo, into tissue culture cells (Lin *et al.*, *J. Biol.*

Chem., 270: 14225-14258, 1995; Du *et al.*, *J. Peptide Res.*, 51: 235-243, 1998; Rojas *et al.*, *Nature Biotech.*, 16: 370-375, 1998).

When cell permeable peptides of limited size (approximately up to 25 amino acids) are to be translocated across cell membrane, chemical synthesis may be used in order to add
5 the h region to either the C-terminus or the N-terminus to the cargo peptide of interest. Alternatively, when longer peptides or proteins are to be imported into cells, nucleic acids can be genetically engineered, using techniques familiar to those skilled in the art, in order to link the extended cDNA sequence encoding the h region to the 5' or the 3' end of a DNA sequence coding for a cargo polypeptide. Such genetically engineered nucleic acids are then
10 translated either *in vitro* or *in vivo* after transfection into appropriate cells, using conventional techniques to produce the resulting cell permeable polypeptide. Suitable hosts cells are then simply incubated with the cell permeable polypeptide which is then translocated across the membrane.

This method may be applied to study diverse intracellular functions and cellular
15 processes. For instance, it has been used to probe functionally relevant domains of intracellular proteins and to examine protein-protein interactions involved in signal transduction pathways (Lin *et al.*, *supra*; Lin *et al.*, *J. Biol. Chem.*, 271: 5305-5308, 1996; Rojas *et al.*, *J. Biol. Chem.*, 271: 27456-27461, 1996; Liu *et al.*, *Proc. Natl. Acad. Sci. USA*, 93: 11819-11824, 1996; Rojas *et al.*, *Bioch. Biophys. Res. Commun.*, 234: 675-680, 1997).

20 Such techniques may be used in cellular therapy to import proteins producing therapeutic effects. For instance, cells isolated from a patient may be treated with imported therapeutic proteins and then re-introduced into the host organism.

Alternatively, the h region of signal peptides of the present invention could be used in combination with a nuclear localization signal to deliver nucleic acids into cell nucleus. Such
25 oligonucleotides may be antisense oligonucleotides or oligonucleotides designed to form triple helixes, as described in examples 62 and 63 respectively, in order to inhibit processing and/or maturation of a target cellular RNA.

As discussed above, the cDNAs or portions thereof obtained using the 5' ESTs of the
30 present invention can be used for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for

tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; for selecting and making oligomers for attachment to a "gene chip" or other support, including for examination for expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, that described in Gyuris *et al.*, *Cell* 75:791-803, 1993, the disclosure of which is hereby incorporated by reference) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.

The proteins or polypeptides provided by the present invention can similarly be used in assays to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation *Molecular Cloning: A*

Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, Fritsch and Maniatis eds., 1989, and *Methods in Enzymology: Guide to Molecular Cloning Techniques*, Academic Press, Berger and Kimmel eds., 1987.

5 Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the
10 case of microorganisms, the protein or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.

Although this invention has been described in terms of certain preferred embodiments, other embodiments which will be apparent to those of ordinary skill in the art in view of the disclosure herein are also within the scope of this invention. Accordingly, the scope of the
15 invention is intended to be defined only by reference to the appended claims. All documents cited herein are incorporated herein by reference in their entirety.

| Step | Search characteristic | | Selection Characteristics | | |
|---------------|-----------------------|--------|---------------------------|--------------|-------------|
| | Program | Strand | Parameters | Identity (%) | Length (bp) |
| miscellaneous | blastn | both | S=61 X=16 | 90 | 17 |
| tRNA | fasta | both | - | 80 | 60 |
| rRNA | blastn | both | S=108 | 80 | 40 |
| mtRNA | blastn | both | S=108 | 80 | 40 |
| Prokaryotic | blastn | both | S=144 | 90 | 40 |
| Fungal | blastn | both | S=144 | 90 | 40 |
| Alu | fasta* | both | - | 70 | 40 |
| L1 | blastn | both | S=72 | 70 | 40 |
| Repeats | blastn | both | S=72 | 70 | 40 |
| Promoters | blastn | top | S=54 X=16 | 90 | 15† |
| Vertebrate | fasta* | both | S=108 | 90 | 30 |
| ESTs | blastn | both | S=108 X=16 | 90 | 30 |
| Proteins | blastx [‡] | top | E = 0.001 | - | - |

Table 1: Parameters used for each step of EST analysis

- * use "Quick Fast" Database scanner
- † alignment further constrained to begin closer than 10bp to EST's end
- ‡ using BLOSUM62 substitution matrix

TABLE II

| <u>SEQ. ID NO.</u> | <u>CATEGORY</u> | <u>VON HEIJNE SCORE</u> | <u>TISSUE SOURCE</u> | <u>INTERNAL DESIGNATION</u> |
|------------------------|-----------------|-----------------------------|--------------------------|---------------------------------|
| ID38 | new | 15.8 | Fetal liver | 65-5-1-C9-PU |
| ID39 | new | 11.4 | Lung (cells) | 30-4-2-A11-PU |
| ID40 | new | 11.1 | Large intestine | 83-3-2-H8-PU |
| ID41 | new | 10.4 | Pancreas | 19-8-1-F2 |
| ID42 | new | 10 | Liver | 22-11-2-H9-PU |
| ID43 | new | 9.4 | Lung (cells) | 30-12-1-H1-PU |
| ID44 | new | 9.2 | Lung | 59-1-3-E7-PU |
| ID45 | new | 9.1 | Large intestine | 83-2-2-D9-PU |
| ID46 | new | 9 | Lung (cells) | 30-2-1-G4-PU |
| ID47 | new | 8.9 | Colon | 23-11-3-C4-PU |
| ID48 | new | 8.9 | Large intestine | 83-2-1-C3-PU |
| ID49 | new | 8.6 | Lung (cells) | 30-3-2-H6-PU |
| ID50 | new | 8.6 | Lung (cells) | 30-13-1-D9-PU |
| ID51 | new | 8.6 | Colon | 23-1-4-E6-PU |
| ID52 | new | 8.2 | Liver | 22-3-3-C4-PU |
| ID53 | new | 8 | Pancreas | 19-4-4-H9 |
| ID54 | new | 7.7 | Lung (cells) | 30-8-1-F2-PU |
| ID55 | new | 7.5 | Lung (cells) | 30-6-1-B1-PU |
| ID56 | new | 7.5 | Lung (cells) | 30-6-3-H1-PU |
| ID57 | new | 7.5 | Colon | 23-10-3-F10-PU |
| ID58 | new | 7.4 | Lung | 42-1-1-E3-PU |
| ID59 | new | 7.3 | Lung | 42-3-3-B1-PU |
| ID60 | new | 7.3 | Lung | 42-3-4-B1-PU |
| ID61 | new | 7.2 | Lung | 59-9-2-E6-PU |
| ID62 | new | 7 | Thyroid | 84-4-2-D2-PU |
| ID63 | new | 7 | Lung (cells) | 30-8-3-E3-PU |
| ID64 | new | 7 | Lung | 59-9-4-A10-PU |
| ID65 | new | 7 | Lung (cells) | 30-10-2-A2-PU |
| ID66 | new | 6.9 | Lung | 59-9-1-B9-PU |
| ID67 | new | 6.5 | Fetal liver | 65-4-4-A3-PU |
| ID68 | new | 6.5 | Lung (cells) | 30-2-1-C8-PU |
| ID69 | new | 6.4 | Colon | 23-9-4-F2-PU |
| ID70 | new | 6.4 | Lung (cells) | 30-9-3-A2-PU |
| ID71 | new | 6.3 | Liver | 22-11-2-A9-PU |
| ID72 | new | 6.3 | Liver | 22-13-4-G8-PU |
| ID73 | new | 6.2 | Liver | 22-1-2-A11-PU |
| ID74 | new | 6.1 | Lung (cells) | 30-6-1-D11-PU |
| ID75 | new | 5.9 | Thyroid | 84-4-3-A5-PU |
| ID76 | new | 5.8 | Lung (cells) | 30-5-4-C1-PU |
| ID77 | new | 5.7 | Liver | 22-5-2-A4-PU |
| ID78 | new | 5.7 | Lung (cells) | 30-2-4-B7-PU |
| ID79 | new | 5.6 | Pancreas | 46-3-4-G2-PU |
| ID80 | new | 5.6 | Thyroid | 84-4-3-E9-PU |
| ID81 | new | 5.5 | Lung (cells) | 30-7-2-C7-PU |
| ID82 | new | 5.5 | Lung (cells) | 30-6-3-H11-PU |
| ID83 | new | 5.5 | Large intestine | 83-5-3-C5-PU |
| ID84 | new | 5.4 | Pancreas | 19-1-4-D10 |
| ID85 | new | 5.3 | Lung | 59-5-3-A7-PU |
| ID86 | new | 5.2 | Lung (cells) | 30-13-1-G11-PU |

| <u>SEQ. ID NO.</u> | <u>CATEGORY</u> | <u>VON HEIJNE SCORE</u> | <u>TISSUE SOURCE</u> | <u>INTERNAL DESIGNATION</u> |
|------------------------|-----------------|-----------------------------|--------------------------|---------------------------------|
| ID87 | new | 5.2 | Lung (cells) | 30-7-3-E3-PU |
| ID88 | new | 5.2 | Lung (cells) | 30-9-1-B10-PU |
| ID89 | new | 5.1 | Lung (cells) | 30-8-1-G2-PU |
| ID90 | new | 5.1 | Lung (cells) | 30-13-2-E9-PU |
| ID91 | new | 5.1 | Thyroid | 84-3-3-B4-PU |
| ID92 | new | 5 | Lung (cells) | 30-4-4-D2-PU |
| ID93 | new | 4.9 | Colon | 23-2-4-D1-PU |
| ID94 | new | 4.9 | Colon | 23-9-1-A7-PU |
| ID95 | new | 4.9 | Lung (cells) | 30-11-3-E2-PU |
| ID96 | new | 4.9 | Fetal liver | 65-4-4-C8-PU |
| ID97 | new | 4.9 | Large intestine | 83-2-4-H6-PU |
| ID98 | new | 4.8 | Lung (cells) | 30-5-2-G2-PU |
| ID99 | new | 4.8 | Liver | 22-9-4-B1-PU |
| ID100 | new | 4.8 | Lung | 42-2-2-F2-PU |
| ID101 | new | 4.8 | Lung (cells) | 30-1-1-D5-PU |
| ID102 | new | 4.8 | Thyroid | 84-2-2-G8-PU |
| ID103 | new | 4.7 | Colon | 23-10-4-H5-PU |
| ID104 | new | 4.7 | Colon | 23-8-3-B1-PU |
| ID105 | new | 4.7 | Lung (cells) | 30-8-3-A7-PU |
| ID106 | new | 4.6 | Lung (cells) | 30-11-2-D9-PU |
| ID107 | new | 4.5 | Lung (cells) | 30-6-4-E3-PU |
| ID108 | new | 4.5 | Large intestine | 83-3-2-D3-PU |
| ID109 | new | 4.5 | Pancreas | 19-2-2-E7 |
| ID110 | new | 4.4 | Pancreas | 46-1-2-H7-PU |
| ID111 | new | 4.4 | Colon | 23-1-3-C5-PU |
| ID112 | new | 4.3 | Lung (cells) | 30-11-2-E12-PU |
| ID113 | new | 4.3 | Fetal liver | 65-2-3-E3-PU |
| ID114 | new | 4.3 | Colon | 23-11-1-G5-PU |
| ID115 | new | 4.2 | Pancreas | 19-2-2-B4 |
| ID116 | new | 4.2 | Lung (cells) | 30-4-4-H10-PU |
| ID117 | new | 4.2 | Lung | 42-3-2-F6-PU |
| ID118 | new | 4.1 | Lung (cells) | 30-1-4-G3-PU |
| ID119 | new | 4.1 | Pancreas | 19-4-2-F6 |
| ID120 | new | 4 | Lung | 42-3-3-F2-PU |
| ID121 | new | 4 | Large intestine | 83-1-3-H10-PU |
| ID122 | new | 4 | Lung (cells) | 30-11-1-D4-PU |
| ID123 | new | 4 | Fetal liver | 65-5-1-E9-PU |
| ID124 | new | 4 | Lung (cells) | 30-2-3-D4-PU |
| ID125 | new | 4 | Colon | 23-8-4-G8-PU |
| ID126 | new | 3.9 | Pancreas | 19-1-2-D9 |
| ID127 | new | 3.9 | Lung (cells) | 30-7-2-D3-PU |
| ID128 | new | 3.8 | Pancreas | 19-3-3-H4 |
| ID129 | new | 3.7 | Fetal liver | 65-4-2-F9-PU |
| ID130 | new | 3.6 | Lung (cells) | 30-3-3-G4-PU |
| ID131 | new | 3.6 | Fetal liver | 65-5-2-C3-PU |
| ID132 | new | 3.6 | Liver | 52-3-2-B1-PU |
| ID133 | new | 3.6 | Large intestine | 83-2-2-B12-PU |
| ID134 | new | 3.6 | Liver | 22-10-4-C1-PU |
| ID135 | new | 3.6 | Thyroid | 84-4-1-H8-PU |
| ID136 | new | 3.6 | Lung (cells) | 30-13-4-B11-PU |
| ID137 | new | 3.6 | Lung (cells) | 30-13-1-G12-PU |

| <u>SEQ. ID</u> <u>NO.</u> | <u>CATEGORY</u> | <u>VON HEIJNE</u> <u>SCORE</u> | <u>TISSUE</u> <u>SOURCE</u> | <u>INTERNAL</u> <u>DESIGNATION</u> |
|------------------------------|-----------------|-----------------------------------|--------------------------------|---------------------------------------|
| ID138 | new | 3.5 | Pancreas | 46-1-4-E11-PU |
| ID139 | new | 3.5 | Thyroid | 84-1-3-C10-PU |
| ID140 | new | 3.5 | Thyroid | 84-4-4-H11-PU |
| ID141 | new | 3.5 | Lung | 59-8-3-A1-PU |
| ID142 | ext-est-not-vrt | 7.6 | Large intestine | 83-4-2-H4-PU |
| ID143 | ext-est-not-vrt | 6.6 | Lung (cells) | 30-2-2-C3-PU |
| ID144 | ext-est-not-vrt | 6.6 | Thyroid | 84-4-1-F7-PU |
| ID145 | ext-est-not-vrt | 5.4 | Pancreas | 19-10-1-C2 |
| ID146 | ext-est-not-vrt | 5.2 | Thyroid | 84-5-1-F9-PU |
| ID147 | ext-est-not-vrt | 5 | Lung | 59-9-3-A5-PU |
| ID148 | ext-est-not-vrt | 4.7 | Lung (cells) | 30-7-3-H4-PU |
| ID149 | ext-est-not-vrt | 4.5 | Lung (cells) | 30-11-3-F3-PU |
| ID150 | ext-est-not-vrt | 4.4 | Lung (cells) | 30-12-1-D12-PU |
| ID151 | est-not-ext | 16.4 | Liver | 22-5-3-G5-PU |
| ID152 | est-not-ext | 14.4 | Large intestine | 83-3-2-E8-PU |
| ID153 | est-not-ext | 10.3 | Liver | 52-3-1-B1-PU |
| ID154 | est-not-ext | 9.5 | Pancreas | 19-9-1-C4 |
| ID155 | est-not-ext | 9.5 | Pancreas | 19-8-4-F5-PU |
| ID156 | est-not-ext | 8.8 | Colon | 23-2-1-D11-PU |
| ID157 | est-not-ext | 8.7 | Large intestine | 83-4-4-B11-PU |
| ID158 | est-not-ext | 8.5 | Liver | 22-13-3-F7-PU |
| ID159 | est-not-ext | 8.1 | Lung | 42-2-3-A4-PU |
| ID160 | est-not-ext | 7.6 | Liver | 22-10-3-C3-PU |
| ID161 | est-not-ext | 7.5 | Lung (cells) | 30-5-1-B12-PU |
| ID162 | est-not-ext | 7.5 | Liver | 52-1-2-B3-PU |
| ID163 | est-not-ext | 6.8 | Pancreas | 19-8-3-B2 |
| ID164 | est-not-ext | 6.8 | Lung | 59-1-3-A4-PU |
| ID165 | est-not-ext | 6.8 | Thyroid | 84-3-1-F10-PU |
| ID166 | est-not-ext | 6.1 | Lung (cells) | 30-12-4-B11-PU |
| ID167 | est-not-ext | 5.9 | Lung (cells) | 30-2-4-B6-PU |
| ID168 | est-not-ext | 5.7 | Thyroid | 84-4-2-D5-PU |
| ID169 | est-not-ext | 5.7 | Fetal liver | 65-2-1-E6-PU |
| ID170 | est-not-ext | 5.6 | Large intestine | 83-5-4-E3-PU |
| ID171 | est-not-ext | 5.3 | Lung (cells) | 30-9-3-E12-PU |
| ID172 | est-not-ext | 5 | Colon | 23-10-3-G8-PU |
| ID173 | est-not-ext | 4.9 | Lung (cells) | 30-10-3-H3-PU |
| ID174 | est-not-ext | 4.7 | Pancreas | 19-3-4-F4 |
| ID175 | est-not-ext | 4.5 | Colon | 23-8-3-H9-PU |
| ID176 | est-not-ext | 4.3 | Large intestine | 83-5-4-A4-PU |
| ID177 | est-not-ext | 3.8 | Pancreas | 19-1-3-E11 |
| ID178 | est-not-ext | 3.8 | Lung | 59-5-4-A8-PU |
| ID179 | est-not-ext | 3.7 | Fetal liver | 65-4-4-H3-PU |
| ID180 | est-not-ext | 3.7 | Lung | 42-2-1-A1-PU |
| ID181 | est-not-ext | 3.6 | Liver | 22-6-2-C1-PU |
| ID182 | est-not-ext | 3.5 | Pancreas | 46-1-2-B2-PU |
| ID183 | est-not-ext | 3.5 | Colon | 23-12-2-G6-PU |
| ID184 | est-not-ext | 3.5 | Lung (cells) | 30-11-2-H2-PU |

TABLE III

| SEQ. ID NO. | SIGNAL PEPTIDE |
|----------------|---|
| ID38 | MMWRPSVLLLLLLLRHGAQG |
| ID39 | MGKICKNWVSFLDNVLLILFLYGLCSG |
| ID40 | MLTVALLALLCASASGNA |
| ID41 | MVLLLCLSCLIFS |
| ID42 | MPVPALCLLWALAMVTRPASA |
| ID43 | MHLRGSHTYPSCPSELRLDSLWQHHRQLLPLWVFLPLSLG |
| ID44 | MPVPASWPHLPSPFLLMTLLLGGLTG |
| ID45 | MAQRCVCVLALVAMLLLVFPTVS |
| ID46 | MDYLISFLLLLLLLL |
| ID47 | MATTVPDGCNRGLKSKYYRLCDKAEAWGIVLETVATAGVVTSAFMLTLPILVCKV QDSNRRKMLPTQFLFLLGVLFGLTFA |
| ID48 | MESGLSWLFLVIFIKGVQC |
| ID49 | MSGTSVLLHVAFLPGRFG |
| ID50 | MLQGLLPVSLLSVAVS |
| ID51 | MHICHVSLLQLCSS |
| ID52 | MIFADRTSSAFTLMRSYSLLLCSLLSFPFLC |
| ID53 | MAFLPSWVCVLVGSFSASLA |
| ID54 | MFLVSCVICTGSFA |
| ID55 | MKKTGDGGTLSTERIGGAALLSLLKRMKMTLMIPLLLLTPITA |
| ID56 | MGFFLPHGISDAXILLAGWCPDTRA |
| ID57 | MWLRPGSCWSTREPRRAPRTSASSLSFLGPSAVCTLLSSHPASRC |
| ID58 | MSEGMVTLLTFSCLVTDSDFMSXLNVLFLLSLFCRLYHG |
| ID59 | MLILGLPLCRPLWI |
| ID60 | MYTYFFVLCXLSHFILLVLPCLIFS |
| ID61 | MDSRVSSPEKQDKENFVGNNKRLGVCGWILFSLFLLVIIT |
| ID62 | MCILFCVVLCLSPTSY |
| ID63 | MHRGDIETLLCLGSSCCQC |
| ID64 | MFLKSGAGLSSCLLPLCWL |
| ID65 | MANAIKKPCAMPAQPHTGNLLWPPLVMVWLGLLPLFS |
| ID66 | MSPPPLLQPLLLPLLV |
| ID67 | MIPYQNKSQTDSHCSLSHKGLAFLKVWLILIGLFSLTGLVA |
| ID68 | MALPGIHLISGSTCPGPCSC |
| ID69 | MPSETLWEIAKAEVEKRGINGXXGDGAEIALPLFSTXAF |
| ID70 | MEWLRPSQISFYPGYSKERLRLVLLCMSLTFLALSTL |
| ID71 | MKAIHLLTLLALLSVNTG |
| ID72 | MDVSASKPVAESWSPGSLPLALTLSTLST |
| ID73 | MGVRVGVSLRAWCVFIQTALLGLPXAWA |
| ID74 | MIIIPRSFFLLLCIPFLTLL |
| ID75 | MTMQRSRSSSWTSCNSWTLVLMSPEWALL |
| ID76 | MITLPQTSSLLCSLMASISPTLT |
| ID77 | MLRTCYVLCVQAGPPSRGWQSLSDGGAFLKGTGELTRALLVLRLCAWPPLVTHGL LLQAWS |
| ID78 | MICSPFSGFAPCQALGTLGVGCHFFHLALG |
| ID79 | MCNPEEAALXGLEEVFSATLAHVNSLVLPQLLPAAPDPSPDWGRECLRLQLHKSSQQL WEVTEESLHSLQERLRYPDSTGLESLLLRGADRVLQA |
| ID80 | MDKLIPSLSSQENRKASHTLHKARNKQHCGLLVHVMCPSLS |
| ID81 | MSXLLPVVLASPPVGHG |
| ID82 | MVLLTMIARVADG |
| ID83 | MFHIAFSEALPVDIFKTQPNCHAEAFSMKAIHITRIRSGLCLELLFVPLLCL |

| <u>SEQ. ID</u> <u>NO.</u> | <u>SIGNAL PEPTIDE</u> |
|------------------------------|---|
| ID84 | MMHCTPSGSAAVSLLTETVLPLAFP |
| ID85 | MTRPFWASCSTWATSRISCAFLASSTA |
| ID86 | MVTHLIRGVVLQGSCLLIQWPELSFS |
| ID87 | MYMWSKLLVAFRVFLGLFS |
| ID88 | MSSRNCFFPSFLFGLYSFRAVDS |
| ID89 | MYMNTCLYLHVYVLTCSG |
| ID90 | MSCRQPTPTQCSLLPNDNRVSTRGGDSAGRHRQVPQVALSASLPQCSLG |
| ID91 | MITGCTKPTAGVVVLQGSRA |
| ID92 | MGLDLILSFSSSP |
| ID93 | MREDNEHERNVPSGVENVKEEGDEDLSWGDEGCQVLRHRLRVCRKVGLLDRLCA LTS LCSP |
| ID94 | MGKRAGAVVSSWAXCSLG |
| ID95 | MQSTSNHLWLLSDILGQGATA |
| ID96 | MKKLRPSQEQLNCPQLADGRAGIRLLVTWLQPAPLLCLSGLELEPSA |
| ID97 | MWSHLNRLLFWSIFSSVTC |
| ID98 | MLALRDLGMGKREGEELIQAEARCLVETFQGTGRPFDPSSL LAQATSNVVC |
| ID99 | MLSVGASTSLCGCLRQLRC |
| ID100 | MFQQMYVLLSQFLYPLAYP |
| ID101 | MTSHFCXIGFLSYTTS |
| ID102 | MICSLTPFRSLTNVLLSGSLLRLC |
| ID103 | MEPPGRSSSLPFSPALTLTFLPPSPT |
| ID104 | MDKLLKVLSGQDTEDRSGLSEVVEASSLSWSTRIKGFIACFAIGILCSLLGTVLL |
| ID105 | MYSRHTVKLKQGLGMVCIFSLRLQA |
| ID106 | MYPSSLVDYFPSLLLYSLPLNIIG |
| ID107 | MATTVPDGCNRGLKSKYYRLCDKAEAWGIVLETVATAGVVTSAFMXTLPILVCKVQ DSNRRKMLPTQFLFLLGVLG |
| ID108 | MRLQHLDHLFFSGVVLG |
| ID109 | MPLPKPSFSNNHLIRLITVAFGLYNPSLCHA |
| ID110 | MEPITFTARKHLLPNEVSVDLGLQLVGSLPVHSLTTPMPLPWVVAEVRRLSRQSTRKEPV TXQXRLCVSPSGLRC |
| ID111 | MGCLWGLALPLFFFCWEVGVSGSSA |
| ID112 | MKQNTDPYLCHISLLDVTQQ |
| ID113 | MVTYFNFTFKPFCILASIIPTLISLLSPNTPSA |
| ID114 | MESGGRPSLCQXILLGTTSVVT A |
| ID115 | MEAQQAQKSAEQPEQKAATEVSXELSESQVHMMAAAVADGTRA |
| ID116 | MPLNSVIWFGSVXPCIS |
| ID117 | MLQQDSISLRRRETANFLDFANLADTLA |
| ID118 | MCYLAELSLTTFXXGYIVTSRATTTTTLAIQPLPFTTSLNLSLPSQT |
| ID119 | MSISLSSLILLPIWINM |
| ID120 | MDRDLLRQSLNCHGSSLLSLLRSEQQDNPHFRSLLGSAEPARGPPPQHPLQGRKEKRPV NIEIQKFISKADLLFALSWSKSDAPA |
| ID121 | MVLATLVTXXNASCSFA |
| ID122 | MMIWKRLIILKVLLNQTCQT |
| ID123 | MDAGKAGQTLKTHCSAQRPDVCRWLSPFILSCCVYFCLWIPEDQLSWFAALVKCLPV LCLA |
| ID124 | MQQRGAAGSRGCALFLLGVLFQGVYI |
| ID125 | MLGTHIYVSLWILFSSPHLIYWYVLLILSFP |
| ID126 | MSIYNLFLNLHGFLGHLLS |
| ID127 | MCMQVDLAFSFPACVCMCTXSCYS |
| ID128 | MAPGEKESGEGPAKSALRKIRTATLVISLARG |
| ID129 | MEPKRGRMWXFEIEDSCIYQDIPSFVLLYPLLHLFYQHLCFP |

| SEQ. ID NO. | SIGNAL PEPTIDE |
|----------------|---|
| ID130 | MEFCSVLQRCLFSFVTS |
| ID131 | MAESQIYVLLFFLLMKFS |
| ID132 | MQTNNA CSLSSGPLQINA |
| ID133 | MGQNNASFHCPLK VLMGLLCNQTA A |
| ID134 | MLPLLSVMWSP IAP |
| ID135 | MWLNCGGLQRWITCPPTFHGCRA |
| ID136 | MWQGCNCSQLSETAVDQEQLGVLTFILQRTTC |
| ID137 | MCLPHPQV VSSNFHILIFLLPTKMLVTLLASKSPSCP |
| ID138 | MHLAVLFXFSDCCRKXLS SGGQLYSIVSSLSNEHVLSAGFDINTPDNLGRTCLHAAASGGN VECLNLLSSGADL |
| ID139 | MSFQWCGWQWGLHDCFLSVFQVLS |
| ID140 | MKVHMTKFKCLICLLTFIFH |
| ID141 | MSFNLQSSKLFIFLGKSLFSLLEA |
| ID142 | MDLMCRKVKHLLFFLLVAAPRWVVS |
| ID143 | MELKSPEEEVVAALPEGMRPDSNLYGFPWELVICA AVVGFFAVLFFLWRSFX |
| ID144 | MELSDVTIEGVGNEVMV VAGVVLLALVLAWLSTYVA |
| ID145 | MIARRNPEPLRFLPDEARSLPPPKLTDPRLLYIGFLGYCSG |
| ID146 | MPPGPWESCFWVGGLLWLSVGSS |
| ID147 | MCARALLACSSRG |
| ID148 | MGDERPHYYGKHGTPQKYDPTFKGPIYNRGCTDIICCVFLLLAIVG |
| ID149 | MAQRLLLRFLASVIS |
| ID150 | MESGGRPSLCQFILLGTTSVVTA |
| ID151 | MALSSQIWAACLLLLLLLASLTSG |
| ID152 | MGVPRPOPWALGLLLFLPGSLG |
| ID153 | MKVVPSLLLSVLLAQVWL |
| ID154 | MLSITVLAALLACASS |
| ID155 | MLGITVLAALLACASS |
| ID156 | MAGNGESEPDRLHLLTGHRVKGEFQLLLPLSLPVTTTP |
| ID157 | MLWWLVLLLLPTLK |
| ID158 | MAPQSLPSSRMAPLGMLLGLLMAACFTFC |
| ID159 | MMLHSALGLCLLLVTVSSNLAIA |
| ID160 | MCTGKCARCVGLSLITLCLVCIVANA |
| ID161 | MDILVPLLQLLVLLLTPLHLMA |
| ID162 | MPFLVLFSSFNIALC |
| ID163 | MQQRGLAIVALAVCAALHA |
| ID164 | MRKTRLWGLLWMLFVSELRA |
| ID165 | MVGAMWKVIVSLVLLMPGPCDG |
| ID166 | MIHLRIIQR CYMAGLENKKNVVF EAKQICIGLVLPFIRC |
| ID167 | MAGSPTCLTLIYLWQLTGSA A |
| ID168 | MGKKGKVGKSRRDKFYHLAKETGYRSRSAFKLIQLNRRFQFLQKARALLDLCAAPXGWL |
| ID169 | MPLSDFILALKDNPFYFAGFGLVXVGTALALA |
| ID170 | MEFGLSWVFLVAIKGVQC |
| ID171 | MILRKRSCLFSSLPIFTWA |
| ID172 | MKNGLMFVKLVNPCSG |
| ID173 | MEAVVFVFSLLDCCA |
| ID174 | MTGFLLPASRGTRRSCSRSRKRQTRRRRNPSFVASCPTLLPFACVPGASXTTLA |
| ID175 | MCGNTMSVPLLTDAA TVSG |
| ID176 | MXXXXXERRTSPHVMADQSSTRNEDFLKKTWSLWRLQWLKDASC |
| ID177 | MFLLLNCIVAVSQN |
| ID178 | MLLVSAAPLGFGQG |
| ID179 | MLRIALTIPSMLSRA |

125

| <u>SEQ. ID</u> <u>NO.</u> | <u>SIGNAL PEPTIDE</u> |
|------------------------------|------------------------|
| ID180 | MTLGGRLPGLRCSVPGVAA |
| ID181 | MAFTLXSLQAALL |
| ID182 | MRPLAGGLLKVVFMVFASLXA |
| ID183 | MFEEPEWAEAAPVAAGLGPVIS |
| ID184 | MHIYTGKYIALYNIYVCGIQG |

125/1

| Minimum signal peptide score | false positive rate | false negative rate | proba(0.1) | proba(0.2) |
|------------------------------------|------------------------|------------------------|------------|------------|
| 3.5 | 0.121 | 0.036 | 0.467 | 0.664 |
| 4 | 0.096 | 0.06 | 0.519 | 0.708 |
| 4.5 | 0.078 | 0.079 | 0.565 | 0.745 |
| 5 | 0.062 | 0.098 | 0.615 | 0.782 |
| 5.5 | 0.05 | 0.127 | 0.659 | 0.813 |
| 6 | 0.04 | 0.163 | 0.694 | 0.836 |
| 6.5 | 0.033 | 0.202 | 0.725 | 0.855 |
| 7 | 0.025 | 0.248 | 0.763 | 0.878 |
| 7.5 | 0.021 | 0.304 | 0.78 | 0.889 |
| 8 | 0.015 | 0.368 | 0.816 | 0.909 |
| 8.5 | 0.012 | 0.418 | 0.836 | 0.92 |
| 9 | 0.009 | 0.512 | 0.856 | 0.93 |
| 9.5 | 0.007 | 0.581 | 0.863 | 0.934 |
| 10 | 0.006 | 0.679 | 0.835 | 0.919 |

TABLE IV

125/2

| Minimum signal peptide score | All ESTs | New ESTs | ESTs matching public EST closer than 40 bp from beginning | ESTs extending known mRNA more than 40 bp | ESTs extending public EST more than 40 bp |
|---------------------------------------|----------|----------|--|---|---|
| 3.5 | 2674 | 947 | 599 | 23 | 150 |
| 4 | 2278 | 784 | 499 | 23 | 126 |
| 4.5 | 1943 | 647 | 425 | 22 | 112 |
| 5 | 1657 | 523 | 353 | 21 | 96 |
| 5.5 | 1417 | 419 | 307 | 19 | 80 |
| 6 | 1190 | 340 | 238 | 18 | 68 |
| 6.5 | 1035 | 280 | 186 | 18 | 60 |
| 7 | 893 | 219 | 161 | 15 | 48 |
| 7.5 | 753 | 173 | 132 | 12 | 36 |
| 8 | 636 | 133 | 101 | 11 | 29 |
| 8.5 | 543 | 104 | 83 | 8 | 26 |
| 9 | 456 | 81 | 63 | 6 | 24 |
| 9.5 | 364 | 57 | 48 | 6 | 18 |
| 10 | 303 | 47 | 35 | 6 | 15 |

TABLE V

125/3

| Tissue | All ESTs | New ESTs | ESTs matching public EST closer than 40 bp from beginning | ESTs extending known mRNA more than 40 bp | ESTs extending public EST more than 40 bp |
|-----------------------|----------|----------|--|---|---|
| Brain | 329 | 131 | 75 | 3 | 24 |
| Cancerous prostate | 134 | 40 | 37 | 1 | 8 |
| Cerebellum | 17 | 9 | 1 | 0 | 6 |
| Colon | 21 | 11 | 4 | 0 | 0 |
| Dystrophic muscle | 41 | 18 | 8 | 0 | 1 |
| Fetal brain | 70 | 37 | 16 | 0 | 1 |
| Fetal kidney | 227 | 116 | 46 | 1 | 19 |
| Fetal liver | 13 | 7 | 2 | 0 | 0 |
| Heart | 30 | 15 | 7 | 0 | 1 |
| Hypertrophic prostate | 86 | 23 | 22 | 2 | 2 |
| Kidney | 10 | 7 | 3 | 0 | 0 |
| Large intestine | 21 | 8 | 4 | 0 | 1 |
| Liver | 23 | 9 | 6 | 0 | 0 |
| Lung | 24 | 12 | 4 | 0 | 1 |
| Lung (cells) | 57 | 38 | 6 | 0 | 4 |
| Lymph ganglia | 163 | 60 | 23 | 2 | 12 |
| Lymphocytes | 23 | 6 | 4 | 0 | 2 |
| Muscle | 33 | 16 | 6 | 0 | 4 |
| Normal prostate | 181 | 61 | 45 | 7 | 11 |
| Ovary | 90 | 57 | 12 | 1 | 2 |
| Pancreas | 48 | 11 | 6 | 0 | 1 |
| Placenta | 24 | 5 | 1 | 0 | 0 |
| Prostate | 34 | 16 | 4 | 0 | 2 |
| Spleen | 56 | 28 | 10 | 0 | 1 |
| Substantia nigra | 108 | 47 | 27 | 1 | 6 |
| Surrenals | 15 | 3 | 3 | 1 | 0 |
| Testis | 131 | 68 | 25 | 1 | 8 |
| Thyroid | 17 | 8 | 2 | 0 | 2 |
| Umbilical cord | 55 | 17 | 12 | 1 | 3 |
| Uterus | 28 | 15 | 3 | 0 | 2 |
| Non tissue-specific | 568 | 48 | 177 | 2 | 28 |
| Total | 2677 | 947 | 601 | 23 | 150 |

TABLE VI

125/4

Description of Transcription Factor Binding Sites present on promoters isolated from SignalTag sequences

Promoter sequence P13H2 (646 bp):

| Matrix | Position | Orientation | Score | Length | Sequence |
|-----------------|----------|-------------|-------|--------|------------------|
| CMYB_01 | -502 | + | 0.983 | 9 | TGTCAGTTG |
| MYOD_Q6 | -501 | - | 0.981 | 10 | CCCAACTGAC |
| S8_01 | -444 | - | 0.960 | 11 | AATAGAATTAG |
| S8_01 | -425 | + | 0.968 | 11 | AACTAAATTAG |
| DELTAEF1_01 | -390 | - | 0.960 | 11 | GCACACCTCAG |
| GATA_C | -384 | - | 0.984 | 11 | AGATAAATCCA |
| CMYB_01 | -349 | + | 0.958 | 9 | CTTCAGTTG |
| GATA1_02 | -343 | + | 0.959 | 14 | TTGTAGATAGGACA |
| GATA_C | -339 | + | 0.953 | 11 | AGATAGGACAT |
| TAL1ALPHA47_01 | -235 | + | 0.973 | 18 | CATAACAGATGGTAAG |
| TAL1BETA47_01 | -235 | + | 0.983 | 18 | CATAACAGATGGTAAG |
| TAL1BETA1TF2_01 | -235 | + | 0.978 | 18 | CATAACAGATGGTAAG |
| MYOD_Q6 | -232 | - | 0.954 | 10 | ACCATCTGTT |
| GATA1_04 | -217 | - | 0.953 | 13 | TCAAGATAAAGTA |
| IK1_01 | -126 | + | 0.983 | 13 | AGTTGGGAATTCC |
| IK2_01 | -126 | + | 0.985 | 12 | AGTTGGGAATTCC |
| CREL_01 | -123 | + | 0.982 | 10 | TGGGAATTCC |
| GATA1_02 | -88 | + | 0.950 | 14 | TCAGTGATATGGCA |
| SRY_02 | -41 | - | 0.951 | 12 | TAAACAAAACA |
| E2F_02 | -33 | + | 0.957 | 8 | TTTAGCGC |
| MZF1_01 | -5 | - | 0.975 | 8 | TGAGGGGA |

Promoter sequence P16B4 (881bp) :

| Matrix | Position | Orientation | Score | Length | Sequence |
|-------------|----------|-------------|-------|--------|--------------|
| NFY_Q6 | -748 | - | 0.956 | 11 | GGACCAATCAT |
| MZF1_01 | -738 | + | 0.982 | 8 | CCTGGGGA |
| CMYB_01 | -684 | + | 0.994 | 9 | TGACCGTTG |
| VMYB_02 | -682 | - | 0.985 | 9 | TCCAACGGT |
| STAT_01 | -673 | + | 0.968 | 9 | TTCTTGGA |
| STAT_01 | -673 | - | 0.951 | 9 | TTCCAGGAA |
| MZF1_01 | -556 | - | 0.956 | 8 | TTGGGGGA |
| IK2_01 | -451 | + | 0.965 | 12 | GAATGGGATTTC |
| MZF1_01 | -424 | + | 0.986 | 8 | AGAGGGGA |
| SRY_02 | -398 | - | 0.955 | 12 | GAAAACAAAACA |
| MZF1_01 | -216 | + | 0.960 | 8 | GAAGGGGA |
| MYOD_Q6 | -190 | + | 0.981 | 10 | AGCATCTGCC |
| DELTAEF1_01 | -176 | + | 0.958 | 11 | TCCCACCTTCC |
| S8_01 | 5 | - | 0.992 | 11 | GAGGCAATTAT |
| MZF1_01 | 16 | - | 0.986 | 8 | AGAGGGGA |

Promoter sequence P29B6 (655 bp) :

| Matrix | Position | Orientation | Score | Length | Sequence |
|-------------|----------|-------------|-------|--------|------------------|
| ARNT_01 | -311 | + | 0.964 | 16 | GGACTCACGTGCTGCT |
| NMYC_01 | -309 | + | 0.965 | 12 | ACTCACGTGCTG |
| USF_01 | -309 | + | 0.985 | 12 | ACTCACGTGCTG |
| USF_01 | -309 | - | 0.985 | 12 | CAGCACGTGAGT |
| NMYC_01 | -309 | - | 0.956 | 12 | CAGCACGTGAGT |
| MYCMAX_02 | -309 | - | 0.972 | 12 | CAGCACGTGAGT |
| USF_C | -307 | + | 0.997 | 8 | TCACGTGC |
| USF_C | -307 | - | 0.991 | 8 | GCACGTGA |
| MZF1_01 | -292 | - | 0.968 | 8 | CATGGGGA |
| ELK1_02 | -105 | + | 0.963 | 14 | CTCTCCGGAAGCCT |
| CETS1P54_01 | -102 | + | 0.974 | 10 | TCCGGAAGCC |
| AP1_Q4 | -42 | - | 0.963 | 11 | AGTGACTGAAC |
| AP1FJ_Q2 | -42 | - | 0.961 | 11 | AGTGACTGAAC |
| PADS_C | 45 | + | 1.000 | 9 | TGTGGTCTC |

TABLE VII

CLAIMS

1. A purified or isolated nucleic acid comprising the sequence of one of SEQ ID NOs: 38-184 or comprising a sequence complementary thereto.
- 5 2. The nucleic acid of Claim 1, wherein said nucleic acid is recombinant.
3. A purified or isolated nucleic acid comprising at least 10 consecutive bases of the sequence of one of SEQ ID NOs: 38-184 or one of the sequences complementary thereto.
4. A purified or isolated nucleic acid comprising at least 15 consecutive bases of
10 one of the sequences of SEQ ID NOs: 38-184 or one of the sequences complementary thereto.
5. The nucleic acid of Claim 4, wherein said nucleic acid is recombinant.
6. A purified or isolated nucleic acid of at least 15 bases capable of hybridizing under stringent conditions to the sequence of one of SEQ ID NOs: 38-184 or one of the
15 sequences complementary to the sequences of SEQ ID NOs: 38-184.
7. The nucleic acid of Claim 6, wherein said nucleic acid is recombinant.
8. A purified or isolated nucleic acid encoding a human gene product, said human gene product having a sequence partially encoded by one of the sequences of SEQ ID NO: 38-184.
- 20 9. A purified or isolated nucleic acid having the sequence of one of SEQ ID NOs: 38-184 or having a sequence complementary thereto.
10. A purified or isolated nucleic acid comprising the nucleotides of one of SEQ ID NOs: 38-184 which encode a signal peptide.
11. A purified or isolated polypeptides comprising a signal peptide encoded by
25 one of the sequences of SEQ ID NOs: 38-184.
12. A vector encoding a fusion protein comprising a polypeptide and a signal peptide, said vector comprising a first nucleic acid encoding a signal peptide encoded by one of the sequences of SEQ ID NOs: 38-184 operably linked to a second nucleic acid encoding a polypeptide.
- 30 13. A method of directing the extracellular secretion of a polypeptide or the insertion of a polypeptide into the membrane comprising the steps of:

obtaining a vector according to Claim 12; and

introducing said vector into a host cell such that said fusion protein is secreted into the extracellular environment of said host cell or inserted into the membrane of said host cell.

14. A method of importing a polypeptide into a cell comprising contacting said
5 cell with a fusion protein comprising a signal peptide encoded by one of the sequences of SEQ ID NOs: 38-184 operably linked to said polypeptide.

15. A method of making a cDNA encoding a human secretory protein that is partially encoded by one of SEQ ID NOs 38-184, comprising the steps of:

obtaining a cDNA comprising one of the sequences of SEQ ID NOs: 38-184;

10 contacting said cDNA with a detectable probe comprising at least 15 consecutive nucleotides of said sequence of SEQ ID NO: 38-184 or a sequence complementary thereto under conditions which permit said probe to hybridize to said cDNA;

identifying a cDNA which hybridizes to said detectable probe; and

isolating said cDNA which hybridizes to said probe.

15 16. An isolated or purified cDNA encoding a human secretory protein, said human secretory protein comprising the protein encoded by one of SEQ ID NOs 38-184 or a fragment thereof of at least 10 amino acids, said cDNA being obtainable by the method of Claim 15.

17. The cDNA of Claim 16 wherein said cDNA comprises the full protein coding
20 sequence partially included in one of the sequences of SEQ ID NOs: 38-184.

18. A method of making a cDNA comprising one of the sequences of SEQ ID NOs: 38-184, comprising the steps of:

contacting a collection of mRNA molecules from human cells with a first primer capable of hybridizing to the polyA tail of said mRNA;

25 hybridizing said first primer to said polyA tail;

reverse transcribing said mRNA to make a first cDNA strand;

making a second cDNA strand complementary to said first cDNA strand using at least one primer comprising at least 15 nucleotides of one of the sequences of SEQ ID NOs 38-184; and

30 isolating the resulting cDNA comprising said first cDNA strand and said second cDNA strand.

19. An isolated or purified cDNA encoding a human secretory protein, said human secretory protein comprising the protein encoded by one of SEQ ID NOs 38-184 or a fragment thereof of at least 10 amino acids, said cDNA being obtainable by the method of Claim 18.

5 20. The cDNA of Claim 19 wherein said cDNA comprises the full protein coding sequence partially included in one of the sequences of SEQ ID NOs: 38-184.

21. The method of Claim 18, wherein the second cDNA strand is made by:
contacting said first cDNA strand with a first pair of primers, said first pair of primers comprising a second primer comprising at least 15 consecutive nucleotides of one of the
10 sequences of SEQ ID NOs 38-184 and a third primer having a sequence therein which is included within the sequence of said first primer;

performing a first polymerase chain reaction with said first pair of nested primers to generate a first PCR product;

contacting said first PCR product with a second pair of primers, said second pair of
15 primers comprising a fourth primer, said fourth primer comprising at least 15 consecutive nucleotides of said sequence of one of SEQ ID NO:s 38-184 , and a fifth primer, said fourth and fifth primers being capable of hybridizing to sequences within said first PCR product; and
performing a second polymerase chain reaction, thereby generating a second PCR product.

20 22. An isolated or purified cDNA encoding a human secretory protein, said human secretory protein comprising the protein encoded by one of SEQ ID NOs 38-184, or a fragment thereof of at least 10 amino acids, said cDNA being obtainable by the method of Claim 21.

23. The cDNA of Claim 22 wherein said cDNA comprises the full protein coding
25 sequence partially included in one of the sequences of SEQ ID NOs: 38-184.

24. The method of Claim 18 wherein the second cDNA strand is made by:
contacting said first cDNA strand with a second primer comprising at least 15
consecutive nucleotides of the sequences of SEQ ID NOs: 38-184;

hybridizing said second primer to said first strand cDNA; and
30 extending said hybridized second primer to generate said second cDNA strand.

25. An isolated or purified cDNA encoding a human secretory protein, said human secretory protein comprising the protein partially encoded by one of SEQ ID NOs 38-184 or comprising a fragment thereof of at least 10 amino acids, said cDNA being obtainable by the method of Claim 24.

5 26. The cDNA of Claim 25, wherein said cDNA comprises the full protein coding sequence partially included in one of the sequences of SEQ ID NOs: 38-184.

27. A method of making a protein comprising one of the sequences of SEQ ID NO: 185-331, comprising the steps of:

obtaining a cDNA encoding the full protein sequence partially included in one of the
10 sequences of sequence of SEQ ID NO: 38-184;

inserting said cDNA in an expression vector such that said cDNA is operably linked to a promoter;

introducing said expression vector into a host cell whereby said host cell produces the protein encoded by said cDNA; and

15 isolating said protein.

28. An isolated protein obtainable by the method of Claim 27.

29. A method of obtaining a promoter DNA comprising the steps of:

obtaining DNAs located upstream of the nucleic acids of SEQ ID NO: 38-184 or the sequences complementary thereto;

20 screening said upstream DNAs to identify a promoter capable of directing transcription initiation; and

isolating said DNA comprising said identified promoter.

30. The method of Claim 29, wherein said obtaining step comprises chromosome walking from said nucleic acids of SEQ ID NO: 38-184 or sequences complementary thereto.

25 31. The method of Claim 30, wherein said screening step comprises inserting said upstream sequences into a promoter reporter vector.

32. The method of Claim 30, wherein said screening step comprises identifying motifs in said upstream DNAs which are transcription factor binding sites or transcription start sites.

30 33. An isolated promoter obtainable by the method of Claim 32.

34. An isolated or purified protein comprising one of the sequences of SEQ ID NO: 185-331.

35. In an array of discrete ESTs or fragments thereof of at least 15 nucleotides in length, the improvement comprising inclusion in said array of at least one of the sequences of
5 SEQ ID NOs: 38-184, or one of the sequences complementary to the sequences of SEQ ID NOs: 38-184, or a fragment thereof of at least 15 consecutive nucleotides.

36. The array of Claim 35 including therein at least two of the sequences of SEQ ID NOs: 38-184, the sequences complementary to the sequences of SEQ ID NOs: 38-184, or
fragments thereof of at least 15 consecutive nucleotides.

10 37. The array of Claim 35 including therein at least five of the sequences of SEQ ID NOs: 38-184, the sequences complementary to the sequences of SEQ ID NOs: 38-184, or fragments thereof of at least 15 consecutive nucleotides.

1/4




Figure 1

2/4




Figure 2






Figure 3

4/4

Promoter P13H2



Promoter P15B4



Promoter P29B6




Figure 4

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME : GENSET SA
- (B) STREET :24, RUE ROYALE
- (C) CITY: PARIS
- (E) COUNTRY : FRANCE
- (F) POSTAL CODE (ZIP) : 75008

(ii) TITLE OF INVENTION: 5' ESTs FOR SECRETED PROTEINS EXPRESSED
IN ENDODERM

(iii) NUMBER OF SEQUENCES: 331

(v) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy Disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: Win95
- (D) SOFTWARE: Word

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 47 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: SINGLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: Other nucleic acid

(ix) FEATURE:

- (A) NAME/KEY: Cap
- (B) LOCATION: 1
- (D) OTHER INFORMATION: m7Gppp added to 1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GGCAUCCUAC UCCCAUCCAA UCCACCCUA ACUCCUCCA UCUCAC

47

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 46 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: SINGLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: Other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

GCAUCCUACU CCCAUCCAAU UCCACCCUA CUCCUCCAU CUCCAC

46

(2) INFORMATION FOR SEQ ID NO: 3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 base pairs
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: Other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

ATCAAGAATT CGCACGAGAC CATTA

25

(2) INFORMATION FOR SEQ ID NO: 4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 base pairs
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: Other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

TAATGGTCTC GTGCGAATTC TTGAT

25

(2) INFORMATION FOR SEQ ID NO: 5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 base pairs
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: Other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

CCGACAAGAC CAACGTCAAG GCCGC

25

(2) INFORMATION FOR SEQ ID NO: 6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 base pairs
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: Other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

TCACCAGCAG GCAGTGGCTT AGGAG

25

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 25 base pairs
 (B) TYPE: NUCLEIC ACID
 (C) STRANDEDNESS: SINGLE
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: Other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

AGTGATTCCT GCTACTTTGG ATGGC

25

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 25 base pairs
 (B) TYPE: NUCLEIC ACID
 (C) STRANDEDNESS: SINGLE
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: Other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

GCTTGGTCTT GTTCTGGAGT TTAGA

25

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 25 base pairs
 (B) TYPE: NUCLEIC ACID
 (C) STRANDEDNESS: SINGLE
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: Other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

TCCAGAATGG GAGACAAGCC AATT

25

(2) INFORMATION FOR SEQ ID NO: 10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 base pairs
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: Other nucleic acid
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

AGGGAGGAGG AAACAGCGTG AGTCC

25

- (2) INFORMATION FOR SEQ ID NO: 11:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 base pairs
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR
 - (ii) MOLECULE TYPE: Other nucleic acid
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

ATGGGAAAGG AAAAGACTCA TATCA

25

- (2) INFORMATION FOR SEQ ID NO: 12:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 base pairs
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR
 - (ii) MOLECULE TYPE: Other nucleic acid
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

AGCAGCAACA ATCAGGACAG CACAG

25

- (2) INFORMATION FOR SEQ ID NO: 13:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 base pairs
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR
 - (ii) MOLECULE TYPE: Other nucleic acid
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

ATCAAGAATT CGCACGAGAC CATT

25

(2) INFORMATION FOR SEQ ID NO: 14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 67 base pairs
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: Other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

ATCGTTGAGA CTCGTACCAG CAGAGTCACG AGAGAGACTA CACGGTACTG GTTTTTTTTTT 60

TTTTTVN 67

(2) INFORMATION FOR SEQ ID NO: 15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 29 base pairs
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: Other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

CCAGCAGAGT CACGAGAGAG ACTACACGG 29

(2) INFORMATION FOR SEQ ID NO: 16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 base pairs
 - (B) TYPE: NUCLEIC ACID
 - (C) STRANDEDNESS: SINGLE
 - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: Other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

CACGAGAGAG ACTACACGGT ACTGG 25

(2) INFORMATION FOR SEQ ID NO: 17:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 526 base pairs
 (B) TYPE: NUCLEIC ACID
 (C) STRANDEDNESS: DOUBLE
 (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: CDNA
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: Homo Sapiens
 (F) TISSUE TYPE: Lymph ganglia
- (ix) FEATURE:
 (A) NAME/KEY: other
 (B) LOCATION: complement(261..376)
 (C) IDENTIFICATION METHOD: blastn
 (D) OTHER INFORMATION: identity 96
 region 166..281
 id N70479
 est
- (ix) FEATURE:
 (A) NAME/KEY: other
 (B) LOCATION: complement(380..486)
 (C) IDENTIFICATION METHOD: blastn
 (D) OTHER INFORMATION: identity 97
 region 54..160
 id N70479
 est
- (ix) FEATURE:
 (A) NAME/KEY: other
 (B) LOCATION: complement(110..145)
 (C) IDENTIFICATION METHOD: blastn
 (D) OTHER INFORMATION: identity 94
 region 403..438
 id N70479
 est
- (ix) FEATURE:
 (A) NAME/KEY: other
 (B) LOCATION: complement(196..229)
 (C) IDENTIFICATION METHOD: blastn
 (D) OTHER INFORMATION: identity 94
 region 315..348
 id N70479
 est
- (ix) FEATURE:
 (A) NAME/KEY: sig_peptide
 (B) LOCATION: 90..140
 (C) IDENTIFICATION METHOD: Von Heijne matrix
 (D) OTHER INFORMATION: score 8.2
 seq LLLITAILAVAVG/FP
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

AATATRARAC AGCTACAATA TTCCAGGGCC ATCACTTGC CATTTTCAT AACAGCGTCA
60

GAGAGAAAGA ACTGACTGAR ACGTTTGAG ATG AAG AAA GTT CTC CTC CTG ATC
113

Met Lys Lys Val Leu Leu Leu Ile
-15 -10

ACA GCC ATC TTG GCA GTG GCT GTW GGT TTC CCA GTC TCT CAA GAC CAG
161

Thr Ala Ile Leu Ala Val Ala Val Gly Phe Pro Val Ser Gln Asp Gln
-5 1 5

GAA CGA GAA AAA AGA AGT ATC AGT GAC AGC GAT GAA TTA GCT TCA GGR
209

Glu Arg Glu Lys Arg Ser Ile Ser Asp Ser Asp Glu Leu Ala Ser Gly
10 15 20

WTT TTT GTG TTC CCT TAC CCA TAT CCA TTT CGC CCA CTT CCA CCA ATT
257

Xaa Phe Val Phe Pro Tyr Pro Tyr Pro Phe Arg Pro Leu Pro Pro Ile
25 30 35

CCA TTT CCA AGA TTT CCA TGG TTT AGA CGT AAN TTT CCT ATT CCA ATA
305

Pro Phe Pro Arg Phe Pro Trp Phe Arg Arg Xaa Phe Pro Ile Pro Ile
40 45 50 55

CCT GAA TCT GCC CCT ACA ACT CCC CTT CCT AGC GAA AAG TAAACAARAA
354

Pro Glu Ser Ala Pro Thr Thr Pro Leu Pro Ser Glu Lys
60 65

GGAAAAGTCA CRATAACCT GGTACCTGA AATTGAAATT GAGCCACTTC CTTGAARAAT
414

CAAAATTCCT GTTAATAAAA RAAAAACAAA TGTAATTGAA ATAGCACACA GCATTCTCTA
474

GTCAATATCT TTAGTGATCT TCTTTAATAA ACATGAAAGC AAAAAAAAAA AA
526

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens

(ix) FEATURE:

- (A) NAME/KEY: sig_peptide
- (B) LOCATION: 1..17
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 8.2
seq LLLITAILAVAVG/FP

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

Met Lys Lys Val Leu Leu Leu Ile Thr Ala Ile Leu Ala Val Ala Val
1 5 10 15

Gly

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 822 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (D) DEVELOPMENTAL STAGE: Fetal
- (F) TISSUE TYPE: kidney

(ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 260..464
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 96
region 153..357
id H57434
est

(ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 118..184
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 98
region 98..164
id H57434
est

(ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 56..113
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 98
region 35..92
id H57434
est

(ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 454..485
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 100
region 348..379
id H57434
est

(ix) FEATURE:

(A) NAME/KEY: other
(B) LOCATION: 118..545
(C) IDENTIFICATION METHOD: blastn
(D) OTHER INFORMATION: identity 98
region 1..428
id N27248
est

(ix) FEATURE:
(A) NAME/KEY: other
(B) LOCATION: 65..369
(C) IDENTIFICATION METHOD: blastn
(D) OTHER INFORMATION: identity 98
region 41..345
id H94779
est

(ix) FEATURE:
(A) NAME/KEY: other
(B) LOCATION: 61..399
(C) IDENTIFICATION METHOD: blastn
(D) OTHER INFORMATION: identity 99
region 6..344
id H09880
est

(ix) FEATURE:
(A) NAME/KEY: other
(B) LOCATION: 408..458
(C) IDENTIFICATION METHOD: blastn
(D) OTHER INFORMATION: identity 92
region 355..405
id H09880
est

(ix) FEATURE:
(A) NAME/KEY: other
(B) LOCATION: 60..399
(C) IDENTIFICATION METHOD: blastn
(D) OTHER INFORMATION: identity 97
region 56..395
id H29351
est

(ix) FEATURE:
(A) NAME/KEY: other
(B) LOCATION: 393..432
(C) IDENTIFICATION METHOD: blastn
(D) OTHER INFORMATION: identity 90
region 391..430
id H29351
est

(ix) FEATURE:
(A) NAME/KEY: sig_peptide
(B) LOCATION: 346..408
(C) IDENTIFICATION METHOD: Von Heijne matrix
(D) OTHER INFORMATION: score 5.5
seq SFLPSALVIWTS/AF

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

ACTCCTTTTA GCATAGGGGC TTCGGCGCCA GCGGCCAGCG CTAGTCGGTC TGGTAAGTGC
60

CTGATGCCGA GTTCCGTCTC TCGCGTCTTT TCCTGGTCCC AGGCAAAGCG GASGNAGATC
120

CTCAAACGGC CTAGTGCTTC GCGCTTCCGG AGAAAATCAG CGGTCTAATT AATTCCTCTG
180

GTTTGTGAA GCAGTTACCA AGAATCTTCA ACCCTTTCCC ACAAAGCTA ATTGAGTACA
240

CGTTCCTGTT GAGTACACGT TCCTGTTGAT TTACAAAAGG TGCAGGTATG AGCAGGTCTG
300

AAGACTAACA TTTTGTGAAG TTGTAAAACA GAAAACCTGT TAGAA ATG TGG TGG TTT
357

Met Trp Trp Phe
-20

CAG CAA GGC CTC AGT TTC CTT CCT TCA GCC CTT GTA ATT TGG ACA TCT
405

Gln Gln Gly Leu Ser Phe Leu Pro Ser Ala Leu Val Ile Trp Thr Ser
-15 -10 -5

GCT GCT TTC ATA TTT TCA TAC ATT ACT GCA GTA ACA CTC CAC CAT ATA
453

Ala Ala Phe Ile Phe Ser Tyr Ile Thr Ala Val Thr Leu His His Ile
1 5 10 15

GAC CCG GCT TTA CCT TAT ATC AGT GAC ACT GGT ACA GTA GCT CCA RAA
501

Asp Pro Ala Leu Pro Tyr Ile Ser Asp Thr Gly Thr Val Ala Pro Xaa
20 25 30

AAA TGC TTA TTT GGG GCA ATG CTA AAT ATT GCG GCA GTT TTA TGT CAA
549

Lys Cys Leu Phe Gly Ala Met Leu Asn Ile Ala Ala Val Leu Cys Gln
35 40 45

AAA TAGAAATCAG GAARATAATT CAACTTAAAG AAKTTCATTT CATGACCAAA
602

Lys

CTCTTCARAA ACATGTCTTT ACAAGCATAT CTCTTGATT GCTTTCTACA CTGTTGAATT
662

GTCTGGCAAT ATTTCTGCAG TGGAAAATTT GATTTARMTA GTTCTTGAAT GATAAATATG
722

GTAAGGTGGG CTTTTCCCC TGTGTAATTG GCTACTATGT CTTACTGAGC CAGTTGTAW
782

TTTGAAATTA AATGATATGA GAGTGACACA AAAAAAAAAA
822

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens

(ix) FEATURE:

- (A) NAME/KEY: sig_peptide
- (B) LOCATION: 1..21
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5.5
seq SFLPSALVIWTS/AF

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

Met Trp Trp Phe Gln Gln Gly Leu Ser Phe Leu Pro Ser Ala Leu Val
1 5 10 15
Ile Trp Thr Ser Ala
20

(2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 405 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Testis

(ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: complement(103..398)
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 96
region 1..296
id AA442893
est

(ix) FEATURE:

- (A) NAME/KEY: sig_peptide
- (B) LOCATION: 185..295
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5.9
seq LSYASSALSPCLT/AP

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

ATCACCTTCT TCTCCATCCT TSTCTGGGCC AGTCCCCARC CCAGTCCCTC TCCTGACCTG
60

CCCAGCCCCAA GTCAGCCTTC AGCACGCGCT TTTCTGCACA CAGATATTCC AGGCCTACCT
120

GGCATTCCAG GACCTCCGMA ATGATGCTCC AGTCCCTTAC AAGCGCTTCC TGGATGAGGG
180

TGGC ATG GTG CTG ACC ACC CTC CCC TTG CCC TCT GCC AAC AGC CCT GTG
229

Met Val Leu Thr Thr Leu Pro Leu Pro Ser Ala Asn Ser Pro Val
-35 -30 -25

AAC ATG CCC ACC ACT GGC CCC AAC AGC CTG AGT TAT GCT AGC TCT GCC
277

Asn Met Pro Thr Thr Gly Pro Asn Ser Leu Ser Tyr Ala Ser Ser Ala
-20 -15 -10

CTG TCC CCC TGT CTG ACC GCT CCA AAK TCC CCC CGG CTT GCT ATG ATG
325

Leu Ser Pro Cys Leu Thr Ala Pro Xaa Ser Pro Arg Leu Ala Met Met
-5 1 5 10

CCT GAC AAC TAAATATCCT TATCCAAATC AATAAARWRA RAATCCTCCC TCCARAAGGG
384

Pro Asp Asn

TTTCTAAAAA CAAAAAAAAA A
405

(2) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 37 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens

(ix) FEATURE:

- (A) NAME/KEY: sig_peptide
- (B) LOCATION: 1..37
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5.9
seq LSYASSALSPCLT/AP

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

Met Val Leu Thr Thr Leu Pro Leu Pro Ser Ala Asn Ser Pro Val Asn
1 5 10 15

Met Pro Thr Thr Gly Pro Asn Ser Leu Ser Tyr Ala Ser Ser Ala Leu
 20 25 30

Ser Pro Cys Leu Thr
 35

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 496 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Cancerous prostate

(ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 149..331
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 98
region 1..183
id AA397994
est

(ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 328..485
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 96
region 179..336
id AA397994
est

(ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: complement(182..496)
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 97
region 14..328
id AA399680
est

(ix) FEATURE:

- (A) NAME/KEY: sig_peptide
- (B) LOCATION: 196..240
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5.5
seq ILSTVTALTFFAXA/LD

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

AAAAAATTGG TCCAGTTTT CACCCTGCCG CAGGGCTGGC TGGGGAGGGC AGCGGTTTAG
 60

ATTAGCCGTG GCCTAGGCCG TTTAACGGGG TGACACGAGC NTGCAGGGCC GAGTCCAAGG
120

CCCGGAGATA GGACCAACCG TCAGGAATGC GAGGAATGTT TTTCTTCGGA CTCTATCGAG
180

GCACACAGAC AGACC ATG GGG ATT CTG TCT ACA GTG ACA GCC TTA ACA TTT
231

Met Gly Ile Leu Ser Thr Val Thr Ala Leu Thr Phe
-15 -10 -5

GCC ARA GCC CTG GAC GGC TGC AGA AAT GGC ATT GCC CAC CCT GCA AGT
279

Ala Xaa Ala Leu Asp Gly Cys Arg Asn Gly Ile Ala His Pro Ala Ser
1 5 10

GAG AAG CAC AGA CTC GAG AAA TGT AGG GAA CTC GAG ASC ASC CAC TCG
327

Glu Lys His Arg Leu Glu Lys Cys Arg Glu Leu Glu Xaa Xaa His Ser
15 20 25

GCC CCA GGA TCA ACC CAS CAC CGA AGA AAA ACA ACC AGA AGA AAT TAT
375

Ala Pro Gly Ser Thr Xaa His Arg Arg Lys Thr Thr Arg Arg Asn Tyr
30 35 40 45

TCT TCA GCC TGAAATGAAG CCGGGATCAA ATGGTTGCTG ATCARAGCCC ATATTAAAT
434

Ser Ser Ala

TGGAAAAGTC AAATTGASCA TTATTAAATA AAGCTTGTTT AATATGTCTC AAACAAAAAA
494

AA
496

(2) INFORMATION FOR SEQ ID NO: 24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens

(ix) FEATURE:

- (A) NAME/KEY: sig_peptide
- (B) LOCATION: 1..15
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5.5
seq ILSTVTALTFAXA/LD

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

Met Gly Ile Leu Ser Thr Val Thr Ala Leu Thr Phe Ala Xaa Ala
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 623 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Testis

(ix) FEATURE:

- (A) NAME/KEY: sig_peptide
- (B) LOCATION: 49..96
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 10.1
seq LVLTLCTLPLAVA/SA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

AAAGATCCCT GCAGCCCGGC AGGAGAGAAG GCTGAGCCTT CTGGCGTC ATG GAG AGG
 57

Met Glu Arg
 -15

CTC GTC CTA ACC CTG TGC ACC CTC CCG CTG GCT GTG GCG TCT GCT GGC
 105

Leu Val Leu Thr Leu Cys Thr Leu Pro Leu Ala Val Ala Ser Ala Gly
 -10 -5 1

TGC GCC ACG ACG CCA GCT CGC AAC CTG AGC TGC TAC CAG TGC TTC AAG
 153

Cys Ala Thr Thr Pro Ala Arg Asn Leu Ser Cys Tyr Gln Cys Phe Lys
 5 10 15

GTC AGC AGC TGG ACG GAG TGC CCG CCC ACC TGG TGC AGC CCG CTG GAC
 201

Val Ser Ser Trp Thr Glu Cys Pro Pro Thr Trp Cys Ser Pro Leu Asp
 20 25 30 35

CAA GTC TGC ATC TCC AAC GAG GTG GTC GTC TCT TTT AAA TGG AGT GTA
 249

Gln Val Cys Ile Ser Asn Glu Val Val Val Ser Phe Lys Trp Ser Val
 40 45 50

CGC GTC CTG CTC AGC AAA CGC TGT GCT CCC AGA TGT CCC AAC GAC AAC
 297

Arg Val Leu Leu Ser Lys Arg Cys Ala Pro Arg Cys Pro Asn Asp Asn
 55 60 65

ATG AAK TTC GAA TGG TCG CCG GCC CCC ATG GTG CAA GGC GTG ATC ACC

16

345
Met Xaa Phe Glu Trp Ser Pro Ala Pro Met Val Gln Gly Val Ile Thr
70 75 80

AGG CGC TGC TGT TCC TGG GCT CTC TGC AAC AGG GCA CTG ACC CCA CAG
393

Arg Arg Cys Cys Ser Trp Ala Leu Cys Asn Arg Ala Leu Thr Pro Gln
85 90 95

GAG GGG CGC TGG GCC CTG CRA GGG GGG CTC CTG CTC CAG GAC CCT TCG
441

Glu Gly Arg Trp Ala Leu Xaa Gly Gly Leu Leu Leu Gln Asp Pro Ser
100 105 110 115

AGG GGC ARA AAA ACC TGG GTG CGG CCA CAG CTG GGG CTC CCA CTC TGC
489

Arg Gly Xaa Lys Thr Trp Val Arg Pro Gln Leu Gly Leu Pro Leu Cys
120 125 130

CTT CCC AWT TCC AAC CCC CTC TGC CCA RGG GAA ACC CAG GAA GGA
534

Leu Pro Xaa Ser Asn Pro Leu Cys Pro Xaa Glu Thr Gln Glu Gly
135 140 145

TAACACTGTG GGTGCCCCCA CCTGTGCATT GGGACCACRA CTTACCCTC TTGGARACAA
594

TAAACTCTCA TGCCCCCAA AAAAAAAAAA
623

(2) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens

(ix) FEATURE:

- (A) NAME/KEY: sig_peptide
- (B) LOCATION: 1..16
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 10.1
seq LVLTLCTLPLAVA/SA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

Met Glu Arg Leu Val Leu Thr Leu Cys Thr Leu Pro Leu Ala Val Ala
1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 27:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 848 base pairs
 (B) TYPE: NUCLEIC ACID
 (C) STRANDEDNESS: DOUBLE
 (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: CDNA
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: Homo Sapiens
 (D) DEVELOPMENTAL STAGE: Fetal
 (F) TISSUE TYPE: kidney
- (ix) FEATURE:
 (A) NAME/KEY: sig_peptide
 (B) LOCATION: 32..73
 (C) IDENTIFICATION METHOD: Von Heijne matrix
 (D) OTHER INFORMATION: score 10.7
 seq LWLLFFLVTAIHA/EL
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

AACTTTGCCT TGTGTTTTCC ACCCTGAAAG A ATG TTG TGG CTG CTC TTT TTT CTG
 55

Met Leu Trp Leu Leu Phe Phe Leu
 -10

GTG ACT GCC ATT CAT GCT GAA CTC TGT CAA CCA GGT GCA GAA AAT GCT
 103

Val Thr Ala Ile His Ala Glu Leu Cys Gln Pro Gly Ala Glu Asn Ala
 -5 1 5 10

TTT AAA GTG AGA CTT AGT ATC AGA ACA GCT CTG GGA GAT AAA GCA TAT
 151

Phe Lys Val Arg Leu Ser Ile Arg Thr Ala Leu Gly Asp Lys Ala Tyr
 15 20 25

GCC TGG GAT ACC AAT GAA GAA TAC CTC TTC AAA GCG ATG GTA GCT TTC
 199

Ala Trp Asp Thr Asn Glu Glu Tyr Leu Phe Lys Ala Met Val Ala Phe
 30 35 40

TCC ATG AGA AAA GTT CCC AAC AGA GAA GCA ACA GAA ATT TCC CAT GTC
 247

Ser Met Arg Lys Val Pro Asn Arg Glu Ala Thr Glu Ile Ser His Val
 45 50 55

CTA CTT TGC AAT GTA ACC CAG AGG GTA TCA TTC TGG TTT GTG GTT ACA
 295

Leu Leu Cys Asn Val Thr Gln Arg Val Ser Phe Trp Phe Val Val Thr
 60 65 70

GAC CCT TCA AAA AAT CAC ACC CTT CCT GCT GTT GAG GTG CAA TCA GCC
 343

Asp Pro Ser Lys Asn His Thr Leu Pro Ala Val Glu Val Gln Ser Ala
 75 80 85 90

ATA AGA ATG AAC AAG AAC CGG ATC AAC AAT GCC TTC TTT CTA AAT GAC
 391

Ile Arg Met Asn Lys Asn Arg Ile Asn Asn Ala Phe Phe Leu Asn Asp

95 100 105
 CAA ACT CTG GAA TTT TTA AAA ATC CCT TCC ACA CTT GCA CCA CCC ATG
 439
 Gln Thr Leu Glu Phe Leu Lys Ile Pro Ser Thr Leu Ala Pro Pro Met
 110 115 120
 GAC CCA TCT GTG CCC ATC TGG ATT ATT ATA TTT GGT GTG ATA TTT TGC
 487
 Asp Pro Ser Val Pro Ile Trp Ile Ile Ile Phe Gly Val Ile Phe Cys
 125 130 135
 ATC ATC ATA GTT GCA ATT GCA CTA CTG ATT TTA TCA GGG ATC TGG CAA
 535
 Ile Ile Ile Val Ala Ile Ala Leu Leu Ile Leu Ser Gly Ile Trp Gln
 140 145 150
 CGT ADA ARA AAG AAC AAA GAA CCA TCT GAA GTG GAT GAC GCT GAA RAT
 583
 Arg Xaa Xaa Lys Asn Lys Glu Pro Ser Glu Val Asp Asp Ala Glu Xaa
 155 160 165 170
 AAK TGT GAA AAC ATG ATC ACA ATT GAA AAT GGC ATC CCC TCT GAT CCC
 631
 Xaa Cys Glu Asn Met Ile Thr Ile Glu Asn Gly Ile Pro Ser Asp Pro
 175 180 185
 CTG GAC ATG AAG GGA GGG CAT ATT AAT GAT GCC TTC ATG ACA GAG GAT
 679
 Leu Asp Met Lys Gly Gly His Ile Asn Asp Ala Phe Met Thr Glu Asp
 190 195 200
 GAG AGG CTC ACC CCT CTC TGAAGGGCTG TTGTTCTGCT TCCTCAARAA
 727
 Glu Arg Leu Thr Pro Leu
 205
 ATTAACATT TGTTTCTGTG TGAAGGCTGA GCATCCTGAA ATACCAAGAG CAGATCATAT
 787
 WTTTGTGTTT ACCATTCTTC TTTTGAATA AATTTTGAAT GTGCTTGAAA AAAAAAAAAA
 847
 C
 848

(2) INFORMATION FOR SEQ ID NO: 28:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: AMINO ACID
 - (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: PROTEIN
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo Sapiens
- (ix) FEATURE:

19

- (A) NAME/KEY: sig_peptide
(B) LOCATION: 1..14
(C) IDENTIFICATION METHOD: Von Heijne matrix
(D) OTHER INFORMATION: score 10.7
seq LWLLFFLVTAIHA/EL

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

Met Leu Trp Leu Leu Phe Phe Leu Val Thr Ala Ile His Ala
1 5 10

(2) INFORMATION FOR SEQ ID NO: 29:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 25 base pairs
 (B) TYPE: NUCLEIC ACID
 (C) STRANDEDNESS: SINGLE
 (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: Other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

GGGAAGATGG AGATAGTATT GCCTG

25

(2) INFORMATION FOR SEQ ID NO: 30:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 26 base pairs
 (B) TYPE: NUCLEIC ACID
 (C) STRANDEDNESS: SINGLE
 (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: Other nucleic acid
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

CTGCCATGTA CATGATAGAG AGATTC

26

(2) INFORMATION FOR SEQ ID NO: 31:

- ```
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 546 base pairs
 (B) TYPE: NUCLEIC ACID
 (C) STRANDEDNESS: DOUBLE
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: Genomic DNA

(ix) FEATURE:
 (A) NAME/KEY: promoter
 (B) LOCATION: 1..517
```

- (ix) FEATURE:  
(A) NAME/KEY: transcription start site  
(B) LOCATION: 518
- (ix) FEATURE:  
(A) NAME/KEY: TF binding-site  
(B) LOCATION: 17..25  
(C) IDENTIFICATION METHOD: matinspector prediction  
(D) OTHER INFORMATION: name CMYB\_01  
score 0.983  
sequence TGTCAGTTG
- (ix) FEATURE:  
(A) NAME/KEY: TF binding-site  
(B) LOCATION: complement(18..27)  
(C) IDENTIFICATION METHOD: matinspector prediction  
(D) OTHER INFORMATION: name MYOD\_Q6  
score 0.961  
sequence CCCAACTGAC
- (ix) FEATURE:  
(A) NAME/KEY: TF binding-site  
(B) LOCATION: complement(75..85)  
(C) IDENTIFICATION METHOD: matinspector prediction  
(D) OTHER INFORMATION: name S8\_01  
score 0.960  
sequence AATAGAATTAG
- (ix) FEATURE:  
(A) NAME/KEY: TF binding-site  
(B) LOCATION: 94..104  
(C) IDENTIFICATION METHOD: matinspector prediction  
(D) OTHER INFORMATION: name S8\_01  
score 0.966  
sequence AACTAAATTAG
- (ix) FEATURE:  
(A) NAME/KEY: TF binding-site  
(B) LOCATION: complement(129..139)  
(C) IDENTIFICATION METHOD: matinspector prediction  
(D) OTHER INFORMATION: name DELTAEF1\_01  
score 0.960  
sequence GCACACCTCAG
- (ix) FEATURE:  
(A) NAME/KEY: TF binding-site  
(B) LOCATION: complement(155..165)  
(C) IDENTIFICATION METHOD: matinspector prediction  
(D) OTHER INFORMATION: name GATA\_C  
score 0.964  
sequence AGATAAATCCA
- (ix) FEATURE:  
(A) NAME/KEY: TF binding-site  
(B) LOCATION: 170..178  
(C) IDENTIFICATION METHOD: matinspector prediction  
(D) OTHER INFORMATION: name CMYB\_01  
score 0.958  
sequence CTTCAAGTTG

- (ix) FEATURE:  
(A) NAME/KEY: TF binding-site  
(B) LOCATION: 176..189  
(C) IDENTIFICATION METHOD: matinspector prediction  
(D) OTHER INFORMATION: name GATA1\_02  
score 0.959  
sequence TTGTAGATAGGACA
- (ix) FEATURE:  
(A) NAME/KEY: TF binding-site  
(B) LOCATION: 180..190  
(C) IDENTIFICATION METHOD: matinspector prediction  
(D) OTHER INFORMATION: name GATA\_C  
score 0.953  
sequence AGATAGGACAT
- (ix) FEATURE:  
(A) NAME/KEY: TF binding-site  
(B) LOCATION: 284..299  
(C) IDENTIFICATION METHOD: matinspector prediction  
(D) OTHER INFORMATION: name TAL1ALPHA47\_01  
score 0.973  
sequence CATAACAGATGGTAAG
- (ix) FEATURE:  
(A) NAME/KEY: TF binding-site  
(B) LOCATION: 284..299  
(C) IDENTIFICATION METHOD: matinspector prediction  
(D) OTHER INFORMATION: name TAL1BETA47\_01  
score 0.983  
sequence CATAACAGATGGTAAG
- (ix) FEATURE:  
(A) NAME/KEY: TF binding-site  
(B) LOCATION: 284..299  
(C) IDENTIFICATION METHOD: matinspector prediction  
(D) OTHER INFORMATION: name TAL1BETA1TF2\_01  
score 0.978  
sequence CATAACAGATGGTAAG
- (ix) FEATURE:  
(A) NAME/KEY: TF binding-site  
(B) LOCATION: complement(287..296)  
(C) IDENTIFICATION METHOD: matinspector prediction  
(D) OTHER INFORMATION: name MYOD\_Q6  
score 0.954  
sequence ACCATCTGTT
- (ix) FEATURE:  
(A) NAME/KEY: TF binding-site  
(B) LOCATION: complement(302..314)  
(C) IDENTIFICATION METHOD: matinspector prediction  
(D) OTHER INFORMATION: name GATA1\_04  
score 0.953  
sequence TCAAGATAAAGTA
- (ix) FEATURE:  
(A) NAME/KEY: TF binding-site  
(B) LOCATION: 393..405  
(C) IDENTIFICATION METHOD: matinspector prediction  
(D) OTHER INFORMATION: name IK1\_01

score 0.963  
sequence AGTTGGGAATTCC

## (ix) FEATURE:

- (A) NAME/KEY: TF binding-site
- (B) LOCATION: 393..404
- (C) IDENTIFICATION METHOD: matinspector prediction
- (D) OTHER INFORMATION: name IK2\_01  
score 0.985  
sequence AGTTGGGAATTC

## (ix) FEATURE:

- (A) NAME/KEY: TF binding-site
- (B) LOCATION: 396..405
- (C) IDENTIFICATION METHOD: matinspector prediction
- (D) OTHER INFORMATION: name CREL\_01  
score 0.962  
sequence TGGGAATTCC

## (ix) FEATURE:

- (A) NAME/KEY: TF binding-site
- (B) LOCATION: 423..436
- (C) IDENTIFICATION METHOD: matinspector prediction
- (D) OTHER INFORMATION: name GATA1\_02  
score 0.950  
sequence TCAGTGATATGGCA

## (ix) FEATURE:

- (A) NAME/KEY: TF binding-site
- (B) LOCATION: complement(478..489)
- (C) IDENTIFICATION METHOD: matinspector prediction
- (D) OTHER INFORMATION: name SRY\_02  
score 0.951  
sequence TAAACAAAACA

## (ix) FEATURE:

- (A) NAME/KEY: TF binding-site
- (B) LOCATION: 486..493
- (C) IDENTIFICATION METHOD: matinspector prediction
- (D) OTHER INFORMATION: name E2F\_02  
score 0.957  
sequence TTTAGCGC

## (ix) FEATURE:

- (A) NAME/KEY: TF binding-site
- (B) LOCATION: complement(514..521)
- (C) IDENTIFICATION METHOD: matinspector prediction
- (D) OTHER INFORMATION: name MZF1\_01  
score 0.975  
sequence TGAGGGGA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

```

TGAGTGCAGT GTTACATGTC AGTTGGGTTA AGTTTGTTAA TGTCAATCAA ATCTTCTATG 60
TCTTGATTG CCTGCTAATT CTATTATTTT TGGAACTAAA TTAGTTTGAT GGTTCATTATTA 120
GTTATTGACT GAGGTGTGCT AATCTCCCAT TATGTGGATT TATCTATTTT TTCAGTTGTA 180
GATAGGACAT TGATAGATAC ATAAGTACCA GGACAAAAGC AGGGAGATCT TTTTCCAAA 240

```

ATCAGGAGAA AAAAATGACA TCTGGAAAAC CTATAGGGAA AGGCATAACA GATGGTAAGG 300  
 ATACTTTATC TTGAGTAGGA GAGCCTTCCT GTGGCAACGT GGAGAAGGGA AGAGGTCGTA 360  
 GAATTGAGGA GTCAGCTCAG TTAGAAGCAG GGAGTTGGGA ATTCCGTTCA TGTGATTTAG 420  
 CATCAGTGAT ATGGCAAATG TGGGACTAAG GGTAGTGATC AGAGGGTTAA AATTGTGTGT 480  
 TTTGTTTTAG CGCTGCTGGG GCATCGCCTT GGGTCCCCTC AAACAGATTC CCATGAATCT 540  
 CTTCAT 546

## (2) INFORMATION FOR SEQ ID NO: 32:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 23 base pairs
  - (B) TYPE: NUCLEIC ACID
  - (C) STRANDEDNESS: SINGLE
  - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: Other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

GTACCAGGGA CTGTGACCAT TGC

23

## (2) INFORMATION FOR SEQ ID NO: 33:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 24 base pairs
  - (B) TYPE: NUCLEIC ACID
  - (C) STRANDEDNESS: SINGLE
  - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: Other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

CTGTGACCAT TGCTCCCAAG AGAG

24

## (2) INFORMATION FOR SEQ ID NO: 34:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 861 base pairs
  - (B) TYPE: NUCLEIC ACID
  - (C) STRANDEDNESS: DOUBLE
  - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: Genomic DNA

(ix) FEATURE:

(A) NAME/KEY: promoter

(B) LOCATION: 1..806

(ix) FEATURE:

- (A) NAME/KEY: transcription start site
- (B) LOCATION: 807

(ix) FEATURE:

- (A) NAME/KEY: TF binding-site
- (B) LOCATION: complement(60..70)
- (C) IDENTIFICATION METHOD: matinspector prediction
- (D) OTHER INFORMATION: name NFY\_Q6  
score 0.956  
sequence GGACCAATCAT

(ix) FEATURE:

- (A) NAME/KEY: TF binding-site
- (B) LOCATION: 70..77
- (C) IDENTIFICATION METHOD: matinspector prediction
- (D) OTHER INFORMATION: name MZF1\_01  
score 0.962  
sequence CCTGGGGA

(ix) FEATURE:

- (A) NAME/KEY: TF binding-site
- (B) LOCATION: 124..132
- (C) IDENTIFICATION METHOD: matinspector prediction
- (D) OTHER INFORMATION: name CMYB\_01  
score 0.994  
sequence TGACCGTG

(ix) FEATURE:

- (A) NAME/KEY: TF binding-site
- (B) LOCATION: complement(126..134)
- (C) IDENTIFICATION METHOD: matinspector prediction
- (D) OTHER INFORMATION: name VMYB\_02  
score 0.985  
sequence TCCAACGGT

(ix) FEATURE:

- (A) NAME/KEY: TF binding-site
- (B) LOCATION: 135..143
- (C) IDENTIFICATION METHOD: matinspector prediction
- (D) OTHER INFORMATION: name STAT\_01  
score 0.968  
sequence TTCCTGGAA

(ix) FEATURE:

- (A) NAME/KEY: TF binding-site
- (B) LOCATION: complement(135..143)
- (C) IDENTIFICATION METHOD: matinspector prediction
- (D) OTHER INFORMATION: name STAT\_01  
score 0.951  
sequence TTCCAGGAA

(ix) FEATURE:

- (A) NAME/KEY: TF binding-site
- (B) LOCATION: complement(252..259)
- (C) IDENTIFICATION METHOD: matinspector prediction
- (D) OTHER INFORMATION: name MZF1\_01  
score 0.956  
sequence TTGGGGGA



- (ix) FEATURE:  
 (A) NAME/KEY: TF binding-site  
 (B) LOCATION: 357..368  
 (C) IDENTIFICATION METHOD: matinspector prediction  
 (D) OTHER INFORMATION: name IK2\_01  
 score 0.965  
 sequence GAATGGGATTTC
- (ix) FEATURE:  
 (A) NAME/KEY: TF binding-site  
 (B) LOCATION: 384..391  
 (C) IDENTIFICATION METHOD: matinspector prediction  
 (D) OTHER INFORMATION: name MZF1\_01  
 score 0.986  
 sequence AGAGGGGA
- (ix) FEATURE:  
 (A) NAME/KEY: TF binding-site  
 (B) LOCATION: complement(410..421)  
 (C) IDENTIFICATION METHOD: matinspector prediction  
 (D) OTHER INFORMATION: name SRY\_02  
 score 0.955  
 sequence GAAACAAAACA
- (ix) FEATURE:  
 (A) NAME/KEY: TF binding-site  
 (B) LOCATION: 592..599  
 (C) IDENTIFICATION METHOD: matinspector prediction  
 (D) OTHER INFORMATION: name MZF1\_01  
 score 0.960  
 sequence GAAGGGGA
- (ix) FEATURE:  
 (A) NAME/KEY: TF binding-site  
 (B) LOCATION: 618..627  
 (C) IDENTIFICATION METHOD: matinspector prediction  
 (D) OTHER INFORMATION: name MYOD\_Q6  
 score 0.981  
 sequence AGCATCTGCC
- (ix) FEATURE:  
 (A) NAME/KEY: TF binding-site  
 (B) LOCATION: 632..642  
 (C) IDENTIFICATION METHOD: matinspector prediction  
 (D) OTHER INFORMATION: name DELTAEF1\_01  
 score 0.958  
 sequence TCCCACCTTCC
- (ix) FEATURE:  
 (A) NAME/KEY: TF binding-site  
 (B) LOCATION: complement(813..823)  
 (C) IDENTIFICATION METHOD: matinspector prediction  
 (D) OTHER INFORMATION: name S8\_01  
 score 0.992  
 sequence GAGGCAATTAT
- (ix) FEATURE:  
 (A) NAME/KEY: TF binding-site  
 (B) LOCATION: complement(824..831)  
 (C) IDENTIFICATION METHOD: matinspector prediction

(D) OTHER INFORMATION: name MZF1\_01  
score 0.986  
sequence AGAGGGGA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

```

TACTATAGGG CACGCGTGGT CGACGGCCGG GCTGTTCTGG AGCAGAGGGC ATGTCAGTAA 60
TGATTGGTCC CTGGGGAAGG TCTGGCTGGC TCCAGCACAG TGAGGCATTT AGGTATCTCT 120
CGGTGACCGT TGGATTCTCT GAAGCAGTAG CTGTTCTGTT TGGATCTGGT AGGGACAGGG 180
CTCAGAGGGC TAGGCACGAG GGAAGGTCAG AGGAGAAGGS AGGSARGGCC CAGTGAGARG 240
GGAGCATGCC TTCCCCAAC CCTGGCTTSC YCTTGGYMAM AGGGCGKTTY TGGGMACTTR 300
AAYTCAGGGC CCAASCAGAA SCACAGGCCC AKTCNTGGCT SMAAGCACAA TAGCCTGAAT 360
GGGATTTTCAG GTTAGNCAGG GTGAGAGGGG AGGCTCTCTG GCTTAGTTTT GTTTTGTITT 420
CCAAATCAAG GTAAGTTGCT CCCTTCTGCT ACGGGCCTTG GTCTTGGCTT GTCCTCACCC 480
AGTCGGAAGT CCCTACCACT TTCAGGAGAG TGGTTTTAGG CCCGTGGGGC TGTTCTGTTC 540
CAAGCAGTGT GAGAACATGG CTGGTAGAGG CTCTAGCTGT GTGCGGGGCC TGAAGGGGAG 600
TGGGTTCTCG CCCAAAGAGC ATCTGCCCAT TCCCACCTT CCCTTCTCCC ACCAGAAGCT 660
TGCCTGAGCT GTTTGGACAA AAATCCAAAC CCCACTTGGC TACTCTGGCC TGGCTTCAGC 720
TTGGAACCCA ATACCTAGGC TTACAGGCCA TCCTGAGCCA GGGGCCTCTG GAAATTCTCT 780
TCCTGATGGT CCTTTAGGTT TGGGCACAAA ATATAATTGC CTCTCCCCTC TCCCATTTTC 840
TCTCTTGGGA GCAATGGTCA C 861

```

(2) INFORMATION FOR SEQ ID NO: 35:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 20 base pairs
  - (B) TYPE: NUCLEIC ACID
  - (C) STRANDEDNESS: SINGLE
  - (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: Other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

CTGGGATGGA AGGCACGGTA

20

(2) INFORMATION FOR SEQ ID NO: 36:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 20 base pairs
  - (B) TYPE: NUCLEIC ACID

- (C) STRANDEDNESS: SINGLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: Other nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

GAGACCACAC AGCTAGACAA

20

(2) INFORMATION FOR SEQ ID NO: 37:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 555 base pairs
  - (B) TYPE: NUCLEIC ACID
  - (C) STRANDEDNESS: DOUBLE
  - (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: Genomic DNA
- (ix) FEATURE:
  - (A) NAME/KEY: promoter
  - (B) LOCATION: 1..500
- (ix) FEATURE:
  - (A) NAME/KEY: transcription start site
  - (B) LOCATION: 501
- (ix) FEATURE:
  - (A) NAME/KEY: TF binding-site
  - (B) LOCATION: 191..206
  - (C) IDENTIFICATION METHOD: matinspector prediction
  - (D) OTHER INFORMATION: name ARNT\_01  
score 0.964  
sequence GGACTCACGTGCTGCT
- (ix) FEATURE:
  - (A) NAME/KEY: TF binding-site
  - (B) LOCATION: 193..204
  - (C) IDENTIFICATION METHOD: matinspector prediction
  - (D) OTHER INFORMATION: name NMYC\_01  
score 0.965  
sequence ACTCACGTGCTG
- (ix) FEATURE:
  - (A) NAME/KEY: TF binding-site
  - (B) LOCATION: 193..204
  - (C) IDENTIFICATION METHOD: matinspector prediction
  - (D) OTHER INFORMATION: name USF\_01  
score 0.985  
sequence ACTCACGTGCTG
- (ix) FEATURE:
  - (A) NAME/KEY: TF binding-site
  - (B) LOCATION: complement(193..204)
  - (C) IDENTIFICATION METHOD: matinspector prediction
  - (D) OTHER INFORMATION: name USF\_01  
score 0.985  
sequence CAGCACGTGAST

- (ix) FEATURE:  
(A) NAME/KEY: TF binding-site  
(B) LOCATION: complement(193..204)  
(C) IDENTIFICATION METHOD: matinspector prediction  
(D) OTHER INFORMATION: name NMYC\_01  
score 0.956  
sequence CAGCACGTGAGT
- (ix) FEATURE:  
(A) NAME/KEY: TF binding-site  
(B) LOCATION: complement(193..204)  
(C) IDENTIFICATION METHOD: matinspector prediction  
(D) OTHER INFORMATION: name MYCMAX\_02  
score 0.972  
sequence CAGCACGTGAGT
- (ix) FEATURE:  
(A) NAME/KEY: TF binding-site  
(B) LOCATION: 195..202  
(C) IDENTIFICATION METHOD: matinspector prediction  
(D) OTHER INFORMATION: name USF\_C  
score 0.997  
sequence TCACGTGC
- (ix) FEATURE:  
(A) NAME/KEY: TF binding-site  
(B) LOCATION: complement(195..202)  
(C) IDENTIFICATION METHOD: matinspector prediction  
(D) OTHER INFORMATION: name USF\_C  
score 0.991  
sequence GCACGTGA
- (ix) FEATURE:  
(A) NAME/KEY: TF binding-site  
(B) LOCATION: complement(210..217)  
(C) IDENTIFICATION METHOD: matinspector prediction  
(D) OTHER INFORMATION: name MZF1\_01  
score 0.968  
sequence CATGGGGA
- (ix) FEATURE:  
(A) NAME/KEY: TF binding-site  
(B) LOCATION: 397..410  
(C) IDENTIFICATION METHOD: matinspector prediction  
(D) OTHER INFORMATION: name ELK1\_02  
score 0.963  
sequence CTCTCCGGAAGCCT
- (ix) FEATURE:  
(A) NAME/KEY: TF binding-site  
(B) LOCATION: 400..409  
(C) IDENTIFICATION METHOD: matinspector prediction  
(D) OTHER INFORMATION: name CETS1P54\_01  
score 0.974  
sequence TCCGGAAGCC
- (ix) FEATURE:  
(A) NAME/KEY: TF binding-site  
(B) LOCATION: complement(460..470)  
(C) IDENTIFICATION METHOD: matinspector prediction

(D) OTHER INFORMATION: name AP1\_Q4  
score 0.963  
sequence AGTGACTGAAC

(ix) FEATURE:

(A) NAME/KEY: TF binding-site  
(B) LOCATION: complement(460..470)  
(C) IDENTIFICATION METHOD: matinspector prediction  
(D) OTHER INFORMATION: name AP1FJ\_Q2  
score 0.961  
sequence AGTGACTGAAC

(ix) FEATURE:

(A) NAME/KEY: TF binding-site  
(B) LOCATION: 547..555  
(C) IDENTIFICATION METHOD: matinspector prediction  
(D) OTHER INFORMATION: name PADS\_C  
score 1.000  
sequence TGTGGTCTC

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

```
CTATAGGGCA CGCKTGGTCG ACGGCCCGGG CTGGTCTGGT CTGKTGTGGA GTCGGGTTGA 60
AGGACAGCAT TTGTXACATC TGGTCTACTG CACCTTCCCT CTGCCGTGCA CTTGGCCTTT 120
KAWAAGCTCA GCACCGGTGC CCATCACAGG GCCGGCAGCA CACACATCCC ATTACTCAGA 180
AGGAACTGAC GGA CTCACGT GCTGCTCCGT CCCCATGAGC TCAGTGGACC TGTCTATGTA 240
GAGCAGTCAG ACAGTGCC TGATAGAGTG AGAGTTCAGC CAGTAAATCC AAGTGATTGT 300
CATTCTGTGC TGCATTAGTA ACTCCCAACC TAGATGTGAA AACTTAGTTC TTTCTCATAG 360
GTTGCTCTGC CCATGGTCCC ACTGCAGACC CAGGCACTCT CCGGAAGCCT GGAAATCACC 420
CGTGTCTTCT GCCTGCTCCC GCTCACATCC CACACTGTGT TTCAGTCACT GAGTTACAGA 480
TTTTGCCTCC TCAATTTCTC TTGTCTTAGT CCCATCCTCT GTTCCCCTGG CCAGTTTGTC 540
TAGCTGTGTG GTCCTC 555
```

(2) INFORMATION FOR SEQ ID NO: 38:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 352 base pairs  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(D) DEVELOPMENTAL STAGE: Fetal  
(F) TISSUE TYPE: liver

(ix) FEATURE:

(A) NAME/KEY: other  
 (B) LOCATION: 49..196  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 97  
                           region 12..159  
                           id AA232452  
                           est

## (ix) FEATURE:

(A) NAME/KEY: other  
 (B) LOCATION: 195..337  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 96  
                           region 157..299  
                           id AA232452  
                           est

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 65..124  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 15.8  
                           seq LLLLLLLLRHGAQG/KP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

```

ACACATTGTC GGGAACGCAG AGCGGAGCGT NGGAGAGCGG ASRWAGCTGG ATAACAGGGG 60
ACCG ATG ATG TGG CGA CCA TCA GTT CTG CTG CTT CTG TTG CTA CTG AGG 109
 Met Met Trp Arg Pro Ser Val Leu Leu Leu Leu Leu Leu Arg
 -20 -15 -10

CAC GGG GCC CAG GGG AAG CCA TCC CCA GAC GCA GGC CCT CAT GGC CAG 157
His Gly Ala Gln Gly Lys Pro Ser Pro Asp Ala Gly Pro His Gly Gln
 -5 1 5 10

GGG AGG GTG CAC CAG GCG GCC CCC CTG AGC GAC GCT CCC CAT GAT GAC 205
Gly Arg Val His Gln Ala Ala Pro Leu Ser Asp Ala Pro His Asp Asp
 15 20 25

GCC CAC GGG AAC TTC CAG TAC GAC CAT GAG GCT TTC CTG GGA CGG GAA 253
Ala His Gly Asn Phe Gln Tyr Asp His Glu Ala Phe Leu Gly Arg Glu
 30 35 40

GTG GCC AAG GAA TTC GAC CAA CTC ACC CCA GAG GAA AGC CAG GCC CGT 301
Val Ala Lys Glu Phe Asp Gln Leu Thr Pro Glu Glu Ser Gln Ala Arg
 45 50 55

CTG GGG CGG ATC GTG GAC CGC ATG GAC CGC GRG GGG ACG GCA ACG GCT 349
Leu Gly Arg Ile Val Asp Arg Met Asp Arg Xaa Gly Thr Ala Thr Ala
 60 65 70 75

GGG
Gly
 352

```

## (2) INFORMATION FOR SEQ ID NO: 39:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 247 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 158..241
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 11.4  
seq LLLILFLYGLCSG/WR

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

```

CTACTTTCCT GCTTACAAGA GAACTTTGGA ACCAAGGAGC AGGACTTTTA GCTGCTTGTT 60
TTATTGCTAT TGTACCAGGC TACATATCTC GGTCAGTAGC TGGATCCTTT GATAATGAAG 120
GCATTGCTAT TTTTGCACCT CAGTTCACAT ACTATTT ATG GGT AAA ATC TGT AAA 175
 Met Gly Lys Ile Cys Lys
 -25
AAC TGG GTC AGT TTT TTG GAC AAT GTG CTG CTG CTT ATC CTA TTT CTA 223
Asn Trp Val Ser Phe Leu Asp Asn Val Leu Leu Leu Ile Leu Phe Leu
 -20 -15 -10
TAT GGT CTC TGC TCG GGG TGG CGG 247
Tyr Gly Leu Cys Ser Gly Trp Arg
 -5 1

```

(2) INFORMATION FOR SEQ ID NO: 40:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 216 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Large intestine

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 61..114
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 11.1  
seq LLALLCASASGNA/IQ

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

ATATAAAACA TCTGGAAGTT TCCAGGGGGC TGCTTTGCAT CTGAAACTGT CAGCCCCAGA 60

ATG TTG ACA GTC GCT CTC CTA GCC CTT CTC TGT GCC TCA GCC TCT GGC 108  
 Met Leu Thr Val Ala Leu Leu Ala Leu Leu Cys Ala Ser Ala Ser Gly  
           -15                              -10                              -5

AAT GCC ATT CAG GCC AGG TCT TCC TCC TAT AGT GGA GAG TAT GGD CTG 156  
 Asn Ala Ile Gln Ala Arg Ser Ser Ser Tyr Ser Gly Glu Tyr Gly Leu  
           1                              5                              10

GTG GTG GAA AGC GAT TCT CTC ATT CTG GCA ACC AGT TGG ACG GCC CCA 204  
 Val Val Glu Ser Asp Ser Leu Ile Leu Ala Thr Ser Trp Thr Ala Pro  
   15                              20                              25                              30

TCA CCG CCC ACG 216  
 Ser Pro Pro Thr

## (2) INFORMATION FOR SEQ ID NO: 41:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 202 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Pancreas

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 107..145
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 10.4  
                                                           seq MVLLLCLSCLIFS/CL

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

AAGATTCAGG CCCTCAGCAA ACAAGGAACC TGGAATGT AACCTGAAT GCACGGTGGG 60

GAGGACATGG CAAGAGAAAA GCGGCAGGAA TAAAGTGATT TTCTGA ATG GTC TTG 115  
                                                                                   Met Val Leu

CTT CTT TGT CTA TCT TGT CTG ATT TTC TCC TGT CTG ACC TTT TCC TGG 163  
 Leu Leu Cys Leu Ser Cys Leu Ile Phe Ser Cys Leu Thr Phe Ser Trp  
 -10                              -5                              1                              5

TTA AAA ATC TGG GGG AAA ATG ACG GAC TCC AAG CCG ATG 202  
 Leu Lys Ile Trp Gly Lys Met Thr Asp Ser Lys Pro Met  
           10                              15

## (2) INFORMATION FOR SEQ ID NO: 42:



- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 290 base pairs  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: CDNA
- (vi) ORIGINAL SOURCE:  
 (A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Liver
- (ix) FEATURE:  
 (A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 21..83  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 10  
 seq LWALAMVTRPASA/AP

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

```

AATACCTTAG ACCCTCAGTC ATG CCA GTG CCT GCT CTG TGC CTG CTC TGG GCC 53
 Met Pro Val Pro Ala Leu Cys Leu Leu Trp Ala
 -20 -15

CTG GCA ATG GTG ACC CGG CCT GCC TCA GCG GCC CCC ATG GGC GGC CCA 101
Leu Ala Met Val Thr Arg Pro Ala Ser Ala Ala Pro Met Gly Gly Pro
-10 -5 1 5

GAA CTG GCA CAG CAT GAG GAG CTG ACC CTG CTC TTC CAT GGG ACC CTG 149
Glu Leu Ala Gln His Glu Glu Leu Thr Leu Leu Phe His Gly Thr Leu
 10 15 20

CAG CTG GGC CAG GCC CTC AAC GGT GTG TAC AGG ACC ACG GAG GGA CGG 197
Gln Leu Gly Gln Ala Leu Asn Gly Val Tyr Arg Thr Thr Glu Gly Arg
 25 30 35

CTG ACA AAG GCC AGG AAC AGC CTG GGT CTC TAT GGC CGC ACA ATA GAA 245
Leu Thr Lys Ala Arg Asn Ser Leu Gly Leu Tyr Gly Arg Thr Ile Glu
 40 45 50

CTC CTG GGG CAG GAG GTC AGC CGG GGC CGG GAT GCA GCC CAG GGC 290
Leu Leu Gly Gln Glu Val Ser Arg Gly Arg Asp Ala Ala Gln Gly
 55 60 65

```

(2) INFORMATION FOR SEQ ID NO: 43:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 259 base pairs  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: CDNA
- (vi) ORIGINAL SOURCE:  
 (A) ORGANISM: Homo Sapiens

(F) TISSUE TYPE: Lung (cells)

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 128..250  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 9.4  
 seq LLPLWVFLPLSLG/PP

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

```

ATAAGGAATA AGCAATGTTT TAAACCACT CAAATGTTC AACTGTTGCC AAAAGATGCT 60
ACGGAGCTCT CCCTAAGCCC GTGGCCCACC CTAAATGTAA CAGGCCCATG TTTACAAACC 120
CAAATCC ATG CAT CTC AGA GGC TCC CAC ACA TAT CCT AGC TGT CCC TCC 169
Met His Leu Arg Gly Ser His Thr Tyr Pro Ser Cys Pro Ser
 -40 -35 -30

TCA GAA CTC CGT TTG GAC AGT CTC TGG CAG CAT CAC CGG CAG CTG CTG 217
Ser Glu Leu Arg Leu Asp Ser Leu Trp Gln His His Arg Gln Leu Leu
 -25 -20 -15

CCT CTC TGG GTG TTC CTG CCA CTC AGC CTG GGC CCC CCT GGG 259
Pro Leu Trp Val Phe Leu Pro Leu Ser Leu Gly Pro Pro Gly
 -10 -5 1

```

(2) INFORMATION FOR SEQ ID NO: 44:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 292 base pairs  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Lung

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 62..139  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 9.2  
 seq FLLMTLLGGLTG/VA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:

```

AAVAGTCTGC RRTCTCCCA GCACAGACGT TTGGACAGAG CAGGCTCCTA AGGTCTCCAG 60
A ATG CCC GTG CCA GCM TCC TGG CCC CAC CTT CCT AGT CCT TTC CTG CTG 109
Met Pro Val Pro Ala Ser Trp Pro His Leu Pro Ser Pro Phe Leu Leu
 -25 -20 -15

ATG ACG CTA CTG CTG GGG GGA CTC ACA GGG GTA GCT GKY GAG GAA GAG 157

```

35

Met Thr Leu Leu Leu Gly Gly Leu Thr Gly Val Ala Xaa Glu Glu Glu  
 -10 -5 1 5

CTG CAG GTG RTT CAG CCT GAC AAG TCC ATA TCA GTT GCA GCT GGA AAG 205  
 Leu Gln Val Xaa Gln Pro Asp Lys Ser Ile Ser Val Ala Ala Gly Lys  
 10 15 20

WMG GCC ACT CTG CAC TGC ACT GTG ACW WCC CTG ATC CMT GTG GGG CCC 253  
 Xaa Ala Thr Leu His Cys Thr Val Thr Xaa Leu Ile Xaa Val Gly Pro  
 25 30 35

ATC CAG TGG TTM AGA GGA GCT GGA CCA GGC CGG GAA TTA 292  
 Ile Gln Trp Xaa Arg Gly Ala Gly Pro Gly Arg Glu Leu  
 40 45 50

## (2) INFORMATION FOR SEQ ID NO: 45:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 319 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Large intestine

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 41..109
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 9.1  
seq LVAMLLLVFPTVS/RS

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:

AACTACCCCG GTAGCCTGAC AGCAGGAGCT CGAGAGAAGC ATG GCT CAG CGG TGC 55  
 Met Ala Gln Arg Cys  
 -20

GTT TGC GTG CTG GCC CTG GTG GCT ATG CTG CTC CTA GTT TTC CCT ACC 103  
 Val Cys Val Leu Ala Leu Val Ala Met Leu Leu Leu Val Phe Pro Thr  
 -15 -10 -5

GTC TCC AGA TCG ATG GGC CCG AGG AGC GGG GAG CAT CAA AGG GCG TCG 151  
 Val Ser Arg Ser Met Gly Pro Arg Ser Gly Glu His Gln Arg Ala Ser  
 1 5 10

CGA ATC CCT TCT CAG TTC AGC AAA GAG GAA CGC GTC GCG ATG AAA GAG 199  
 Arg Ile Pro Ser Gln Phe Ser Lys Glu Glu Arg Val Ala Met Lys Glu  
 15 20 25 30

GCG CTG AAA GGT GCC ATC CAG ATT CCA ACA GTG ACT TTT AGC TCT GAG 247  
 Ala Leu Lys Gly Ala Ile Gln Ile Pro Thr Val Thr Phe Ser Ser Glu  
 35 40 45

36

AAG TCC AAT ACT ACA GCC CTG GCT GAG TTC GGA AAT ACA TTC ATA AAG 295  
 Lys Ser Asn Thr Thr Ala Leu Ala Glu Phe Gly Asn Thr Phe Ile Lys  
                   50                                  55                                  60

TCT TTC CTA CAG TGG TCA GCA CCG 319  
 Ser Phe Leu Gln Trp Ser Ala Pro  
                   65                                  70

## (2) INFORMATION FOR SEQ ID NO: 46:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 307 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 251..298
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 9  
seq LISFLLLLLLLLP/AR

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

ACAAGTTTAT ATACATAAT AGTTTCAAGG GTTTTGCCAC TTAATTATAC TAAGTTACTT 60  
 AACCTCTCAA TGCCTTATCT GTAGATTTTG TTTTGTAGAG GGTGGGATAG TAATAGTAAC 120  
 TACAAGGTTT CACAAGGTTG TGAAATTGAA TGAGAAATAC ATGGCACTTT AACAAAGTGGC 180  
 AGGATAGTTC AGACGGTTTC ACAAGGTTGT GAAATTGAAT GAGAAATACA TGGCACCTTA 240  
 ACAAGTCACT ATG GAT TAT TTA ATT TCT TTT CTT CTT CTT CTG CTG CTG 289  
                   Met Asp Tyr Leu Ile Ser Phe Leu Leu Leu Leu Leu Leu  
                   -15                                  -10                                  -5  
 CTT CTC CCT GCC CGG GGG 307  
 Leu Leu Pro Ala Arg Gly  
                   1

## (2) INFORMATION FOR SEQ ID NO: 47:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 395 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Colon

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: 132..383  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 8.9  
seq LLGVLGIFGLTFA/FI

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

```

AGAGTGCCTC AAGGGCAGAA TGGAATGAGC AGAACCCTTT GGTTTCCCGG GAAGAGCTCT 60
CAACCTTGAG TCAGGAAGAC TGATTCTCC TCCAGCTCC GCAGGAACAT GGAAGTGTGA 120
TCAGGTCCAG A ATG GCT ACA ACA GTC CCT GAT GGT TGC CGC AAT GGC CTG 170
 Met Ala Thr Thr Val Pro Asp Gly Cys Arg Asn Gly Leu
 -80 -75

AAA TCC AAG TAC TAC AGA CTT TGT GAT AAG GCT GAA GCT TGG GGC ATC 218
Lys Ser Lys Tyr Tyr Arg Leu Cys Asp Lys Ala Glu Ala Trp Gly Ile
 -70 -65 -60

GTC CTA GAA ACG GTG GCC ACA GCC GGG GTT GTG ACC TCG GTG GCC TTC 266
Val Leu Glu Thr Val Ala Thr Ala Gly Val Val Thr Ser Val Ala Phe
 -55 -50 -45 -40

ATG CTC ACT CTC CCG ATC CTC GTC TGC AAG GTG CAG GAC TCC AAC AGG 314
Met Leu Thr Leu Pro Ile Leu Val Cys Lys Val Gln Asp Ser Asn Arg
 -35 -30 -25

CGA AAA ATG CTG CCT ACT CAG TTT CTC TTC CTC CTG GGT GTG TTG GGC 362
Arg Lys Met Leu Pro Thr Gln Phe Leu Phe Leu Leu Gly Val Leu Gly
 -20 -15 -10

ATC TTT GGC CTC ACC TTC GCC TTC ATC ATC GGA 395
Ile Phe Gly Leu Thr Phe Ala Phe Ile Ile Gly
 -5 1

```

## (2) INFORMATION FOR SEQ ID NO: 48:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 294 base pairs  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Large intestine

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide

38

(B) LOCATION: 82..138  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 8.9  
 seq WLFLVIFIKGVQC/QE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:

```

AGCTCTGGGA GAAGAGCCCC AGCCCCAGCA ATTCCCAGGA GATTCCATTC GGTGATCAGC 60
GCTGAACACA GAGGACTCAC C ATG GAG TCT GGG CTG AGC TGG CTT TTC CTT 111
 Met Glu Ser Gly Leu Ser Trp Leu Phe Leu
 -15 -10

GTT ATT TTT ATA AAA GGT GTC CAG TGT CAG GAG CAG CTG GTG GAA TCT 159
Val Ile Phe Ile Lys Gly Val Gln Cys Gln Glu Gln Leu Val Glu Ser
 -5 1 5

GGG GGA GGC GTG GTC AAG CCT GGA GGG TCC CTG CGA CTC TCC TGT GAA 207
Gly Gly Gly Val Val Lys Pro Gly Gly Ser Leu Arg Leu Ser Cys Glu
 10 15 20

GCC TCT GGA TTT ACT TTC AGT GAC TTC TNC ATG ATG TGG ATC CGG CAG 255
Ala Ser Gly Phe Thr Phe Ser Asp Phe Xaa Met Met Trp Ile Arg Gln
 25 30 35

ACT CCA GGG AAG GGT CTG GAG TAT GTG GGC ATA CAT CAG 294
Thr Pro Gly Lys Gly Leu Glu Tyr Val Gly Ile His Gln
 40 45 50

```

(2) INFORMATION FOR SEQ ID NO: 49:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 177 base pairs  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Lung (cells)

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 115..168  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 8.6  
 seq VLLHVAFLPGREG/RP

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:

```

TTCTTAAGAT TCCATGAGTT GACTAGTTCA ATTCTGTTCC ATGGGGTGTT GGCTGGTCCC 60
TGTGTTCACT TGGTGCCGGG GCTGGGCTGG AAGGTCCAAG ACATCTTTTC TCAC ATG 117
 Met

```

TCT GGT ACC TCA GTG CTT CTC CAC GTG GCC TTT CTA CCT GGC AGG TTT 165  
Ser Gly Thr Ser Val Leu Leu His Val Ala Phe Leu Pro Gly Arg Phe  
-15 -10 -5

GGG CGC CCT CTG  
Gly Arg Pro Leu  
1

(2) INFORMATION FOR SEQ ID NO: 50:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 251 base pairs  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Lung (cells)

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide  
(B) LOCATION: 93..143  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 8.6  
seq LLPVSLLLSVAVS/AT

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50:

AATTCTGTCT CACTGGAGAG GAGGCAGGGA CAGACCCAGC AGCACCCACC TGAGCGAGAA 60

GAGCAGACAC CGTGCTCCTG GAATCACCCA GC ATG TTG CAA GGT CTC CTG CCA 113  
Met Leu Gln Gly Leu Leu Pro  
-15

GTC AGT CTC CTC CTC TCT GTT GCA GTA AGT GCT ATA AAA GAA CTC CCT 161  
Val Ser Leu Leu Leu Ser Val Ala Val Ser Ala Ile Lys Glu Leu Pro  
-10 -5 1 5

GGG GTG AAG AAG TAT GAA GTG GTT TAT CCT ATA AGA CTT CAT CCA CTG 209  
Gly Val Lys Lys Tyr Glu Val Val Tyr Pro Ile Arg Leu His Pro Leu  
10 15 20

CAT AAA AGA GAG GCC AAA GAG CCA GAG CAA CAG GAA CGA CGG 251  
His Lys Arg Glu Ala Lys Glu Pro Glu Gln Gln Glu Arg Arg  
25 30 35

(2) INFORMATION FOR SEQ ID NO: 51:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 249 base pairs  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens

(F) TISSUE TYPE: Colon

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide

(B) LOCATION: 160..204

(C) IDENTIFICATION METHOD: Von Heijne matrix

(D) OTHER INFORMATION: score 8.6  
seq ICHVSLLLQLCSS/CK

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51:

```
AATCCATTGT TTTCCCTAGC AGTGTGGGGC TCTCTGACAT GCTTGTTCGT CTTGGAGGGG 60
TTCTGAGAGG CTCTCCCTAG TCTTAAGTGC TTCTGTCTTA CCAGACCTTC CTTCTGTCCC 120
CTCACTTAAC AGACCATCTG CTCCGGCCAC CATTCCCAC ATG CAC ATT TGT CAT 174
 Met His Ile Cys His
 -15
GTG TCT CTA CTG CTG CAG CTT TGC TCA TCT TGC AAG AAG TCC CCA CTC 222
Val Ser Leu Leu Leu Gln Leu Cys Ser Ser Cys Lys Lys Ser Pro Leu
-10 -5 1 5
AAA CTT CTG CTA CAG AAA GCC CAA AGG 249
Lys Leu Leu Leu Gln Lys Ala Gln Arg
 10 15
```

(2) INFORMATION FOR SEQ ID NO: 52:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 167 base pairs

(B) TYPE: NUCLEIC ACID

(C) STRANDEDNESS: DOUBLE

(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens

(F) TISSUE TYPE: Liver

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide

(B) LOCATION: 57..155

(C) IDENTIFICATION METHOD: Von Heijne matrix

(D) OTHER INFORMATION: score 8.2  
seq LLCSSLFSFPFLC/HP

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52:

```
CATCATGAAT ATCTATCCCC AGTCCTCCAC TCTTGACTCC CTCTGGAGT GGATAG ATG 59
 Met
```



ATC TTT GCT GAC AGG ACA CAC TCC AGC GCT TTC ACC CTG ATG AGG TCC 107  
 Ile Phe Ala Asp Arg Thr His Ser Ser Ala Phe Thr Leu Met Arg Ser  
 -30 -25 -20

TAT TCT TTG CTT TTG TGC TCA CTC TTG TTC TCA TTC CCA TTC TTA TGC 155  
 Tyr Ser Leu Leu Leu Cys Ser Leu Leu Phe Ser Phe Pro Phe Leu Cys  
 -15 -10 -5

CAC CCT CTG CGG 167  
 His Pro Leu Arg  
 1

## (2) INFORMATION FOR SEQ ID NO: 53:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 236 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Pancreas

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 21..80
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 8  
seq VCVLVGSFASLA/GT

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53:

ATCGAAAAAG CTCTGGCACA ATG GCT TTT CTT CCT TCC TGG GTT TGT GTA CTA 53  
 Met Ala Phe Leu Pro Ser Trp Val Cys Val Leu  
 -20 -15 -10

GTT GGT TCC TTT TCT GCT TCC TTA GCA GGG ACT TCC AAT CTC TCA GAG 101  
 Val Gly Ser Phe Ser Ala Ser Leu Ala Gly Thr Ser Asn Leu Ser Glu  
 -5 1 5

ACA GAG CCC CCT CTG TGG AAG GAG AGT CCT GGT CAG CTC AGT GAC TAC 149  
 Thr Glu Pro Pro Leu Trp Lys Glu Ser Pro Gly Gln Leu Ser Asp Tyr  
 10 15 20

AGG GTG GAG AAC AGC ATG TAC ATT ATT AAT CCC TGG GTA TAC CTT GAG 197  
 Arg Val Glu Asn Ser Met Tyr Ile Ile Asn Pro Trp Val Tyr Leu Glu  
 25 30 35

AGA ATG GGG ATG TAT AAA ATC ATA TTG AAT CAG ACG AAG 236  
 Arg Met Gly Met Tyr Lys Ile Ile Leu Asn Gln Thr Lys  
 40 45 50

## (2) INFORMATION FOR SEQ ID NO: 54:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 234 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 157..198
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 7.7  
seq FLVSCVICTGSFA/FN

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54:

```

ATTAAGCAGT CACCCATTCA GGAATGAGAA TATTATACAC CTATATATTT ATTTGTATA 60
TATTAACAAA ATTATATATG ACATTGTAGC AGGTAGGTTT GACCCAGTTG CAGGTTGGGG 120
CTGAGATGAA ATGTAA AATT GTATGTCTCA TTCTGG ATG TTT TTA GTC TCG TGC 174
 Met Phe Leu Val Ser Cys
 -10
GTT ATC TGC ACT GGG AGC TTT GCC TTT AAT AAC TCA AAC GTT CCT CTC 222
Val Ile Cys Thr Gly Ser Phe Ala Phe Asn Asn Ser Asn Val Pro Leu
 -5 1 5
CCC AGC AGC CGG 234
Pro Ser Ser Arg
 10

```

## (2) INFORMATION FOR SEQ ID NO: 55:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 465 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 34..284
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 99

43

region 11..261  
id AA171572  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 268..335  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 91  
region 246..313  
id AA171572  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 354..390  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 97  
region 334..370  
id AA171572  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 394..430  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 94  
region 376..412  
id AA171572  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 300..465  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 90  
region 6..171  
id AA218270  
est

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: 262..393  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 7.5  
seq LMIPLLLLTPITA/TS

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55:

TTCTGGAGCC GAAGAGAGTC GGAAGAACAA GTGATGCCAT GGACAAATATT ACCAGGCAGA 60  
ACCAATTCTA CGATACCCAA GTCATCAAAC AAGAAAACGA GTCAGGCTAC GAGAGGAGAC 120  
CACTGGAAAT GGAGCAGCAG CAGGCCTATC GTCCAGAAAT GAAGACAGAG ATGAAGCAAG 180  
GAGCACCAC CAGCTTCCTC CCGCCTGAAG CTTCTCAACT CGAGCCAGAC AGGCAGCAAT 240  
TCCAGAGTCG AAAGAGGCCT T ATG AAG AAA ACC GGG GAC GGG GGT ACT TTG 291  
Met Lys Lys Thr Gly Asp Gly Gly Thr Leu  
-40 -35

```

AGC ACC GAG AGG ATA GGA GGG GCC GCT CTC CTC AGC CTC CTG CTG AAG 339
Ser Thr Glu Arg Ile Gly Gly Ala Ala Leu Leu Ser Leu Leu Leu Lys
 -30 -25 -20

AGG ATG AAG ATG ACT TTG ATG ATA CCC TTG TTG CTA TTG ACA CCT ATA 387
Arg Met Lys Met Thr Leu Met Ile Pro Leu Leu Leu Leu Thr Pro Ile
 -15 -10 -5

ACT GCG ACC TCC AMT TCA AGG TGG CCC GAG ATC GGA GTA GTG GCT ATC 435
Thr Ala Thr Ser Xaa Ser Arg Trp Pro Glu Ile Gly Val Val Ala Ile
 1 5 10

CGC TCA CAA TTG AGG GCT TTG CAT ACC TGT 465
Arg Ser Gln Leu Arg Ala Leu His Thr Cys
15 20

```

## (2) INFORMATION FOR SEQ ID NO: 56:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 405 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 58..132
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 7.5  
seq XILLAGWCPDTRA/GG

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56:

```

AACTTTGTGC CCAGAGCTCC AGCCACAGTG AGCATGGAGC TGGGCGGCCC AGGGTAA 57

ATG GGC TTC TTT CTT CCC CAT GGC ATC TCA GAC GCC KGA ATA CTC CTG 105
Met Gly Phe Phe Leu Pro His Gly Ile Ser Asp Ala Xaa Ile Leu Leu
-25 -20 -15 -10

GCT GGC TGG TGT CCA GAT ACT AGG GCA GGA GGC TGG GCT GAC CTC TGC 153
Ala Gly Trp Cys Pro Asp Thr Arg Ala Gly Gly Trp Ala Asp Leu Cys
 -5 1 5

CTT CCT GAA AAC AGA GGC CCA AAG CCA CCG TCC CCT CGG AGT GCT CTG 201
Leu Pro Glu Asn Arg Gly Pro Lys Pro Pro Ser Pro Arg Ser Ala Leu
 10 15 20

GGC AGT GGG AGG GGC CTG GGT TCT GGC CAG CCT GAG GTT GAA CCA CCA 249
Gly Ser Gly Arg Gly Leu Gly Ser Gly Gln Pro Glu Val Glu Pro Pro
 25 30 35

```

45

|                                                                 |     |
|-----------------------------------------------------------------|-----|
| GCC CCG GAG CAG GCC TGG GAG TCC TTG CAG GGT GGC CTG GGT GAM TGC | 297 |
| Ala Pro Glu Gln Ala Trp Glu Ser Leu Gln Gly Gly Leu Gly Xaa Cys |     |
| 40 45 50 55                                                     |     |
|                                                                 |     |
| TCA MCA GCM CGG CCC TCC CCA GGG TTC TGG GCC AGA GCC TCC CTG GCC | 345 |
| Ser Xaa Ala Arg Pro Ser Pro Gly Phe Trp Ala Arg Ala Ser Leu Ala |     |
| 60 65 70                                                        |     |
|                                                                 |     |
| GTT GGA GCG GGA NST GTG GGT GGA ACA CTT CTG AAT TGG GAR ATT GCC | 393 |
| Val Gly Ala Gly Xaa Val Gly Gly Thr Leu Leu Asn Trp Glu Ile Ala |     |
| 75 80 85                                                        |     |
|                                                                 |     |
| TCG GAC CTC CAG                                                 | 405 |
| Ser Asp Leu Gln                                                 |     |
| 90                                                              |     |

## (2) INFORMATION FOR SEQ ID NO: 57:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 313 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Colon

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 95..232
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 7.5  
seq VCTLLSSHPSRC/RP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57:

|                                                                   |     |
|-------------------------------------------------------------------|-----|
| AACCCCGGCA AGGAGCGGGC TCTCGTCACT TCCGGCGCCC GCCGACACGC ACTTCCGTTC | 60  |
|                                                                   |     |
| GTCCGCAGCG GGCCCTAGGC GGCCGCCATG TTGA ATG TGG CTC CGC CCG GGG AGC | 115 |
| Met Trp Leu Arg Pro Gly Ser                                       |     |
| -45 -40                                                           |     |
|                                                                   |     |
| TGC TGG AGT ACG AGG GAG CCA AGA AGG GCT CCA AGG ACC TCT GCC TCT   | 163 |
| Cys Trp Ser Thr Arg Glu Pro Arg Arg Ala Pro Arg Thr Ser Ala Ser   |     |
| -35 -30 -25                                                       |     |
|                                                                   |     |
| TCT CTG AGC TCG TTC TTA GGC CCC TCT GCC GTC TGC ACG CTC CTT TCC   | 211 |
| Ser Leu Ser Ser Phe Leu Gly Pro Ser Ala Val Cys Thr Leu Leu Ser   |     |
| -20 -15 -10                                                       |     |
|                                                                   |     |
| AGC CAC CCG GCC TCC CGA TGC CGG CCT AGC ACG TTC CTC GCG CCA GGC   | 259 |
| Ser His Pro Ala Ser Arg Cys Arg Pro Ser Thr Phe Leu Ala Pro Gly   |     |
| -5 1 5                                                            |     |
|                                                                   |     |
| TTT TGC ATC TGC CCT TCC CAC TGT CTT TCG TGT GCA AAC GCC ACA GAT   | 307 |

46

Phe Cys Ile Cys Pro Ser His Cys Leu Ser Cys Ala Asn Ala Thr Asp  
 10 15 20 25

CCC GCG  
 Pro Ala

313

## (2) INFORMATION FOR SEQ ID NO: 58:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 209 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 66..182
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 7.4  
seq LFLLSLFCRLYHG/TI

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58:

AATTACCATG TTGCCTCAAT TCTTAGGAAG ACTTCTTTT AATTGAGAGG TCTTCTTGCT 60  
 CCTTT ATG TCA GAA GGA ATG GTC ACA TTG CTG ACT TTT TCT TGT TTA TGG 110  
 Met Ser Glu Gly Met Val Thr Leu Leu Thr Phe Ser Cys Leu Trp  
 -35 -30 -25  
 ACT GAT GAC TCA TTT ATG AGT KAT CTA AAC GTC TTG TTC CTT CTT TCT 158  
 Thr Asp Asp Ser Phe Met Ser Xaa Leu Asn Val Leu Phe Leu Leu Ser  
 -20 -15 -10  
 CTC TTC TGC CGT CTC TAT CAT GGG ACT ATT TTC TTT CTG CTA GCA CTT 206  
 Leu Phe Cys Arg Leu Tyr His Gly Thr Ile Phe Phe Leu Leu Ala Leu  
 -5 1 5  
 CTG 209  
 Leu

## (2) INFORMATION FOR SEQ ID NO: 59:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 227 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

- (vi) ORIGINAL SOURCE:  
 (A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Lung
- (ix) FEATURE:  
 (A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 69..110  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 7.3  
 seq LILGLPLCRPLWI/QR

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59:

```

AAGTCTGTCC GTGGATACTG TGAACATCAG GCTACTCGGC CGGGCTCCTG CGCTCAGGGC 60
TTCGAGAA ATG CTC ATT TTG GGG CTG CCC CTC TGC CGG CCT CTC TGG ATT 110
 Met Leu Ile Leu Gly Leu Pro Leu Cys Arg Pro Leu Trp Ile
 -10 -5

CAG AGG GCA GCC GCT GCT CCT TTT GTT TTG TGG GCC TGG CTC TGG GCC 158
Gln Arg Ala Ala Ala Pro Phe Val Leu Trp Ala Trp Leu Trp Ala
 1 5 10 15

CGG AGC AGC ACC TCC CTG GGG AGG CCG CCT TTC CTT CCG CGG CTT CTT 206
Arg Ser Ser Thr Ser Leu Gly Arg Pro Pro Phe Leu Pro Arg Leu Leu
 20 25 30

CCG TCT CCT CCT GAC CCC GAG 227
Pro Ser Pro Pro Asp Pro Glu
 35

```

(2) INFORMATION FOR SEQ ID NO: 60:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 162 base pairs  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: CDNA
- (vi) ORIGINAL SOURCE:  
 (A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Lung
- (ix) FEATURE:  
 (A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 16..90  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 7.3  
 seq HFILLVLPCLIFS/HF

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60:

```

ACATCATCTT GCTCT ATG TAT ATA TAT TTT TTT GTC TTA TGT GKK CTG TCT 51
 Met Tyr Ile Tyr Phe Phe Val Leu Cys Xaa Leu Ser
 -25 -20 -15

```

CAC TTC ATT CTT CTT GTC TTA CCT TGT TTA ATT TTT TCC CAT TTT ACT 99  
 His Phe Ile Leu Leu Val Leu Pro Cys Leu Ile Phe Ser His Phe Thr  
                   -10                  -5                  1

TTA TTT TTA TTT TAC AGT GCC TTA TTA GAT ATA CCT CTT TTT TTC AAG 147  
 Leu Phe Leu Phe Tyr Ser Ala Leu Leu Asp Ile Pro Leu Phe Phe Lys  
           5                  10                  15

TAT TCC CTG ATC GAG 162  
 Tyr Ser Leu Ile Glu  
   20

## (2) INFORMATION FOR SEQ ID NO: 61:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 318 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 112..237
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 7.2  
                                   seq ILFSLSFLLVIIIT/FP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61:

AATACTTTCT CCTCTCCCCT CTCCCAAGCA CATCTGAGTT GCTGCCTGTT CTTCACTT 60

AGCTCCAAAC CCATGAAAAA TTGCCAAGTA TAAAAGCTTC TCAAGAATGA G ATG GAT 117  
                                                                                   Met Asp

TCT AGG GTG TCT TCA CCT GAG AAG CAA GAT AAA GAG AAT TTC GTG GGT 165  
 Ser Arg Val Ser Ser Pro Glu Lys Gln Asp Lys Glu Asn Phe Val Gly  
 -40                  -35                  -30                  -25

GTC AAC AAT AAA CGG CTT GGT GTA TGT GGC TGG ATC CTG TTT TCC CTC 213  
 Val Asn Asn Lys Arg Leu Gly Val Cys Gly Trp Ile Leu Phe Ser Leu  
                   -20                  -15                  -10

TCT TTC CTG TTG GTG ATC ATT ACC TTC CCC ATC TCC ATA TGG ATG TGC 261  
 Ser Phe Leu Leu Val Ile Ile Thr Phe Pro Ile Ser Ile Trp Met Cys  
                   -5                  1                  5

TTG AAG ATC ATT AAG GMG TAT GAA CGT GMT GTT GTA TTC CGT CTG GGA 309  
 Leu Lys Ile Ile Lys Xaa Tyr Glu Arg Xaa Val Val Phe Arg Leu Gly  
   10                  15                  20

CGA CAT GGG 318



Arg His Gly  
25

(2) INFORMATION FOR SEQ ID NO: 62:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 154 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Thyroid

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 101..148
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 7  
seq LFCVVLCLSPTS/CY

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62:

```
TGTTTTTCCT TCTAGAGGTC CATATGTTTA CAGGCAAATT CCTACGTACA CTATATACTT 60
CCAACCATCC CTCCTTTTCC CTTTCAGAAA TAGTAGCACA ATG TGT ATA CTG TTC 115
 Met Cys Ile Leu Phe
 -15

TGT GTT GTG TTA TGT TTG TCT CCA ACA TCT TAT TGT TAT 154
Cys Val Val Leu Cys Leu Ser Pro Thr Ser Tyr Cys Tyr
-10 -5 1
```

(2) INFORMATION FOR SEQ ID NO: 63:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 163 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 80..136
- (C) IDENTIFICATION METHOD: Von Heijne matrix.
- (D) OTHER INFORMATION: score 7  
seq ETLCLGSSCCQC/RI

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63:

```

GGCAGCATTC AATCCAGGAA GTGCCAGCAT CACATGGTGA CTTCTGGTAG CTGTAACATT 60
TAGTGACTGT CTCCATGTC ATG CAC AGG GGT GAC ATC GAG ACC CTC TTA TGC 112
 Met His Arg Gly Asp Ile Glu Thr Leu Leu Cys
 -15 -10

CTG GGA AGT TCC TGC TGT CAA TGC AGA ATA TTC TCT TTT TTT TTT TTT 160
Leu Gly Ser Ser Cys Cys Gln Cys Arg Ile Phe Ser Phe Phe Phe
 -5 1 5

TTT
Phe
 163

```

## (2) INFORMATION FOR SEQ ID NO: 64:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 411 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 331..387
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 7  
seq AGLSSCLLPLCWL/ER

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64:

```

AAGCCTAGGT GTGGCGCCCC GACCGGACTT TCACTTCTGG CCAGCCCTTT CCCACCTGG 60
GCGCGGGASS GGTGCCAGTC TTAAACAAC CTCTCGATGG GTCCACGAA GATGTTTCCA 120
GACCCCTTGA ATGCCAAGTT CAAGTTTAGC TATGTCTCGC GGAGAGGCCG GTGAAGAAG 180
CAACGAGAAT GAAGCACCC CAGTTCTCTGC TGAGCACATG GGCATCTGCA ATAAAGATTT 240
AATTTCCAG CTTCTCCTGA AGCTCGGTAT GGCCACAACA CTAAATTCTG CCCGAGGAGA 300
TACAGCAAAA TAGTATGGGA CTTCCAAGAA ATG TTT TTA AAG TCA GGG GCA GGC 354
 Met Phe Leu Lys Ser Gly Ala Gly
 -15

CTT TCT TCA TGC CTT CTT CCT CTT TGC TGG CTG GAA CGC AAA GAC CAT 402
Leu Ser Ser Cys Leu Leu Pro Leu Cys Trp Leu Glu Arg Lys Asp His
 -10 -5 1 5

```

GGC AGG AGG  
Gly Arg Arg

411

## (2) INFORMATION FOR SEQ ID NO: 65:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 368 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 9..122
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 7  
seq LVMVWLGLLPLFS/GP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65:

|                                                                  |     |
|------------------------------------------------------------------|-----|
| ACCTCCTA ATG GCA AAT GCA ATA ATT AAG AAG CCT TGT GCA ATG CCG GCA | 50  |
| Met Ala Asn Ala Ile Ile Lys Lys Pro Cys Ala Met Pro Ala          |     |
| -35 -30 -25                                                      |     |
| CAG CCT CAC ACA GGG AAT CTC CTG TGG CCA CCT CTT GTC ATG GTG TGG  | 98  |
| Gln Pro His Thr Gly Asn Leu Leu Trp Pro Pro Leu Val Met Val Trp  |     |
| -20 -15 -10                                                      |     |
| CTC GGG CTG TTG CCT CTT TTC TCT GGG CCC CAC TTG CAA GCC GTT CAG  | 146 |
| Leu Gly Leu Leu Pro Leu Phe Ser Gly Pro His Leu Gln Ala Val Gln  |     |
| -5 1 5                                                           |     |
| CAT CTG GCC CTT GCC TAC CTC CCT CTG AAC TCT GTG GTT CTT GCA CAT  | 194 |
| His Leu Ala Leu Ala Tyr Leu Pro Leu Asn Ser Val Val Leu Ala His  |     |
| 10 15 20                                                         |     |
| AAT AGT CCA GCC ATA CTG AAT GTA TGG TTA ACT CTG AGA TGC CCT CTC  | 242 |
| Asn Ser Pro Ala Ile Leu Asn Val Trp Leu Thr Leu Arg Cys Pro Leu  |     |
| 25 30 35 40                                                      |     |
| CCT TAC AGG ATC TGC CTC TGG CCC TTT GAA CAT GCT TTT CCG TCT ATT  | 290 |
| Pro Tyr Arg Ile Cys Leu Trp Pro Phe Glu His Ala Phe Pro Ser Ile  |     |
| 45 50 55                                                         |     |
| AGA AAC ACA CAC TCC TGC CTG TCT TCC TCC TGC TGC TGC CCT GCT TCA  | 338 |
| Arg Asn Thr His Ser Cys Leu Ser Ser Ser Cys Cys Cys Pro Ala Ser  |     |
| 60 65 70                                                         |     |
| GCC CCT CTT TTA GTT GAT TAC CTC TTC TTT                          | 368 |
| Ala Pro Leu Leu Val Asp Tyr Leu Phe Phe                          |     |
| 75 80                                                            |     |

## (2) INFORMATION FOR SEQ ID NO: 66:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 407 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 18..74
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 6.9  
seq LQPLLLLLPLLN/EP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66:

```

AACCCAGGTC CCCAGCG ATG TCT CCA CCA CCG CTG CTG CAA CCC CTG CTG 50
 Met Ser Pro Pro Pro Leu Leu Gln Pro Leu Leu
 -15 -10

CTG CTG CTG CCT CTG CTG AAT GTG GAG CCT TCC GGG GCC ACA CTG ATC 98
Leu Leu Leu Pro Leu Leu Asn Val Glu Pro Ser Gly Ala Thr Leu Ile
 -5 1 5

CGC ATC CCT CTT CAT CGA GTC CAA CCT GGA CGC AGG ATC CTG AAC CTA 146
Arg Ile Pro Leu His Arg Val Gln Pro Gly Arg Arg Ile Leu Asn Leu
 10 15 20

CTG AGG GGA TGG AKA GAA CCA GCA GAG CTC CCC AAG TTG GGG GCC CCA 194
Leu Arg Gly Trp Xaa Glu Pro Ala Glu Leu Pro Lys Leu Gly Ala Pro
 25 30 35 40

TCC CCT GGG GAC AAG CCC ATC TTC GTA CCT CTC TCG AAC TAC AGG GAT 242
Ser Pro Gly Asp Lys Pro Ile Phe Val Pro Leu Ser Asn Tyr Arg Asp
 45 50 55

GTG CAG TAT TTT GGG GAA ATT GGG CTG GGA ACG CCT CCA CAA AAC TTC 290
Val Gln Tyr Phe Gly Glu Ile Gly Leu Gly Thr Pro Pro Gln Asn Phe
 60 65 70

ACT GTT GCC TTT GAC ACT GGC TCC TCC AAT CTC TGG GTC CCG TCC AGG 338
Thr Val Ala Phe Asp Thr Gly Ser Ser Asn Leu Trp Val Pro Ser Arg
 75 80 85

AGA TGC CAC TTY TTC AGT GTG CCC TGC TGG TTA CAC ACC GAT TTG ATC 386
Arg Cys His Phe Phe Ser Val Pro Cys Trp Leu His Thr Asp Leu Ile
 90 95 100

CCA AAG CCT CTA GCT CCT TCC
Pro Lys Pro Leu Ala Pro Ser 407
105 110

```

## (2) INFORMATION FOR SEQ ID NO: 67:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 395 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (D) DEVELOPMENTAL STAGE: Fetal
- (F) TISSUE TYPE: liver

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 264..389
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 6.5  
seq ILIGLFSLTGLVA/GN

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67:

```

ATATAGTTTT GAAAGACTAC TTGAAAAACA TAATCAAATG ATACTTGGAG TTTGTTCCGA 60
AAGGGTATTC TTTCTCTCT CTTCCACAA CAGTGTGCGC TTCCTNNNNA TAGTTGATAT 120
ACCTGTGCTT TAAAATAGCA CAGCTACTAG TAGAGGCCAT TTTATACCAA AATCATTTC 180
CTTCATGTTT TGTGGTACAT CAGTTTGGCA GTAGAGGTTA CAGAGTTTGA AATCAAAAGG 240
AGCATTGGTT CCTTCAGGGA AAA ATG ATA CCA ATC TAC CAA AAT AAA AGC CAA 293
 Met Ile Pro Ile Tyr Gln Asn Lys Ser Gln
 -40 -35

ACA GAC TCT CAT TGT TCT TTA TCC CAC AAG GGG CTT GCC TTT TTG AAG 341
Thr Asp Ser His Cys Ser Leu Ser His Lys Gly Leu Ala Phe Leu Lys
 -30 -25 -20

GTG TGG TTA ATT TTG ATA GGA CTC TTC TCT CTA ACA GGG TTA GTG GCT 389
Val Trp Leu Ile Leu Ile Gly Leu Phe Ser Leu Thr Gly Leu Val Ala
 -15 -10 -5

GGG AAT
Gly Asn
1

```

395

## (2) INFORMATION FOR SEQ ID NO: 68:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 205 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens

(F) TISSUE TYPE: Lung (cells)

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide

(B) LOCATION: 86..145

(C) IDENTIFICATION METHOD: Von Heijne matrix

(D) OTHER INFORMATION: score 6.5  
seq LLSGSTCPGPCSC/GS

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68:

```

AGGTGTCTGC CCTGCTTATG GGATTGTGCA GTTGACCTGA GCAGAGGATG GAGCTCACTC 60
CTCTTTAAAC CAAGGGCCCT GAGCC ATG GCT CTT CCC GGG ATC CAC CTT CTC 112
 Met Ala Leu Pro Gly Ile His Leu Leu
 -20 -15

TCA GGC TCA ACT TGC CCT GGA CCC TGT TCC TGT GGA TCC TTG AGG AGC 160
Ser Gly Ser Thr Cys Pro Gly Pro Cys Ser Cys Gly Ser Leu Arg Ser
-10 -5 1 5

CCT CCT GGG CCT GTG ACT GAT AAA CCC CTC CCC CTG CCG CCC CAG 205
Pro Pro Gly Pro Val Thr Asp Lys Pro Leu Pro Leu Pro Pro Gln
 10 15 20

```

(2) INFORMATION FOR SEQ ID NO: 69:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 245 base pairs

(B) TYPE: NUCLEIC ACID

(C) STRANDEDNESS: DOUBLE

(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens

(F) TISSUE TYPE: Colon

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide

(B) LOCATION: 60..182

(C) IDENTIFICATION METHOD: Von Heijne matrix

(D) OTHER INFORMATION: score 6.4  
seq IALIPLFSTXAFA/IX

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69:

```

AATTCTAGGC TGGTCACTAC TCCGAGCCTG TDWCGTTTGC GGCAGCCAGG CCGTCGACG 59
ATG CCC AGT GAA ACT CTC TGG GAA ATT GCA AAA GCT GAA GTG GAA AAA 107
Met Pro Ser Glu Thr Leu Trp Glu Ile Ala Lys Ala Glu Val Glu Lys

```

55

|                                                                 |     |     |     |
|-----------------------------------------------------------------|-----|-----|-----|
| -40                                                             | -35 | -30 |     |
| AGG GGA ATT AAT GGA ART YAA GGT GAT GGA GCT GAA ATT GCA TTA ATT |     |     | 155 |
| Arg Gly Ile Asn Gly Xaa Xaa Gly Asp Gly Ala Glu Ile Ala Leu Ile |     |     |     |
| -25                                                             | -20 | -15 | -10 |
| CCC CTT TTT TCC ACT WCA GCT TTT GCA ATT DCC CAG ATA GTK TCA CTG |     |     | 203 |
| Pro Leu Phe Ser Thr Xaa Ala Phe Ala Ile Xaa Gln Ile Val Ser Leu |     |     |     |
| -5                                                              | 1   | 5   |     |
| GGC ATC GTC GAC GGC AGT DCT CCA CCA RGA TCC AGG ACC CCG         |     |     | 245 |
| Gly Ile Val Asp Gly Ser Xaa Pro Pro Xaa Ser Arg Thr Pro         |     |     |     |
| 10                                                              | 15  | 20  |     |

## (2) INFORMATION FOR SEQ ID NO: 70:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 234 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 61..171
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 6.4  
seq LCMSLTFLALSTL/RF

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 70:

|                                                                   |     |
|-------------------------------------------------------------------|-----|
| ATGCTACCCA GGACAATGCT AGGGGCACAT GGGCACAGCA TGAAATAACT GCATCTCAGA | 60  |
| ATG GAA TGG TTA CGC CCC TCC CAA ATC TCC TTC TAT CCG GGT TAC AGC   | 108 |
| Met Glu Trp Leu Arg Pro Ser Gln Ile Ser Phe Tyr Pro Gly Tyr Ser   |     |
| -35 -30 -25                                                       |     |
| AAG GAA AGG CTC CGT TTG GTG CTA CTA TGC ATG TCC CTA ACC TTT CTA   | 156 |
| Lys Glu Arg Leu Arg Leu Val Leu Leu Cys Met Ser Leu Thr Phe Leu   |     |
| -20 -15 -10                                                       |     |
| GCA CTT TCT ACT CTC CGC TTT TTA ACA CAG AGA GTG CAG ATG CAG GCT   | 204 |
| Ala Leu Ser Thr Leu Arg Phe Leu Thr Gln Arg Val Gln Met Gln Ala   |     |
| -5 1 5 10                                                         |     |
| GGG TGC CCT CTG CGG AGT CCA CGC CTC TGG                           | 234 |
| Gly Cys Pro Leu Arg Ser Pro Arg Leu Trp                           |     |
| 15 20                                                             |     |

## (2) INFORMATION FOR SEQ ID NO: 71:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 163 base pairs  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: CDNA
- (vi) ORIGINAL SOURCE:  
 (A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Liver
- (ix) FEATURE:  
 (A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 41..94  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 6.3  
 seq HLTLLALLSVNTG/KE
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71:

```

AATCATTTCC TCCTCAGATT ACCAAGCAAG AACAGCTAAA ATG AAA GCC ATC ATT 55
 Met Lys Ala Ile Ile
 -15

CAT CTT ACT CTT CTT GCT CTC CTT TCT GTA AAC ACA GGT AAG GAA TAT 103
His Leu Thr Leu Leu Ala Leu Leu Ser Val Asn Thr Gly Lys Glu Tyr
 -10 -5 1

TTT TAC ATT TTA ATT CTT CCA ATC ATG TAT GTN GTC TTT GAG GTA GAA 151
Phe Tyr Ile Leu Ile Leu Pro Ile Met Tyr Val Val Phe Glu Val Glu
 5 10 15

TCA GCC GGC CAG 163
Ser Ala Gly Gln
20

```

(2) INFORMATION FOR SEQ ID NO: 72:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 155 base pairs  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: CDNA
- (vi) ORIGINAL SOURCE:  
 (A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Liver
- (ix) FEATURE:  
 (A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 21..107  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 6.3  
 seq SLPLALTLSLSTS/LH



## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72:

ACACTACTAT TTTAAGGAAA ATG GAT GTG TCA GCC AGC AAG CCA GTG GCA GAG 53  
 Met Asp Val Ser Ala Ser Lys Pro Val Ala Glu  
 -25 -20

TCT TGG TCT CCA GGC TCC CTG CCT CTT GCA CTG ACT CTT TCT CTT TCA 101  
 Ser Trp Ser Pro Gly Ser Leu Pro Leu Ala Leu Thr Leu Ser Leu Ser  
 -15 -10 -5

ACC TCC CTG CAT GAC AGC TGG AAA GAG CCC ATC CCT AAT CTT CAC CAA 149  
 Thr Ser Leu His Asp Ser Trp Lys Glu Pro Ile Pro Asn Leu His Gln  
 1 5 10

CCG GCG 155  
 Pro Ala  
 15

## (2) INFORMATION FOR SEQ ID NO: 73:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 149 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Liver

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 33..116
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 6.2  
 seq IQTALLGLPXAWA/SS

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 73:

ACCTGGTTGT AACCCAGCCT TCTTCCTTAC AG ATG GGG GTG AGG GTT GGG GTA 53  
 Met Gly Val Arg Val Gly Val  
 -25

TCC CTT AGA GCC TGG TGT GTC TTC ATA CAA ACA GCT TTG CTG GGG CTG 101  
 Ser Leu Arg Ala Trp Cys Val Phe Ile Gln Thr Ala Leu Leu Gly Leu  
 -20 -15 -10

CCT ARA GCC TGG GCC AGC AGT GGG GTA GTA TCA AGT ACA GGG CCG GGG 149  
 Pro Xaa Ala Trp Ala Ser Ser Gly Val Val Ser Ser Thr Gly Pro Gly  
 -5 1 5 10

## (2) INFORMATION FOR SEQ ID NO: 74:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 106 base pairs  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: CDNA
- (vi) ORIGINAL SOURCE:  
 (A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Lung (cells)
- (ix) FEATURE:  
 (A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 20..85  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 6.1  
 seq FFLLLCIPFLTLL/LY
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74:

```

CCATGAAACC ATCAAGATT ATG ATT ATA TCC ATC ATC CCT AGA AGT TTC TTC 52
 Met Ile Ile Ser Ile Ile Pro Arg Ser Phe Phe.
 -20 -15

CTA CTG CTT TGT ATT CCC TTT CTT ACC CTC CTC TTG TAT ACA TAC CCC 100
Leu Leu Leu Cys Ile Pro Phe Leu Thr Leu Leu Leu Tyr Thr Tyr Pro
-10 -5 1 5

CCC AGG 106
Pro Arg

```

(2) INFORMATION FOR SEQ ID NO: 75:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 433 base pairs  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: CDNA
- (vi) ORIGINAL SOURCE:  
 (A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Thyroid
- (ix) FEATURE:  
 (A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 272..358  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 5.9  
 seq WTLVLMSPWEALL/QY
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 75:

```

ACCCTGCCCT CTTCTTGTGT TGTGTTTGTC ACAGCCTTGC CCCTCTTGCT CGCCTTGAAA 60

```

```

ATGGNMAAGA TGCTCGCAGG CTGCTTTCTG CTGATCCTCG GACAGATCGT CCTCCTCCCT 120
GCCGAGGCCA GGGAGCGGTC ACGTGGGAGG TCCATCTCTA GGGGCAGACA CGCTCGGACC 180
CACCCGCAGA CGGCCCTTCT GGAGAGTTCC TGTGAGAACA AGCGGGCAGA CCTGGTTTTTC 240
ATCATTGACA GCTCTCGCAG TGNNAACACC C ATG ACT ATG CAA AGG TCA AGG 292
 Met Thr Met Gln Arg Ser Arg
 -25
AGT TCA TCG TGG ACA TCT TGC AAT TCT TGG ACA TTG GTC CTG ATG TCA 340
Ser Ser Ser Trp Thr Ser Cys Asn Ser Trp Thr Leu Val Leu Met Ser
-20 -15 -10
CCC GAG TGG GCC YTG CTC CAA TAT GGC AGC ACT GTC AAG AAT GAG TTC 388
Pro Glu Trp Ala Leu Leu Gln Tyr Gly Ser Thr Val Lys Asn Glu Phe
-5 1 5 10
TCC YSM AAG ACC TTC AAG AGG AAG TCC GAG GTG GAG CGT GCT GTC 433
Ser Xaa Lys Thr Phe Lys Arg Lys Ser Glu Val Glu Arg Ala Val
15 20 25

```

## (2) INFORMATION FOR SEQ ID NO: 76:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 328 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 239..307
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5.8  
seq LCSLMASISPTLT/AV

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76:

```

CCTTTCTGGC TGTGGCTGAC TCCTCGGACA CTCTTCCTTC TCATCTTCCT TCGGCTTCTA 60
GACCACAGTC TTCTTCTTTG CTTTTGTGCC TTCCAGGCAG ATTGGCAATG AAAGTTGTGC 120
CGCTCGATGT CCCTGAACTG CCCAGGCCT CCTCCTCCCC TCAAGGCACT CCACGGCTAG 180
CCACCTGGCA GCCTGGGCTG CTACTAGAA GGCTACTGCC CTCTACCCCA CTGCTTTC 238
ATG ATC ACC CTC CCT CAG ACC TCC AGC CTG CTC TGT AGC CTC ATG GCC 286
Met Ile Thr Leu Pro Gln Thr Ser Ser Leu Leu Cys Ser Leu Met Ala
-20 -15 -10

```

TCC ATC TCC CCC ACC CTC ACT GCT GTG ATT CTG TGG CCC CCG 328  
Ser Ile Ser Pro Thr Leu Thr Ala Val Ile Leu Trp Pro Pro  
-5 1 5

(2) INFORMATION FOR SEO ID NO: 77:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 334 base pairs  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA.

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Liver

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide  
(B) LOCATION: 101..289  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 5.7  
seq PLVTHGLLLOAWS/RR

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 77:

|                                                                 |            |            |            |                     |            |    |
|-----------------------------------------------------------------|------------|------------|------------|---------------------|------------|----|
| AAGTTAATCA                                                      | GTCACTGCCC | CTGGTCTGGG | CAAGGGGCAG | TTGGTGAAC           | TGCTGCCTCC | 60 |
| AGAGAACCTT                                                      | CCCTGGTGTG | GAGGCAGCCA | GGGACCCAGG | ATG CTC CGG ACC TGT | 115        |    |
|                                                                 |            |            |            | Met Leu Arg Thr Cys |            |    |
|                                                                 |            |            |            | -60                 |            |    |
| TAC GTG CTC TGT TCC CAA GCT GGT CCC CCC TCC AGG GGC TGG CAG TCC | 163        |            |            |                     |            |    |
| Tyr Val Leu Cys Ser Gln Ala Gly Pro Pro Ser Arg Gly Trp Gln Ser |            |            |            |                     |            |    |
| -55 -50 -45                                                     |            |            |            |                     |            |    |
| CTG AGC TTT GAT GGC GGG GCC TTC CAC CTT AAG GGC ACA GGA GAG CTG | 211        |            |            |                     |            |    |
| Leu Ser Phe Asp Gly Gly Ala Phe His Leu Lys Gly Thr Gly Glu Leu |            |            |            |                     |            |    |
| -40 -35 -30                                                     |            |            |            |                     |            |    |
| ACA CGG GCC TTG CTG GTT CTC CGG CTG TGT GCC TGG CCC CCA CTC GTC | 259        |            |            |                     |            |    |
| Thr Arg Ala Leu Leu Val Leu Arg Leu Cys Ala Trp Pro Pro Leu Val |            |            |            |                     |            |    |
| -25 -20 -15                                                     |            |            |            |                     |            |    |
| ACT CAC GGG CTG TTG CTC CAG GCC TGG TCT CGG CGA CTC CTG GGC TCC | 307        |            |            |                     |            |    |
| Thr His Gly Leu Leu Leu Gln Ala Trp Ser Arg Arg Leu Leu Gly Ser |            |            |            |                     |            |    |
| -10 -5 1 5                                                      |            |            |            |                     |            |    |
| CGG CTC TCA RGC GCA TTT CTC CGA GCA                             | 334        |            |            |                     |            |    |
| Arg Leu Ser Xaa Ala Phe Leu Arg Ala                             |            |            |            |                     |            |    |
| 10 15                                                           |            |            |            |                     |            |    |

(2) INFORMATION FOR SEO ID NO: 78:

(i) SEQUENCE CHARACTERISTICS:

61

- (A) LENGTH: 392 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 270..359
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5.7  
seq LGVGCHFFHLALG/RF

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 78:

```

CAACTCTAAA AATCTTTACA CAGCCTATGG AGAGAAACCT AAGCAAGTSC CCAAATCCTC 60
AAGTGTTCCA GGAGAATGAA AAGAATTATA AAGGCTAAAG AATTATTAGA ATCAGTGCAG 120
TGAACATGTA GACCAAAGCA TTCCTGCATG CCAGGAAAAT GGTGCATTG AATGTTTTTG 180
CTTCTCATGA GAAAGGCAAT TTAAGTTGCA AGGCAAAGGC AAACTTTGA AGATGGCCAC 240
GTGGA CTCTG GATCCTTCTC TCTTTGTTT ATG ATT TGT TCT CCC TTC AGT GGT 293
 Met Ile Cys Ser Pro Phe Ser Gly
 -30 -25

TTT GCT CCT TGC CAA GCA TTA GGT ACC CTT GGG GTG GGA TGC CAC TTT 341
Phe Ala Pro Cys Gln Ala Leu Gly Thr Leu Gly Val Gly Cys His Phe
 -20 -15 -10

TTC CAC TTA GCC TTG GGC AGG TTT CTT CTC TCC TTA TCC AAT AAT ATT 389
Phe His Leu Ala Leu Gly Arg Phe Leu Leu Ser Leu Ser Asn Asn Ile
 -5 1 5 10

TAC
Tyr
 392

```

(2) INFORMATION FOR SEQ ID NO: 79:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 511 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Pancreas

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 62..355  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 5.6  
 seq LLLRGADRVLQA/HI

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 79:

```

AAGGCAGTCC CGGCGCGGGG CAACCACAGC GCTCAGGAGG CCCTGAGTCC GGCACCTGGC 60
C ATG TGC AAC CCT GAG GAG GCA GCT CTG CKS GGN CTG GAG GAG GTC TTC 109
 Met Cys Asn Pro Glu Glu Ala Ala Leu Xaa Gly Leu Glu Glu Val Phe
 -95 -90 -85

TCA GCC ACC CTC GCC CAT GTC AAC AGC CTT GTC CTC CAG CCC CTG CTC 157
Ser Ala Thr Leu Ala His Val Asn Ser Leu Val Leu Gln Pro Leu Leu
 -80 -75 -70

CCA GCC GCC CCA GAT CCC TCG GAT CCC TGG GGC AGA GAG TGC CTG CGG 205
Pro Ala Ala Pro Asp Pro Ser Asp Pro Trp Gly Arg Glu Cys Leu Arg
 -65 -60 -55

CTC TTG CAA CAG CTG CAC AAG AGC TCC CAG CAA CTC TGG GAG GTG ACG 253
Leu Leu Gln Gln Leu His Lys Ser Ser Gln Gln Leu Trp Glu Val Thr
 -50 -45 -40 -35

GAG GAA AGC CTG CAC TCA CTG CAG GAG AGG CTG CGT TAC CCG GAC TCC 301
Glu Glu Ser Leu His Ser Leu Gln Glu Arg Leu Arg Tyr Pro Asp Ser
 -30 -25 -20

ACC GGT CTG GAG TCC CTG CTG CTG CTG CGA GGT GCT GAC CGT GTA CTG 349
Thr Gly Leu Glu Ser Leu Leu Leu Leu Arg Gly Ala Asp Arg Val Leu
 -15 -10 -5

CAG GCC CAC ATA GAG TAC ATT GAG TCC TAC ACA AGC TGC ATG GTG GTG 397
Gln Ala His Ile Glu Tyr Ile Glu Ser Tyr Thr Ser Cys Met Val Val
 1 5 10

CAG GCC TTC CAG AAR GHA GCY AAG AGG AGA AGC GAG TTC TGG CGG GGC 445
Gln Ala Phe Gln Lys Xaa Ala Lys Arg Arg Ser Glu Phe Trp Arg Gly
 15 20 25 30

CAG CGG AAK GCG CTG CGG CAG CTG CTT TCA GGT GTK AGC TCA GAG GGC 493
Gln Arg Xaa Ala Leu Arg Gln Leu Leu Ser Gly Val Ser Ser Glu Gly
 35 40 45

TCG GTG GGC GCA TCG CTG 511
Ser Val Gly Ala Ser Leu
 50

```

(2) INFORMATION FOR SEQ ID NO: 80:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 340 base pairs  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR

- (ii) MOLECULE TYPE: CDNA
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Homo Sapiens
  - (F) TISSUE TYPE: Thyroid
- (ix) FEATURE:
  - (A) NAME/KEY: sig\_peptide
  - (B) LOCATION: 131..265
  - (C) IDENTIFICATION METHOD: Von Heijne matrix
  - (D) OTHER INFORMATION: score 5.6  
seq LLVIHWVMCP SLS/QS
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 80:

```

CTTTTCTGGT CCAGAGCCCC CACAGGAAGG AGAVNNBSAA AAGATTACTG TTGACTGCAC 60
AGTTCAGGG GCCAAGGCAG AAGAAATCCT GGAGAAAGGT CCAAAGACAG CGATCTCCTG 120
GACATGAAAG ATG GAC AAG CTG ATA CCC AGC TTG AGC TCT CAA GAG AAC 169
 Met Asp Lys Leu Ile Pro Ser Leu Ser Ser Gln Glu Asn
 -45 -40 -35

AGA AAG GCG TCT CAC ACT CTC CAC AAA GCT AGA AAC AAA CAA CAC TGT 217
Arg Lys Ala Ser His Thr Leu His Lys Ala Arg Asn Lys Gln His Cys
 -30 -25 -20

GGA GGA TTT TTA CTG GTC ATA CAT TGG GTC ATG TGC CCT TCC CTG AGC 265
Gly Gly Phe Leu Leu Val Ile His Trp Val Met Cys Pro Ser Leu Ser
 -15 -10 -5

CAA TCT GCA GTC AGA AGG ATG AAG TAC TCT AAT TGG CCA GTT TTG GGT 313
Gln Ser Ala Val Arg Arg Met Lys Tyr Ser Asn Trp Pro Val Leu Gly
 1 5 10 15

CAC GTG CCT GTT CCT GGC TGT CAT TGC 340
His Val Pro Val Pro Gly Cys His Cys
 20 25

```

## (2) INFORMATION FOR SEQ ID NO: 81:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 231 base pairs
  - (B) TYPE: NUCLEIC ACID
  - (C) STRANDEDNESS: DOUBLE
  - (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: CDNA
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Homo Sapiens
  - (F) TISSUE TYPE: Lung (cells)
- (ix) FEATURE:
  - (A) NAME/KEY: sig\_peptide
  - (B) LOCATION: 127..177
  - (C) IDENTIFICATION METHOD: Von Heijne matrix
  - (D) OTHER INFORMATION: score 5.5

seq LPVVLASPPVGHG/LP

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 81:

```

TAATTGGGCA GCCAGGGTCT CCTGGAGCAT GGCGGTGACA TTCAGAGCCC CACAGCAACT 60
CCGGGCATCC CACCTCTGCC TAGGTGGGAT ACATCTTGAG CCTACGGCAG TCCCTCTGTC 120
GGTCTC ATG AGC CAK CTT CTT CCT GTG GTT CTT GCC TCA CCT CCA GTA 168
 Met Ser Xaa Leu Leu Pro Val Val Leu Ala Ser Pro Pro Val
 -15 -10 -5
GGC CAT GGG CTT CCC TCC CCA GTA CCT CTG TTA CAG GAC CCC TGC CCC 216
Gly His Gly Leu Pro Ser Pro Val Pro Leu Leu Gln Asp Pro Cys Pro
 1 5 10
CTC CCT GCT GTC GGG 231
Leu Pro Ala Val Gly
 15

```

(2) INFORMATION FOR SEQ ID NO: 82:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 128 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 54..92
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5.5  
seq MVLLTMIARVADG/LP

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 82:

```

AGACGGCGCC AAGGGCCTTC CGGGCCAGTG TTGGATCCCT GTAGTTTGTG AAG ATG 56
 Met
GTG TTG CTA ACA ATG ATC GCC CGA GTG GCG GAC GGG CTC CCG CTG GCC 104
Val Leu Leu Thr Met Ile Ala Arg Val Ala Asp Gly Leu Pro Leu Ala
 -10 -5 1
GCC TCG ATG CAG GAG GAC GAA GAG 128
Ala Ser Met Gln Glu Asp Glu Glu
 5 10

```

(2) INFORMATION FOR SEQ ID NO: 83:



- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 208 base pairs  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: CDNA
- (vi) ORIGINAL SOURCE:  
 (A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Large intestine
- (ix) FEATURE:  
 (A) NAME/KEY: other  
 (B) LOCATION: complement(82..206)  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 100  
                                   region 159..283  
                                   id AA255968  
                                   est
- (ix) FEATURE:  
 (A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 32..190  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 5.5  
                                   seq LLELLFVPLLCFL/SK
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 83:

```

CACTAAAGCT GCCCTCTCC TACTGTTCCC T ATG TTT CAT ATT GCT TTT TCT 52
 Met Phe His Ile Ala Phe Ser
 -50

GAG GCT CTA CCT GTA GAC ATC TTC AAG ACC CAA CCC AAC TGT CAT GAA 100
Glu Ala Leu Pro Val Asp Ile Phe Lys Thr Gln Pro Asn Cys His Glu
-45 -40 -35

GCC TTC TCC ATG AAG GCT ATC CAT ATA ACC AGA ATA AGA AGT GGT CTT 148
Ala Phe Ser Met Lys Ala Ile His Ile Thr Arg Ile Arg Ser Gly Leu
-30 -25 -20 -15

TGC CTC CTT GAA CTT TTG TTT GTA CCA CTT TTA TGT TTC TTA TCC AAA 196
Cys Leu Leu Glu Leu Leu Phe Val Pro Leu Leu Cys Phe Leu Ser Lys
-10 -5 1

AAA TGG CCT TGG 208
Lys Trp Pro Trp
5

```

(2) INFORMATION FOR SEQ ID NO: 84:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 260 base pairs  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Pancreas

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: 147..221  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 5.4  
seq SLLTETVLPLAFP/GP

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 84:

```

ATTATTTTAA ATATTATCAT GGACAGTTGT TATTGGAAAT GACAGTTCAC CATTGCAAAT 60
CAATGCAGTG GCTACAAGTC CCCC GTGTCA CACAAAATA GACGGGGTAG CTCTGACAGC 120
ATGCATCCTK ATGCCCTGTT CTATTA ATG ATG CAC TGC ACC CCA TCA GGG TCT 173
 Met Met His Cys Thr Pro Ser Gly Ser
 -25 -20

GCA GCT GTA TCA TTA CTC ACA GAG ACG GTT CTG CCT TTG GCT TTC CCT 221
Ala Ala Val Ser Leu Leu Thr Glu Thr Val Leu Pro Leu Ala Phe Pro
-15 -10 -5

GGT CCT CCA TGG CTA GGA ACA TCA TTT AAC AGG GKT TTG 260
Gly Pro Pro Trp Leu Gly Thr Ser Phe Asn Arg Xaa Leu
 1 5 10

```

(2) INFORMATION FOR SEQ ID NO: 85:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 316 base pairs  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Lung

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: 95..178  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 5.3  
seq RISCAFSLASSTA/RQ

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 85:

```

AGGAAGTGGC CAGTCGGCAG GTCTGAGGCG GCGCTGTGTG TGTGAAGCGT ACCTAGGGCG 60

```

67

GGAGGCGACA TGGAGACAGG GGCGGCCAAG CTGT ATG ACC AGG CCC TTT TGG GCA 115  
Met Thr Arg Pro Phe Trp Ala  
-25

TCC TGC AGC ACG TGG GCA ACG TCC AGG ATT TCC TGC GCG TTC TCT TTG 163  
Ser Cys Ser Thr Trp Ala Thr Ser Arg Ile Ser Cys Ala Phe Ser Leu  
-20 -15 -10

GCT TCC TCT ACC GCA AGA CAG ACT TCT ATC GCT TGC TGC GCC ACC CAT 211  
Ala Ser Ser Thr Ala Arg Gln Thr Ser Ile Ala Cys Cys Ala Thr His  
-5 1 5 10

CGG ACC GCA TGG GCT TCC CGC CCG GGG CCG CGC AGG CCT TGG TGC TGC 259  
Arg Thr Ala Trp Ala Ser Arg Pro Gly Pro Arg Arg Pro Trp Cys Cys  
15 20 25

AGG TAT TCA AAA CCT TTG ACC ACA TGG CCC GTC AGG ATG ATG AGA AGA 307  
Arg Tyr Ser Lys Pro Leu Thr Trp Pro Val Arg Met Met Arg Arg  
30 35 40

GAA GGC CTA 316  
Glu Gly Leu  
45

## (2) INFORMATION FOR SEQ ID NO: 86:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 452 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 192..269
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5.2  
seq SCCLIQWPELSFS/NT

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 86:

ACTAAACAGM CDNHWACATT CAGGTGGGKA CCTTCCTCCA GAAGTTACTC CTACATCAGA 60

AAAGATGACC CCCTTCTTCC TGATGCTCAG AGCCATCAAT ACTCCTTTGT CTCTCACCTA 120

GCACCCAATT CATCTGGAAA TCCTATTGGC ACCACCTTAA ATATGTAAAC AGAACCTGAT 180

CAAGAGCCCC C ATG GTC ACC CAC CTA ATT AGG GGG GTG GTG TTG CAG GGC 230  
Met Val Thr His Leu Ile Arg Gly Val Val Leu Gln Gly  
-25 -20 -15

TCC TGC TGT CTC ATA CAG TGG CCA GAG TTA AGC TTT TCA AAC ACA AAT 278

68

Ser Cys Cys Leu Ile Gln Trp Pro Glu Leu Ser Phe Ser Asn Thr Asn  
 -10 -5 1

GGT GTT TGT CCC ATC TAT CCC CCA CCT TCT ATC ASG TSC CTG AGA ATG 326  
 Gly Val Cys Pro Ile Tyr Pro Pro Pro Ser Ile Xaa Xaa Leu Arg Met  
 5 10 15

TCA TCC TGC TCT CCT CTG ACT GTA TCT CTC TGC CCT TGC TAT GTA GAA 374  
 Ser Ser Cys Ser Pro Leu Thr Val Ser Leu Cys Pro Cys Tyr Val Glu  
 20 25 30 35

TGT GCA TCC ACC CCA GGG CCT CTC TGC TTG CTC TTT TCT TGG CCA AGA 422  
 Cys Ala Ser Thr Pro Gly Pro Leu Cys Leu Leu Phe Ser Trp Pro Arg  
 40 45 50

AAC ACC TCT CCC AAC ATG CCC TCT GGC TAC 452  
 Asn Thr Ser Pro Asn Met Pro Ser Gly Tyr  
 55 60

## (2) INFORMATION FOR SEQ ID NO: 87:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 254 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 60..116
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5.2  
seq LLVAFRVFLGLFS/LP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 87:

ACTGTAGCCA AATTAAATC TGAGTCTGGC GTTTCVTTT GGGAAGGTGC TCAGTAGCT 59

ATG TAC ATG TGG TCC AAA CTC TTG GTG GCA TTC AGG GTC TTT CTT GGC 107  
 Met Tyr Met Trp Ser Lys Leu Leu Val Ala Phe Arg Val Phe Leu Gly  
 -15 -10 -5

CTT TTC AGC CTC CCC TCT AAC CAC AAC ACA TAC TGT CCC TTC CAG CCT 155  
 Leu Phe Ser Leu Pro Ser Asn His Asn Thr Tyr Cys Pro Phe Gln Pro  
 1 5 10

TGG GGA ATT CCT TGC AGC CTC AGA ATA GGA GGC CTC CTC CAT CTG CAG 203  
 Trp Gly Ile Pro Cys Ser Leu Arg Ile Gly Gly Leu Leu His Leu Gln  
 15 20 25

TGC CCT TTG CCC CCC TCT CTA CAT CCT CTK CCT AGT CTA CTC ACC AGC 251  
 Cys Pro Leu Pro Pro Ser Leu His Pro Leu Pro Ser Leu Leu Thr Ser

|     |    |    |    |     |
|-----|----|----|----|-----|
| 30  | 35 | 40 | 45 |     |
| CGG |    |    |    | 254 |
| Arg |    |    |    |     |

## (2) INFORMATION FOR SEQ ID NO: 88:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 212 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 78..146
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5.2  
seq FLFGLYSFRAVDS/SR

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 88:

|                                                                   |     |
|-------------------------------------------------------------------|-----|
| TAGAAAAGCA AGAACTGGGA CTAGTTTCAG GATTTTCTGA ATCTAGAGAA TAAAATAAAC | 60  |
| AGTTGCTAGA TGAGCTA ATG TCA TCT AGA AAC TGT TTC TTT CCA TCT TTC    | 110 |
| Met Ser Ser Arg Asn Cys Phe Phe Pro Ser Phe                       |     |
| -20 -15                                                           |     |
| CTC TTT GGG CTT TAT TCT TTC AGG GCT GTT GAC AGT TCT AGG ATT AAG   | 158 |
| Leu Phe Gly Leu Tyr Ser Phe Arg Ala Val Asp Ser Ser Arg Ile Lys   |     |
| -10 -5 1                                                          |     |
| CTC AGT TTA TTA ACC AAG GAG GAA GAA ACC CCT TCT GCC TAC TAC AGA   | 206 |
| Leu Ser Leu Leu Thr Lys Glu Glu Glu Thr Pro Ser Ala Tyr Tyr Arg   |     |
| 5 10 15 20                                                        |     |
| TCC CTG                                                           | 212 |
| Ser Leu                                                           |     |

## (2) INFORMATION FOR SEQ ID NO: 89:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 140 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

70

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: 33..86  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 5.1  
seq CLYLHVYVLTCSG/CN

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 89:

```

ATTTCAGAAA GGAGGAGTTG ATGATCTTCT AG ATG TAT ATG AAC ACC TGT CTA 53
 Met Tyr Met Asn Thr Cys Leu
 -15

TAT CTG CAT GTA TAT GTT TTG ACC TGC AGT GGT TGC AAT GTT GAT ATG 101
Tyr Leu His Val Tyr Val Leu Thr Cys Ser Gly Cys Asn Val Asp Met
-10 -5 1 5

TGT TCA AGA TTA TTC CTG TCT ACA AAA CTG AAG GCC CGG 140
Cys Ser Arg Leu Phe Leu Ser Thr Lys Leu Lys Ala Arg
 10 15

```

## (2) INFORMATION FOR SEQ ID NO: 90:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 221 base pairs  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: 54..200  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 5.1  
seq VALSASLPQCSLG/LL

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 90:

```

ACTCCACCCC CAGCCCTGCC CCTCCACACC TCGCCCCAAG AGCAGCCAGA GAG ATG 56
 Met

TCC TGC CGA CAA CCC ACC CCA ACA CAG TGT TCC CTA CTC CCA AAC GAC 104
Ser Cys Arg Gln Pro Thr Pro Thr Gln Cys Ser Leu Leu Pro Asn Asp
-45 -40 -35

AAC CGT GTC TCT ACG AGG GGA GGG GAC AGT GCT GGG CGC CAC CGC CAA 152
Asn Arg Val Ser Thr Arg Gly Gly Asp Ser Ala Gly Arg His Arg Gln
-30 -25 -20

```

GTC CCT CAG GTG GCT CTG AGT GCA AGT CTG CCC CAA TGC TCC CTT GGA 200  
 Val Pro Gln Val Ala Leu Ser Ala Ser Leu Pro Gln Cys Ser Leu Gly  
 -15 -10 -5

CTC CTC ATA AAC CCC CGC CTG 221  
 Leu Leu Ile Asn Pro Arg Leu  
 1 5

## (2) INFORMATION FOR SEQ ID NO: 91:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 158 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Thyroid

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 84..143
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5.1  
seq PTAGVVVLQGSRA/SV

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 91:

GAAATGTTTC CTTTGTGTT AAAAAAGGTG AAGTTTGGG ATTACTAGGA CACAATGGAG 60

CTGGTAAAAG TACTTCVATT AAA ATG ATA ACT GGG TGC ACA AAG CCA ACT GCA 113  
 Met Ile Thr Gly Cys Thr Lys Pro Thr Ala  
 -20 -15

GGA GTG GTG GTG TTA CAA GGC AGC AGA GCA TCA GTA AGG CAA CGG 158  
 Gly Val Val Val Leu Gln Gly Ser Arg Ala Ser Val Arg Gln Arg  
 -10 -5 1 5

## (2) INFORMATION FOR SEQ ID NO: 92:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 70 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 20..61
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5  
seq GLDLILSFSSSSP/GP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 92:

```

TATCTAGTGT GTCACGCCA ATG GGC TTG GAC TTA ATC CTT TCT TTC TCC TCC 52
 Met Gly Leu Asp Leu Ile Leu Ser Phe Ser Ser
 -10 -5

TCT TCC CCC GGT CCT GGG
Ser Ser Pro Gly Pro Gly
 1

```

70

## (2) INFORMATION FOR SEQ ID NO: 93:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 218 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Colon

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 12..197
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.9  
seq LDRLCALTS LCSP/GP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 93:

```

GAATTCAGG G ATG CGG GAG GAC AAT GAG CAT GAA CGA AAC GTG CCG AGT 50
 Met Arg Glu Asp Asn Glu His Glu Arg Asn Val Pro Ser
 -60 -55 -50

GGA GTT GAG AAC GTA AAG GAA GAA GGG GGA GAT GAG GAC CTC TCC TGG 98
Gly Val Glu Asn Val Lys Glu Glu Gly Gly Asp Glu Asp Leu Ser Trp
 -45 -40 -35

GGA GAT GAG GGC TGC CAA GTC CTA AGA CAC AGG CTC AGG GTC TGC AGG 146
Gly Asp Glu Gly Cys Gln Val Leu Arg His Arg Leu Arg Val Cys Arg
 -30 -25 -20

AAG GTC GGC TTG TTG GAT CGT CTC TGT GCG CTG ACT TCT CTT TGC TCC 194
Lys Val Gly Leu Leu Asp Arg Leu Cys Ala Leu Thr Ser Leu Cys Ser
 -15 -10 -5

CCA GGG CCT CTA CCC GCT ACC CTG

```

218



Pro Gly Pro Leu Pro Ala Thr Leu  
 1 5

## (2) INFORMATION FOR SEQ ID NO: 94:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 96 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Colon

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 10..63
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.9  
seq GAVVSSWAXCSLG/XP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 94:

```

AGCCTTCGC ATG GGG AAA CGG GCT GGT GCA GTG GTG TCA TCT TGG GCT CAN 51
 Met Gly Lys Arg Ala Gly Ala Val Val Ser Ser Trp Ala Xaa
 -15 -10 -5

TGC AGC CTC GGA SKT CCT GGG ATC CAG CGA TCC TCC CGC TTA ACG 96
Cys Ser Leu Gly Xaa Pro Gly Ile Gln Arg Ser Ser Arg Leu Thr
 1 5 10

```

## (2) INFORMATION FOR SEQ ID NO: 95:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 302 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 57..119
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.9  
seq WLLSDILGQGATA/NV

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 95:

```

AGTGGCGCGG CGGAGACCCG GCTGGTATAA CAAGAGGATT GCCTGATCCA GCCAAG ATG 59
 Met
CAG AGC ACT TCT AAT CAT CTG TGG CTT TTA TCT GAT ATT TTA GGC CAA 107
Gln Ser Thr Ser Asn His Leu Trp Leu Leu Ser Asp Ile Leu Gly Gln
-20 -15 -10 -5
GGA GCT ACT GCA AAC GTC TTT CGT GGA AGA CAT AAG AAA ACT GGT GAT 155
Gly Ala Thr Ala Asn Val Phe Arg Gly Arg His Lys Lys Thr Gly Asp
 1 5 10
TTA TTT GCT ATC AAA GTA TTT AAT AAC ATA AGC TTC CTT CGT CCA GTG 203
Leu Phe Ala Ile Lys Val Phe Asn Asn Ile Ser Phe Leu Arg Pro Val
 15 20 25
GAT GTT CAA ATG AGA GAA TTT GAA GTG TTG AAA AAA CTC AAT CAC AAA 251
Asp Val Gln Met Arg Glu Phe Glu Val Leu Lys Lys Leu Asn His Lys
 30 35 40
AAT ATT GTC AAA TTA TTT GCT ATT GAA GAG GAG ACA ACA ACA AGA CGG 299
Asn Ile Val Lys Leu Phe Ala Ile Glu Glu Glu Thr Thr Thr Arg Arg
45 50 55 60
CGG
Arg
 302

```

## (2) INFORMATION FOR SEQ ID NO: 96:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 309 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (D) DEVELOPMENTAL STAGE: Fetal
- (F) TISSUE TYPE: liver

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 109..255
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.9  
seq LLCLSGLELEPSA/SD

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 96:

```

AAAGTCACWW AAPCAAGTTA GTAAGTTATG AAATTAGTTA CATGCATGGA ATATTCATGC 60
TTGAATGARS CTAAAAGTT TATCTAACCC AAACCTCAGA TTTTACAG ATG AAG AAG 117
 Met Lys Lys
CTG AGG CCC AGC CAG GAA CAG CTG AAC TGT CCG GAG CCA CAA CTG GCA 165

```

75

Leu Arg Pro Ser Gln Glu Gln Leu Asn Cys Pro Glu Pro Gln Leu Ala  
 -45 -40 -35

GAT GGC AGA GCT GGG ATT AGA TTG CTA GTA ACC TGG CTC CAA CCT GCA 213  
 Asp Gly Arg Ala Gly Ile Arg Leu Leu Val Thr Trp Leu Gln Pro Ala  
 -30 -25 -20 -15

CCT CTG CTC TGC CTC TCT GGG CTG GAA CTA GAA CCC AGT GCT TCT GAC 261  
 Pro Leu Leu Cys Leu Ser Gly Leu Glu Leu Glu Pro Ser Ala Ser Asp  
 -10 -5 1

TTT GGA TTT AGT TCT CAT ACC ACT CTC CTG TGC TGC CTT GTT GAA AAT 309  
 Phe Gly Phe Ser Ser His Thr Thr Leu Cys Cys Leu Val Glu Asn  
 5 10 15

## (2) INFORMATION FOR SEQ ID NO: 97:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 372 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Large intestine

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 151..207
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.9  
seq RLLFWSIFSSVTC/RK

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 97:

AGATTGGTCG AACAAACCAG TATTATGCAA ACCTCATCCA AACCCCTCTGA TTTCCTTAAC 60

TTGGCTAAGA AAAAGAGGAA GTTCTCCGAG TGACTCACCA CTGTGGTTCT ACTATGCCTT 120

CTGACCCCGT CTTGGACTTC AACTGGGAGA ATG TGG AGC CAT TTG AAC AGG CTC 174  
 Met Trp Ser His Leu Asn Arg Leu  
 -15

CTC TTC TGG AGC ATA TTT TCT TCT GTC ACT TGT AGA AAA GCT GTA TTG 222  
 Leu Phe Trp Ser Ile Phe Ser Ser Val Thr Cys Arg Lys Ala Val Leu  
 -10 -5 1 5

GAT TGT GAG GCA ATG AAA ACA AAT GAA TTC CCT TCT CCA TGT TTG GAC 270  
 Asp Cys Glu Ala Met Lys Thr Asn Glu Phe Pro Ser Pro Cys Leu Asp  
 10 15 20

TCA AAG ACT AAG GTG GTT ATG AAG GGT CAA AAT GTA TCT ATG TTT TGT 318  
 Ser Lys Thr Lys Val Val Met Lys Gly Gln Asn Val Ser Met Phe Cys  
 25 30 35

TCC CAT AAG AAC AAA TCA CTG CAG ATC ACC TAT TCA TTG TTT CGA CGT 366  
 Ser His Lys Asn Lys Ser Leu Gln Ile Thr Tyr Ser Leu Phe Arg Arg  
           40                                  45                                  50

AAG ACA 372  
 Lys Thr  
       55

## (2) INFORMATION FOR SEQ ID NO: 98:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 384 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 136..291
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.8  
seq SLLLAQATSNVVC/SL

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 98:

AATGGGCAGG GACCGAGGCT GAAAGAGACA GGAGTCCTCC AGCCGAGGAG AAGCTGATGC 60  
 AGCTGGGCTT GTCCCAGAGG GAGAGGGGTT TTCTTCTCCA ACGGGGAGCG GTGGAGGCAG 120  
 CTGAGGAAGT TTACC ATG CTT GCT CTG CGG GAC CTG GGC ATG GGG AAG CGA 171  
           Met Leu Ala Leu Arg Asp Leu Gly Met Gly Lys Arg  
                   -50                                  -45  
 GAA GGC GAG GAG CTG ATC CAG GCG GAG GCC CGG TGT CTG GTG GAG ACA 219  
 Glu Gly Glu Glu Leu Ile Gln Ala Glu Ala Arg Cys Leu Val Glu Thr  
 -40                                  -35                                  -30                                  -25  
 TTC CAG GGG ACA GAA GGA CGC CCA TTC GAT CCC TCC CTG CTG CTG GCC 267  
 Phe Gln Gly Thr Glu Gly Arg Pro Phe Asp Pro Ser Leu Leu Leu Ala  
                   -20                                  -15                                  -10  
 CAG GCC ACC TCC AAC GTA GTC TGC TCC CTC CTC TTT GGC CTC CGC TTC 315  
 Gln Ala Thr Ser Asn Val Val Cys Ser Leu Leu Phe Gly Leu Arg Phe  
                   -5                                  1                                  5  
 TCC TAT GAG GAT AAG GAG TTC CAG GCC GTG GTC CGG GCA GCT GGT GGT 363  
 Ser Tyr Glu Asp Lys Glu Phe Gln Ala Val Val Arg Ala Ala Gly Gly  
           10                                  15                                  20  
 ACC TGC TGG GAG TCA GCT CCC 384  
 Thr Cys Trp Glu Ser Ala Pro  
       25                                  30

## (2) INFORMATION FOR SEQ ID NO: 99:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 217 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Liver

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 17..73
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.8  
seq STSLCGCLRQLRC/SM

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 99:

```

ACGCAGCTGG TCAGCA ATG CTC AGT GTG GGA GCC AGC ACC AGT TTG TGT GGG 52
 Met Leu Ser Val Gly Ala Ser Thr Ser Leu Cys Gly
 -15 -10

TGC CTG CGC CAA CTG CGG TGC AGC ATG CTG GAT CTG CAG TGG AGC TTT 100
Cys Leu Arg Gln Leu Arg Cys Ser Met Leu Asp Leu Gln Trp Ser Phe
 -5 1 5

CTC GAG GAT GGG GAG CCA TGC AGA GCC CGC CTC TCA CCC CTG CCT CCA 148
Leu Glu Asp Gly Glu Pro Cys Arg Ala Arg Leu Ser Pro Leu Pro Pro
 10 15 20 25

CTT GCT CAC TTG GCT GGA ATC TGG ATA GTC CTG CCA AGG GCT AGT TTT 196
Leu Ala His Leu Ala Gly Ile Trp Ile Val Leu Pro Arg Ala Ser Phe
 30 35 40

TCA GTC ATG GAT TAC CAT GCG
Ser Val Met Asp Tyr His Ala
 45

```

## (2) INFORMATION FOR SEQ ID NO: 100:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 152 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens

(F) TISSUE TYPE: Lung

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 84..140  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 4.8  
 seq VLLSQFLYPLAYP/HP

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 100:

```

ATTTCCTTTG GGTGCTCCAA CTCTTGTAAC TTCACAGGCA ACAACGTTAT CTACGTTCCA 60
GCCCGCTAAT AAACCTAATA AGA ATG TTC CAA CAA ATG TAC GTT CTT CTT TCC 113
 Met Phe Gln Gln Met Tyr Val Leu Leu Ser
 -15 -10

CAG TTT CTC TAC CCY TTA GCT TAT CCT CAC CCT ATT GGG 152
Gln Phe Leu Tyr Pro Leu Ala Tyr Pro His Pro Ile Gly
 -5 1

```

(2) INFORMATION FOR SEQ ID NO: 101:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 296 base pairs  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Lung (cells)

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 225..272  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 4.8  
 seq HFCXIGFLSYTTS/LV

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 101:

```

ATTCTAAATG TTCTCAGATG ACTTTCATTT CACTCACATC CTGAGATTAT GCTGTGGCAT 60
TAATCAATTA CTACTTTTTA TAATTTTTTT TCAGTAGATC TACTAGAAAG AAAGAAAAGA 120
TCTACTAGAA GTCAAGAAAA TGAATGCTCA GTTAAGTGAG GGGAGAAGGA AAGTATTTAT 180
TGTTATTACT ATTTTTTATA ACGTCAGAGA CCTAATAGTG AAGA ATG ACT AGT CAT 236
 Met Thr Ser His
 -15

TTT TGT KTG ATT GGT TTT TTA TCT TAT ACA ACC TCC TTG GTC TAC TGG 284
Phe Cys Xaa Ile Gly Phe Leu Ser Tyr Thr Thr Ser Leu Val Tyr Trp
 -10 -5 1

```

AAT GCA GGC CGG  
Asn Ala Gly Arg  
5

296

## (2) INFORMATION FOR SEQ ID NO: 102:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 255 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Thyroid

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 115..189
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.8  
seq NVLLSGSLLRSLC/LK

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 102:

|                                                                   |             |
|-------------------------------------------------------------------|-------------|
| TCTCTGACTT CCTCTGCTTT TCTCTGAATC TTCTACTCTG CTGCAGCCAC ATTGGCTTCC | 60          |
| TTCTTCAAGC ACTGGAAGCT CGCTCCTGTT TCAGGGCCTT TGTTCCAAAC ATAC ATG   | 117         |
|                                                                   | Met         |
|                                                                   | -25         |
| ATT TGC TCT CTC ACT CCC TTC AGG TCT TTG ACT AAT GTC CTT CTC AGT   | 165         |
| Ile Cys Ser Leu Thr Pro Phe Arg Ser Leu Thr Asn Val Leu Leu Ser   |             |
|                                                                   | -20 -15 -10 |
| GGA AGC CTT CTC CGA TCA CTT TGT TTG AAA TAT AAA CCA CTC ACC TCC   | 213         |
| Gly Ser Leu Leu Arg Ser Leu Cys Leu Lys Tyr Lys Pro Leu Thr Ser   |             |
|                                                                   | -5 1 5      |
| ATC TTC CTT GTC TCA ATG TGT CCT ATA CCC TTT CCC TGC CAT           | 255         |
| Ile Phe Leu Val Ser Met Cys Pro Ile Pro Phe Pro Cys His           |             |
|                                                                   | 10 15 20    |

## (2) INFORMATION FOR SEQ ID NO: 103:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 194 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Colon

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: 93..173  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 4.7  
seq PALTLTFLPPSPT/LP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 103:

```

ACTTCTAGGG AAGGGCTGGG GAGGAGGGGG TGGTGACACG GTGGAGACAC CGGCTAGGCC 60
AGGGGGCCTG CCCTTGGGAC AGGTCCAGAC CC ATG GAG CCC CCC GGG AGG AGC 113
 Met Glu Pro Pro Gly Arg Ser
 -25
AGC AGC CTT CCC TTT TCC CCT CCC GCA CTC ACT CTC ACC TTC TTG CCC 161
Ser Ser Leu Pro Phe Ser Pro Pro Ala Leu Thr Leu Thr Phe Leu Pro
-20 -15 -10 -5
CCA TCG CCC ACC CTG CCA CTT CCC TCC CCT GGG 194
Pro Ser Pro Thr Leu Pro Leu Pro Ser Pro Gly
 1 5

```

## (2) INFORMATION FOR SEQ ID NO: 104:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 282 base pairs  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Colon

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: 94..258  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 4.7  
seq IGILCSLLGTVLL/WV

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 104:

```

AAGGGCGGCT GCCTAGCACC CGGAAGAGCC GTCAACTTAG CGAGCGCAAC AGGCTGCCGC 60
TGAGGAGCTG GAGCTGGTGG GGACTGGGCC GCA ATG GAC AAG CTG AAG AAG GTG 114
 Met Asp Lys Leu Lys Lys Val
 -55 -50
CTG ASC GGG CAG GAC ACG GAG GAC CGG AGC GGC CTG TCC GAG GTT GTT 162

```



81

Leu Ser Gly Gln Asp Thr Glu Asp Arg Ser Gly Leu Ser Glu Val Val  
                     -45                    -40                    -35  
 GAG GCA TCT TCA TTA AGC TGG AGT ACC AGG ATA AAA GGC TTC ATT GCG 210  
 Glu Ala Ser Ser Leu Ser Trp Ser Thr Arg Ile Lys Gly Phe Ile Ala  
                     -30                    -25                    -20  
 TGT TTT GCT ATA GGA ATT CTC TGC TCA CTG CTG GGT ACT GTT CTG CTG 258  
 Cys Phe Ala Ile Gly Ile Leu Cys Ser Leu Leu Gly Thr Val Leu Leu  
                     -15                    -10                    -5  
 TGG GTG CCC AGG AAG GGA CAT GGG 282  
 Trp Val Pro Arg Lys Gly His Gly  
     1                                    5

## (2) INFORMATION FOR SEQ ID NO: 105:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 179 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 84..158
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.7  
seq LGMVCIFSLRLQA/VF

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 105:

ATTCTCTTTT TGTTTGTGTTT CTTTGCTTTT CACATGTTAC CAGCTACATA ATTCTTGAC 60  
 AGAAAAAAT AAATATAAG TCT ATG TAC TCC AGG CAT ACT GTA AAA CTA AAA 113  
                     Met Tyr Ser Arg His Thr Val Lys Leu Lys  
                     -25                    -20  
 CAA GGT TTG GGT ATG GTT TGT ATT TTC AGT TTA AGG CTG CAA GCA GTA 161  
 Gln Gly Leu Gly Met Val Cys Ile Phe Ser Leu Arg Leu Gln Ala Val  
     -15                    -10                    -5                    1  
 TTT ACA ACA GAG GGA AGG 179  
 Phe Thr Thr Glu Gly Arg  
                     5

## (2) INFORMATION FOR SEQ ID NO: 106:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 212 base pairs

(B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Lung (cells)

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 48..119  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 4.6  
 seq SLLLYSLPLNIIG/LN

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 106:

|                                                                 |     |
|-----------------------------------------------------------------|-----|
| ATAGCAATAG AAAGAGCCAG AATATGTGCT TTAGTTTGTT TTAATGA ATG TAT CCT | 56  |
| Met Tyr Pro                                                     |     |
| TCA CTT TTA GTT GAC TAT TTC CCT AGT CTT TTG CTA TAC AGT TTA CCC | 104 |
| Ser Leu Leu Val Asp Tyr Phe Pro Ser Leu Leu Leu Tyr Ser Leu Pro |     |
| -20 -15 -10                                                     |     |
| TTG AAC ATC ATA GGT TTG AAC TGT GCA TAT CCA CTT ATA AAT AAT TTT | 152 |
| Leu Asn Ile Ile Gly Leu Asn Cys Ala Tyr Pro Leu Ile Asn Asn Phe |     |
| -5 1 5 10                                                       |     |
| TTA AAA AAT AAT AGT TAC ACT TGT GTG CVT GTC CCT CTT GCT TTC CCT | 200 |
| Leu Lys Asn Asn Ser Tyr Thr Cys Val Xaa Val Pro Leu Ala Phe Pro |     |
| 15 20 25                                                        |     |
| TCC ATG CCG TCG                                                 | 212 |
| Ser Met Pro Ser                                                 |     |
| 30                                                              |     |

(2) INFORMATION FOR SEQ ID NO: 107:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 345 base pairs  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Lung (cells)

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 109..339  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 4.5  
 seq LPTQFLFLLGVLG/IF

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 107:

```

ATTAGCTSTC CAAGGCTCTCC CCCAGCACTG AGGAGCTCGC CTGCTGCCCT CTTGCGCGCG 60
GGAAGCAGCA CCAAGTTCAC GGCCAACGCC TTGGCACTAG GGTCCAGA ATG GCT ACA 117
 Met Ala Thr
 -75
ACA GTC CCT GAT GGT TGC CGC AAT GGC CTG AAA TCC AAG TAC TAC AGA 165
Thr Val Pro Asp Gly Cys Arg Asn Gly Leu Lys Ser Lys Tyr Tyr Arg
 -70 -65 -60
CTT TGT GAT AAG GCT GAA GCT TGG GGC ATC GTC CTA GAA ACG GTG GCC 213
Leu Cys Asp Lys Ala Glu Ala Trp Gly Ile Val Leu Glu Thr Val Ala
 -55 -50 -45
ACA GCC GGG GTT GTG ACC TCG GTG GCC TTC ATG CKG ACT CTC CCG ATC 261
Thr Ala Gly Val Val Thr Ser Val Ala Phe Met Xaa Thr Leu Pro Ile
 -40 -35 -30
CTC GTC TGC AAG GTG CAG GAC TCC AAC AGG CGA AAA ATG CTG CCT ACT 309
Leu Val Cys Lys Val Gln Asp Ser Asn Arg Arg Lys Met Leu Pro Thr
 -25 -20 -15
CAG TTT CTC TTC CTC CTG GGT GTG TTG GGC ATC TTT 345
Gln Phe Leu Phe Leu Leu Gly Val Leu Gly Ile Phe
-10 -5 1

```

## (2) INFORMATION FOR SEQ ID NO: 108:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 266 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Large intestine

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 63..113
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.5  
seq HLDHLFFSGVVLG/QG

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 108:

```

AACTGGCATC ACTGCTAATG AAAAATGCTG GACTTGGGAT GATATTATGM AGTTAGAAAT 60
TG ATG AGA TTG CAG CAC CTC GAT CAT TTA TTT TTC TCT GGT GTG GTT 107
Met Arg Leu Gln His Leu Asp His Leu Phe Phe Ser Gly Val Val
 -15 -10 -5

```

```

CTG GGG CAG GGG TTG GAC CTT GGA AGA GTG TGT TTA CGA AAA TGG GGT 155
Leu Gly Gln Gly Leu Asp Leu Gly Arg Val Cys Leu Arg Lys Trp Gly
 1 5 10

TAC AGA AGA TGT GAA GAT ATT TGT TGG ATT AAA ACC AAT AAA AAC AAT 203
Tyr Arg Arg Cys Glu Asp Ile Cys Trp Ile Lys Thr Asn Lys Asn Asn
 15 20 25 30

CCT GGG AAG ACT AAG ACT TTA GAT CCA AAG GCT GTC TTT CAG AGA ACA 251
Pro Gly Lys Thr Lys Thr Leu Asp Pro Lys Ala Val Phe Gln Arg Thr
 35 40 45

AAG GCT GGG CTC GGG 266
Lys Ala Gly Leu Gly
 50

```

## (2) INFORMATION FOR SEQ ID NO: 109:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 311 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Pancreas

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 78..170
- (C) IDENTIFICATION METHOD: Von Heijne.matrix
- (D) OTHER INFORMATION: score 4.5  
seq VAFGLYNPSLCHA/CT

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 109:

```

ACTGACGTGT CTTTGCTCCT GATACCATT TTCCCCACAC CACACCACTG TCCTCTGTGC 60

CTGTGGAAAC CACTCAA ATG CCT CTC CCC AAG CCT TCT TTC AGT AAC AAC 110
 Met Pro Leu Pro Lys Pro Ser Phe Ser Asn Asn
 -30 -25

CAT CTC ATC CGG TTG ATT ACT GTA GCT TTC GGC CTG TAT AAC CCC TCC 158
His Leu Ile Arg Leu Ile Thr Val Ala Phe Gly Leu Tyr Asn Pro Ser
-20 -15 -10 -5

TTA TGT CAT GCC TGT ACC AGA TGT TCC ACT GCA TCT GTA TCC CAC CAG 206
Leu Cys His Ala Cys Thr Arg Cys Ser Thr Ala Ser Val Ser His Gln
 1 5 10

ATT GCA CAT TCC CCG AAG CAG AAA CCT TCT AAT CTG GGG GCC ATT CAG 254
Ile Ala His Ser Pro Lys Gln Lys Pro Ser Asn Leu Gly Ala Ile Gln
 15 20 25

```

GGC CTA GCA CAG TGC CTA GTA GAG CAT ATG TGT TGT AGA ATA AAT ATA 302  
Gly Leu Ala Gln Cys Leu Val Glu His Met Cys Cys Arg Ile Asn Ile  
30 35 40

GAC ACA TGG  
Asp Thr Trp  
45

(2) INFORMATION FOR SEQ ID NO: 110:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 458 base pairs  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Pancreas

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide  
(B) LOCATION: 177..401  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 4.4  
seq QXRLCVSPSGLRC/EP

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 110:

ATAAATAGGC ACTGAAGACA TGTTAATGGA AGGTGGATTT GTGATTCAGA ACCTCTAGAC 60

TACCTGGGCG AGTCTTTTAA AATGTTTCTG CATATGAAGT GTGTAAAATA GATTGCTTGA 120

TCCAAAACAG AAAAACAGTG ATAAGTGTG TGCTGAGTTC CCAGACCCTT CCCAAG ATG 179  
Met  
-75

GAA CCA ATA ACA TTC ACA GCA AGG AAA CAT CTG CTT CCT AAC GAG GTC 227  
Glu Pro Ile Thr Phe Thr Ala Arg Lys His Leu Leu Pro Asn Glu Val  
-70 -65 -60

TCG GTG GAT TTT GGC CTG CAG CTG GTG GGC TCC CTG CCT GTG CAT TCC 275  
Ser Val Asp Phe Gly Leu Gln Leu Val Gly Ser Leu Pro Val His Ser  
-55 -50 -45

CTG ACC ACC ATG CCC ATG CTG CCC TGG GTT GTG GCT GAG GTG CGA AGA 323  
Leu Thr Thr Met Pro Met Leu Pro Trp Val Val Ala Glu Val Arg Arg  
-40 -35 -30

CTC AGC AGG CAG TCC ACC AGA AAG GAA CCT GTA ACC ANG CAA NTC CGG 371  
Leu Ser Arg Gln Ser Thr Arg Lys Glu Pro Val Thr Xaa Gln Xaa Arg  
-25 -20 -15

CCT TGC GTT TCA CCC TCT GGA CTG AGA TGT GAA CCT GAG CCA GGG AGA 419  
Leu Cys Val Ser Pro Ser Gly Leu Arg Cys Glu Pro Glu Pro Gly Arg  
-10 -5 1 5

AGT CAA CAG TGG GAT CCC CTG ATC TAT TCC AGC ATC TTT 458  
 Ser Gln Gln Trp Asp Pro Leu Ile Tyr Ser Ser Ile Phe  
           10                    15

## (2) INFORMATION FOR SEQ ID NO: 111:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 177 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Colon

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 58..132
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.4  
seq FFCWEVGVSGSSA/GP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 111:

AAAAGGTACC CGCGAGAGAC AGCCAGCAGT TCTGTGGAGC AGCGGTGGCC GGCTAGG 57  
 ATG GGC TGT CTC TGG GGT CTG GCT CTG CCC CTT TTC TTC TTC TGC TGG 105  
 Met Gly Cys Leu Trp Gly Leu Ala Leu Pro Leu Phe Phe Phe Cys Trp  
 -25                    -20                    -15                    -10  
 GAG GTT GGG GTC TCT GGG AGC TCT GCA GGC CCC AGC ACC CGC AGA GCA 153  
 Glu Val Gly Val Ser Gly Ser Ser Ala Gly Pro Ser Thr Arg Arg Ala  
                     -5                    1                    5  
 GAC ACT GCG ATG ACA ACG GAC GAC 177  
 Asp Thr Ala Met Thr Thr Asp Asp  
           10                    15

## (2) INFORMATION FOR SEQ ID NO: 112:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 175 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 62..121
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.3  
seq YLCHISLLDVTQQ/FP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 112:

```

ACAAGAAGAT CAGACACGTA CACTGAAAAA GAACCCACGT TACAGAGCAG TGTGTTGAG 60
G ATG AAA CAA AAC ACA GAT CCA TAT CTG TGT CAT ATA AGC TTG CTC GAT 109
 Met Lys Gln Asn Thr Asp Pro Tyr Leu Cys His Ile Ser Leu Leu Asp
 -20 -15 -10 -5

GTA ACT CAA CAA TTT CCA AAT CCA CTT CCT GGC AGA ACC ATC TTT CCT 157
Val Thr Gln Gln Phe Pro Asn Pro Leu Pro Gly Arg Thr Ile Phe Pro
 1 5 10

GGT TCC TCA ACC CCC AGG
Gly Ser Ser Thr Pro Arg
 15

```

## (2) INFORMATION FOR SEQ ID NO: 113:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 186 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (D) DEVELOPMENTAL STAGE: Fetal
- (F) TISSUE TYPE: liver

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 34..138
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.3  
seq LISLLSPNTPSA/SI

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 113:

```

ATAPATTGTG GTAAAATACA AAATATGTAA AAT ATG GTG ACA TAT TTT AAC TTC 54
 Met Val Thr Tyr Phe Asn Phe
 -35 -30

ACC TTC AAG CCA TTT TGC ATT CTG GCC TCA ATT ATT GTT CCC ACT CTT 102
Thr Phe Lys Pro Phe Cys Ile Leu Ala Ser Ile Ile Val Pro Thr Leu
 -25 -20 -15

ATC TCT TTA CTT TCA TCT CCA AAT ACT CCA AGT GCA TCT ATT TAC TAT 150
Ile Ser Leu Leu Ser Ser Pro Asn Thr Pro Ser Ala Ser Ile Tyr Tyr

```

-10                      -5                      1

|     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| TCT | CCA | AAG | TGT | CTT | TGT | CCA | TTA | GCC | ACC | CCC | AGG |     |
| Ser | Pro | Lys | Cys | Leu | Cys | Pro | Leu | Ala | Thr | Pro | Arg | 186 |
| 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |     |

(2) INFORMATION FOR SEQ ID NO: 114:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 197 base pairs  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Colon

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide  
(B) LOCATION: 114..182  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 4.3  
seq QXILLGTTSVVTA/AL

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 114:

|            |            |            |            |            |            |         |         |     |
|------------|------------|------------|------------|------------|------------|---------|---------|-----|
| ATCCGGTCAG | GTTAGGCCGG | GGGGGTGCGG | TCCTGGTCGG | AAGGAGGTGG | ASAGTCGGGG | 60      |         |     |
| GTCACCAGGC | CTATCCTTGG | CGCCACAGTC | GGCCACCGGG | GCTCGCCGCC | GTC ATG    | 116     |         |     |
|            |            |            |            |            | Met        |         |         |     |
| GAG AGC    | GGA GGG    | CGG CCC    | TCG CTG    | TGC CAG    | TKC ATC    | CTC CTG | GGC ACC | 164 |
| Glu Ser    | Gly Gly    | Arg Pro    | Ser Leu    | Cys Gln    | Xaa Ile    | Leu Leu | Gly Thr |     |
|            | -20        |            | -15        |            |            | -10     |         |     |
| ACC TCT    | GTG GTC    | ACC GCC    | GCC CTG    | TAC TCC    | GTG        |         |         | 197 |
| Thr Ser    | Val Val    | Thr Ala    | Ala Leu    | Tyr Ser    | Val        |         |         |     |
|            | -5         |            | 1          |            | 5          |         |         |     |

(2) INFORMATION FOR SEQ ID NO: 115:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 377 base pairs  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Pancreas



## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 105..233
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.2  
seq HMMAAAVADGTRA/AT

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 115:

```

AAGCCCCTGT TGAAGACGCA GGGCCAACAG GGGCCAACGA AGATGACTCT GATGTCCCGG 60
CCGTGGTCCC TCTGTCTGAG TATGATGCTG TAGAAAGGGA GAAA ATG GAG GCA CAG 116
 Met Glu Ala Gln
 -40

CAA GCC CAA AAA AGC GCA GAG CAG CCC GAG CAG AAG GCA GCC ACT GAG 164
Gln Ala Gln Lys Ser Ala Glu Gln Pro Glu Gln Lys Ala Ala Thr Glu
 -35 -30 -25

GTG TCK SAG GAG CTC AGC GAG AGT CAG GTT CAT ATG ATG GCA GCA GCT 212
Val Ser Xaa Glu Leu Ser Glu Ser Gln Val His Met Met Ala Ala Ala
 -20 -15 -10

GTC GCT GAC GGG ACG AGG GCA GCT ACC ATT ATT GAA GAA AGG TCT CCT 260
Val Ala Asp Gly Thr Arg Ala Ala Thr Ile Ile Glu Glu Arg Ser Pro
 -5 1 5

TCT TGG ATA TCT GCT TCA GTG ACA GAA CCT CTT GAA CAA GTA GAA GCT 308
Ser Trp Ile Ser Ala Ser Val Thr Glu Pro Leu Glu Gln Val Glu Ala
 10 15 20 25

GAA GCC GCA CTG TTA ACT GAG GAG GTA TTG GAA AGA GAA GTA ATT GCA 356
Glu Ala Ala Leu Leu Thr Glu Glu Val Leu Glu Arg Glu Val Ile Ala
 30 35 40

GAA GAA GAA CCC CCC ACG ATG 377
Glu Glu Glu Pro Pro Thr Met
 45

```

## (2) INFORMATION FOR SEQ ID NO: 116:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 370 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 308..358
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.2

seq SVIWFSGSVXPCIS/XV

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 116:

```

TCTTTACAAT TAGCTAGTTG CGATTGGCTA AGTTGTWAGG GCCTAAATAC TTACTAAGCT 60
GTCTGGAGCC TAACCCAGCA GAAGGGTTAG ATATTTCTTT TAGCTTAGGG GCACAGTGAG 120
AAAAATTGCT GAGACTAAGG GCCCCATAAA CATAGGAAAT TGGAGAACTT CTAGCTGAAA 180
CTGATCATGG TTCCTCCTTG ATCAGTCTTG GGGCAGGAAC TGGGACTGGG GCCTGCCTCA 240
CCTGAAGCCC ATGAAGAGTG TATACCTGAA TAAACTCTTA TAAAGAAAGG AGGGGAATGC 300
ATTAGGA ATG CCA CTA AAC TCA GTG ATA TGG TTT GGA TCT GTG WHC CCA 349
 Met Pro Leu Asn Ser Val Ile Trp Phe Gly Ser Val Xaa Pro
 -15 -10 -5

TGC ATA TCT CAK GTT GAA TTG 370
Cys Ile Ser Xaa Val Glu Leu
 1

```

(2) INFORMATION FOR SEQ ID NO: 117:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 363 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 253..342
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.2  
seq FLDFANLADLTLA/ES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 117:

```

AAGAGGAAGG AGCTGTGGGA AGCTCGCAGC AGGTATCGGA GCTTAAGCCA GTGGATTGG 60
GGGCCCTGGG CTCCCTAGCC GGCTGCGGTG TGAGAATGGA GTGGGCAKGA AAGCAGCGGG 120
ACTTTCAGGT AAGGGCAGCT CCGGGCTGGG ATCATTTGGC CTCCTTTCCT GGCCCTTCTC 180
TCCGGCTGTT TTCTGGGAGT CARGMGAGTG TCTGTAGTCT CTGCTCGGGG TTTGGGGCTC 240
AGGAATGATG TC ATG CTC CAA CAG TTG GAT TCT ATT AGC TTA AGG AGG AGG 291
 Met Leu Gln Gln Leu Asp Ser Ile Ser Leu Arg Arg Arg
 -30 -25 -20

```

GAA ACA GCC AAT TTT CTT GAC TTT GCA AAT CTA GCT GAT CTC ACT CTT 339  
 Glu Thr Ala Asn Phe Leu Asp Phe Ala Asn Leu Ala Asp Leu Thr Leu  
           -15                               -10                               -5

GCT GAA TCT GAG GTG TTT AGA CTT 363  
 Ala Glu Ser Glu Val Phe Arg Leu  
           1                               5

## (2) INFORMATION FOR SEQ ID NO: 118:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 435 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 1..90
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 90  
                           region 163..252  
                           id AA236618  
                           est

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 268..411
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.1  
                           seq FTTLSNLSLPSQT/KD

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 118:

CGTCCATCAG ATCCTGACCC TAAGGCTGGT GACTTTGTAG CTATGAAAGC AGGAAATGAA 60  
 GGCATAGTAC AATTCCTAA AGATGAAAAA CAATATCTTG TTCCCTCTG TTTTGTAT 120  
 TACAAGAAAT AATCTATCTA CTACTCGTCA GCACCTGTCT TTGTGTCTGA AGCCAAGAAT 180  
 AAATTCATCA ACTTGCTAGC CACTGCTGCA ACTGAAGCCA ACCGCAGTCA ATGTTGGCTA 240  
 TATGTTGAGT TGCCGGAGGC GCCTGGA ATG TGC TAC CTT GCA GAA TTG TCC CTG 294  
                           Met Cys Tyr Leu Ala Glu Leu Ser Leu  
                                   -45                               -40  
 ACA ACA TTT CKV MAT GGC TAT ATT GTT ACC AGT AGG GCC ACA ACA ACA 342  
 Thr Thr Phe Xaa Xaa Gly Tyr Ile Val Thr Ser Arg Ala Thr Thr Thr  
                           -35                               -30                               -25  
 ACA ACA CTT GCA ATC CAA CCT GGG CTT CCT TTC ACC ACA CTA AGC AAT 390  
 Thr Thr Leu Ala Ile Gln Pro Gly Leu Pro Phe Thr Thr Leu Ser Asn

|                                                             |     |  |  |  |  |  |  |     |  |  |  |  |     |  |  |  |  |  |     |
|-------------------------------------------------------------|-----|--|--|--|--|--|--|-----|--|--|--|--|-----|--|--|--|--|--|-----|
|                                                             | -20 |  |  |  |  |  |  | -15 |  |  |  |  | -10 |  |  |  |  |  |     |
| CTA TCT TTG CCA AGT CAG ACA AAA GAT GAA CTC CAC CCT CCC TGG |     |  |  |  |  |  |  |     |  |  |  |  |     |  |  |  |  |  | 435 |
| Leu Ser Leu Pro Ser Gln Thr Lys Asp Glu Leu His Pro Pro Trp |     |  |  |  |  |  |  |     |  |  |  |  |     |  |  |  |  |  |     |
|                                                             | -5  |  |  |  |  |  |  | 1   |  |  |  |  | 5   |  |  |  |  |  |     |

(2) INFORMATION FOR SEQ ID NO: 119:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 127 base pairs  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Pancreas

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide  
(B) LOCATION: 56..106  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 4.1  
seq LSSLILLPIWINM/AO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 119:

ATGCCCCCTC AGCCCTGTGG CTGGGGGCAG AGCTCAGACT GTCTTCTGAA GATTG ATG 58  
Met

TCT ATT TCC TTG AGC TCT TTA ATT TTG TTG CCA ATT TGG ATA AAC ATG 106  
Ser Ile Ser Leu Ser Ser Leu Ile Leu Leu Pro Ile Trp Ile Asn Met  
-15 -10 -5

GCA CAA ATC CAG CGG GGA GGT 127  
Ala Gln Ile Gln Arg Gly Gly  
1 5

(2) INFORMATION FOR SEO ID NO: 120:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 462 base pairs  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Lung

(ix) FEATURE:

- (A) NAME/KEY: sig peptide

(B) LOCATION: 88..345  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 4  
 seq LLFALSWKSDAPA/TS

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 120:

```

ACGCTTCCTG TACCACCCTG CTCAAGTAGC GGACACGGAA CAGGGAAC TAAGCCCGTC 60
GGCCTCCGGG CCCTGCATTC TCTAGCC ATG GAC CGG GAC CTT TTG CGG CAG TCG 114
 Met Asp Arg Asp Leu Leu Arg Gln Ser
 -85 -80

CTA AAT TGC CAC GGG TCG TCT TTG CTC TCT CTA CTT CGG AGC GAA CAG 162
Leu Asn Cys His Gly Ser Ser Leu Leu Ser Leu Leu Arg Ser Glu Gln
 -75 -70 -65

CAG GAC AAT CCA CAC TTC CGT AGC CTC CTG GGG TCG GCC GCC GAG CCA 210
Gln Asp Asn Pro His Phe Arg Ser Leu Leu Gly Ser Ala Ala Glu Pro
 -60 -55 -50

GCC CGG GGC CCG CCG CCC CAG CAC CCG TTG CAG GGC AGA AAA GAG AAG 258
Ala Arg Gly Pro Pro Pro Gln His Pro Leu Gln Gly Arg Lys Glu Lys
 -45 -40 -35 -30

AGA GTT GAC AAC ATC GAG ATA CAG AAA TTC ATC TCC AAA AAA GCG GAT 306
Arg Val Asp Asn Ile Glu Ile Gln Lys Phe Ile Ser Lys Lys Ala Asp
 -25 -20 -15

CTG CTT TTT GCA CTT TCC TGG AAA TCA GAT GCA CCT GCA ACT TCT GAA 354
Leu Leu Phe Ala Leu Ser Trp Lys Ser Asp Ala Pro Ala Thr Ser Glu
 -10 -5 1

ATT AAT GAA GAC AGT GAA GAT CAT TAT GCA ATC ATG CCA CCT TTA GAG 402
Ile Asn Glu Asp Ser Glu Asp His Tyr Ala Ile Met Pro Pro Leu Glu
 5 10 15

CAA TTC ATG GAG ATA CCT AGT ATG GAT CGG AGA GAG CTG TTT TTC CGA 450
Gln Phe Met Glu Ile Pro Ser Met Asp Arg Arg Glu Leu Phe Phe Arg
 20 25 30 35

GAT ATT GAG CGT
Asp Ile Glu Arg 462

```

(2) INFORMATION FOR SEQ ID NO: 121:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 320 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Large intestine

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 246..296
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4  
seq TLVTXXNASCSFA/SV

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 121:

```

GGTTTCTTGG TTTTCTTGTT TTCCCATATG TTTGTATCCC TAAACAAAAG ATTGCTTAGT 60
TCTGCATGTT TTTCAACTTT ATGTAAATGA AATCACA CTG CATTTATTCT TCTCTGACTT 120
TATTTAGCTG AACATTATGC ATCTGATCCC CATCCATATT GTCATGGGTA ACTAGCATT 180
ATTGTCTTCA CTGCTGAACA AGTAGAACCT ATTCAGTTCA CTGCCCCTT GTCTTCCCAG 240
ATTCC ATG GTT CTG GCC ACA CTA GTG ACT TST KTA AAT GCA TCC TGC TCT 290
 Met Val Leu Ala Thr Leu Val Thr Xaa Xaa Asn Ala Ser Cys Ser
 -15 -10 -5

TTT GCG TCT GTG CAT CTT GCC CAG GGT GGG 320
Phe Ala Ser Val His Leu Ala Gln Gly Gly
 1 5

```

## (2) INFORMATION FOR SEQ ID NO: 122:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 283 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 167..226
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4  
seq IILKVLLNQTCT/VQ

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 122:

```

AAAAGGTCTT CGAATTTCAA CTCGTCAAGT ACATCACA CT CAGTTTGAA AAGTCCAAGC 60
CACATGGAAA AATACCCGCA AAAAGAGAAA ACCAAAGAAG ATCTGGATT CACGAAGCAAC 120
CTACACTTGC CAGAACTAA ATTTTCTGAA TTGTCAA AAC TGAAGA ATG ATG ATA 175
 Met Met Ile
 -20

TGG AAA AGG CTA ATC ATA TTG AAA GTG TTA TTA AAT CAA ACT TGC CAA 223

```

```
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 322 base pairs
 (B) TYPE: NUCLEIC ACID
 (C) STRANDEDNESS: DOUBLE
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: Homo Sapiens
 (D) DEVELOPMENTAL STAGE: Fetal
 (F) TISSUE TYPE: liver

(ix) FEATURE:
 (A) NAME/KEY: sig_peptide
 (B) LOCATION: 23..205
 (C) IDENTIFICATION METHOD: Von Heijne matrix
 (D) OTHER INFORMATION: score 4
 seq AALVKCLPVLCLA/GF
```

|                                                                 |            |    |     |     |     |     |     |     |     |     |     |     |     |  |     |
|-----------------------------------------------------------------|------------|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|-----|
| GCTCTGGGGC                                                      | TATCAGGCCA | GC | ATG | GAC | GCT | GGC | AAA | GCG | GGG | CAG | ACC | CTG |     |  | 52  |
|                                                                 |            |    | Met | Asp | Ala | Gly | Lys | Ala | Gly | Gln | Thr | Leu |     |  |     |
|                                                                 |            |    | -60 |     |     |     |     |     | -55 |     |     |     |     |  |     |
| AAG ACT CAC TGC TCA GCC CAG CGC CCA GAT GTC TGC AGG TGG CTG AGC |            |    |     |     |     |     |     |     |     |     |     |     |     |  | 100 |
| Lys Thr His Cys Ser Ala Gln Arg Pro Asp Val Cys Arg Trp Leu Ser |            |    |     |     |     |     |     |     |     |     |     |     |     |  |     |
|                                                                 | -50        |    |     |     |     | -45 |     |     |     | -40 |     |     |     |  |     |
| CCC TTC ATC CTC TCC TGC TGC GTG TAC TTC TGC CTC TGG ATT CCC GAG |            |    |     |     |     |     |     |     |     |     |     |     |     |  | 148 |
| Pro Phe Ile Leu Ser Cys Cys Val Tyr Phe Cys Leu Trp Ile Pro Glu |            |    |     |     |     |     |     |     |     |     |     |     |     |  |     |
|                                                                 | -35        |    |     |     | -30 |     |     |     | -25 |     |     |     | -20 |  |     |
| GAC CAG CTG TCC TGG TTC GCT GCC CTG GTC AAG TGC CTG CCC GTC CTC |            |    |     |     |     |     |     |     |     |     |     |     |     |  | 196 |
| Asp Gln Leu Ser Trp Phe Ala Ala Leu Val Lys Cys Leu Pro Val Leu |            |    |     |     |     |     |     |     |     |     |     |     |     |  |     |
|                                                                 |            |    | -15 |     |     |     |     | -10 |     |     |     | -5  |     |  |     |
| TGC CTG GCT GGG TTC CTG TGG GTC ATG TCC CCA AGC GGG GGC TAC ACC |            |    |     |     |     |     |     |     |     |     |     |     |     |  | 244 |
| Cys Leu Ala Gly Phe Leu Trp Val Met Ser Pro Ser Gly Gly Tyr Thr |            |    |     |     |     |     |     |     |     |     |     |     |     |  |     |
|                                                                 |            |    | 1   |     |     |     | 5   |     |     |     | 10  |     |     |  |     |
| CAG CTC CTC CAG GGA GCC CTT GTG TGC TCG GCT GTG GGG GAC GCT TGC |            |    |     |     |     |     |     |     |     |     |     |     |     |  | 292 |
| Gln Leu Leu Gln Gly Ala Leu Val Cys Ser Ala Val Gly Asp Ala Cys |            |    |     |     |     |     |     |     |     |     |     |     |     |  |     |
|                                                                 | 15         |    |     |     |     | 20  |     |     |     | 25  |     |     |     |  |     |

CTC ATC TGG CCG GCA GCC TTC GTC CCA GGG 322  
 Leu Ile Trp Pro Ala Ala Phe Val Pro Gly  
 30 35

## (2) INFORMATION FOR SEQ ID NO: 124:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 316 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 107..190
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4  
seq PLLGVLFQGVYI/VF

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 124:

ATTTAAGTTG TCTCTCGGCC TCCTGCTCTG ACGTCACTTC CGGTGTTACC TGTGTCGTTA 60  
 CCGGGAGCTG TAAACAAGGT GTGCAAGCAT CTGAAGAGCT GCCGGG ATG CAG CAG 115  
 Met Gln Gln  
 AGA GGA GCA GCT GGA AGC CGT GGC TGC GCT CTC TTC CCT CTG CTG GGC 163  
 Arg Gly Ala Ala Gly Ser Arg Gly Cys Ala Leu Phe Pro Leu Leu Gly  
 -25 -20 -15 -10  
 GTC CTG TTC TTC CAG GGT GTT TAT ATC GTC TTT TCC TTG GAG ATT CGT 211  
 Val Leu Phe Phe Gln Gly Val Tyr Ile Val Phe Ser Leu Glu Ile Arg  
 -5 1 5  
 GCA GAT GCC CAT GTC CGA GGT TAT GTT GGA GAA AAG ATC AAG TTG AAA 259  
 Ala Asp Ala His Val Arg Gly Tyr Val Gly Glu Lys Ile Lys Leu Lys  
 10 15 20  
 TGC ACT TTC AAG TCA ACT TCA GAT GTC ACT GAC AAG CTT ACT ATA GAC 307  
 Cys Thr Phe Lys Ser Thr Ser Asp Val Thr Asp Lys Leu Thr Ile Asp  
 25 30 35  
 TGG ACA CAG 316  
 Trp Thr Gln  
 40

## (2) INFORMATION FOR SEQ ID NO: 125:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 153 base pairs



(B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Colon

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 1..96  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 4  
 seq LIYWYVLLILSFP/FI

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 125:

|                                                                 |     |
|-----------------------------------------------------------------|-----|
| ATG CTC GGA ACA CAT ATC TAC GTG TCC TTA TGG ATT ATT CTT TTC TCT | 48  |
| Met Leu Gly Thr His Ile Tyr Val Ser Leu Trp Ile Ile Leu Phe Ser |     |
| -30 -25 -20                                                     |     |
| TCC CCA CAT CTT ATC TAT TGG TAT GTT CTG TTG ATT TTG TCT TTT CCA | 96  |
| Ser Pro His Leu Ile Tyr Trp Tyr Val Leu Leu Ile Leu Ser Phe Pro |     |
| -15 -10 -5                                                      |     |
| TTT ATC ATC AAA TTT TCT ATG AAC ACC TTG TCC AGA CCA CCA CCT GAC | 144 |
| Phe Ile Ile Lys Phe Ser Met Asn Thr Leu Ser Arg Pro Pro Pro Asp |     |
| 1 5 10 15                                                       |     |
| ACC CCC CAG                                                     | 153 |
| Thr Pro Gln                                                     |     |

(2) INFORMATION FOR SEQ ID NO: 126:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 131 base pairs  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Pancreas

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 69..125  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 3.9  
 seq FLNLHGFLGHLLS/GE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 126:

ACATCAGGAT AAAAAATCTG TAATACTAAA AATGTTAAAT AATTTAGTT GCCAAATTTT 60  
 CAGTTGAA ATG TCA ATA TAT AAT TTA TTT CTT AAT TTG CAT GGC TTT TTA 110  
           Met Ser Ile Tyr Asn Leu Phe Leu Asn Leu His Gly Phe Leu  
                                   -15                                  -10  
 GGT CAT TTA TTA TCT GGG GAG 131  
 Gly His Leu Leu Ser Gly Glu  
           -5                                  1

## (2) INFORMATION FOR SEQ ID NO: 127:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 429 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 343..417
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 3.9  
seq PACVCMCTXSCYS/CQ

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 127:

CCTTGCTTCC STAACAGACT TTAGCCCTAG GGAAGTCAGA CCTGATCAGT GCAGGGCGTT 60  
 CTTGCCGATA AGTTGGGGAT GGTGGACCT GAGCACCTCT TGGTCAGCTG GCCTCTCCCA 120  
 GGGCTCCAGG CTACCCACAC CTGCTTGCAG TGCGACCTCG GTTGCCCAGG TGGGGTCCCT 180  
 TATGGGGGTG TACATCATAG CTCCTGTGCT GGTGAACTGC AGTTGATAAA TCCCATAGTC 240  
 GTGCAACAGC CCACCTGCAC CTTCCCAAAA CTGCGGCCTC TCTGAGACAC TTTGCCTGCA 300  
 TGCATTACCC TATGGCCACC CCCGACGTTG CTTTGCCAGC AT ATG TGC ATG CAA 354  
                                                                                   Met Cys Met Gln  
                                                                                   -25  
 GTG GAC CTT GCC TTC TCT TTT CCA CCA GCA TGC GTG TGC ATG TGC ACC 402  
 Val Asp Leu Ala Phe Ser Phe Pro Pro Ala Cys Val Cys Met Cys Thr  
           -20                                  -15                                  -10  
 CKG TCA TGC TAC AGC TGC CAG TGT GAG 429  
 Xaa Ser Cys Tyr Ser Cys Gln Cys Glu  
           -5                                  1

## (2) INFORMATION FOR SEQ ID NO: 128:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 265 base pairs  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: CDNA
- (vi) ORIGINAL SOURCE:  
 (A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Pancreas
- (ix) FEATURE:  
 (A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 56..151  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 3.8  
 seq IRTATLVISLARG/WQ
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 128:

```

AACACTCATT TTAGCCAGTG TCCAGGCTAT CAGCAGAGAA AGACAGGTGG GCAGC ATG 58
 Met
GCT CCG GGC GAA AAG GAA AGC GGG GAG GGC CCA GCC AAG AGC GCC CTC 106
Ala Pro Gly Glu Lys Glu Ser Gly Glu Gly Pro Ala Lys Ser Ala Leu
-30 -25 -20

CGG AAG ATA CGC ACA GCC ACC CTG GTC ATC AGC TTG GCC CGA GGT TGG 154
Arg Lys Ile Arg Thr Ala Thr Leu Val Ile Ser Leu Ala Arg Gly Trp
-15 -10 -5 1

CAG CAG TGG GCG AAT GAG AAC AGC ATC AGG CAG GCC CAG GAG CCT ACA 202
Gln Gln Trp Ala Asn Glu Asn Ser Ile Arg Gln Ala Gln Glu Pro Thr
 5 10 15

GGC TGG CTG CCG GGA GGG ACC CAG GAC TCA CCT CAA GCT CCT AAA CCA 250
Gly Trp Leu Pro Gly Gly Thr Gln Asp Ser Pro Gln Ala Pro Lys Pro
 20 25 30

ATC ACA CCC CGG GGG 265
Ile Thr Pro Arg Gly
 35

```

(2) INFORMATION FOR SEQ ID NO: 129:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 222 base pairs  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: CDNA
- (vi) ORIGINAL SOURCE:  
 (A) ORGANISM: Homo Sapiens  
 (D) DEVELOPMENTAL STAGE: Fetal

100

(F) TISSUE TYPE: liver

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 67..192  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 3.7  
 seq PLLHLFYQHLCFP/VP

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 129:

```

ACAACTTTAT GTCTCAAATG TTTGTATTAG AGATTTTCT TGAAGTAAAA CCTACCTCTA 60
CTAGGA ATG GAA CCA AAA AGG GGG AGR ATG TGG TKA TTT GAA ATT GAA 108
 Met Glu Pro Lys Arg Gly Arg Met Trp Xaa Phe Glu Ile Glu
 -40 -35 -30

GAT AGC TGT ATA TAC CAG GAC ATC CCA TCG TTT GTC TTA CTT TAC CCA 156
Asp Ser Cys Ile Tyr Gln Asp Ile Pro Ser Phe Val Leu Leu Tyr Pro
 -25 -20 -15

CTT CTC CAT TTG TTT TAC CAG CAT CTC TGT TTT CCT GTT CCA TGC ACT 204
Leu Leu His Leu Phe Tyr Gln His Leu Cys Phe Pro Val Pro Cys Thr
 -10 -5 1

AGA AAT CCT GGG CCC GGG 222
Arg Asn Pro Gly Pro Gly
 5 10

```

(2) INFORMATION FOR SEQ ID NO: 130:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 211 base pairs  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 131..181  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 3.6  
 seq SVLQRCLEFSVTS/VF

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 130:

```

CACATTCTGC ACTCTAGCCC AGAAGTCACA AACTGATGGC TCTAGTGTCA ATTCTGCCTG 60
TAGTGCTGAC CACTCATACA GCTGGCCTGC TTCCCTGATT TATCTATTAG CAACTCCTAC 120
TTCTGGCCAT ATG GAA TTT TGT TCA GTT CTT CAA AGG TGC CTA TTC TCC 169

```

101

Met Glu Phe Cys Ser Val Leu Gln Arg Cys Leu Phe Ser  
 -15 -10 -5

TTT GTC ACT TCG GTC TTT CAT ATG CTG TTC CCT CTG CCT GGG 211  
 Phe Val Thr Ser Val Phe His Met Leu Phe Pro Leu Pro Gly  
 1 5 10

## (2) INFORMATION FOR SEQ ID NO: 131:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 264 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (D) DEVELOPMENTAL STAGE: Fetal
- (F) TISSUE TYPE: liver

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 196..249
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 3.6  
seq IYVLLFFLLMKFS/FD

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 131:

TAAACTAAGA GTGACATGAC CAGATTTGGA CTTGACAAAG GTGCCTAGAA ATGAATGAAG 60  
 GACAGTTATA ACAGTTCACC CACAGAAACA TAGAGTGCAT TTCTGTCGAT ATCAAAGGAA 120  
 CTTAGTGGAG AAATGACAAC GACCTGGATG AAAGCCCTGG CTTGACTTGG GGACCCAGTA 180  
 CAGGGTCAAC AAACT ATG GCA GAG AGC CAA ATC TAC GTG CTG CTT TTT TTT 231  
 Met Ala Glu Ser Gln Ile Tyr Val Leu Leu Phe Phe  
 -15 -10  
 TTG TTA ATG AAG TTT TCT TTT GAC ACA CGA GGG 264  
 Leu Leu Met Lys Phe Ser Phe Asp Thr Arg Gly  
 -5 1 5

## (2) INFORMATION FOR SEQ ID NO: 132:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 93 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

102

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Liver

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: 13..66  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 3.6  
seq ACSLSSGPLQINA/LP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 132:

```

AAAAA CTCT GA ATG CAG ACA AAC AAT GCT TGT TCC CTG TCC TCT GGC CCT 51
 Met Gln Thr Asn Asn Ala Cys Ser Leu Ser Ser Gly Pro
 -15 -10

TTG CAA ATA AAT GCC TTA CCA GAC CTG CCC TGC CAC CCC GGG 93
Leu Gln Ile Asn Ala Leu Pro Asp Leu Pro Cys His Pro Gly
-5 1 5

```

## (2) INFORMATION FOR SEQ ID NO: 133:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 390 base pairs  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Large intestine

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: 304..381  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 3.6  
seq KVL MGLLCNQTA A/KR

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 133:

```

CAAATATTCC CTCCTCTGGG GAACTTCTAA TTCCCAGCA GAAATCATGC CTCCAGTGAC 60
GGTCCATGCA GGCTTCTGGA GCGTTGGGCA ATCTTCCTCA TCTGTGGACT TGCTGGCCTC 120
TTTCCCCTTG GCTTCTTGAG GCCTGCGCTG CATCTGATTT CTCTGTCTCG GGGGCCTAGC 180
ATGGTCATTG GCCCTCCCAG TGTTTCTTGG ATGATCATCG TGCTGTTCTT GAGTCAGGGC 240
TGCCATTGGA GGTGACATCT GTGACTGCAA CCTGTGCCTG AATTGGTGGG CGGAACCTGC 300
TCA ATG GGC CAG AAC AAT GCT TCC TTC CAC TGC CCC TGC CTG AAA GTC 348
 Met Gly Gln Asn Asn Ala Ser Phe His Cys Pro Cys Leu Lys Val
 -25 -20 -15

```

103

CTC ATG GGC CTC CTT TGC AAT CAA ACT GCT GCC AAG AGA CCT 390  
 Leu Met Gly Leu Leu Cys Asn Gln Thr Ala Ala Lys Arg Pro  
 -10 -5 1

## (2) INFORMATION FOR SEQ ID NO: 134:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 124 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Liver

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 29..70
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 3.6  
seq LPLLSVMWSPIAP/LT

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 134:

ACACCTTTCT ATCTGACTAC CTGCCCTA ATG TTG CCC TTA CTC TCA GTA ATG 52  
 Met Leu Pro Leu Leu Ser Val Met  
 -10

TGG TCT CCT ATT GCG CCA CTC ACA GTA GGA TCC AAG GAC CCA TGC CAC 100  
 Trp Ser Pro Ile Ala Pro Leu Thr Val Gly Ser Lys Asp Pro Cys His  
 -5 1 5 10

TTT ATA CCA GTT CAT GAC GAG ATG 124  
 Phe Ile Pro Val His Asp Glu Met  
 15

## (2) INFORMATION FOR SEQ ID NO: 135:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 179 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Thyroid

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 87..155

|                                                                 |            |            |                                     |            |            |  |     |
|-----------------------------------------------------------------|------------|------------|-------------------------------------|------------|------------|--|-----|
| ATTCAAAGTA                                                      | CATTTGACAA | CCCACTGCAA | GTTGTGGCAT                          | ACATGGGTGC | CATGAACCAT |  | 60  |
| GATACCAACT                                                      | ACAGCTTTC  | GGTTCA     | ATG TGG CTT AAT TGT GGT GGC CTA CAA |            |            |  | 113 |
|                                                                 |            |            | Met Trp Leu Asn Cys Gly Gly Leu Gln | -20        | -15        |  |     |
| AGA TGG ATC ACC TGC CCA CCC ACA TTT CAT GGA TGC AGA GCT CTG TTC |            |            |                                     |            |            |  | 161 |
| Arg Trp Ile Thr Cys Pro Pro Thr Phe His Gly Cys Arg Ala Leu Phe | -10        | -5         |                                     | 1          |            |  |     |
| CCA GTA CTG GAC GCC GGG                                         |            |            |                                     |            |            |  | 179 |
| Pro Val Leu Asp Ala Gly                                         | 5          |            |                                     |            |            |  |     |

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 145 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

(vi) ORIGINAL SOURCE:  
(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Lung (cells)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 136:

|            |            |       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|------------|------------|-------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| ACTCTGCCCG | GTGGATGCTT | TCTCC | ATG | TGG | CAA | GGC | TGT | AAC | TGT | TCA | CAG | 52  |     |     |     |     |
|            |            |       | Met | Trp | Gln | Gly | Cys | Asn | Cys | Ser | Gln |     |     |     |     |     |
|            |            |       |     | -30 |     |     |     |     |     | -25 |     |     |     |     |     |     |
|            |            |       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| CTG        | TCT        | GAA   | ACA | GCA | GTG | GAC | CAG | GAG | CAG | CTT | GGA | GTT | TTA | ACT | TTC | 100 |
| Leu        | Ser        | Glu   | Thr | Ala | Val | Asp | Gln | Glu | Gln | Leu | Gly | Val | Leu | Thr | Phe |     |
|            |            |       | -20 |     |     |     | -15 |     |     |     |     |     | -10 |     |     |     |
|            |            |       |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| ATT        | TTA        | CAA   | AGA | ACA | ACA | TGT | TTG | AAT | GTT | TCA | GCA | GGC | AAG | AGG |     | 145 |
| Ile        | Leu        | Gln   | Arg | Thr | Thr | Cys | Leu | Asn | Val | Ser | Ala | Gly | Lys | Arg |     |     |
|            |            | -5    |     |     |     |     | 1   |     |     |     | 5   |     |     |     |     |     |



## (2) INFORMATION FOR SEQ ID NO: 137:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 211 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 86..196
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 3.6  
seq LVTLASKSPSCP/LH

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 137:

```

AGGGGCTGTK DGTGCTGCA GCAACACTGA CKDATACT GCAAGCTCAG TGTATTAGTC 60
AGCTCTGATA TTCTAGCATT CTTGA ATG TGT CTC CCC CAT CCC CAG GTT GTC 112
 Met Cys Leu Pro His Pro Gln Val Val
 -35 -30

TCT TCT AAT TTT CAC ATC CTC ATC TTC CTC CTG CCC ACG AAG ATG CTC 160
Ser Ser Asn Phe His Ile Leu Ile Phe Leu Leu Pro Thr Lys Met Leu
 -25 -20 -15

GTG ACA CTT CTC GCH TCA AAA TCT CCG AGT TGC CCC CTT CAC CCC CTA 208
Val Thr Leu Leu Ala Ser Lys Ser Pro Ser Cys Pro Leu His Pro Leu
 -10 -5 1

CGG
Arg
5
211

```

## (2) INFORMATION FOR SEQ ID NO: 138:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 333 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Pancreas

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 1..222

(C) IDENTIFICATION METHOD: Von Heijne matrix

(D) OTHER INFORMATION: score 3.5  
seq ECLNLLLSSGADL/RR

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 138:

|                                                                 |     |
|-----------------------------------------------------------------|-----|
| ATG CAC TTA GCT GTT CTC TTT RGA TTC TCT GAC TGT TGT CGT AAG CKT | 48  |
| Met His Leu Ala Val Leu Phe Xaa Phe Ser Asp Cys Cys Arg Lys Xaa |     |
| -70 -65 -60                                                     |     |
| CTT TCC TCA GGT CAG TTG TAC AGC ATT GTG TCT TCA CTC AGC AAT GAG | 96  |
| Leu Ser Ser Gly Gln Leu Tyr Ser Ile Val Ser Ser Leu Ser Asn Glu |     |
| -55 -50 -45                                                     |     |
| CAT GTG CTT TCA GCT GGG TTT GAC ATC AAT ACA CCT GAC AAC CTT GGC | 144 |
| His Val Leu Ser Ala Gly Phe Asp Ile Asn Thr Pro Asp Asn Leu Gly |     |
| -40 -35 -30                                                     |     |
| CGT ACC TGT CTT CAT GCT GCT GCT TCC GGA GGG AAT GTT GAA TGT CTT | 192 |
| Arg Thr Cys Leu His Ala Ala Ala Ser Gly Gly Asn Val Glu Cys Leu |     |
| -25 -20 -15                                                     |     |
| AAT TTG CTG TTG AGC AGT GGA GCT GAC TTG AGG AGG AGG GAC AAA TTT | 240 |
| Asn Leu Leu Leu Ser Ser Gly Ala Asp Leu Arg Arg Arg Asp Lys Phe |     |
| -10 -5 1 5                                                      |     |
| GGC AGG ACC CCA CTG SAC TAT GCA GCT GCT AAC GGT AGC KAC CAG TGT | 288 |
| Gly Arg Thr Pro Leu Xaa Tyr Ala Ala Asn Gly Ser Xaa Gln Cys     |     |
| 10 15 20                                                        |     |
| GCA GTA ACA TTG GTG ACT GCY GGG GCA GGT GTC AAC GAG GGC MRG     | 333 |
| Ala Val Thr Leu Val Thr Ala Gly Ala Gly Val Asn Glu Gly Xaa     |     |
| 25 30 35                                                        |     |

(2) INFORMATION FOR SEQ ID NO: 139:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 107 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Thyroid

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 9..80
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 3.5  
seq LHDCFLSVFQVLS/SI

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 139:

107

GAAGATGG ATG TCC TTC CAA TGG TGT GGC TGG CAG TGG GGT TTG CAT GAC 50  
 Met Ser Phe Gln Trp Cys Gly Trp Gln Trp Gly Leu His Asp  
 -20 -15

TGC TTC TTG TCT GTG TTT CAA GTG CTC TCA TCT ATT GGT TTG GTT TCC 98  
 Cys Phe Leu Ser Val Phe Gln Val Leu Ser Ser Ile Gly Leu Val Ser  
 -10 -5 1 5

TTT CTT TTT 107  
 Phe Leu Phe

## (2) INFORMATION FOR SEQ ID NO: 140:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 220 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Thyroid

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 50..109
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 3.5  
seq KFCLICLLTFIFH/HC

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 140:

GAGCGGAGAG GCAGATGCAC ACGGCACTCG AGTGTGAGGA AAAATAGAA ATG AAG GTA 58  
 Met Lys Val  
 -20

CAT ATG CAC ACA AAA TTT TGC CTC ATT TGT TTG CTG ACA TTT ATT TTT 106  
 His Met His Thr Lys Phe Cys Leu Ile Cys Leu Leu Thr Phe Ile Phe  
 -15 -10 -5

CAT CAT TGC AAC CAT TGC CAT GAA GAA CAT GAC CAT GGC CCT GAA GCG 154  
 His His Cys Asn His Cys His Glu Glu His Asp His Gly Pro Glu Ala  
 1 5 10 15

CTT CAC AGA YAG CAT CGT GGA ATG ACA GAA TTG GAG CCA AGC AAA TTT 202  
 Leu His Arg Xaa His Arg Gly Met Thr Glu Leu Glu Pro Ser Lys Phe  
 20 25 30

TCA AAG CAA GCC CGC GGG 220  
 Ser Lys Gln Ala Arg Gly  
 35

## (2) INFORMATION FOR SEQ ID NO: 141:

108

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 317 base pairs
  - (B) TYPE: NUCLEIC ACID
  - (C) STRANDEDNESS: DOUBLE
  - (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: CDNA
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Homo Sapiens
  - (F) TISSUE TYPE: Lung
- (ix) FEATURE:
  - (A) NAME/KEY: sig\_peptide
  - (B) LOCATION: 87..161
  - (C) IDENTIFICATION METHOD: Von Heijne matrix
  - (D) OTHER INFORMATION: score 3.5  
seq IFLGKSLFSLLEA/MI
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 141:

```

AGAGCCAGGG ACTCGGGTGC CTGGGGCAGA CGAGGCCGGC TTCTCCGCGG ACAGCTAGGG 60
AGAGTGTCTT GGGTGTCAAG CAGAAC ATG TCT TTC AAC CTG CAA TCA TCA AAG 113
 Met Ser Phe Asn Leu Gln Ser Ser Lys
 -25 -20

AAA CTG TTC ATT TTC TTA GGA AAA TCA CTG TTT AGT CTT CTG GAG GCT 161
Lys Leu Phe Ile Phe Leu Gly Lys Ser Leu Phe Ser Leu Leu Glu Ala
-15 -10 -5

ATG ATT TTT GCC TTA CTC CCA AAG CCA CGG AAG AAC GTT GCT GGT GAA 209
Met Ile Phe Ala Leu Leu Pro Lys Pro Arg Lys Asn Val Ala Gly Glu
 1 5 10 15

ATA GTC CTC ATC ACA GGT GCT GGA AGT GGA CTC GGA AGG CTC TTA GCC 257
Ile Val Leu Ile Thr Gly Ala Gly Ser Gly Leu Gly Arg Leu Leu Ala
 20 25 30

TTG CAG TTT GCC CGG CTG GGA TCT GTT CTT GTT CTC TGG GAT ATC AAT 305
Leu Gln Phe Ala Arg Leu Gly Ser Val Leu Val Leu Trp Asp Ile Asn
 35 40 45

AAG GAG GGG AGG 317
Lys Glu Gly Arg
 50

```

## (2) INFORMATION FOR SEQ ID NO: 142:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 392 base pairs
  - (B) TYPE: NUCLEIC ACID
  - (C) STRANDEDNESS: DOUBLE
  - (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: CDNA
- (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Large intestine

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 40..94  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 92  
region 1..55  
id H30111  
est

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: 15..92  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 7.6  
seq FLLLVAAPRWVS/EM

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 142:

```

GGTTTCTGAG AGTC ATG GAT CTC ATG TGC AGG AAA GTG AAG CAC CTG TTG 50
 Met Asp Leu Met Cys Arg Lys Val Lys His Leu Leu
 -25 -20 -15

TTC TTC CTC CTG CTG GTG GCG GCT CCC AGA TGG GTC GTG TCC GAA ATG 98
Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp Val Val Ser Glu Met
 -10 -5 1

CAG ATT GAG GAG TCG GGC CCA GGC CTG GTG AAG CCC TCG GAG ACC CTG 146
Gln Ile Glu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu
 5 10 15

ACC CTC ACC TGC AAT GTC TTT GGT GGC GCC ATC AAC ACT AAT GCT TAT 194
Thr Leu Thr Cys Asn Val Phe Gly Gly Ala Ile Asn Thr Asn Ala Tyr
 20 25 30

TAC TGG GCC TGG GTC CGC CAG TCC CCA GGG AAG GGT CTG GAG TGG ATT 242
Tyr Trp Ala Trp Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45 50

GGT AGT GTT TAT TAT AGT GGC AGC ACC TAC TAC AAC CCG TCC CTC AAG 290
Gly Ser Val Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys
 55 60 65

AGT CGA GTC ACC ATG TCC ATG GCC ACG TCC AGG AAT CAG TTC TCC CTG 338
Ser Arg Val Thr Met Ser Met Ala Thr Ser Arg Asn Gln Phe Ser Leu
 70 75 80

CAG ATG AGT TCT GTG ATG GCC ACA GAC ACG GCT GTC TAT TAT TGT GCG 386
Gln Met Ser Ser Val Met Ala Thr Asp Thr Ala Val Tyr Tyr Cys Ala
 85 90 95

AGA CAA
Arg Gln
100

```

## (2) INFORMATION FOR SEQ ID NO: 143:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 253 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 91..253
- (C) IDENTIFICATION METHOD: fasta
- (D) OTHER INFORMATION: identity 98.8  
region 109..271  
id HSU73682  
vrt

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 220..253
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 94  
region 1..34  
id M78620  
est

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 65..220
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 6.6  
seq FFAVLFFLRSEFX/SV

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 143:

```

ATATGANGTG CCTGGTAGAA CTTTATTTAC ATGTTAGGAA ATTTTAACAT GAGCTTTTCA 60
AGAA ATG GAA TTG AAA AGT CCA GAG GAA GAG GTT GTG GCA GCA CTG CCT 109
 Met Glu Leu Lys Ser Pro Glu Glu Glu Val Val Ala Ala Leu Pro
 -50 -45 -40

GAA GGT ATG AGA CCA GAT TCT AAT CTT TAT GGT TTT CCA TGG GAA TTG 157
Glu Gly Met Arg Pro Asp Ser Asn Leu Tyr Gly Phe Pro Trp Glu Leu
 -35 -30 -25

GTG ATA TGT GCA GCT GTT GTT GGA TTT TTT GCT GTT CTC TTT TTT TTG 205
Val Ile Cys Ala Ala Val Val Gly Phe Phe Ala Val Leu Phe Phe Leu
 -20 -15 -10

TGG AGA AGT TTT RGA TCG GTT AGG AGT CGG CTT TAT GTG GGA CGA GGG 253
Trp Arg Ser Phe Xaa Ser Val Arg Ser Arg Leu Tyr Val Gly Arg Gly
 -5 1 5 10

```

## (2) INFORMATION FOR SEQ ID NO: 144:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 407 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Thyroid

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 213..303
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 100  
region 141..231  
id AA040646  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 306..389
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 95  
region 233..316  
id AA040646  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 144..214
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 92  
region 71..141  
id AA040646  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 78..231
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 98  
region 29..182  
id HUML1879  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 147..287
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 98  
region 168..308  
id HSC0FB071  
est

## (ix) FEATURE:

- (A) NAME/KEY: other

112

(B) LOCATION: 60..113  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 98  
 region 1..54  
 id R72047  
 est

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 177..293  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 6.6  
 seq LALVLAWLSTYVA/DS

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 144:

```

CTGTCCCTGG TATAACAGCT TCCGGGAGAA GCCGGAAGAG ACCGGACCCT GAACAGAATC 60
GCAGATTGCC AGCCCTTTTC CCGACCCCTA CGGAAAGACG AGTCCAGGGG CCGTCCTGGC 120
GAGGTCAAAA CATTTAGTCT GGTCTTTTCA GCGTGGACCC TGCCAGCWGC CAGGCC ATG 179
 Met
GAG CTC TCT GAT GTC ACC CTC ATT GAG GGT GTG GGT AAT GAG GTG ATG 227
Glu Leu Ser Asp Val Thr Leu Ile Glu Gly Val Gly Asn Glu Val Met
 -35 -30 -25

GTG GTG GCA GGT GTG GTG GTG CTG ATT CTA GCC TTG GTC CTA GCT TGG 275
Val Val Ala Gly Val Val Val Leu Ile Leu Ala Leu Val Leu Ala Trp
 -20 -15 -10

CTC TCT ACC TAC GTA GCA GAC AGC GGT AGC AAC CAG CTC CTG GGC GCT 323
Leu Ser Thr Tyr Val Ala Asp Ser Gly Ser Asn Gln Leu Leu Gly Ala
 -5 1 5 10

ATT GTG TCA GCA GGC GAC ACA TCC GTC CTC CAS CTG GGG CAT GTG GAC 371
Ile Val Ser Ala Gly Asp Thr Ser Val Leu Xaa Leu Gly His Val Asp
 15 20 25

CAC CTG GTG GCA GGC CAA GGC AAC CCC GAG CGC AGG 407
His Leu Val Ala Gly Gln Gly Asn Pro Glu Arg Arg
 30 35

```

## (2) INFORMATION FOR SEQ ID NO: 145:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 353 base pairs  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Pancreas

## (ix) FEATURE:



113

(A) NAME/KEY: other  
(B) LOCATION: 167..303  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 100  
region 110..246  
id H53379  
est

(ix) FEATURE:  
(A) NAME/KEY: other  
(B) LOCATION: 57..171  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 97  
region 1..115  
id H53379  
est

(ix) FEATURE:  
(A) NAME/KEY: other  
(B) LOCATION: 308..350  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 95  
region 250..292  
id H53379  
est

(ix) FEATURE:  
(A) NAME/KEY: other  
(B) LOCATION: 64..303  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 99  
region 1..240  
id N87636  
est

(ix) FEATURE:  
(A) NAME/KEY: other  
(B) LOCATION: 167..322  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 97  
region 52..207  
id R25125  
est

(ix) FEATURE:  
(A) NAME/KEY: other  
(B) LOCATION: 115..171  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 96  
region 1..57  
id R25125  
est

(ix) FEATURE:  
(A) NAME/KEY: other  
(B) LOCATION: 94..205  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 99  
region 1..112  
id W00411  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
 (B) LOCATION: 201..302  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 98  
                           region 107..208  
                           id W00411  
                           est

## (ix) FEATURE:

(A) NAME/KEY: other  
 (B) LOCATION: 57..205  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 97  
                           region 2..150  
                           id N83940  
                           est

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 153..275  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 5.4  
                           seq RLLYIGFLGYCSG/LI

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 145:

```

AGTTTGGGCG CTGCACCGCG TCGCCGTGC CCGTGAGTCC GGCGCGCAGA GGAGGAGGAG 60
AAAGCTGACC GCTTAGGCCG GGGTAGTGGT CGTCGTGGTT TTCCTTGTAG TTCGTGGTCT 120
GAGACCAGGC CTCAAGTGGA AACGGCGTCA CC ATG ATC GCA CGG CGG AAC CCA 173
 Met Ile Ala Arg Arg Asn Pro
 -40 -35
GAA CCC TTA CGG TTT CTG CCG GAT GAG GCC CGG AGC CTG CCC CCG CCC 221
Glu Pro Leu Arg Phe Leu Pro Asp Glu Ala Arg Ser Leu Pro Pro Pro
 -30 -25 -20
AAG CTG ACC GAC CCG CGG CTC CTC TAC ATC GGC TTC TTG GGC TAC TGC 269
Lys Leu Thr Asp Pro Arg Leu Leu Tyr Ile Gly Phe Leu Gly Tyr Cys
 -15 -10 -5
TCC GGC CTG ATT GAT AAC CTG ATC CGG CGG AGG CCG ATC GCG ACG GCT 317
Ser Gly Leu Ile Asp Asn Leu Ile Arg Arg Arg Pro Ile Ala Thr Ala
 1 5 10
GGT TTG CAT CGC CAG CTT CTA TAT ATY MCG GCC GGC 353
Gly Leu His Arg Gln Leu Leu Tyr Ile Xaa Ala Gly
 15 20 25

```

## (2) INFORMATION FOR SEQ ID NO: 146:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 195 base pairs  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE

(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens

(F) TISSUE TYPE: Thyroid

(ix) FEATURE:

(A) NAME/KEY: other

(B) LOCATION: 53..191

(C) IDENTIFICATION METHOD: blastn

(D) OTHER INFORMATION: identity 100  
region 27..165  
id T96213  
est

(ix) FEATURE:

(A) NAME/KEY: other

(B) LOCATION: 40..191

(C) IDENTIFICATION METHOD: blastn

(D) OTHER INFORMATION: identity 99  
region 1..152  
id AA156832  
est

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide

(B) LOCATION: 52..123

(C) IDENTIFICATION METHOD: Von Heijne matrix

(D) OTHER INFORMATION: score 5.2  
seq VGGLILWLSVGSS/GD

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 146:

```

TTTGGCTTTA GGAATTACT CCATACCAGC TCTGAGATTT CCAGCTCAGC G ATG CCC 57
 Met Pro

CCA GGT CCC TGG GAG AGC TGC TTC TGG GTG GGG GGC CTC ATT TTG TGG 105
Pro Gly Pro Trp Glu Ser Cys Phe Trp Val Gly Gly Leu Ile Leu Trp
 -20 -15 -10

CTC AGC GTT GGA AGT TCA GGG GAT GCA CCT CCT ACC CCA CAG CCA AAG 153
Leu Ser Val Gly Ser Ser Gly Asp Ala Pro Pro Thr Pro Gln Pro Lys
 -5 1 5 10

TGC GCT GAC TTC CAG AGC GCC AAC CTT TTT GAA GGC ACT CGG 195
Cys Ala Asp Phe Gln Ser Ala Asn Leu Phe Glu Gly Thr Arg
 15 20

```

(2) INFORMATION FOR SEQ ID NO: 147:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 317 base pairs

(B) TYPE: NUCLEIC ACID

(C) STRANDEDNESS: DOUBLE

(D) TOPOLOGY: LINEAR

116

- (ii) MOLECULE TYPE: CDNA
- (vi) ORIGINAL SOURCE:  
 (A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Lung
- (ix) FEATURE:  
 (A) NAME/KEY: other  
 (B) LOCATION: 248..317  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 95  
                           region 1..70  
                           id T27030  
                           est
- (ix) FEATURE:  
 (A) NAME/KEY: other  
 (B) LOCATION: 252..317  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 95  
                           region 2..67  
                           id SSC6F01  
                           est
- (ix) FEATURE:  
 (A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 210..251  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 5  
                           seq CARALLLACSSRG/RH
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 147:

```

ACACTTCCAG CTGCTCCCTC CAAAGTTTGT CCTAGTTTCC CCCTTCCCAG CTCTCCCCAT 60
TCGCAGSCTC TTCCATCTTC AACTCTTCTT CCKKGCTVAC STCKTMCTC VTCCGATGGT 120
CTCTCCTTGG CTTCKCTCCA CSCCGCTTGC YTCTTCTCTA GTCTTTCCTT GGCCCTGGCA 180
TTAGTCTCCT TACCCGTGTC CCTGTCCCA ATG TGT GCC CGG GCT TTG CTC CTT 233
 Met Cys Ala Arg Ala Leu Leu Leu
 -10

GCG TGC AGT TCG AGG GGM AGA CAT CGT TTG GCN TGT CAG TGT TCA ACC 281
Ala Cys Ser Ser Arg Gly Arg His Arg Leu Ala Cys Gln Cys Ser Thr
 -5 1 5 10

TCA GCA ACG CCA TCA TGG GCA GCG GCA TCC TGG GGC 317
Ser Ala Thr Pro Ser Trp Ala Ala Ala Ser Trp Gly
 15 20

```

## (2) INFORMATION FOR SEQ ID NO: 148:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 367 base pairs  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens

(F) TISSUE TYPE: Lung (cells)

(ix) FEATURE:

(A) NAME/KEY: other

(B) LOCATION: 200..369

(C) IDENTIFICATION METHOD: blastn

(D) OTHER INFORMATION: identity 98  
region 109..278  
id H38087  
est

(ix) FEATURE:

(A) NAME/KEY: other

(B) LOCATION: 58..129

(C) IDENTIFICATION METHOD: blastn

(D) OTHER INFORMATION: identity 94  
region 41..112  
id H38087  
est

(ix) FEATURE:

(A) NAME/KEY: other

(B) LOCATION: 200..360

(C) IDENTIFICATION METHOD: blastn

(D) OTHER INFORMATION: identity 98  
region 63..223  
id R85713  
est

(ix) FEATURE:

(A) NAME/KEY: other

(B) LOCATION: 64..129

(C) IDENTIFICATION METHOD: blastn

(D) OTHER INFORMATION: identity 100  
region 1..66  
id R85713  
est

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide

(B) LOCATION: 44..181

(C) IDENTIFICATION METHOD: Von Heijne matrix

(D) OTHER INFORMATION: score 4.7  
seq IICCVFLLLAIVG/YV

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 148:

AAGAGAGAGC GCGG3CGGCC GCCGGGGCTG GTCGCCTGCA GGG ATG GGG GAC GAG 55  
Met Gly Asp Glu  
-45

CGG CCC CAC TAC TAC GGG AAA CAC GGA ACG CCA CAG AAG TAT GAT CCC 103  
Arg Pro His Tyr Tyr Gly Lys His Gly Thr Pro Gln Lys Tyr Asp Pro  
-40 -35 -30

118

```

ACT TTC AAA GGA CCC ATT TAC AAT AGG GGC TGC ACG GAT ATC ATA TGC 151
Thr Phe Lys Gly Pro Ile Tyr Asn Arg Gly Cys Thr Asp Ile Ile Cys
-25 -20 -15

TGT GTG TTC CTG CTC CTG GCC ATT GTG GGC TAC GTG GCT GTA GGC ATC 199
Cys Val Phe Leu Leu Leu Ala Ile Val Gly Tyr Val Ala Val Gly Ile
-10 -5 1 5

ATA GCC TGG ACT CAT GGA GAC CCT CGA AAG GTG ATC TAC CCC ACT GAC 247
Ile Ala Trp Thr His Gly Asp Pro Arg Lys Val Ile Tyr Pro Thr Asp
10 15 20

AGC CGG GGC GAG TTC TGC GGG CAG AAG GGC ACA AAA AAC GAG AAC AAA 295
Ser Arg Gly Glu Phe Cys Gly Gln Lys Gly Thr Lys Asn Glu Asn Lys
25 30 35

CCC TAT CTG TTT TAT TTC AAC ATT GTG AAA TGT GCC AGC CCC CTG GTT 343
Pro Tyr Leu Phe Tyr Phe Asn Ile Val Lys Cys Ala Ser Pro Leu Val
40 45 50

CTG CTG GAA TTC CAA TGT CCC ACT 367
Leu Leu Glu Phe Gln Cys Pro Thr
55 60

```

## (2) INFORMATION FOR SEQ ID NO: 149:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 327 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 85..328
- (C) IDENTIFICATION METHOD: fasta
- (D) OTHER INFORMATION: identity 98.8  
region 1..244  
id HSU78678  
vrt

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 85..328
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 97  
region 20..263  
id N41898  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 98..328

119

(C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 95  
                           region 38..268  
                           id H69272  
                           est

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 85..132  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 4.5  
                           seq RLLRRFLASVIS/RK

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 149:

```

CCCCCGAGG GAAGTGACGA CAGGCGTGCC CTTGACAGGC AGGGAGGGCT AGGCTGTGCA 60
TCCCTCCGCT CGCATTGCAG GGAG ATG GCT CAG CGA CTT CTT CTG AGG AGG 111
 Met Ala Gln Arg Leu Leu Leu Arg Arg
 -15 -10

TTC CTG GCC TCT GTC ATC TCC AGG AAG CCC TCT CAG GGT CAG TGG CCA 159
Phe Leu Ala Ser Val Ile Ser Arg Lys Pro Ser Gln Gly Gln Trp Pro
 -5 1 5

CCC CTC ACT TCC AGA GCC CTG CAG ACC CCA CAA TGC AGT CCT GGT GGC 207
Pro Leu Thr Ser Arg Ala Leu Gln Thr Pro Gln Cys Ser Pro Gly Gly
 10 15 20 25

CTG ACT GTA ACA CCC AAC CCA GCC CGG ACA ATA TAC ACC ACG AGG ATC 255
Leu Thr Val Thr Pro Asn Pro Ala Arg Thr Ile Tyr Thr Thr Arg Ile
 30 35 40

TCC TTG ACA ACC TTT AAT ATC CAG GAT GGA CCT GAC TTT CAA GAC CGA 303
Ser Leu Thr Thr Phe Asn Ile Gln Asp Gly Pro Asp Phe Gln Asp Arg
 45 50 55

GTG GTC AAC AGT GAG ACA CCG GCG 327
Val Val Asn Ser Glu Thr Pro Ala
 60 65

```

## (2) INFORMATION FOR SEQ ID NO: 150:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 378 base pairs  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

(A) NAME/KEY: other  
 (B) LOCATION: 203..340

120

(C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 91  
                           region 33..170  
                           id T50032  
                           est

## (ix) FEATURE:

(A) NAME/KEY: other  
 (B) LOCATION: 329..376  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 100  
                           region 160..207  
                           id T50032  
                           est

## (ix) FEATURE:

(A) NAME/KEY: other  
 (B) LOCATION: 170..210  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 97  
                           region 1..41  
                           id T50032  
                           est

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 109..177  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 4.4  
                           seq QFILLGTTSVVTA/AL

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 150:

```

AAGGTTAGGC CGGGGGGGTG CGGTCCTGGT CGGAAGGAGG HSBKWSYCG MGVVNGTCAC 60
CAGGCCTATC CTTGGCGCCA CAGTCGGCCA CCGGGGCTCG CCGCCGTC ATG GAG AGC 117
 Met Glu Ser
GGA GGG CGG CCC TCG CTG TGC CAG TTC ATC CTC CTG GGC ACC ACC TCT 165
Gly Gly Arg Pro Ser Leu Cys Gln Phe Ile Leu Leu Gly Thr Thr Ser
-20 -15 -10 -5
GTG GTC ACC GCC GCC CTG TAC TCC GTG TAC CGG CAG AAG GCC CGG GTC 213
Val Val Thr Ala Ala Leu Tyr Ser Val Tyr Arg Gln Lys Ala Arg Val
 1 5 10
TCC CAA GAG CTC AAG GGA GCT AAA AAA GTT CAT TTG GGT GAA GAT TTA 261
Ser Gln Glu Leu Lys Gly Ala Lys Lys Val His Leu Gly Glu Asp Leu
 15 20 25
AAG AGT ATT CTT TCA GAA GCT CCA GGA AAA TGC GTS CCT DAT GCT GTY 309
Lys Ser Ile Leu Ser Glu Ala Pro Gly Lys Cys Val Pro Xaa Ala Val
 30 35 40
ATA GAA GGA GCT GTG CGG TCT GTT AAA GAA ACG CTT AAC AGC CAG TTT 357
Ile Glu Gly Ala Val Arg Ser Val Lys Glu Thr Leu Asn Ser Gln Phe
 45 50 55 60
GTG GAA AAC TGC AAG GGG GAS 378
Val Glu Asn Cys Lys Gly Xaa

```



(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 267 base pairs  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: LINEAR

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Liver

[illegible][illegible]

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: 49..120  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 16.4  
seq LLLLLLLASLTSG/SV

|           |            |            |            |          |     |     |     |     |     |     |     |     |     |     |     |     |
|-----------|------------|------------|------------|----------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| AAAGCAAGC | TCAAGACCCA | GCAGTGGGAC | AGCCAGACAG | ACGGCACG | ATG | GCA | CTG | 57  |     |     |     |     |     |     |     |     |
|           |            |            |            |          | Met | Ala | Leu |     |     |     |     |     |     |     |     |     |
| AGC       | TCC        | CAG        | ATC        | TGG      | GCC | GCT | TGC | CTC | CTG | CTC | CTC | CTC | CTC | GCC | 105 |     |
| Ser       | Ser        | Gln        | Ile        | Trp      | Ala | Ala | Cys | Leu | Leu | Leu | Leu | Leu | Leu | Leu | Ala |     |
|           | -20        |            |            |          |     | -15 |     |     |     |     | -10 |     |     |     |     |     |
| AGC       | CTG        | ACC        | AGT        | GGC      | TCT | GTT | TTC | CCA | CAA | CAG | ACG | GGA | CAA | CTT | GCA | 153 |
| Ser       | Leu        | Thr        | Ser        | Gly      | Ser | Val | Phe | Pro | Gln | Gln | Thr | Gly | Gln | Leu | Ala |     |
|           | -5         |            |            |          | 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |
| GAG       | CTG        | CAA        | CCC        | CAG      | GAC | AGA | GCT | GGA | GCC | AGG | GCC | AGC | TGG | ATG | CCC | 201 |
| Gln       | Leu        | Gln        | Pro        | Gln      | Asp | Arg | Ala | Gly | Ala | Arg | Ala | Ser | Trp | Met | Pro |     |
|           |            |            | 15         |          |     |     |     | 20  |     |     |     |     | 25  |     |     |     |

122

ATG TTC CAG AGG CGA AGG AGG CGA GAC ACC CAC TTC CCC ATC TGC ATT 249  
Met Phe Gln Arg Arg Arg Arg Arg Asp Thr His Phe Pro Ile Cys Ile  
30 35 40

TTC TGC TGC GGC GCT GGG 267  
Phe Cys Cys Gly Pro Gly  
45

## (2) INFORMATION FOR SEQ ID NO: 152:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 343 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Large intestine

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 69..297
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 96  
region 25..253  
id C16912  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 181..269
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 94  
region 64..152  
id T68684  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 133..173
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 90  
region 18..58  
id T68684  
est

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 107..175
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 14.4  
seq LGLLLFLLPGSLG/AE

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 152:

123

```

ACAGGATGTG AGAGAGGAAC TGGGGTCTCC AGTCACGGGA GCCAGGAGCC GGCCAGGGCC 60
GCAGGAGNGA AGGGAGCGAG GCTGAAGGGA ACGTCGTCCT CTCAGC ATG GGG GTC 115
 Met Gly Val
CCG CGG CCT CAG CCC TGG GCG CTG GGG CTC CTG CTC TTT CTC CTT CCT 163
Pro Arg Pro Gln Pro Trp Ala Leu Gly Leu Leu Leu Phe Leu Leu Pro
-20 -15 -10 -5
GGG AGC CTG GGC GCA GAA AGC CAC CTC TCC CTC CTG TAC CAC CTT ACC 211
Gly Ser Leu Gly Ala Glu Ser His Leu Ser Leu Leu Tyr His Leu Thr
 1 5 10
GCG GTG TCC TCG CCT GCC CCG GGG ACT CCT GCC TTC TGG GTG TCC GGC 259
Ala Val Ser Ser Pro Ala Pro Gly Thr Pro Ala Phe Trp Val Ser Gly
 15 20 25
TGG CTG GGC CCG CAG CAG TAC CTG AGC TAC AAT AGC CTG CGG GGC GAG 307
Trp Leu Gly Pro Gln Gln Tyr Leu Ser Tyr Asn Ser Leu Arg Gly Glu
 30 35 40
GCG NVS NNT GTG GAG CTT GGG TCT GGG AAA ACC AGG 343
Ala Xaa Xaa Val Glu Leu Gly Ser Gly Lys Thr Arg
45 50 55

```

## (2) INFORMATION FOR SEQ ID NO: 153:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 284 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Liver

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 25..177
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 100  
region 1..153  
id T60354  
est

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 132..185
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 10.3  
seq SLLLSVLLAQVWL/VP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 153:

```

AGAGGTTCT GGGCTGCAAA GCTGAAGCTT TGGTTTCTGC TCTAAATGAA GGACTTTTCC 60

```

```

AGGACCCAAG GCCACACACT GGAAGTCTTG CAGCTGAAGG GAGGCACTCC TTGGCCTCCG 120
CAGCCGATCA C ATG AAG GTG GTG CCA AGT CTC CTG CTC TCC GTC CTC CTG 170
 Met Lys Val Val Pro Ser Leu Leu Ser Val Leu Leu
 -15 -10

GCA CAG GTG TGG CTG GTA CCC GGC TTG GCC CCC AGT CCT CAG TCG CCA 218
Ala Gln Val Trp Leu Val Pro Gly Leu Ala Pro Ser Pro Gln Ser Pro
-5 1 5 10

GAG ACC CCA GCC CCT CAG AAC CAG ACC AGC AGG GTA GTG CAG GCT CCC 266
Glu Thr Pro Ala Pro Gln Asn Gln Thr Ser Arg Val Val Gln Ala Pro
 15 20 25

AGG GAG GAA GAG GAA TGG 284
Arg Glu Glu Glu Glu Trp
 30

```

## (2) INFORMATION FOR SEQ ID NO: 154:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 607 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Pancreas

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 23..517
- (C) IDENTIFICATION METHOD: fasta
- (D) OTHER INFORMATION: identity 96.4  
region 1..495  
id S82198  
vrt

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 155..266
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 97  
region 118..229  
id T47757  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 64..155
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 95  
region 26..117  
id T47757  
est

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 23..70  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 9.5  
 seq ITVLAALLACASS/CG

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 154:

```

GGCCAGTCCT GAGCACCTAA CC ATG TTG AGC ATC ACT GTC CTC GCT GCG CTC 52
 Met Leu Ser Ile Thr Val Leu Ala Ala Leu
 -15 -10

TTG GCC TGT GCC TCC AGC TGT GGG GTG CCC AGC TTC CCG CCC AAC CTA 100
Leu Ala Cys Ala Ser Ser Cys Gly Val Pro Ser Phe Pro Pro Asn Leu
 -5 1 5 10

TCC GCC CGA GWR GTG GGA GGA GAG GAT GCC CGG CCC CAC AGC TGG CCC 148
Ser Ala Arg Xaa Val Gly Gly Glu Asp Ala Arg Pro His Ser Trp Pro
 15 20 25

TGG CAG ATC TCC CTC CAG TAC CTC AAG AAC GAC ACG TGG AGG CAT ACG 196
Trp Gln Ile Ser Leu Gln Tyr Leu Lys Asn Asp Thr Trp Arg His Thr
 30 35 40

TGT GGC GGG ACT TTG ATT GCT AGC AAC TTC GWM CTC ACT GCC GCC CAC 244
Cys Gly Gly Thr Leu Ile Ala Ser Asn Phe Xaa Leu Thr Ala Ala His
 45 50 55

TGC ATC AGC AAC ACC CGG ACC TAC CGT GTG GCC GTG GGA AAG AAC AAC 292
Cys Ile Ser Asn Thr Arg Thr Tyr Arg Val Ala Val Gly Lys Asn Asn
 60 65 70

CTG GAG GTG GAA GAC GAA GAA GGA TCC CTG TTT GTG GGT GTG GAC ACC 340
Leu Glu Val Glu Asp Glu Glu Gly Ser Leu Phe Val Gly Val Asp Thr
 75 80 85 90

ATC CAC GTC CAC AAG ASM TBG AAT GCC CKC CTG TTG CGC AAT GAT ATT 388
Ile His Val His Lys Xaa Xaa Asn Ala Xaa Leu Leu Arg Asn Asp Ile
 95 100 105

GCC CTC ATC AAG CTT GCA GAG CAT GTG GAG CTG AGT GAC ACC ATC CAG 436
Ala Leu Ile Lys Leu Ala Glu His Val Glu Leu Ser Asp Thr Ile Gln
 110 115 120

GTG GCS TGC STG CCA GAG AAG GAC TCC CTG CTC CCC AAG GAC TAC CCS 484
Val Ala Cys Xaa Pro Glu Lys Asp Ser Leu Leu Pro Lys Asp Tyr Pro
 125 130 135

TGC TAT GTC AGC CGG CTG SSG CCG CCK WCT GGA GGG GWY TCC GGT GGC 532
Cys Tyr Val Ser Arg Leu Xaa Pro Pro Xaa Gly Gly Xaa Ser Gly Gly
 140 145 150

CCA CTG AAC TGC CAG TTG GAG AAC GGT TCC TGG GAG GTG TTT GGC WTC 580
Xaa Leu Asn Cys Gln Leu Glu Asn Gly Ser Trp Glu Val Phe Gly Xaa
 155 160 165 170

GTC AGC TTT GGC TCC CGG CGG GGC TGC
Val Ser Phe Gly Ser Arg Arg Gly Cys
 607

```

## (2) INFORMATION FOR SEQ ID NO: 155:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 392 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Pancreas

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 156..267
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 97  
region 118..229  
id T47757  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 65..156
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 94  
region 26..117  
id T47757  
est

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 24..71
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 9.5  
seq ITVLAALLACASS/CG

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 155:

```

AAGCCAGTCC TGAGCACCTA ACC ATG TTG GGC ATC ACT GTC CTC GCT GCG CTC 53
 Met Leu Gly Ile Thr Val Leu Ala Ala Leu
 -15 -10

TTG GCC TGT GCC TCC AGC TGT GGG GTG CCC AGC TTC CCG CCC AAC CTA 101
Leu Ala Cys Ala Ser Ser Cys Gly Val Pro Ser Phe Pro Pro Asn Leu
 -5 1 5 10

TCC GCC CGA GTG GTG GGA GGA GAG GAT GCC CGG CCC CAC ARM TGG CCC 149
Ser Ala Arg Val Val Gly Gly Glu Asp Ala Arg Pro His Xaa Trp Pro
 15 20 25

TGG CAG ATC TCC CTC CAG TAC CTC AAG AAC GAC ACG TGG AGG CAT ACG 197
Trp Gln Ile Ser Leu Gln Tyr Leu Lys Asn Asp Thr Trp Arg His Thr
 30 35 40

```

|                                                                 |     |
|-----------------------------------------------------------------|-----|
| TGT GGC GGG ACT TTG ATT GCT AGC AAC TTC GTC CTC ACT GCC GCC CAC | 245 |
| Cys Gly Gly Thr Leu Ile Ala Ser Asn Phe Val Leu Thr Ala Ala His |     |
| 45 50 55                                                        |     |
| TGC ATC AGC RAC ACC CGG ACC TAC CGT GTG GCC GTG GGA AAG AAC AAC | 293 |
| Cys Ile Ser Xaa Thr Arg Thr Tyr Arg Val Ala Val Gly Lys Asn Asn |     |
| 60 65 70                                                        |     |
| CTG GAG GTG GAA GAC GAA GAA GGA TCC CTG TWT GTG GGT GTG GAC ACC | 341 |
| Leu Glu Val Glu Asp Glu Glu Gly Ser Leu Xaa Val Gly Val Asp Thr |     |
| 75 80 85 90                                                     |     |
| ATC CAC GTC CAC AGG AGA TGG AAT GCC CTC CTG TTG CGC AAT GAT ATT | 389 |
| Ile His Val His Arg Arg Trp Asn Ala Leu Leu Leu Arg Asn Asp Ile |     |
| 95 100 105                                                      |     |
| GCC                                                             | 392 |
| Ala                                                             |     |

## (2) INFORMATION FOR SEQ ID NO: 156:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 240 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Colon

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 102..240
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 97  
region 83..221  
id H83276  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 66..240
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 97  
region 23..197  
id H51676  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 91..240
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 95  
region 71..220  
id AA007645

128

est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 16..68  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 98  
region 1..53  
id AA007645  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 64..240  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 99  
region 74..250  
id W95024  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 119..161  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 97  
region 417..459  
id AA149660  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 19..52  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 100  
region 314..347  
id AA149660  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 66..95  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 93  
region 361..390  
id AA149660  
est

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: 85..198  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 8.8  
seq LLLPLLSLPVTTTP/WT

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 156:

AGCACTCTAG TTCAAGAGTG AAAAGTCTCA CCCAGGAGGA ACAGCCCTCC TTGAAGCAAT 60

GGCAGGGCCA GCAGGGAGGT GGGC ATG GCA GGG AAT GGA GAG AGT GAG CCA 111  
Met Ala Gly Asn Gly Glu Ser Glu Pro



129

-35

-30

|                                                                 |     |
|-----------------------------------------------------------------|-----|
| GAC AGA CTT CAC CTC CTT ACT GGA CAC AGG GTC AAG GGC GAG TTT CAA | 159 |
| Asp Arg Leu His Leu Leu Thr Gly His Arg Val Lys Gly Glu Phe Gln |     |
| -25                    -20                    -15               |     |
|                                                                 |     |
| TTG CTG CTC CCT TTA CTT TCT CTA CCT GTG ACT ACT CCC TGG ACC AAT | 207 |
| Leu Leu Leu Pro Leu Leu Ser Leu Pro Val Thr Thr Pro Trp Thr Asn |     |
| -10                    -5                    1                  |     |
|                                                                 |     |
| CCT GAG GAG GGC ACA TTT TCC AGA AGC CAC GGG                     | 240 |
| Pro Glu Glu Gly Thr Phe Ser Arg Ser His Gly                     |     |
| 5                    10                                         |     |

## (2) INFORMATION FOR SEQ ID NO: 157:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 320 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Large intestine

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: complement(241..322)
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 100  
region 27..108  
id HSBC2H071  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: complement(241..322)
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 100  
region 328..409  
id N27679  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: complement(241..322)
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 98  
region 144..225  
id W28299  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: complement(254..322)
- (C) IDENTIFICATION METHOD: blastn

130

(D) OTHER INFORMATION: identity 95  
 region 199..267  
 id C02881  
 est

## (ix) FEATURE:

(A) NAME/KEY: other  
 (B) LOCATION: complement(241..294)  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 94  
 region 111..164  
 id T60610  
 est

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 51..92  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 8.7  
 seq LWWLVLLLLPTLK/SV

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 157:

|                                                                 |     |
|-----------------------------------------------------------------|-----|
| TTTTCAGCAA CTAAAAAAGC CACAGGAGTT GAACTGCTAG GATTCTGACT ATG CTG  | 56  |
| Met Leu                                                         |     |
| TGG TGG CTA GTG CTC CTA CTC CTA CCT ACA TTA AAA TCT GTT TTT TGT | 104 |
| Trp Trp Leu Val Leu Leu Leu Leu Pro Thr Leu Lys Ser Val Phe Cys |     |
| -10 -5 1                                                        |     |
| TCT CTT GTA ACT AGC CTT TAC CTT CCT AAC ACA GAG GAT CTG TCA CTG | 152 |
| Ser Leu Val Thr Ser Leu Tyr Leu Pro Asn Thr Glu Asp Leu Ser Leu |     |
| 5 10 15 20                                                      |     |
| TGG CTC TGG CCC AAA CCT GAC CTT CAC TCT GGA ACG AGA ACA GAG GTT | 200 |
| Trp Leu Trp Pro Lys Pro Asp Leu His Ser Gly Thr Arg Thr Glu Val |     |
| 25 30 35                                                        |     |
| TCT ACC CAC ACC GTC CCC TCG AAG CCG GGG ACA GCC TCA CCT TGC TGG | 248 |
| Ser Thr His Thr Val Pro Ser Lys Pro Gly Thr Ala Ser Pro Cys Trp |     |
| 40 45 50                                                        |     |
| CCT CTC GCT GGA GCA GTG CCC TCA CCA ACT GTC TCA CGT CTG GAG GCA | 296 |
| Pro Leu Ala Gly Ala Val Pro Ser Pro Thr Val Ser Arg Leu Glu Ala |     |
| 55 60 65                                                        |     |
| CTG ACT CGG GCA GTG CAG GTA GCT                                 | 320 |
| Leu Thr Arg Ala Val Gln Val Ala                                 |     |
| 70 75                                                           |     |

## (2) INFORMATION FOR SEQ ID NO: 158:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 256 base pairs  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR

131

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Liver

(ix) FEATURE:

- (A) NAME/KEY: other  
(B) LOCATION: 114..200  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 100  
region 51..137  
id AA120830  
est

(ix) FEATURE:

- (A) NAME/KEY: other  
(B) LOCATION: 197..252  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 91  
region 135..190  
id AA120830  
est

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide  
(B) LOCATION: 98..184  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 8.5  
seq LLGLLMAACFTFC/LS

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 158:

```

AGCGTTTGCG CAGGGGGAGC TGGTCGCCGC CGCGGCCGCC TGGAAATTGTG GGAGTNGTGT 60
CTGCCACTCG GCTGCCGGAG GCGGAARGTC CGTGACT ATG GCT CCC CAR AGC CTG 115
 Met Ala Pro Gln Ser Leu
 -25
CCT TCA TCT AGG ATG GCT CCT CTG GGC ATG CTG CTT GGG CTG CTG ATG 163
Pro Ser Ser Arg Met Ala Pro Leu Gly Met Leu Leu Gly Leu Leu Met
 -20 -15 -10
GCC GCC TGC TTC ACC TTC TGC CTC AGT CAT CAG AAC CTG AAG GAG TAT 211
Ala Ala Cys Phe Thr Phe Cys Leu Ser His Gln Asn Leu Lys Glu Tyr
 -5 1 5
GCC CTG ACC AAC CCA GAK AAG ASC AGC ACC AAA GAA ACG GAA GGG 256
Ala Leu Thr Asn Pro Xaa Lys Xaa Ser Thr Lys Glu Thr Glu Gly
 10 15 20

```

(2) INFORMATION FOR SEQ ID NO: 159:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 278 base pairs  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens

(F) TISSUE TYPE: Lung

(ix) FEATURE:

(A) NAME/KEY: other

(B) LOCATION: 25..247

(C) IDENTIFICATION METHOD: blastn

(D) OTHER INFORMATION: identity 99  
region 1..223  
id T94936  
est

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide

(B) LOCATION: 69..137

(C) IDENTIFICATION METHOD: Von Heijne matrix

(D) OTHER INFORMATION: score 8.1  
seq LLLVTVSSNLAIA/IK

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 159:

AATCCAGAAT ACATTTCCAW CAAGAGCACT GGCCAAGTCA GCTTCTTCTG AGAGAGTCTC 60

TAGAAGAC ATG ATG CTA CAC TCA GCT TTG GGT CTC TGC CTC TTA CTC GTC 110

Met Met Leu His Ser Ala Leu Gly Leu Cys Leu Leu Leu Val  
-20 -15 -10

ACA GTT TCT TCC AAC CTT GCC ATT GCA ATA AAA AAG GAA AAG AGG CCT 158

Thr Val Ser Ser Asn Leu Ala Ile Ala Ile Lys Lys Glu Lys Arg Pro  
-5 1 5

CCT CAG ACA CTC TCA AGA GGA TGG GGA GAT GAC ATC ACT TGG GTA CAA 206

Pro Gln Thr Leu Ser Arg Gly Trp Gly Asp Asp Ile Thr Trp Val Gln  
10 15 20

ACT TAT GAA GAA GGT CTC TTT TAT GCT CAA AAA AGT AAG AAG CCA TTA 254

Thr Tyr Glu Gly Leu Phe Tyr Ala Gln Lys Ser Lys Lys Pro Leu  
25 30 35

ATG GTT ATT CAT CAC CTG GAC GGG 278

Met Val Ile His His Leu Asp Gly

40 45

(2) INFORMATION FOR SEQ ID NO: 160:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 290 base pairs

(B) TYPE: NUCLEIC ACID

(C) STRANDEDNESS: DOUBLE

(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

133

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Liver

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 15..203  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 99  
region 6..194  
id T55097  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 199..262  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 93  
region 189..252  
id T55097  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 22..203  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 99  
region 10..191  
id W86026  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 239..283  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 91  
region 225..269  
id W86026  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 30..283  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 96  
region 1..254  
id H49257  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 42..283  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 98  
region 1..242  
id W84512  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 35..214  
(C) IDENTIFICATION METHOD: blastn

134

(D) OTHER INFORMATION: identity 90  
region 1..180  
id T69237  
est

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: 33..110  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 7.6  
seq LITLCLVCIVANA/LL

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 160:

|                                                                 |     |
|-----------------------------------------------------------------|-----|
| AACTCACCGC CTGTCCTTCC TGACACCTCA CC ATG TGT ACG GGA AAA TGT GCC | 53  |
| Met Cys Thr Gly Lys Cys Ala                                     |     |
| -25 -20                                                         |     |
| CGC TGT GTG GGG CTC TCC CTC ATT ACC CTC TGC CTC GTC TGC ATT GTG | 101 |
| Arg Cys Val Gly Leu Ser Leu Ile Thr Leu Cys Leu Val Cys Ile Val |     |
| -15 -10 -5                                                      |     |
| GCC AAC GCC CTC CTG CTG GTA CCT AAT GGG GAG ACC TCC TGG ACC AAC | 149 |
| Ala Asn Ala Leu Leu Leu Val Pro Asn Gly Glu Thr Ser Trp Thr Asn |     |
| 1 5 10                                                          |     |
| ACC AAC CAT CTC AGC TTG CAA GTC TGG CTC ATG GGC GGC TTC ATT GGC | 197 |
| Thr Asn His Leu Ser Leu Gln Val Trp Leu Met Gly Gly Phe Ile Gly |     |
| 15 20 25                                                        |     |
| GGG GGC CTA ATG GTA CTG TGT CCG GGG ATT GCA GCC GTT CGG GCA GGG | 245 |
| Gly Gly Leu Met Val Leu Cys Pro Gly Ile Ala Ala Val Arg Ala Gly |     |
| 30 35 40 45                                                     |     |
| GGC AAG NNS TGC TGT GGT GCT GGG TGC TGT GGA AAC CGG CTG CGG     | 290 |
| Gly Lys Xaa Cys Cys Gly Ala Gly Cys Cys Gly Asn Arg Leu Arg     |     |
| 50 55 60                                                        |     |

## (2) INFORMATION FOR SEQ ID NO: 161:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 197 base pairs  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 78..192  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 95  
region 65..179

135

id T60981  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 13..75  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 92  
region 1..63  
id T60981  
est

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: 90..158  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 7.5  
seq LVLLLTPLHLMA/LL

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 161:

ACAGCGGGAG GGGACGCCAG CGCCTGCAGA GGCTGAGCAG GGAAAAAGCC AGTDCCCCAG 60  
CGGAAGCACA GCTCABBAGC TGGTCTGCC ATG GAC ATC CTG GTC CCA CTC CTG 113  
Met Asp Ile Leu Val Pro Leu Leu  
-20  
CAG CTG CTG GTG CTG CTT CTT ACC CTG CCC CTG CAC CTC ATG GCT CTG 161  
Gln Leu Leu Val Leu Leu Thr Leu Pro Leu His Leu Met Ala Leu  
-15 -10 -5 1  
CTG GGC TGC TGG CAG CCC CTG TGC AAA AGC TTT GGG 197  
Leu Gly Cys Trp Gln Pro Leu Cys Lys Ser Phe Gly  
5 10

## (2) INFORMATION FOR SEQ ID NO: 162:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 175 base pairs  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Liver

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: complement(112..142)  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 93  
region 187..217  
id AA146544  
est

136

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: complement(112..142)  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 93  
region 187..217  
id AA146541  
est

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: 107..151  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 7.5  
seq FLVLFSFFNIALC/AP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 162:

```
ATTCTTTTTT CGGACTTGA AGTTTTATG ATTAGTGTCT TTCTGGCAGA CTTCA GTGAC 60
TTTCTAGAA GCAGGTAAGA CCTAGCATGC TTTGTCCTGT GCGTTG ATG CCT TTT 115
 Met Pro Phe
 -15
TTG GTT TTG TTT TCG TTT TTT AAC ATT GCA TTA TGT GCT CCA AGG AAA 163
Leu Val Leu Phe Ser Phe Phe Asn Ile Ala Leu Cys Ala Pro Arg Lys
 -10 -5 1
TTT GCA AGA AAG 175
Phe Ala Arg Lys
 5
```

## (2) INFORMATION FOR SEQ ID NO: 163:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 383 base pairs  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Pancreas

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 49..192  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 98  
region 43..186  
id R38459  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 188..240



137

(C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 100  
 region 183..235  
 id R38459  
 est

## (ix) FEATURE:

(A) NAME/KEY: other  
 (B) LOCATION: 7..50  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 100  
 region 2..45  
 id R38459  
 est

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 60..116  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 6.8  
 seq AIVALAVCAALHA/SE

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 163:

```

AATTCCTGA TCGAACAGCC TCACTTGTGT TGCTGTCAGT GCCAGTAGGG CAGGCAGGA 59
ATG CAG CAG AGA GGA CTC GCC ATC GTG GCC TTG GCT GTC TGT GCG GCC 107
Met Gln Gln Arg Gly Leu Ala Ile Val Ala Leu Ala Val Cys Ala Ala
 -15 -10 -5

CTA CAT GCC TCA GAA GCC ATA CTT CCC ATT GCC TCC AGC TGT TGC ACG 155
Leu His Ala Ser Glu Ala Ile Leu Pro Ile Ala Ser Ser Cys Cys Thr
 1 5 10

GAG GTT TCA CAT CAT ATT TCC AGA AGG CTC CTG GAA AGA GTG AAT ATG 203
Glu Val Ser His His Ile Ser Arg Arg Leu Leu Glu Arg Val Asn Met
 15 20 25

TGT CGC ATC CAG AGA GCT GAT GGG GAT TGT GAC TTG GCT GCT GTC ATC 251
Cys Arg Ile Gln Arg Ala Asp Gly Asp Cys Asp Leu Ala Ala Val Ile
 30 35 40 45

CTT CAT GTC AAG CGC AGA AGA ATC TGT GTC AGC CCG CAC AAC CAT ACT 299
Leu His Val Lys Arg Arg Arg Ile Cys Val Ser Pro His Asn His Thr
 50 55 60

GTT AAG CAG TGG ATG AAA GTG CAA GCT GCC AAG AAA AAT GGT AAA GGA 347
Val Lys Gln Trp Met Lys Val Gln Ala Ala Lys Lys Asn Gly Lys Gly
 65 70 75

AAT GTT TGC CAC AGG AAG AAA CAC CAT GGC AAG AGG 383
Asn Val Cys His Arg Lys Lys His His Gly Lys Arg
 80 85

```

## (2) INFORMATION FOR SEQ ID NO: 164:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 352 base pairs

(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Lung

(ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 2..354  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 99  
region 2..354  
id HUM517F10B  
est

(ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 75..230  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 100  
region 1..156  
id H04128  
est

(ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 225..343  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 98  
region 152..270  
id H04128  
est

(ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 309..354  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 97  
region 1..46  
id AA099288  
est

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: 29..88  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 6.8  
seq GLLWMLFVSELRA/AT

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 164:

AAVCAGTTGG AGCTGGTGCA CAGGAAGG ATG AGG AAG ACC AGG CTC TGG GGG 52  
Met Arg Lys Thr Arg Leu Trp Gly  
-20 -15

CTG CTG TGG ATG CTC TTT GTC TCA GAA CTC CGA GCT GCA ACT AAA TTA 100

139

```

Leu Leu Trp Met Leu Phe Val Ser Glu Leu Arg Ala Ala Thr Lys Leu
 -10 -5 1
ACT GAG GAA AAG TAT GAA CTG AAA GAG GGG CAG ACC CTG GAT GTG AAA 148
Thr Glu Glu Lys Tyr Glu Leu Lys Glu Gly Gln Thr Leu Asp Val Lys
 5 10 15 20
TGT GAC TAC ACG CTA GAG AAG TTT GCC AGC AGC CAG AAA GCT TGG CAG 196
Cys Asp Tyr Thr Leu Glu Lys Phe Ala Ser Ser Gln Lys Ala Trp Gln
 25 30 35
ATA ATA AGG GAC GGA GAG ATG CCC AAG ACC CTG GCA TGC ACA GAG AGG 244
Ile Ile Arg Asp Gly Glu Met Pro Lys Thr Leu Ala Cys Thr Glu Arg
 40 45 50
CCT TCA AAG AAT TCC CAT CCA GTC CAA GTG GGG AGG ATC ATA CTA GAA 292
Pro Ser Lys Asn Ser His Pro Val Gln Val Gly Arg Ile Ile Leu Glu
 55 60 65
GAC TAC CAT GAT CAT GGT TTA CTG CGC GTC CGA ATG GTC AAC CTT CAA 340
Asp Tyr His Asp His Gly Leu Leu Arg Val Arg Met Val Asn Leu Gln
 70 75 80
GTG VAA GAT TCT
Val Xaa Asp Ser
 85

```

## (2) INFORMATION FOR SEQ ID NO: 165:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 293 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Thyroid

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 36..241
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 98  
region 1..206  
id T08694  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 33..233
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 98  
region 1..201  
id AA095665  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
 (B) LOCATION: 56..241  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 97  
                           region 18..203  
                           id R35300  
                           est

## (ix) FEATURE:

(A) NAME/KEY: other  
 (B) LOCATION: 97..211  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 98  
                           region 1..115  
                           id AA093039  
                           est

## (ix) FEATURE:

(A) NAME/KEY: other  
 (B) LOCATION: 118..292  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 95  
                           region 1..175  
                           id HSC1GA121  
                           est

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 102..167  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 6.8  
                           seq VSLVLLMPGPCDG/LF

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 165:

```

CTCACTTCTG CCTGAATTGG GAAGCGCTGC AAGGACAACC GGCTGGGGTC CTTGCGCGCC 60
GCGGCTCAGG GAGGAGCACC GACTGCGCCG CACCCTGAGA G ATG GTT GGT GCC ATG 116
 Met Val Gly Ala Met
 -20

TGG AAG GTG ATT GTT TCG CTG GTC CTG TTG ATG CCT GGC CCC TGT GAT 164
Trp Lys Val Ile Val Ser Leu Val Leu Leu Met Pro Gly Pro Cys Asp
 -15 -10 -5

GGG CTG TTT CGC TCC CTA TAC AGA AGT GTT BBC ATG CCA CCT AAG GGA 212
Gly Leu Phe Arg Ser Leu Tyr Arg Ser Val Xaa Met Pro Pro Lys Gly
 1 5 10 15

GAC TCA GGA CAG CCA TTA TTT CTC ACC CCT TAC ATT GAA GCT GGG AAG 260
Asp Ser Gly Gln Pro Leu Phe Leu Thr Pro Tyr Ile Glu Ala Gly Lys
 20 25 30

ATC CAA AAA GGN AGA GAA YNN RGT TTG GTC GGG 293
Ile Gln Lys Gly Arg Glu Xaa Xaa Leu Val Gly
 35 40

```

141

## (2) INFORMATION FOR SEQ ID NO: 166:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 263 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: complement(1..158)
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 98  
region 160..317  
id N66156  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: complement(155..262)
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 99  
region 55..162  
id N66156  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 167..262
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 96  
region 8..103  
id HUMGS02822  
est

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 81..200
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 6.1  
seq ICIGILVLPFIRC/CC

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 166:

```

AAGAATAGGA TNATTCACGT GTAATAATAG AGTCATTAAG AAATATTAAG CATTGCAGCT 60
AAAAATTGAA CAACCTGTGA ATG ATA CAT TTA AGA ATT ATT CAA AGG TGC TAC 113
 Met Ile His Leu Arg Ile Ile Gln Arg Cys Tyr
 -40 -35 -30

ATG GCA GGG TTA GAG AAT AAA AAG AAC GTG GTG TTT GAA GCA AAA CAG 161
Met Ala Gly Leu Glu Asn Lys Lys Asn Val Val Phe Glu Ala Lys Gln
 -25 -20 -15

```

142

|                                                                 |     |
|-----------------------------------------------------------------|-----|
| ATC TGT ATT GGC ATC TTG GTT CTC CCT TTT ATC AGA TGT TGT TGC CTT | 209 |
| Ile Cys Ile Gly Ile Leu Val Leu Pro Phe Ile Arg Cys Cys Cys Leu |     |
| -10 -5 1                                                        |     |
| GTG CAA ATC ACA TTT TCT CTG AGT CTC CAT TTT CTC ATT TAT AAC ATG | 257 |
| Val Gln Ile Thr Phe Ser Leu Ser Leu His Phe Leu Ile Tyr Asn Met |     |
| 5 10 15                                                         |     |
| CGG CGG                                                         | 263 |
| Arg Arg                                                         |     |
| 20                                                              |     |

## (2) INFORMATION FOR SEQ ID NO: 167:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 347 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 61..344
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 98  
region 18..301  
id H73135  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 49..109
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 100  
region 1..61  
id AA251602  
est

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 54..119
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5.9  
seq LIYILWQLTGSAA/SG

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 167:

|                                                                 |     |
|-----------------------------------------------------------------|-----|
| AATACCTAAG AGGGAAGTGG CTTCAATTCA GTGGCTGACT TCCAGAGAGC AAT ATG  | 56  |
| Met                                                             |     |
| GCT GGT TCC CCA ACA TGC CTC ACC CTC ATC TAT ATC CTT TGG CAG CTC | 104 |
| Ala Gly Ser Pro Thr Cys Leu Thr Leu Ile Tyr Ile Leu Trp Gln Leu |     |

143

| -20                                                             | -15 | -10 |     |
|-----------------------------------------------------------------|-----|-----|-----|
| ACA GGG TCA GCA GCC TCT GGA CCC GTG AAA GAG CTG GTC GGT TCC GTT |     |     | 152 |
| Thr Gly Ser Ala Ala Ser Gly Pro Val Lys Glu Leu Val Gly Ser Val |     |     |     |
| -5                                                              | 1   | 5   | 10  |
| GGT GGG GCC GTG ACT TTC CCC CTG AAG TCC AAA GTA AAG CAA GTC GAC |     |     | 200 |
| Gly Gly Ala Val Thr Phe Pro Leu Lys Ser Lys Val Lys Gln Val Asp |     |     |     |
| 15                                                              | 20  | 25  |     |
| TCT ATT GTC TGG ACC TTC AAC ACA ACC CCT CTT GTC ACC ATA CAG CCA |     |     | 248 |
| Ser Ile Val Trp Thr Phe Asn Thr Thr Pro Leu Val Thr Ile Gln Pro |     |     |     |
| 30                                                              | 35  | 40  |     |
| GAA GGG GGC ACT ATC ATA GTG ACC CAA AAT CGT AAT AGG GAG AGA GTA |     |     | 296 |
| Glu Gly Gly Thr Ile Ile Val Thr Gln Asn Arg Asn Arg Glu Arg Val |     |     |     |
| 45                                                              | 50  | 55  |     |
| GAC TTC CCA GAT GGA GGC TAC TCC CTG AAG CTC AGC AAA CTG AAG AAG |     |     | 344 |
| Asp Phe Pro Asp Gly Gly Tyr Ser Leu Lys Leu Ser Lys Leu Lys Lys |     |     |     |
| 60                                                              | 65  | 70  | 75  |
| GGG                                                             |     |     | 347 |
| Gly                                                             |     |     |     |

## (2) INFORMATION FOR SEQ ID NO: 168:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 394 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Thyroid

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 86..206
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 100  
region 81..201  
id AA159880  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 5..85
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 100  
region 1..81  
id AA159880  
est

## (ix) FEATURE:

- (A) NAME/KEY: other

144

(B) LOCATION: 244..309  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 100  
 region 239..304  
 id AA159880  
 est

## (ix) FEATURE:

(A) NAME/KEY: other  
 (B) LOCATION: 239..354  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 94  
 region 1..116  
 id AA109004  
 est

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 56..232  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 5.7  
 seq ALLDLCAAPXGWL/QV

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 168:

|                                                                  |     |
|------------------------------------------------------------------|-----|
| AAGTGTGGAG AAAGCGGCTC TGGGTCTAGA TTGAGGGATA CTCCCCCTTT CCACC ATG | 58  |
| Met                                                              |     |
| GGC AAG AAG GGC AAA GTT GGC AAG AGC CGA CGA GAC AAG TTT TAT CAC  | 106 |
| Gly Lys Lys Gly Lys Val Gly Lys Ser Arg Arg Asp Lys Phe Tyr His  |     |
| -55 -50 -45                                                      |     |
| TTG GCG AAG GAG ACG GGT TAC CGT TCC CGA TCT GCT TTC AAG CTG ATC  | 154 |
| Leu Ala Lys Glu Thr Gly Tyr Arg Ser Arg Ser Ala Phe Lys Leu Ile  |     |
| -40 -35 -30                                                      |     |
| CAG CTC AAT CGC CGC TTT CAG TTC CTG CAG AAA GCC CGA GCC TTG CTG  | 202 |
| Gln Leu Asn Arg Arg Phe Gln Phe Leu Gln Lys Ala Arg Ala Leu Leu  |     |
| -25 -20 -15                                                      |     |
| GAC CTG TGT GCT GCG CCA SGG GGA TGG CTG CAG GTA GCT GCC AAG TTT  | 250 |
| Asp Leu Cys Ala Ala Pro Xaa Gly Trp Leu Gln Val Ala Ala Lys Phe  |     |
| -10 -5 1 5                                                       |     |
| ATG CCT GTA TCC AGC CTT ATT GTG GGA GTG GAC CTG GTT CCA ATC AAG  | 298 |
| Met Pro Val Ser Ser Leu Ile Val Gly Val Asp Leu Val Pro Ile Lys  |     |
| 10 15 20                                                         |     |
| CCT CTC CCC AAT GTG GTG ACT CTC CAG GAG GAC ATC ACA ACA GAA CGT  | 346 |
| Pro Leu Pro Asn Val Val Thr Leu Gln Glu Asp Ile Thr Thr Glu Arg  |     |
| 25 30 35                                                         |     |
| TGT ARG CAA AGG CAC TGG ACA TCA GCC TCA GCT CTG GAR AGG AAG ATG  | 394 |
| Cys Xaa Gln Arg His Trp Thr Ser Ala Ser Ala Leu Glu Arg Lys Met  |     |
| 40 45 50                                                         |     |

## (2) INFORMATION FOR SEQ ID NO: 169:



- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 299 base pairs
  - (B) TYPE: NUCLEIC ACID
  - (C) STRANDEDNESS: DOUBLE
  - (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: CDNA
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Homo Sapiens
  - (D) DEVELOPMENTAL STAGE: Fetal
  - (F) TISSUE TYPE: liver
- (ix) FEATURE:
  - (A) NAME/KEY: other
  - (B) LOCATION: 22..296
  - (C) IDENTIFICATION METHOD: blastn
  - (D) OTHER INFORMATION: identity 96  
region 68..342  
id R21563  
est
- (ix) FEATURE:
  - (A) NAME/KEY: other
  - (B) LOCATION: 23..176
  - (C) IDENTIFICATION METHOD: blastn
  - (D) OTHER INFORMATION: identity 95  
region 1..154  
id R23529  
est
- (ix) FEATURE:
  - (A) NAME/KEY: other
  - (B) LOCATION: 158..296
  - (C) IDENTIFICATION METHOD: blastn
  - (D) OTHER INFORMATION: identity 94  
region 135..273  
id R23529  
est
- (ix) FEATURE:
  - (A) NAME/KEY: other
  - (B) LOCATION: 3..271
  - (C) IDENTIFICATION METHOD: blastn
  - (D) OTHER INFORMATION: identity 98  
region 1..269  
id HSC2LG091  
est
- (ix) FEATURE:
  - (A) NAME/KEY: other
  - (B) LOCATION: 22..179
  - (C) IDENTIFICATION METHOD: blastn
  - (D) OTHER INFORMATION: identity 94  
region 68..225  
id R20326  
est
- (ix) FEATURE:
  - (A) NAME/KEY: other
  - (B) LOCATION: 180..262

146

(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 97  
region 224..306  
id R20326  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 198..296  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 97  
region 168..266  
id T77109  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 26..78  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 90  
region 5..57  
id T77109  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 78..108  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 96  
region 56..86  
id T77109  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 115..145  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 96  
region 91..121  
id T77109  
est

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: 75..170  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 5.7  
seq FGLVXVGTALALA/RK

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 169:

```
AACGGAGGGC CAGAGAGTCA CGGCGGTTTT CGTAACACCC CAGGGCCTGT AAGGTTTGGT 60
GTTTCCTTTT CAAG ATG CCA CTT TCA GAC TTT ATT CTG GCT CTK AAG GAC 110
 Met Pro Leu Ser Asp Phe Ile Leu Ala Leu Lys Asp
 -30 -25

AAT CCC TAC TTT GGG GCT GGA TTT GGG CTG GTG WGT GTG GGC ACA GCC 158
Asn Pro Tyr Phe Gly Ala Gly Phe Gly Leu Val Xaa Val Gly Thr Ala
-20 -15 -10 -5
```

```

CTG GCC CTG GCC CGG AAG GGT GTC CAA CTG GGC CTG GTG GCA TTC CGG 206
Leu Ala Leu Ala Arg Lys Gly Val Gln Leu Gly Leu Val Ala Phe Arg
 1 5 10

CGC CAT TAC ATG ATC ACA CTG GAA GTC CCT GCT CGA GAC AGG AGC TAT 254
Arg His Tyr Met Ile Thr Leu Glu Val Pro Ala Arg Asp Arg Ser Tyr
 15 20 25

GSC TGG TTG CTT AGC TGG CTC ACC CGC CAC AGT ACC CGT ACT GGG 299
Xaa Trp Leu Leu Ser Trp Leu Thr Arg His Ser Thr Arg Thr Gly
 30 35 40

```

## (2) INFORMATION FOR SEQ ID NO: 170:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 359 base pairs

(B) TYPE: NUCLEIC ACID

(C) STRANDEDNESS: DOUBLE

(D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens

(F) TISSUE TYPE: Large intestine

## (ix) FEATURE:

(A) NAME/KEY: other

(B) LOCATION: 321..358

(C) IDENTIFICATION METHOD: blastn

(D) OTHER INFORMATION: identity 92  
region 241..278  
id SSC1D10  
est

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide

(B) LOCATION: 81..137

(C) IDENTIFICATION METHOD: Von Heijne matrix

(D) OTHER INFORMATION: score 5.6  
seq WVFLVAIIKGVQC/QA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 170:

```

ACCTCTGGGA GAAGMRTCCC AGCCCCAGAA TTCCCAGGAG TCTCCGTTCTG GTGATCAGCA 60
CTGAACACCGG AGGACTCACC ATG GAG TTT GGG CTG AGC TGG GTT TTC CTC GTT 113
 Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val
 -15 -10

GCT ATT ATA AAA GGT GTC CAG TGT CAG GCA CAG CTC GAG GAA TCT GGG 161
Ala Ile Ile Lys Gly Val Gln Cys Gln Ala Gln Leu Glu Ser Gly
 -5 1 5

GGA GGC TTG GTC CAG CCT GGA GGG TCC CTG AGA CTC TCA TGT AGA GGT 209
Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Arg Gly
 10 15 20

```

```

TCT GGA TTC ACC CTC AGT GAC CAC TAC ATG AGT TGG ATC CGC CAG TCC 257
Ser Gly Phe Thr Leu Ser Asp His Tyr Met Ser Trp Ile Arg Gln Ser
 25 30 35 40

CCT GGG AAG GGA MTG MAG TGG GTC GCC TAT ATC AGT TAC AGT GGT TCA 305
Pro Gly Lys Gly Xaa Xaa Trp Val Ala Tyr Ile Ser Tyr Ser Gly Ser
 45 50 55

ACC ATT TAT TAT GGG GAC TCT GTG GAC GGC CGA TTC ACC ATC TCC AGG 353
Thr Ile Tyr Tyr Gly Asp Ser Val Asp Gly Arg Phe Thr Ile Ser Arg
 60 65 70

GAC AAT
Asp Asn
 359

```

## (2) INFORMATION FOR SEQ ID NO: 171:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 177 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 145..176
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 90  
region 56..87  
id N87931  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 145..176
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 90  
region 287..318  
id C17084  
est

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 46..108
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5.3  
seq SLFSSLPIFLTWA/HI

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 171:

```

CAGGCCTTGT TCGGCATATT TGTCTCTTTA AAACACCCAT TCTTC ATG ATT TTA AGG 57

```

149

Met Ile Leu Arg  
-20

[illegible]

(2) INFORMATION FOR SEO ID NO: 172:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 188 base pairs  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Colon

(ix) FEATURE:

- (A) NAME/KEY: other  
(B) LOCATION: 21..137  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 96  
region 178..294  
id AA148442  
est

(ix) FEATURE:

- (A) NAME/KEY: other  
(B) LOCATION: 144..184  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 97  
region 303..343  
id AA148442  
est

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide  
(B) LOCATION: 99..146  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 5  
seq GLMEVKLVNPCSG/EG

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 172:

AAGGGCGGCA TGGCSCTGGC GTGGACTGCG GGGACGGGGT TGGCGCCCGG CAGCACGTGT 60

150

TCCTGGTTTC AGAATATTTA AAAGATGCTT CAAAGAAG ATG AAA AAT GGG CTA ATG 116  
Met Lys Asn Gly Leu Met  
-15

TTT GTA AAA CTG GTT AAC CCC TGT TCA GGA GAA GGA GCC ATT TAC TTG 164  
Phe Val Lys Leu Val Asn Pro Cys Ser Gly Glu Gly Ala Ile Tyr Leu  
-10 -5 1 5

TTC AAT ATG TGT CTA CAG CAG CGG 188  
Phe Asn Met Cys Leu Gln Gln Arg  
10

## (2) INFORMATION FOR SEQ ID NO: 173:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 182 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 37..181
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 95  
region 17..161  
id W24468  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 62..181
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 100  
region 3..122  
id W38688  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 62..181
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 97  
region 3..122  
id W80906  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 71..181
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 100  
region 1..111

151

id AA213429  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 71..181  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 100  
region 3..113  
id AA054464  
est

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: 66..110  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 4.9  
seq AVVFVFSLLDCCA/LI

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 173:

```
TTCAGGGGTG GGTCTGGGGCA TCCGAGCGGG TTTGACGGAA GGAGCGGCGG.CGACGGAGGA 60
GGAGG ATG GAG GCG GTG GTG TTC GTC TTC TCT CTC CTC GAT TGT TGC GCG 110
 Met Glu Ala Val Val Phe Val Phe Ser Leu Leu Asp Cys Cys Ala
 -15 -10 -5

CTC ATC TTC CTC TCG GTC TAC TTC ATA ATT ACA TTG TCT GAT TTA GAA 158
Leu Ile Phe Leu Ser Val Tyr Phe Ile Ile Thr Leu Ser Asp Leu Glu
 1 5 10 15

TGT GAT TAC ATT AAT GCT AGA TCG 182
Cys Asp Tyr Ile Asn Ala Arg Ser
 20
```

## (2) INFORMATION FOR SEQ ID NO: 174:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 349 base pairs  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Pancreas

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 141..310  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 100  
region 118..287  
id W25106  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 22..105  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 100  
region 1..84  
id W25106  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 107..136  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 100  
region 85..114  
id W25106  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 142..351  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 99  
region 121..330  
id N31560  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 24..112  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 96  
region 1..89  
id N31560  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 36..351  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 98  
region 1..316  
id W17036  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 141..351  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 99  
region 105..315  
id AA039274  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 37..112  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 97  
region 1..76  
id AA039274



153

est

## (ix) FEATURE:

(A) NAME/KEY: other  
 (B) LOCATION: complement(107..299)  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 98  
 region 236..428  
 id W72617  
 est

## (ix) FEATURE:

(A) NAME/KEY: other  
 (B) LOCATION: complement(32..105)  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 97  
 region 432..505  
 id W72617  
 est

## (ix) FEATURE:

(A) NAME/KEY: other  
 (B) LOCATION: complement(321..351)  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 96  
 region 181..211  
 id W72617  
 est

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 164..331  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 4.7  
 seq FACVPGASXTTLA/FP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 174:

```

AGTTGCCAGA AGGGGCGGGA CCTGCAACGT CCGACAGAAC GAGGGGACGT AACGGAGGCA 60
GGTTGGAGCC GCTGCCGTCG CCATGACCCG CGGTAACCAG CGTGACTCGC CCGCCAGAAG 120
AATATGAAAA AGCAGAGCGA CTCGGTTAAG GGAAAGCGCC GAG ATG ACG GGC TTT 175
 Met Thr Gly Phe
 -55

CTG CTG CCG CCC GCA AGC AGA GGG ACT CGG AGA TCA TGC AGC AGA AGC 223
Leu Leu Pro Pro Ala Ser Arg Gly Thr Arg Arg Ser Cys Ser Arg Ser
 -50 -45 -40

AGA AAA AGG CAA ACG AGA AGA AGG AGG AAC CCA AGT AGC TTT GTG GCT 271
Arg Lys Arg Arg Gln Thr Arg Arg Arg Arg Asn Pro Ser Ser Phe Val Ala
 -35 -30 -25

TCG TGT CCA ACC CTC TTG CCC TTC GCC TGT GTG CCT GGA GCC AGT BCC 319
Ser Cys Pro Thr Leu Leu Pro Phe Ala Cys Val Pro Gly Ala Ser Xaa
 -20 -15 -10 -5

ACC ACG CTC GCG TTT CCT CCT GTA GTG CTC 349
Thr Thr Leu Ala Phe Pro Pro Val Val Leu

```

## (2) INFORMATION FOR SEQ ID NO: 175:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 273 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Colon

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 42..271
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 96  
region 1..230  
id R20112  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 79..271
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 92  
region 91..283  
id W35748  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 108..222
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 93  
region 78..192  
id AA074652  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 31..81
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 100  
region 1..51  
id AA074652  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 222..271
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 100  
region 191..240  
id AA074652

155

est

## (ix) FEATURE:

(A) NAME/KEY: other  
 (B) LOCATION: 79..271  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 91  
 region 91..283  
 id W35757  
 est

## (ix) FEATURE:

(A) NAME/KEY: other  
 (B) LOCATION: 79..271  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 92  
 region 93..285  
 id W74958  
 est

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 94..150  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 4.5  
 seq SVPLLTDAATVSG/AE

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 175:

```

AAAGAGTGTG TCTGCGGGAG AAAGAGGAGA ATCGCCCAAG CGGCCTCGGA AGTCCCAGGG 60
AGTGGAGGCC CCCGCCGTGG AGCCGTGTGG TGT ATG TGT GGT AAC ACC ATG TCT 114
 Met Cys Gly Asn Thr Met Ser
 -15

GTG CCC CTG CTC ACC GAT GCT GCC ACC GTG TCT GGA GCT GAG CGG GAA 162
Val Pro Leu Leu Thr Asp Ala Ala Thr Val Ser Gly Ala Glu Arg Glu
 -10 -5 1

ACG GCC GCG GTT ATT TTT TTA CAT GGA CTT GGA GAC ACA GGG CAC AGC 210
Thr Ala Ala Val Ile Phe Leu His Gly Leu Gly Asp Thr Gly His Ser
 5 10 15 20

TGG GCT GAC GCC CTC TCC ACC ATC CGG CTC CCT CAC GTC AAG TAC ATC 258
Trp Ala Asp Ala Leu Ser Thr Ile Arg Leu Pro His Val Lys Tyr Ile
 25 30 35

TGT CCC CAT GCG CGG 273
Cys Pro His Ala Arg
 40

```

## (2) INFORMATION FOR SEQ ID NO: 176:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 371 base pairs  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR

- (ii) MOLECULE TYPE: CDNA
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Homo Sapiens
  - (F) TISSUE TYPE: Large intestine
- (ix) FEATURE:
  - (A) NAME/KEY: other
  - (B) LOCATION: complement(53..194)
  - (C) IDENTIFICATION METHOD: blastn
  - (D) OTHER INFORMATION: identity 98  
region 178..319  
id R00081  
est
- (ix) FEATURE:
  - (A) NAME/KEY: other
  - (B) LOCATION: complement(202..322)
  - (C) IDENTIFICATION METHOD: blastn
  - (D) OTHER INFORMATION: identity 98  
region 52..172  
id R00081  
est
- (ix) FEATURE:
  - (A) NAME/KEY: other
  - (B) LOCATION: complement(322..372)
  - (C) IDENTIFICATION METHOD: blastn
  - (D) OTHER INFORMATION: identity 92  
region 3..53  
id R00081  
est
- (ix) FEATURE:
  - (A) NAME/KEY: other
  - (B) LOCATION: complement(202..322)
  - (C) IDENTIFICATION METHOD: blastn
  - (D) OTHER INFORMATION: identity 98  
region 76..196  
id T53389  
est
- (ix) FEATURE:
  - (A) NAME/KEY: other
  - (B) LOCATION: complement(104..194)
  - (C) IDENTIFICATION METHOD: blastn
  - (D) OTHER INFORMATION: identity 98  
region 202..292  
id T53389  
est
- (ix) FEATURE:
  - (A) NAME/KEY: other
  - (B) LOCATION: complement(322..372)
  - (C) IDENTIFICATION METHOD: blastn
  - (D) OTHER INFORMATION: identity 92  
region 27..77  
id T53389  
est

(ix) FEATURE:  
(A) NAME/KEY: other  
(B) LOCATION: complement(70..105)  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 100  
region 292..327  
id T53389  
est

(ix) FEATURE:  
(A) NAME/KEY: other  
(B) LOCATION: complement(247..322)  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 98  
region 70..145  
id R50426  
est

(ix) FEATURE:  
(A) NAME/KEY: other  
(B) LOCATION: complement(322..372)  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 92  
region 21..71  
id R50426  
est

(ix) FEATURE:  
(A) NAME/KEY: other  
(B) LOCATION: complement(202..248)  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 97  
region 145..191  
id R50426  
est

(ix) FEATURE:  
(A) NAME/KEY: other  
(B) LOCATION: 3..194  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 96  
region 1..192  
id H26655  
est

(ix) FEATURE:  
(A) NAME/KEY: other  
(B) LOCATION: complement(225..322)  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 96  
region 71..168  
id R52030  
est

(ix) FEATURE:  
(A) NAME/KEY: other  
(B) LOCATION: complement(322..372)  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 92  
region 22..72  
id R52030

158

est

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 189..317
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.3  
seq SLWRLQWLKDASC/DP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 176:

```

CCGTGAGTCG TACACTTGAT GGCTCCCTGC TAGTCCGCCA GAAGGCAGAG GTCCAGGTGW 60
GGCTTGGAGC CAATGGGAAG GTGGCTGTGA TTGTCAGCAA TGACCATGCT GGGAAACTGT 120
GTGGGGCCTG TGGAAACTTT GACGGGGACC AGACCAATGA TTGGCATGAC TCCCAGGAGA 180
AGCCAGCG ATG GWG DGG ATS CSA GAG CGC AGG ACT TCT CCC CAT GTT ATG 230
 Met Xaa Xaa Xaa Xaa Glu Arg Arg Thr Ser Pro His Val Met
 -40 -35 -30

GCT GAT CAG TCA TCC ACC AGG AAC GAA GAT TTC CTG AAG AAG ACC TGG 278
Ala Asp Gln Ser Thr Arg Asn Glu Asp Phe Leu Lys Lys Thr Trp
 -25 -20 -15

TCC CTC TGG AGG TTG CAG TGG CTG AAG GAT GCA TCA TGT GAT CCC TAC 326
Ser Leu Trp Arg Leu Gln Trp Leu Lys Asp Ala Ser Cys Asp Pro Tyr
 -10 -5 1

CCT GCT CTA CCS MTT TTC TGG GYM ACA GAG GCC AAA TGT GAG AGC 371
Pro Ala Leu Pro Xaa Phe Trp Xaa Thr Glu Ala Lys Cys Glu Ser
 5 10 15

```

## (2) INFORMATION FOR SEQ ID NO: 177:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 329 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Pancreas

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 238..329
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 90  
region 18..109  
id T29009  
est

## (ix) FEATURE:

- (A) NAME/KEY: other

159

(B) LOCATION: 238..329  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 90  
                           region 13..104  
                           id R01547  
                           est

## (ix) FEATURE:

(A) NAME/KEY: other  
 (B) LOCATION: 238..329  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 90  
                           region 46..137  
                           id T91432  
                           est

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 249..290  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 3.8  
                           seq FLLNCIVAVSQN/MG

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 177:

```

AAAAAAAGG CTGATACTTC CCAGGACGCG GAGGTAACGG GCCAGGGCCA AAGCGACTTT 60
CGCTACTTGG ATTGGTCGGC GTAGTTTGGG CGGCCGGACC TTAGAAAGTC ACACATCTGC 120
GCGCCTGTGC GGCCCTGCT TCTGCGGATG CTGAGGCACG TAAAAAAATT TGAAGAAGGG 180
AATTCGCGG CATTCTTGGC CTGGCTTCCT GCGGTACASC AAGTTCGGAG GTGTTAACCG 240
CTGCTGTC ATG TTT CTT TTG CTA AAC TGC ATC GTC GCT GTG TCC CAA AAC 290
 Met Phe Leu Leu Asn Cys Ile Val Ala Val Ser Gln Asn
 -10 -5

ATG GGC ATC GGC AAG AAC GGG GAC CTG CCS VGG CCG CAG 329
Met Gly Ile Gly Lys Asn Gly Asp Leu Pro Xaa Pro Gln
 1 5 10

```

## (2) INFORMATION FOR SEQ ID NO: 178:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 194 base pairs  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Lung

## (ix) FEATURE:

(A) NAME/KEY: other  
 (B) LOCATION: complement(163..192)

160

(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 90  
region 175..204  
id H33662  
est

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: 15..56  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 3.8  
seq LLVSAAPLGFGQG/VW

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 178:

|                                                                 |     |
|-----------------------------------------------------------------|-----|
| AGGTTGTTTA CTGA ATG CTT CTG GTA TCT GCA GCC CCG CTG GGG TTC GGA | 50  |
| Met Leu Leu Val Ser Ala Ala Pro Leu Gly Phe Gly                 |     |
| -10 -5                                                          |     |
| CAG GGG GTC TGG AAT AGG GCT TCA CAA CTA CAG CAG GGC TAS GAC CCT | 98  |
| Gln Gly Val Trp Asn Arg Ala Ser Gln Leu Gln Gln Gly Xaa Asp Pro |     |
| 1 5 10                                                          |     |
| CTT GGG GCT GGA AGG AGC TGG AGA GGC CTC TGC AAG CTG TCA CAG GCT | 146 |
| Leu Gly Ala Gly Arg Ser Trp Arg Gly Leu Cys Lys Leu Ser Gln Ala |     |
| 15 20 25 30                                                     |     |
| CTT GGT GCT GGC ACT GGC TCA GGC TTT CAC ACA CAC ACA CGC GCA CCA | 194 |
| Leu Gly Ala Gly Thr Gly Ser Gly Phe His Thr His Thr Arg Ala Pro |     |
| 35 40 45                                                        |     |

## (2) INFORMATION FOR SEQ ID NO: 179:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 187 base pairs  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(D) DEVELOPMENTAL STAGE: Fetal  
(F) TISSUE TYPE: liver

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: complement(2..174)  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 100  
region 1..173  
id M85423  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: complement(91..183)



161

(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 98  
region 467..559  
id AA126476  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: complement(28..89)  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 98  
region 560..621  
id AA126476  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: complement(2..32)  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 90  
region 616..646  
id AA126476  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 47..183  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 100  
region 1..137  
id R33928  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 55..183  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 100  
region 14..142  
id H67425  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
(B) LOCATION: 56..183  
(C) IDENTIFICATION METHOD: blastn  
(D) OTHER INFORMATION: identity 100  
region 1..128  
id W04820  
est

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: 80..127  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 3.7  
seq IALTLPMSLSRA/AG

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 179:

162

```

ACCTTCTTGT TATTTATGCT ATTCTCTTTG TGGCTCCATT CTTCTTTCAA TCTTCTCAGC 60
TTATAACCGT CTTTCCCTT ATG CTA AGG ATA GCC CTT ACA CTC ATC CCA TCT 112
 Met Leu Arg Ile Ala Leu Thr Leu Ile Pro Ser
 -15 -10

ATG CTG TCA AGG GCT GCT GGT TGG TGC TGG TAC AAG GAG CCC ACT CAG 160
Met Leu Ser Arg Ala Ala Gly Trp Cys Trp Tyr Lys Glu Pro Thr Gln
-5 1 5 10

CAG TTT TCT TAC CTT TGC CTG CCG GGG 187
Gln Phe Ser Tyr Leu Cys Leu Pro Gly
 15 20

```

## (2) INFORMATION FOR SEQ ID NO: 180:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 145 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 71..109
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 97  
region 16..54  
id AA129105  
est

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 23..79
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 3.7  
seq LPGLRCSVPGVAA/RL

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 180:

```

ACGGCAGAAG GGACGTCCCC AA ATG ACA CTC GGA GGC CGC CTC CCT GGG CTC 52
 Met Thr Leu Gly Gly Arg Leu Pro Gly Leu
 -15 -10

CGG TGC TCG GTG CCG GGA GTA GCG GCA CGG CTT TCT ACC CCG CCT CAG 100
Arg Cys Ser Val Pro Gly Val Ala Ala Arg Leu Ser Thr Pro Pro Gln
-5 1 5

GTG CGC CAG CAC GTT TTC TGG GCA GCA TCT GTG TGT DAG GMA ACG 145
Val Arg Gln His Val Phe Trp Ala Ala Ser Val Cys Xaa Xaa Thr
10 15 20

```

## (2) INFORMATION FOR SEQ ID NO: 181:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 289 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Liver

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 23..291
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 97  
region 1..269  
id T29966  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 123..291
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 97  
region 100..268  
id HSC1VD021  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 23..124
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 96  
region 1..102  
id HSC1VD021  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 56..291
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 97  
region 1..236  
id T35162  
est

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: 122..291
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 97  
region 41..210  
id R12259  
est

## (ix) FEATURE:

(A) NAME/KEY: other  
 (B) LOCATION: 123..251  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 96  
                           region 75..203  
                           id N35783  
                           est

## (ix) FEATURE:

(A) NAME/KEY: other  
 (B) LOCATION: 48..124  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 93  
                           region 1..77  
                           id N35783  
                           est

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 89..130  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 3.6  
                           seq AFTLXSLQAALL/CV

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 181:

```

AGTAGGAASG CGCCGSCCGT GGAGGCGCCA CGTCCCTTGC SGCGGCGGGA GAGAMATCGC 60
TTGGA CTTCG GGGCGGCCTC GGACGGCC ATG GCC TTT ACC CTG TAS TCA CTG 112
 Met Ala Phe Thr Leu Xaa Ser Leu
 -10

CTG CAG GCA GCC CTG CTC TGC GTC AAC GCC ATC GCA GTG CTG CAC GAG 160
Leu Gln Ala Ala Leu Leu Cys Val Asn Ala Ile Ala Val Leu His Glu
 -5 1 5 10

GAG CGA TTC CTC AAG AAC ATT GGC TGG GGA ACA GAC CAG GGA ATT GGT 208
Glu Arg Phe Leu Lys Asn Ile Gly Trp Gly Thr Asp Gln Gly Ile Gly
 15 20 25

GGA TTT GGA GAA GAG CCG GGA ATT AAA TCA SAG STA ATG AVS CTT ATT 256
Gly Phe Gly Glu Glu Pro Gly Ile Lys Ser Xaa Xaa Met Xaa Leu Ile
 30 35 40

CGA TCT GTA AGA ACC GTG ATG AGA GTG CCA TTG 289
Arg Ser Val Arg Thr Val Met Arg Val Pro Leu
 45 50

```

## (2) INFORMATION FOR SEQ ID NO: 182:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 356 base pairs  
 (B) TYPE: NUCLEIC ACID  
 (C) STRANDEDNESS: DOUBLE  
 (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

- (vi) ORIGINAL SOURCE:  
 (A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Pancreas
- (ix) FEATURE:  
 (A) NAME/KEY: other  
 (B) LOCATION: 243..358  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 98  
                           region 99..214  
                           id R74138  
                           est
- (ix) FEATURE:  
 (A) NAME/KEY: other  
 (B) LOCATION: 2..99  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 92  
                           region 2..99  
                           id R74138  
                           est
- (ix) FEATURE:  
 (A) NAME/KEY: other  
 (B) LOCATION: 243..358  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 98  
                           region 68..183  
                           id C18563  
                           est
- (ix) FEATURE:  
 (A) NAME/KEY: other  
 (B) LOCATION: 32..99  
 (C) IDENTIFICATION METHOD: blastn  
 (D) OTHER INFORMATION: identity 94  
                           region 1..68  
                           id C18563  
                           est
- (ix) FEATURE:  
 (A) NAME/KEY: sig\_peptide  
 (B) LOCATION: 81..143  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 3.5  
                           seq LKVVFMVFASLXA/WY
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 182:

ACTTCCTGAC CCAGGGGCTC CGCTGGCTGC GGTGCGCTGG GAKYTGCCGC CAGGGCCAGG 60

AGGGGAKYGG CACCTGGAAG ATG CGC CCA TTG GCT GGT GGC CTG CTC AAG GTG 113  
                   Met Arg Pro Leu Ala Gly Gly Leu Leu Lys Val  
                   -20                          -15

GTG TTC ATG GTC TTC GCC TCC TTG KRW GCC TGG TAT TCG GGG TAC CTG 161  
   Val Phe Met Val Phe Ala Ser Leu Xaa Ala Trp Tyr Ser Gly Tyr Leu  
   -10                  -5                          1                          5

166

|                                                                 |     |
|-----------------------------------------------------------------|-----|
| CTC GCA GAS NTC ATT CCA GAT GCA CCC CTG TCC AGT GCT GCC TAT AGC | 209 |
| Leu Ala Xaa Xaa Ile Pro Asp Ala Pro Leu Ser Ser Ala Ala Tyr Ser |     |
| 10 15 20                                                        |     |
| ATC CGC AGC ATC GGG GAG AGG CCT GTC CTC AAA GCT CCA GTC CCC AAA | 257 |
| Ile Arg Ser Ile Gly Glu Arg Pro Val Leu Lys Ala Pro Val Pro Lys |     |
| 25 30 35                                                        |     |
| AGG CAA AAA TGT GAC CAC TGG ACT CCC TGC CCA TCT GAS RCC TAT GCC | 305 |
| Arg Gln Lys Cys Asp His Trp Thr Pro Cys Pro Ser Xaa Xaa Tyr Ala |     |
| 40 45 50                                                        |     |
| TAC AGG TTA CTC AGC GGA GGT GGC AGA AGC AAG TAC GCC AAA ATC TGC | 353 |
| Tyr Arg Leu Leu Ser Gly Gly Gly Arg Ser Lys Tyr Ala Lys Ile Cys |     |
| 55 60 65 70                                                     |     |
| TTT                                                             | 356 |
| Phe                                                             |     |

## (2) INFORMATION FOR SEQ ID NO: 183:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 289 base pairs
- (B) TYPE: NUCLEIC ACID
- (C) STRANDEDNESS: DOUBLE
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Colon

## (ix) FEATURE:

- (A) NAME/KEY: other
- (B) LOCATION: complement(207..287)
- (C) IDENTIFICATION METHOD: blastn
- (D) OTHER INFORMATION: identity 91  
region 220..300  
id H49636  
est

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: 116..181
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 3.5  
seq AAPVAAGLGPVIS/RP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 183:

|                                                                   |     |
|-------------------------------------------------------------------|-----|
| AGTCACGCTT TGGTTTCCGG GTCGGTTCTG GCAGGTCTGA GCGCTCCGAC TTCCAGAGGA | 60  |
| GCGCTGTGCA CGTGGAGAAG AGCGGGGACT CGGCGACCCT GCCCTCCCGA CCCTC ATG  | 118 |
| Met                                                               |     |
| TTC GAA GAG CCT GAG TGG GCC GAG GCG GCC CCA GTA GCC GCG GGC CTT   | 166 |
| Phe Glu Glu Pro Glu Trp Ala Glu Ala Ala Pro Val Ala Ala Gly Leu   |     |

167

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|     | -20 |     |     | -15 |     |     |     |     | -10 |     |     |     |     |     |     |     |
| GGG | CCC | GTA | ATC | TCA | CGA | CCT | CCG | CCT | GCG | GCC | TCC | TCG | CAA | AAC | AAG | 214 |
| Gly | Pro | Val | Ile | Ser | Arg | Pro | Pro | Pro | Ala | Ala | Ser | Ser | Gln | Asn | Lys |     |
| -5  |     |     |     |     | 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |
|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| GGC | TCC | AAG | CGC | CGC | CAG | CTC | TTG | GCC | ACA | TTA | CGG | GCC | CTA | GAG | GCA | 262 |
| Gly | Ser | Lys | Arg | Arg | Gln | Leu | Leu | Ala | Thr | Leu | Arg | Ala | Leu | Glu | Ala |     |
|     |     |     | 15  |     |     |     |     | 20  |     |     |     |     | 25  |     |     |     |
|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| GCA | TCT | CTT | TCC | CAG | CAT | CCC | CCC | ATG |     |     |     |     |     |     |     | 289 |
| Ala | Ser | Leu | Ser | Gln | His | Pro | Pro | Met |     |     |     |     |     |     |     |     |
|     |     | 30  |     |     |     |     | 35  |     |     |     |     |     |     |     |     |     |

(2) INFORMATION FOR SEQ ID NO: 184:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 139 base pairs  
(B) TYPE: NUCLEIC ACID  
(C) STRANDEDNESS: DOUBLE  
(D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: CDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Lung (cells)

(ix) FEATURE:

- [illegible]

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide  
(B) LOCATION: 50..118  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 3.5  
seq ALYNIYYVCGIQG/IT

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 184:

ACCGTTGTCA CCAGCCTTGT TTCTAGTGTG TATATATGTC GCCCCCGTG ATG CAT ATA 58  
Met His Ile

TAC ACA GGT ATT AAA TAT ATC GCT CTA TAT AAT ATT ATA TAT GTG TGT 106  
Tyr Thr Gly Ile Lys Tyr Ile Ala Leu Tyr Asn Ile Ile Tyr Val Cys  
-20 -15 -10 -5

GGT ATC CAA GGA ATC ACT TTT ATG AGG GCA CGG 139  
Gly Ile Gln Gly Ile Thr Phe Met Arg Ala Arg  
1 5

## (2) INFORMATION FOR SEQ ID NO: 185:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 96 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (D) DEVELOPMENTAL STAGE: Fetal
- (F) TISSUE TYPE: liver

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -20..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 15.8  
seq LLLLLLLRHGAQG/KP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 185:

```

Met Met Trp Arg Pro Ser Val Leu Leu Leu Leu Leu Leu Arg His
-20 -10 -5

Gly Ala Gln Gly Lys Pro Ser Pro Asp Ala Gly Pro His Gly Gln Gly
 1 5 10

Arg Val His Gln Ala Ala Pro Leu Ser Asp Ala Pro His Asp Asp Ala
 15 20 25

His Gly Asn Phe Gln Tyr Asp His Glu Ala Phe Leu Gly Arg Glu Val
 30 35 40

Ala Lys Glu Phe Asp Gln Leu Thr Pro Glu Glu Ser Gln Ala Arg Leu
45 50 55 60

Gly Arg Ile Val Asp Arg Met Asp Arg Xaa Gly Thr Ala Thr Ala Gly
 65 70 75

```

## (2) INFORMATION FOR SEQ ID NO: 186:.

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -28..-1



(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 11.4  
seq LLLILFLYGLCSG/WR

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 186:

Met Gly Lys Ile Cys Lys Asn Trp Val Ser Phe Leu Asp Asn Val Leu  
-25 -20 -15

Leu Leu Ile Leu Phe Leu Tyr Gly Leu Cys Ser Gly Trp Arg  
-10 -5 1

(2) INFORMATION FOR SEQ ID NO: 187:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 52 amino acids  
(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:  
(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Large intestine

```
(ix) FEATURE:
(A) NAME/KEY: sig_peptide
(B) LOCATION: -18..-1
(C) IDENTIFICATION METHOD: Von Heijne matrix
(D) OTHER INFORMATION: score 11.1
 seq LLALLCASASGNA/IQ
```

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 187:

Met Leu Thr Val Ala Leu Leu Ala Leu Leu Cys Ala Ser Ala Ser Gly  
-15 -10 -5  
Asn Ala Ile Gln Ala Arg Ser Ser Ser Tyr Ser Gly Glu Tyr Gly Leu  
1 5 10  
Val Val Glu Ser Asp Ser Leu Ile Leu Ala Thr Ser Trp Thr Ala Pro  
15 20 25 30  
Ser Pro Pro Thr

(2) INFORMATION FOR SEQ ID NO: 188:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 32 amino acids  
(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

170

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Pancreas

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -13..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 10.4  
seq MVLLLCLSCLIFS/CL

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 188:

Met Val Leu Leu Leu Cys Leu Ser Cys Leu Ile Phe Ser Cys Leu Thr  
-10 -5 1  
Phe Ser Trp Leu Lys Ile Trp Gly Lys Met Thr Asp Ser Lys Pro Met  
5 10 15

## (2) INFORMATION FOR SEQ ID NO: 189:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 90 amino acids  
(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Liver

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -21..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 10  
seq LWALAMVTRPASA/AP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 189:

Met Pro Val Pro Ala Leu Cys Leu Leu Trp Ala Leu Ala Met Val Thr  
-20 -15 -10  
Arg Pro Ala Ser Ala Ala Pro Met Gly Gly Pro Glu Leu Ala Gln His  
-5 1 5 10  
Glu Glu Leu Thr Leu Leu Phe His Gly Thr Leu Gln Leu Gly Gln Ala  
15 20 25  
Leu Asn Gly Val Tyr Arg Thr Thr Glu Gly Arg Leu Thr Lys Ala Arg  
30 35 40  
Asn Ser Leu Gly Leu Tyr Gly Arg Thr Ile Glu Leu Leu Gly Gln Glu  
45 50 55  
Val Ser Arg Gly Arg Asp Ala Ala Gln Gly  
60 65

## (2) INFORMATION FOR SEQ ID NO: 190:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 44 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -41..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 9.4  
seq LLPLWVFLPLSLG/PP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 190:

Met His Leu Arg Gly Ser His Thr Tyr Pro Ser Cys Pro Ser Ser Glu  
-40 -35 -30

Leu Arg Leu Asp Ser Leu Trp Gln His His Arg Gln Leu Leu Pro Leu  
-25 -20 -15 -10

Trp Val Phe Leu Pro Leu Ser Leu Gly Pro Pro Gly  
-5 1

## (2) INFORMATION FOR SEQ ID NO: 191:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 77 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -26..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 9.2  
seq FLLMTLLLGGLTG/VA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 191:

Met Pro Val Pro Ala Ser Trp Pro His Leu Pro Ser Pro Phe Leu Leu

172

-25                      -20                      -15  
 Met Thr Leu Leu Leu Gly Gly Leu Thr Gly Val Ala Xaa Glu Glu Glu  
 -10                      -5                      1                      5  
 Leu Gln Val Xaa Gln Pro Asp Lys Ser Ile Ser Val Ala Ala Gly Lys  
                     10                      15                      20  
 Xaa Ala Thr Leu His Cys Thr Val Thr Xaa Leu Ile Xaa Val Gly Pro  
                     25                      30                      35  
 Ile Gln Trp Xaa Arg Gly Ala Gly Pro Gly Arg Glu Leu  
                     40                      45                      50

## (2) INFORMATION FOR SEQ ID NO: 192:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 93 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Large intestine

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -23...-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 9.1  
seq LVAMLLLVFPTVS/RS

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 192:

Met Ala Gln Arg Cys Val Cys Val Leu Ala Leu Val Ala Met Leu Leu  
                     -20                      -15                      -10  
 Leu Val Phe Pro Thr Val Ser Arg Ser Met Gly Pro Arg Ser Gly Glu  
                     -5                      1                      5  
 His Gln Arg Ala Ser Arg Ile Pro Ser Gln Phe Ser Lys Glu Glu Arg  
                     10                      15                      20                      25  
 Val Ala Met Lys Glu Ala Leu Lys Gly Ala Ile Gln Ile Pro Thr Val  
                     30                      35                      40  
 Thr Phe Ser Ser Glu Lys Ser Asn Thr Thr Ala Leu Ala Glu Phe Gly  
                     45                      50                      55  
 Asn Thr Phe Ile Lys Ser Phe Leu Gln Trp Ser Ala Pro  
                     60                      65                      70

## (2) INFORMATION FOR SEQ ID NO: 193:

173

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 19 amino acids
  - (B) TYPE: AMINO ACID
  - (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: PROTEIN
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Homo Sapiens
  - (F) TISSUE TYPE: Lung (cells)
- (ix) FEATURE:
  - (A) NAME/KEY: sig\_peptide
  - (B) LOCATION: -16..-1
  - (C) IDENTIFICATION METHOD: Von Heijne matrix
  - (D) OTHER INFORMATION: score 9  
seq LISFLLLLLLLLLP/AR

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 193:

Met Asp Tyr Leu Ile Ser Phe Leu Leu Leu Leu Leu Leu Leu Pro  
 -15 -10 -5

Ala Arg Gly  
 1

(2) INFORMATION FOR SEQ ID NO: 194:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 88 amino acids
  - (B) TYPE: AMINO ACID
  - (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: PROTEIN
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Homo Sapiens
  - (F) TISSUE TYPE: Colon
- (ix) FEATURE:
  - (A) NAME/KEY: sig\_peptide
  - (B) LOCATION: -84..-1
  - (C) IDENTIFICATION METHOD: Von Heijne matrix
  - (D) OTHER INFORMATION: score 8.9  
seq LLGVLGIFGLTFA/FI

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 194:

Met Ala Thr Thr Val Pro Asp Gly Cys Arg Asn Gly Leu Lys Ser Lys  
 -80 -75 -70

Tyr Tyr Arg Leu Cys Asp Lys Ala Glu Ala Trp Gly Ile Val Leu Glu  
 -65 -60 -55

Thr Val Ala Thr Ala Gly Val Val Thr Ser Val Ala Phe Met Leu Thr  
 -50 -45 -40

174

Leu Pro Ile Leu Val Cys Lys Val Gln Asp Ser Asn Arg Arg Lys Met  
 -35 -30 -25

Leu Pro Thr Gln Phe Leu Phe Leu Leu Gly Val Leu Gly Ile Phe Gly  
 -20 -15 -10 -5

Leu Thr Phe Ala Phe Ile Ile Gly  
 1

## (2) INFORMATION FOR SEQ ID NO: 195:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 71 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Large intestine

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -19..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 8.9  
seq WLFLVIFIKGVQC/QE

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 195:

Met Glu Ser Gly Leu Ser Trp Leu Phe Leu Val Ile Phe Ile Lys Gly  
 -15 -10 -5

Val Gln Cys Gln Glu Gln Leu Val Glu Ser Gly Gly Gly Val Val Lys  
 1 5 10

Pro Gly Gly Ser Leu Arg Leu Ser Cys Glu Ala Ser Gly Phe Thr Phe  
 15 20 25

Ser Asp Phe Xaa Met Met Trp Ile Arg Gln Thr Pro Gly Lys Gly Leu  
 30 35 40 45

Glu Tyr Val Gly Ile His Gln  
 50

## (2) INFORMATION FOR SEQ ID NO: 196:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

175

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -18..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 8.6  
seq VLLHVAFLPGRFG/RP

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 196:

Met Ser Gly Thr Ser Val Leu Leu His Val Ala Phe Leu Pro Gly Arg  
-15 -10 -5  
Phe Gly Arg Pro Leu  
1

(2) INFORMATION FOR SEQ ID NO: 197:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 53 amino acids  
(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -17..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 8.6  
seq LLPVSLLLSVAVS/AI

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 197:

Met Leu Gln Gly Leu Leu Pro Val Ser Leu Leu Leu Ser Val Ala Val  
-15 -10 -5  
Ser Ala Ile Lys Glu Leu Pro Gly Val Lys Lys Tyr Glu Val Val Tyr  
1 5 10 15  
Pro Ile Arg Leu His Pro Leu His Lys Arg Glu Ala Lys Glu Pro Glu  
20 25 30  
Gln Gln Glu Arg Arg  
35

(2) INFORMATION FOR SEQ ID NO: 198:

## (i) SEQUENCE CHARACTERISTICS:

176

(A) LENGTH: 30 amino acids  
 (B) TYPE: AMINO ACID  
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Colon

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: -15..-1  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 8.6  
 seq ICHVSLLLQLCSS/CK

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 198:

```
Met His Ile Cys His Val Ser Leu Leu Leu Gln Leu Cys Ser Ser Cys
-15 -10 -5 1

Lys Lys Ser Pro Leu Lys Leu Leu Leu Gln Lys Ala Gln Arg
 5 10 15
```

(2) INFORMATION FOR SEQ ID NO: 199:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 37 amino acids  
 (B) TYPE: AMINO ACID  
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Liver

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: -33..-1  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 8.2  
 seq LLCSSLFSFPFLC/HP

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 199:

```
Met Ile Phe Ala Asp Arg Thr His Ser Ser Ala Phe Thr Leu Met Arg
 -30 -25 -20

Ser Tyr Ser Leu Leu Leu Cys Ser Leu Leu Phe Ser Phe Pro Phe Leu
 -15 -10 -5

Cys His Pro Leu Arg
 1
```



## (2) INFORMATION FOR SEQ ID NO: 200:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 72 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Pancreas

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -20..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 8  
seq VCVLVGSFSASLA/GT

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 200:

Met Ala Phe Leu Pro Ser Trp Val Cys Val Leu Val Gly Ser Phe Ser  
-20 -15 -10 -5

Ala Ser Leu Ala Gly Thr Ser Asn Leu Ser Glu Thr Glu Pro Pro Leu  
1 5 10

Trp Lys Glu Ser Pro Gly Gln Leu Ser Asp Tyr Arg Val Glu Asn Ser  
15 20 25

Met Tyr Ile Ile Asn Pro Trp Val Tyr Leu Glu Arg Met Gly Met Tyr  
30 35 40

Lys Ile Ile Leu Asn Gln Thr Lys  
45 50

## (2) INFORMATION FOR SEQ ID NO: 201:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -14..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 7.7  
seq FLVSCVICTGSFA/FN

178

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 201:

Met Phe Leu Val Ser Cys Val Ile Cys Thr Gly Ser Phe Ala Phe Asn  
                   -10                  -5                  1

Asn Ser Asn Val Pro Leu Pro Ser Ser Arg  
           5                  10

(2) INFORMATION FOR SEQ ID NO: 202:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 68 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -44..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 7.5  
seq LMIPLLLTPITA/TS

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 202:

Met Lys Lys Thr Gly Asp Gly Gly Thr Leu Ser Thr Glu Arg Ile Gly  
                   -40                  -35                  -30

Gly Ala Ala Leu Leu Ser Leu Leu Leu Lys Arg Met Lys Met Thr Leu  
                   -25                  -20                  -15

Met Ile Pro Leu Leu Leu Thr Pro Ile Thr Ala Thr Ser Xaa Ser  
                   -10                  -5                  1

Arg Trp Pro Glu Ile Gly Val Val Ala Ile Arg Ser Gln Leu Arg Ala  
   5                  10                  15                  20

Leu His Thr Cys

(2) INFORMATION FOR SEQ ID NO: 203:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 116 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens

179

(F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: -25..-1  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 7.5  
 seq XILLAGWCPDTRA/GG

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 203:

```

Met Gly Phe Phe Leu Pro His Gly Ile Ser Asp Ala Xaa Ile Leu Leu
-25 -20 -15 -10

Ala Gly Trp Cys Pro Asp Thr Arg Ala Gly Gly Trp Ala Asp Leu Cys
 -5 1 5

Leu Pro Glu Asn Arg Gly Pro Lys Pro Pro Ser Pro Arg Ser Ala Leu
 10 15 20

Gly Ser Gly Arg Gly Leu Gly Ser Gly Gln Pro Glu Val Glu Pro Pro
 25 30 35

Ala Pro Glu Gln Ala Trp Glu Ser Leu Gln Gly Gly Leu Gly Xaa Cys
 40 45 50 55

Ser Xaa Ala Arg Pro Ser Pro Gly Phe Trp Ala Arg Ala Ser Leu Ala
 60 65 70

Val Gly Ala Gly Xaa Val Gly Gly Thr Leu Leu Asn Trp Glu Ile Ala
 75 80 85

Ser Asp Leu Gln
 90

```

## (2) INFORMATION FOR SEQ ID NO: 204:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 73 amino acids  
 (B) TYPE: AMINO ACID  
 (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Colon

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: -46..-1  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 7.5  
 seq VCTLLSSH PASRC/RP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 204:

180

```

Met Trp Leu Arg Pro Gly Ser Cys Trp Ser Thr Arg Glu Pro Arg Arg
-45 -40 -35

Ala Pro Arg Thr Ser Ala Ser Ser Leu Ser Ser Phe Leu Gly Pro Ser
-30 -25 -20 -15

Ala Val Cys Thr Leu Leu Ser Ser His Pro Ala Ser Arg Cys Arg Pro
 -10 -5 1

Ser Thr Phe Leu Ala Pro Gly Phe Cys Ile Cys Pro Ser His Cys Leu
 5 10 15

Ser Cys Ala Asn Ala Thr Asp Pro Ala
 20 25

```

## (2) INFORMATION FOR SEQ ID NO: 205:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 48 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -39..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 7.4  
seq LFLLSLFCRLYHG/TI

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 205:

```

Met Ser Glu Gly Met Val Thr Leu Leu Thr Phe Ser Cys Leu Trp Thr
 -35 -30 -25

Asp Asp Ser Phe Met Ser Xaa Leu Asn Val Leu Phe Leu Leu Ser Leu
 -20 -15 -10

Phe Cys Arg Leu Tyr His Gly Thr Ile Phe Phe Leu Leu Ala Leu Leu
 -5 1 5

```

## (2) INFORMATION FOR SEQ ID NO: 206:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 53 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

181

- (A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Lung

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide  
(B) LOCATION: -14..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 7.3  
seq LILGLPLCRPLWI/QR

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 206:

```

Met Leu Ile Leu Gly Leu Pro Leu Cys Arg Pro Leu Trp Ile Gln Arg
 -10 -5 1
Ala Ala Ala Ala Pro Phe Val Leu Trp Ala Trp Leu Trp Ala Arg Ser
 5 10 15
Ser Thr Ser Leu Gly Arg Pro Pro Phe Leu Pro Arg Leu Leu Pro Ser
 20 25 30
Pro Pro Asp Pro Glu
 35

```

## (2) INFORMATION FOR SEQ ID NO: 207:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 49 amino acids  
(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Lung

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide  
(B) LOCATION: -25..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 7.3  
seq HFILLVLPCLIFS/HF

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 207:

```

Met Tyr Ile Tyr Phe Phe Val Leu Cys Xaa Leu Ser His Phe Ile Leu
-25 -20 -15 -10
Leu Val Leu Pro Cys Leu Ile Phe Ser His Phe Thr Leu Phe Leu Phe
 -5 1 5
Tyr Ser Ala Leu Leu Asp Ile Pro Leu Phe Phe Lys Tyr Ser Leu Ile
 10 15 20
Glu

```

## (2) INFORMATION FOR SEQ ID NO: 208:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 69 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -42..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 7.2  
seq ILFSLSFLLVIIT/FP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 208:

Met Asp Ser Arg Val Ser Ser Pro Glu Lys Gln Asp Lys Glu Asn Phe  
-40 -35 -30

Val Gly Val Asn Asn Lys Arg Leu Gly Val Cys Gly Trp Ile Leu Phe  
-25 -20 -15

Ser Leu Ser Phe Leu Leu Val Ile Ile Thr Phe Pro Ile Ser Ile Trp  
-10 -5 1 5

Met Cys Leu Lys Ile Ile Lys Xaa Tyr Glu Arg Xaa Val Val Phe Arg  
10 15 20

Leu Gly Arg His Gly  
25

## (2) INFORMATION FOR SEQ ID NO: 209:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Thyroid

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -16..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 7  
seq LFCVVLCLSPSY/CY

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 209:

Met Cys Ile Leu Phe Cys Val Val Leu Cys Leu Ser Pro Thr Ser Tyr  
-15 -10 -5  
Cys Tyr  
1

(2) INFORMATION FOR SEQ ID NO: 210:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -19..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 7  
seq ETLCLGSSCCQC/RI

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 210:

Met His Arg Gly Asp Ile Glu Thr Leu Leu Cys Leu Gly Ser Ser Cys  
-15 -10 -5  
Cys Gln Cys Arg Ile Phe Ser Phe Phe Phe Phe  
1 5

(2) INFORMATION FOR SEQ ID NO: 211:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -19..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 7





## (2) INFORMATION FOR SEQ ID NO: 213:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 130 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -19..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 6.9  
seq LQPLLLLLPLLNV/EP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 213:

```

Met Ser Pro Pro Pro Leu Leu Gln Pro Leu Leu Leu Leu Leu Pro Leu
 -15 -10 -5

Leu Asn Val Glu Pro Ser Gly Ala Thr Leu Ile Arg Ile Pro Leu His
 1 5 10

Arg Val Gln Pro Gly Arg Arg Ile Leu Asn Leu Leu Arg Gly Trp Xaa
 15 20 25

Glu Pro Ala Glu Leu Pro Lys Leu Gly Ala Pro Ser Pro Gly Asp Lys
 30 35 40 45

Pro Ile Phe Val Pro Leu Ser Asn Tyr Arg Asp Val Gln Tyr Phe Gly
 50 55 60

Glu Ile Gly Leu Gly Thr Pro Pro Gln Asn Phe Thr Val Ala Phe Asp
 65 70 75

Thr Gly Ser Ser Asn Leu Trp Val Pro Ser Arg Arg Cys His Phe Phe
 80 85 90

Ser Val Pro Cys Trp Leu His Thr Asp Leu Ile Pro Lys Pro Leu Ala
 95 100 105

Pro Ser
110

```

## (2) INFORMATION FOR SEQ ID NO: 214:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 44 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(D) DEVELOPMENTAL STAGE: Fetal  
(F) TISSUE TYPE: liver

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -42..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 6.5  
seq ILIGLFSLTGLVA/GN

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 214:

Met Ile Pro Ile Tyr Gln Asn Lys Ser Gln Thr Asp Ser His Cys Ser  
-40 -35 -30  
Leu Ser His Lys Gly Leu Ala Phe Leu Lys Val Trp Leu Ile Leu Ile  
-25 -20 -15  
Gly Leu Phe Ser Leu Thr Gly Leu Val Ala Gly Asn  
-10 -5 1

## (2) INFORMATION FOR SEQ ID NO: 215:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 40 amino acids  
(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -20..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 6.5  
seq LLSGSTCPGPCSC/GS

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 215:

Met Ala Leu Pro Gly Ile His Leu Leu Ser Gly Ser Thr Cys Pro Gly  
-20 -15 -10 -5  
Pro Cys Ser Cys Gly Ser Leu Arg Ser Pro Pro Gly Pro Val Thr Asp  
1 5 10  
Lys Pro Leu Pro Leu Pro Pro Gln  
15 20

## (2) INFORMATION FOR SEQ ID NO: 216:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 62 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Colon

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -41..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 6.4  
seq IALIPLFSTXAFA/IX

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 216:

```

Met Pro Ser Glu Thr Leu Trp Glu Ile Ala Lys Ala Glu Val Glu Lys
-40 -35 -30

Arg Gly Ile Asn Gly Xaa Xaa Gly Asp Gly Ala Glu Ile Ala Leu Ile
-25 -20 -15 -10

Pro Leu Phe Ser Thr Xaa Ala Phe Ala Ile Xaa Gln Ile Val Ser Leu
 -5 1 5

Gly Ile Val Asp Gly Ser Xaa Pro Pro Xaa Ser Arg Thr Pro
10 15 20

```

## (2) INFORMATION FOR SEQ ID NO: 217:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 58 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -37..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 6.4  
seq LCMSLTFLALSTL/RF

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 217:

```

Met Glu Trp Leu Arg Pro Ser Gln Ile Ser Phe Tyr Pro Gly Tyr Ser

```

188

-35                      -30                      -25  
 Lys Glu Arg Leu Arg Leu Val Leu Leu Cys Met Ser Leu Thr Phe Leu  
   -20                      -15                      -10  
 Ala Leu Ser Thr Leu Arg Phe Leu Thr Gln Arg Val Gln Met Gln Ala  
   -5                      1                      5                      10  
 Gly Cys Pro Leu Arg Ser Pro Arg Leu Trp  
                     15                      20

## (2) INFORMATION FOR SEQ ID NO: 218:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 41 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Liver

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -18..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 6.3  
seq HLTLLALLSVNTG/KE

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 218:

Met Lys Ala Ile Ile His Leu Thr Leu Leu Ala Leu Leu Ser Val Asn  
                     -15                      -10                      -5  
 Thr Gly Lys Glu Tyr Phe Tyr Ile Leu Ile Leu Pro Ile Met Tyr Val  
                     1                      5                      10  
 Val Phe Glu Val Glu Ser Ala Gly Gln  
   15                      20

## (2) INFORMATION FOR SEQ ID NO: 219:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 45 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Liver

## (ix) FEATURE:

189

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -29..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 6.3  
seq SLPLALTLSSLSTS/LH

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 219:

```

Met Asp Val Ser Ala Ser Lys Pro Val Ala Glu Ser Trp Ser Pro Gly
 -25 -20 -15

Ser Leu Pro Leu Ala Leu Thr Leu Ser Leu Ser Thr Ser Leu His Asp
 -10 -5 1

Ser Trp Lys Glu Pro Ile Pro Asn Leu His Gln Pro Ala
 5 10 15

```

(2) INFORMATION FOR SEQ ID NO: 220:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 39 amino acids
  - (B) TYPE: AMINO ACID
  - (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: PROTEIN
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Homo Sapiens
  - (F) TISSUE TYPE: Liver
- (ix) FEATURE:
  - (A) NAME/KEY: sig\_peptide
  - (B) LOCATION: -28..-1
  - (C) IDENTIFICATION METHOD: Von Heijne matrix
  - (D) OTHER INFORMATION: score 6.2  
seq IQTALLGLPXAWA/SS

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 220:

```

Met Gly Val Arg Val Gly Val Ser Leu Arg Ala Trp Cys Val Phe Ile
 -25 -20 -15

Gln Thr Ala Leu Leu Gly Leu Pro Xaa Ala Trp Ala Ser Ser Gly Val
 -10 -5 1

Val Ser Ser Thr Gly Pro Gly
 5 10

```

(2) INFORMATION FOR SEQ ID NO: 221:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 29 amino acids
  - (B) TYPE: AMINO ACID
  - (D) TOPOLOGY: LINEAR

190

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens

(F) TISSUE TYPE: Lung (cells)

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide

(B) LOCATION: -22..-1

(C) IDENTIFICATION METHOD: Von Heijne matrix

(D) OTHER INFORMATION: score 6.1

seq FFLLLCIPFLTLL/LY

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 221:

Met Ile Ile Ser Ile Ile Pro Arg Ser Phe Phe Leu Leu Leu Cys Ile  
           -20                          -15                          -10

Pro Phe Leu Thr Leu Leu Leu Tyr Thr Tyr Pro Pro Arg  
       -5                          1                          5

(2) INFORMATION FOR SEQ ID NO: 222:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 54 amino acids

(B) TYPE: AMINO ACID

(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens

(F) TISSUE TYPE: Thyroid

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide

(B) LOCATION: -29..-1

(C) IDENTIFICATION METHOD: Von Heijne matrix

(D) OTHER INFORMATION: score 5.9

seq WTLVLMSPEWALL/QY

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 222:

Met Thr Met Gln Arg Ser Arg Ser Ser Ser Trp Thr Ser Cys Asn Ser  
                           -25                          -20                          -15

Trp Thr Leu Val Leu Met Ser Pro Glu Trp Ala Leu Leu Gln Tyr Gly  
                           -10                          -5                          1

Ser Thr Val Lys Asn Glu Phe Ser Xaa Lys Thr Phe Lys Arg Lys Ser  
       5                          10                          15

Glu Val Glu Arg Ala Val  
       20                          25

## (2) INFORMATION FOR SEQ ID NO: 223:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -23..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5.8  
seq LCSLMASISPTLT/AV

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 223:

Met Ile Thr Leu Pro Gln Thr Ser Ser Leu Leu Cys Ser Leu Met Ala  
          -20                          -15                          -10  
Ser Ile Ser Pro Thr Leu Thr Ala Val Ile Leu Trp Pro Pro  
          -5                                  1                                  5

## (2) INFORMATION FOR SEQ ID NO: 224:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 78 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Liver

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -63..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5.7  
seq PLVTHGLLLQAWS/RR

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 224:

Met Leu Arg Thr Cys Tyr Val Leu Cys Ser Gln Ala Gly Pro Pro Ser  
          -60                          -55                          -50  
Arg Gly Trp Gln Ser Leu Ser Phe Asp Gly Gly Ala Phe His Leu Lys  
          -45                          -40                          -35  
Gly Thr Gly Glu Leu Thr Arg Ala Leu Leu Val Leu Arg Leu Cys Ala

192

-30                      -25                      -20  
 Trp Pro Pro Leu Val Thr His Gly Leu Leu Leu Gln Ala Trp Ser Arg  
 -15                      -10                      -5                      1  
 Arg Leu Leu Gly Ser Arg Leu Ser Xaa Ala Phe Leu Arg Ala  
                     5                      10                      15

## (2) INFORMATION FOR SEQ ID NO: 225:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 41 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -30..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5.7  
seq LGVGCHFFHLALG/RF

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 225:

Met Ile Cys Ser Pro Phe Ser Gly Phe Ala Pro Cys Gln Ala Leu Gly  
 -30                      -25                      -20                      -15  
 Thr Leu Gly Val Gly Cys His Phe Phe His Leu Ala Leu Gly Arg Phe  
                     -10                      -5                      1  
 Leu Leu Ser Leu Ser Asn Asn Ile Tyr  
                     5                      10

## (2) INFORMATION FOR SEQ ID NO: 226:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 150 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Pancreas

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -98..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix



193

(D) OTHER INFORMATION: score 5.6  
seq LLLLRGADRVLQA/HI

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 226:

```

Met Cys Asn Pro Glu Glu Ala Ala Leu Xaa Gly Leu Glu Glu Val Phe
 -95 -90 -85

Ser Ala Thr Leu Ala His Val Asn Ser Leu Val Leu Gln Pro Leu Leu
 -80 -75 -70

Pro Ala Ala Pro Asp Pro Ser Asp Pro Trp Gly Arg Glu Cys Leu Arg
 -65 -60 -55

Leu Leu Gln Gln Leu His Lys Ser Ser Gln Gln Leu Trp Glu Val Thr
 -50 -45 -40 -35

Glu Glu Ser Leu His Ser Leu Gln Glu Arg Leu Arg Tyr Pro Asp Ser
 -30 -25 -20

Thr Gly Leu Glu Ser Leu Leu Leu Leu Arg Gly Ala Asp Arg Val Leu
 -15 -10 -5

Gln Ala His Ile Glu Tyr Ile Glu Ser Tyr Thr Ser Cys Met Val Val
 1 5 10

Gln Ala Phe Gln Lys Xaa Ala Lys Arg Arg Ser Glu Phe Trp Arg Gly
 15 20 25 30

Gln Arg Xaa Ala Leu Arg Gln Leu Leu Ser Gly Val Ser Ser Glu Gly
 35 40 45

Ser Val Gly Ala Ser Leu
 50

```

(2) INFORMATION FOR SEQ ID NO: 227:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 70 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Thyroid

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -45..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5.6  
seq LLVIHWMCP SLS/QS

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 227:

194

```

Met Asp Lys Leu Ile Pro Ser Leu Ser Ser Gln Glu Asn Arg Lys Ala
-45 -40 -35 -30

Ser His Thr Leu His Lys Ala Arg Asn Lys Gln His Cys Gly Gly Phe
 -25 -20 -15

Leu Leu Val Ile His Trp Val Met Cys Pro Ser Leu Ser Gln Ser Ala
 -10 -5 1

Val Arg Arg Met Lys Tyr Ser Asn Trp Pro Val Leu Gly His Val Pro
 5 10 15

Val Pro Gly Cys His Cys
20 25

```

## (2) INFORMATION FOR SEQ ID NO: 228:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -17..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5.5  
seq LPVVLASPPVGHG/LP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 228:

```

Met Ser Xaa Leu Leu Pro Val Val Leu Ala Ser Pro Pro Val Gly His
 -15 -10 -5

Gly Leu Pro Ser Pro Val Pro Leu Leu Gln Asp Pro Cys Pro Leu Pro
 1 5 10 15

Ala Val Gly

```

## (2) INFORMATION FOR SEQ ID NO: 229:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens

195

(F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -13..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 5.5  
seq MVLLTMIARVADG/LP

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 229:

Met Val Leu Leu Thr Met Ile Ala Arg Val Ala Asp Gly Leu Pro Leu  
-10 -5 1

Ala Ala Ser Met Gln Glu Asp Glu Glu  
5 10

## (2) INFORMATION FOR SEQ ID NO: 230:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 59 amino acids  
(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Large intestine

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -53..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 5.5  
seq LLELLFVPLLCFL/SK

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 230:

Met Phe His Ile Ala Phe Ser Glu Ala Leu Pro Val Asp Ile Phe Lys  
-50 -45 -40

Thr Gln Pro Asn Cys His Glu Ala Phe Ser Met Lys Ala Ile His Ile  
-35 -30 -25

Thr Arg Ile Arg Ser Gly Leu Cys Leu Leu Glu Leu Leu Phe Val Pro  
-20 -15 -10

Leu Leu Cys Phe Leu Ser Lys Lys Trp Pro Trp  
-5 1 5

## (2) INFORMATION FOR SEQ ID NO: 231:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 38 amino acids

(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Pancreas

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -25..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 5.4  
seq SLLTETVLPLAFP/GP

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 231:

```
Met Met His Cys Thr Pro Ser Gly Ser Ala Ala Val Ser Leu Leu Thr
-25 -20 -15 -10

Glu Thr Val Leu Pro Leu Ala Phe Pro Gly Pro Pro Trp Leu Gly Thr
 -5 1 5

Ser Phe Asn Arg Xaa Leu
 10
```

(2) INFORMATION FOR SEQ ID NO: 232:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 74 amino acids  
(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Lung

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -28..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 5.3  
seq RISCAFSLASSTA/RQ

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 232:

```
Met Thr Arg Pro Phe Trp Ala Ser Cys Ser Thr Trp Ala Thr Ser Arg
 -25 -20 -15

Ile Ser Cys Ala Phe Ser Leu Ala Ser Ser Thr Ala Arg Gln Thr Ser
 -10 -5 1

Ile Ala Cys Cys Ala Thr His Arg Thr Ala Trp Ala Ser Arg Pro Gly
5 10 15 20
```

Pro Arg Arg Pro Trp Cys Cys Arg Tyr Ser Lys Pro Leu Thr Thr Trp  
                   25                                  30                                  35

Pro Val Arg Met Met Arg Arg Glu Gly Leu  
                   40                                  45

## (2) INFORMATION FOR SEQ ID NO: 233:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 87 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -26..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5.2  
seq SCCLIQWPELSFS/NT

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 233:

Met Val Thr His Leu Ile Arg Gly Val Val Leu Gln Gly Ser Cys Cys  
   -25                                  -20                                  -15

Leu Ile Gln Trp Pro Glu Leu Ser Phe Ser Asn Thr Asn Gly Val Cys  
  -10                                  -5                                  1                                  5

Pro Ile Tyr Pro Pro Pro Ser Ile Xaa Xaa Leu Arg Met Ser Ser Cys  
                   10                                  15                                  20

Ser Pro Leu Thr Val Ser Leu Cys Pro Cys Tyr Val Glu Cys Ala Ser  
                   25                                  30                                  35

Thr Pro Gly Pro Leu Cys Leu Leu Phe Ser Trp Pro Arg Asn Thr Ser  
                   40                                  45                                  50

Pro Asn Met Pro Ser Gly Tyr  
   55                                  60

## (2) INFORMATION FOR SEQ ID NO: 234:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 65 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide  
(B) LOCATION: -19..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 5.2  
seq LLVAFRVFLGLFS/LP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 234:

```

Met Tyr Met Trp Ser Lys Leu Leu Val Ala Phe Arg Val Phe Leu Gly
 -15 -10 -5

Leu Phe Ser Leu Pro Ser Asn His Asn Thr Tyr Cys Pro Phe Gln Pro
 1 5 10

Trp Gly Ile Pro Cys Ser Leu Arg Ile Gly Gly Leu Leu His Leu Gln
 15 20 25

Cys Pro Leu Pro Pro Ser Leu His Pro Leu Pro Ser Leu Leu Thr Ser
 30 35 40 45

Arg

```

## (2) INFORMATION FOR SEQ ID NO: 235:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 45 amino acids  
(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide  
(B) LOCATION: -23..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 5.2  
seq FLFGLYSFRAVDS/SR

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 235:

```

Met Ser Ser Arg Asn Cys Phe Phe Pro Ser Phe Leu Phe Gly Leu Tyr
 -20 -15 -10

Ser Phe Arg Ala Val Asp Ser Ser Arg Ile Lys Leu Ser Leu Leu Thr
 -5 1 5

Lys Glu Glu Glu Thr Pro Ser Ala Tyr Tyr Arg Ser Leu
 10 15 20

```

## (2) INFORMATION FOR SEQ ID NO: 236:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -18..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5.1  
seq CLYLHVYVLTCSG/CN

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 236:

```

Met Tyr Met Asn Thr Cys Leu Tyr Leu His Val Tyr Val Leu Thr Cys
 -15 -10 -5

Ser Gly Cys Asn Val Asp Met Cys Ser Arg Leu Phe Leu Ser Thr Lys
 1 5 10

Leu Lys Ala Arg
15

```

## (2) INFORMATION FOR SEQ ID NO: 237:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 56 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells),

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -49..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5.1  
seq VALSASLPQCSLG/LL

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 237:

```

Met Ser Cys Arg Gln Pro Thr Pro Thr Gln Cys Ser Leu Leu Pro Asn

```

200

-45                      -40                      -35

Asp Asn Arg Val Ser Thr Arg Gly Gly Asp Ser Ala Gly Arg His Arg  
                  -30                      -25                      -20

Gln Val Pro Gln Val Ala Leu Ser Ala Ser Leu Pro Gln Cys Ser Leu  
                  -15                      -10                      -5

Gly Leu Leu Ile Asn Pro Arg Leu  
                  1                      5

## (2) INFORMATION FOR SEQ ID NO: 238:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Thyroid

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -20..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5.1  
seq PTAGVVVLQGSRA/SV

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 238:

Met Ile Thr Gly Cys Thr Lys Pro Thr Ala Gly Val Val Val Leu Gln  
 -20                      -15                      -10                      -5

Gly Ser Arg Ala Ser Val Arg Gln Arg  
                  1                      5

## (2) INFORMATION FOR SEQ ID NO: 239:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -14..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix



201

(D) OTHER INFORMATION: score 5  
seq GLDLILSFSSSSP/GP

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 239:

Met Gly Leu Asp Leu Ile Leu Ser Phe Ser Ser Ser Ser Pro Gly Pro  
-10 -5 1

Gly

(2) INFORMATION FOR SEQ ID NO: 240:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 69 amino acids  
(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Colon

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -62..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 4.9  
seq LDRLCALTS LCSP/GP

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 240:

Met Arg Glu Asp Asn Glu His Glu Arg Asn Val Pro Ser Gly Val Glu  
-60 -55 -50

Asn Val Lys Glu Glu Gly Gly Asp Glu Asp Leu Ser Trp Gly Asp Glu  
-45 -40 -35

Gly Cys Gln Val Leu Arg His Arg Leu Arg Val Cys Arg Lys Val Gly  
-30 -25 -20 -15

Leu Leu Asp Arg Leu Cys Ala Leu Thr Ser Leu Cys Ser Pro Gly Pro  
-10 -5 1

Leu Pro Ala Thr Leu  
5

(2) INFORMATION FOR SEQ ID NO: 241:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 amino acids  
(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Colon

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -18..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 4.9  
seq GAVVSSWAXCSLG/XP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 241:

Met Gly Lys Arg Ala Gly Ala Val Val Ser Ser Trp Ala Xaa Cys Ser  
-15 -10 -5  
Leu Gly Xaa Pro Gly Ile Gln Arg Ser Ser Arg Leu Thr  
1 5 10

## (2) INFORMATION FOR SEQ ID NO: 242:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 82 amino acids  
(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -21..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 4.9  
seq WLLSDILGQGATA/NV

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 242:

Met Gln Ser Thr Ser Asn His Leu Trp Leu Leu Ser Asp Ile Leu Gly  
-20 -15 -10  
Gln Gly Ala Thr Ala Asn Val Phe Arg Gly Arg His Lys Lys Thr Gly  
-5 1 5 10  
Asp Leu Phe Ala Ile Lys Val Phe Asn Asn Ile Ser Phe Leu Arg Pro  
15 20 25  
Val Asp Val Gln Met Arg Glu Phe Glu Val Leu Lys Lys Leu Asn His  
30 35 40  
Lys Asn Ile Val Lys Leu Phe Ala Ile Glu Glu Glu Thr Thr Thr Arg  
45 50 55

Arg Arg  
60

## (2) INFORMATION FOR SEQ ID NO: 243:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 67 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (D) DEVELOPMENTAL STAGE: Fetal
- (F) TISSUE TYPE: liver

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -49..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.9  
seq LLCLSGLELEPSA/SD

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 243:

```

Met Lys Lys Leu Arg Pro Ser Gln Glu Gln Leu Asn Cys Pro Glu Pro
 -45 -40 -35

Gln Leu Ala Asp Gly Arg Ala Gly Ile Arg Leu Leu Val Thr Trp Leu
 -30 -25 -20

Gln Pro Ala Pro Leu Leu Cys Leu Ser Gly Leu Glu Leu Glu Pro Ser
 -15 -10 -5

Ala Ser Asp Phe Gly Phe Ser Ser His Thr Thr Leu Leu Cys Cys Leu
 1 5 10 15

Val Glu Asn

```

## (2) INFORMATION FOR SEQ ID NO: 244:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 74 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Large intestine

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -19..-1

204

(C) IDENTIFICATION METHOD: Von Heijne matrix

(D) OTHER INFORMATION: score 4.9  
seq RLLFWSIFSSVTC/RK

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 244:

```

Met Trp Ser His Leu Asn Arg Leu Leu Phe Trp Ser Ile Phe Ser Ser
 -15 -10 -5
Val Thr Cys Arg Lys Ala Val Leu Asp Cys Glu Ala Met Lys Thr Asn
 1 5 10
Glu Phe Pro Ser Pro Cys Leu Asp Ser Lys Thr Lys Val Val Met Lys
 15 20 25
Gly Gln Asn Val Ser Met Phe Cys Ser His Lys Asn Lys Ser Leu Gln
 30 35 40 45
Ile Thr Tyr Ser Leu Phe Arg Arg Lys Thr
 50 55

```

(2) INFORMATION FOR SEQ ID NO: 245:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 83 amino acids

(B) TYPE: AMINO ACID

(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens

(F) TISSUE TYPE: Lung (cells)

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide

(B) LOCATION: -52...-1

(C) IDENTIFICATION METHOD: Von Heijne matrix

(D) OTHER INFORMATION: score 4.8  
seq SLLLAQATSNVVC/SL

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 245:

```

Met Leu Ala Leu Arg Asp Leu Gly Met Gly Lys Arg Glu Gly Glu Glu
 -50 -45 -40
Leu Ile Gln Ala Glu Ala Arg Cys Leu Val Glu Thr Phe Gln Gly Thr
 -35 -30 -25
Glu Gly Arg Pro Phe Asp Pro Ser Leu Leu Leu Ala Gln Ala Thr Ser
 -20 -15 -10 -5
Asn Val Val Cys Ser Leu Leu Phe Gly Leu Arg Phe Ser Tyr Glu Asp
 1 5 10
Lys Glu Phe Gln Ala Val Val Arg Ala Ala Gly Gly Thr Cys Trp Glu
 15 20 25

```

Ser Ala Pro  
30

(2) INFORMATION FOR SEQ ID NO: 246:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 67 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Liver

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -19..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.8  
seq STSLCGCLRQLRC/SM

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 246:

Met Leu Ser Val Gly Ala Ser Thr Ser Leu Cys Gly Cys Leu Arg Gln  
                  -15                  -10                  -5  
Leu Arg Cys Ser Met Leu Asp Leu Gln Trp Ser Phe Leu Glu Asp Gly  
                  1                          5                          10  
Glu Pro Cys Arg Ala Arg Leu Ser Pro Leu Pro Pro Leu Ala His Leu  
          15                          20                          25  
Ala Gly Ile Trp Ile Val Leu Pro Arg Ala Ser Phe Ser Val Met Asp  
          30                          35                          40                          45  
Tyr His Ala

(2) INFORMATION FOR SEQ ID NO: 247:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -19..-1

206

(C) IDENTIFICATION METHOD: Von Heijne matrix

(D) OTHER INFORMATION: score 4.8  
seq VLLSQFLYPLAYP/HP

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 247:

Met Phe Gln Gln Met Tyr Val Leu Leu Ser Gln Phe Leu Tyr Pro Leu  
-15 -10 -5

Ala Tyr Pro His Pro Ile Gly  
1

(2) INFORMATION FOR SEQ ID NO: 248:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 amino acids

(B) TYPE: AMINO ACID

(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens

(F) TISSUE TYPE: Lung (cells)

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide

(B) LOCATION: -16..-1

(C) IDENTIFICATION METHOD: Von Heijne matrix

(D) OTHER INFORMATION: score 4.8  
seq HFCXIGFLSYTTS/LV

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 248:

Met Thr Ser His Phe Cys Xaa Ile Gly Phe Leu Ser Tyr Thr Thr Ser  
-15 -10 -5

Leu Val Tyr Trp Asn Ala Gly Arg  
1 5

(2) INFORMATION FOR SEQ ID NO: 249:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 47 amino acids

(B) TYPE: AMINO ACID

(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens

(F) TISSUE TYPE: Thyroid

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide

207

(B) LOCATION: -25..-1  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 4.8  
 seq NVLLSGSLLRSLC/LK

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 249:

```

Met Ile Cys Ser Leu Thr Pro Phe Arg Ser Leu Thr Asn Val Leu Leu
-25 -20 -15 -10

Ser Gly Ser Leu Leu Arg Ser Leu Cys Leu Lys Tyr Lys Pro Leu Thr
 -5 1 5

Ser Ile Phe Leu Val Ser Met Cys Pro Ile Pro Phe Pro Cys His
 10 15 20

```

(2) INFORMATION FOR SEQ ID NO: 250:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 34 amino acids  
 (B) TYPE: AMINO ACID  
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:  
 (A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Colon

(ix) FEATURE:  
 (A) NAME/KEY: sig\_peptide  
 (B) LOCATION: -27..-1  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 4.7  
 seq PALTLTFLPPSPT/LP

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 250:

```

Met Glu Pro Pro Gly Arg Ser Ser Ser Leu Pro Phe Ser Pro Pro Ala
 -25 -20 -15

Leu Thr Leu Thr Phe Leu Pro Pro Ser Pro Thr Leu Pro Leu Pro Ser
-10 -5 1 5

Pro Gly

```

(2) INFORMATION FOR SEQ ID NO: 251:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 63 amino acids  
 (B) TYPE: AMINO ACID  
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Colon

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -55..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 4.7  
seq IGILCSLLGTVLL/WV

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 251:

```

Met Asp Lys Leu Lys Lys Val Leu Ser Gly Gln Asp Thr Glu Asp Arg
-55 -50 -45 -40

Ser Gly Leu Ser Glu Val Val Glu Ala Ser Ser Leu Ser Trp Ser Thr
 -35 -30 -25

Arg Ile Lys Gly Phe Ile Ala Cys Phe Ala Ile Gly Ile Leu Cys Ser
 -20 -15 -10

Leu Leu Gly Thr Val Leu Leu Trp Val Pro Arg Lys Gly His Gly
 -5 1 5

```

## (2) INFORMATION FOR SEQ ID NO: 252:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 amino acids  
(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -25..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 4.7  
seq LGMVCIFSLRLQA/VF

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 252:

```

Met Tyr Ser Arg His Thr Val Lys Leu Lys Gln Gly Leu Gly Met Val
-25 -20 -15 -10

Cys Ile Phe Ser Leu Arg Leu Gln Ala Val Phe Thr Thr Glu Gly Arg
 -5 1 5

```

## (2) INFORMATION FOR SEQ ID NO: 253:



- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 55 amino acids  
 (B) TYPE: AMINO ACID  
 (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: PROTEIN
- (vi) ORIGINAL SOURCE:  
 (A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Lung (cells)
- (ix) FEATURE:  
 (A) NAME/KEY: sig\_peptide  
 (B) LOCATION: -24..-1  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 4.6  
 seq SLLLYSLPLNIIG/LN
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 253:

```

Met Tyr Pro Ser Leu Leu Val Asp Tyr Phe Pro Ser Leu Leu Leu Tyr
 -20 -15 -10

Ser Leu Pro Leu Asn Ile Ile Gly Leu Asn Cys Ala Tyr Pro Leu Ile
 -5 1 5

Asn Asn Phe Leu Lys Asn Asn Ser Tyr Thr Cys Val Xaa Val Pro Leu
 10 15 20

Ala Phe Pro Ser Met Pro Ser
 25 30

```

(2) INFORMATION FOR SEQ ID NO: 254:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 79 amino acids  
 (B) TYPE: AMINO ACID  
 (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: PROTEIN
- (vi) ORIGINAL SOURCE:  
 (A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Lung (cells)
- (ix) FEATURE:  
 (A) NAME/KEY: sig\_peptide  
 (B) LOCATION: -77..-1  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 4.5  
 seq LPTQFLFLGVLG/IF
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 254:

```

Met Ala Thr Thr Val Pro Asp Gly Cys Arg Asn Gly Leu Lys Ser Lys
 -75 -70 -65

```

210

Tyr Tyr Arg Leu Cys Asp Lys Ala Glu Ala Trp Gly Ile Val Leu Glu  
 -60 -55 -50  
 Thr Val Ala Thr Ala Gly Val Val Thr Ser Val Ala Phe Met Xaa Thr  
 -45 -40 -35 -30  
 Leu Pro Ile Leu Val Cys Lys Val Gln Asp Ser Asn Arg Arg Lys Met  
 -25 -20 -15  
 Leu Pro Thr Gln Phe Leu Phe Leu Leu Gly Val Leu Gly Ile Phe  
 -10 -5 1

## (2) INFORMATION FOR SEQ ID NO: 255:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 68 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Large intestine

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -17..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.5  
seq HLDHLFFSGVVLG/QG

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 255:

Met Arg Leu Gln His Leu Asp His Leu Phe Phe Ser Gly Val Val Leu  
 -15 -10 -5  
 Gly Gln Gly Leu Asp Leu Gly Arg Val Cys Leu Arg Lys Trp Gly Tyr  
 1 5 10 15  
 Arg Arg Cys Glu Asp Ile Cys Trp Ile Lys Thr Asn Lys Asn Asn Pro  
 20 25 30  
 Gly Lys Thr Lys Thr Leu Asp Pro Lys Ala Val Phe Gln Arg Thr Lys  
 35 40 45  
 Ala Gly Leu Gly  
 50

## (2) INFORMATION FOR SEQ ID NO: 256:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 78 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

211

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Pancreas

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -31..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 4.5  
seq VAFGLYNPSLCHA/CT

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 256:

Met Pro Leu Pro Lys Pro Ser Phe Ser Asn Asn His Leu Ile Arg Leu  
-30 -25 -20  
Ile Thr Val Ala Phe Gly Leu Tyr Asn Pro Ser Leu Cys His Ala Cys  
-15 -10 -5 1  
Thr Arg Cys Ser Thr Ala Ser Val Ser His Gln Ile Ala His Ser Pro  
5 10 15  
Lys Gln Lys Pro Ser Asn Leu Gly Ala Ile Gln Gly Leu Ala Gln Cys  
20 25 30  
Leu Val Glu His Met Cys Cys Arg Ile Asn Ile Asp Thr Trp  
35 40 45

(2) INFORMATION FOR SEQ ID NO: 257:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 94 amino acids  
(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Pancreas

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -75..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 4.4  
seq QXRLCVSPSGLRC/EP

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 257:

Met Glu Pro Ile Thr Phe Thr Ala Arg Lys His Leu Leu Pro Asn Glu  
-75 -70 -65 -60  
Val Ser Val Asp Phe Gly Leu Gln Leu Val Gly Ser Leu Pro Val His  
-55 -50 -45

Ser Leu Thr Thr Met Pro Met Leu Pro Trp Val Val Ala Glu Val Arg  
                   -40                  -35                  -30

Arg Leu Ser Arg Gln Ser Thr Arg Lys Glu Pro Val Thr Xaa Gln Xaa  
                   -25                  -20                  -15

Arg Leu Cys Val Ser Pro Ser Gly Leu Arg Cys Glu Pro Glu Pro Gly  
                   -10                  -5                  1                  5

Arg Ser Gln Gln Trp Asp Pro Leu Ile Tyr Ser Ser Ile Phe  
                   10                  15

## (2) INFORMATION FOR SEQ ID NO: 258:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 40 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Colon

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -25..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.4  
seq FFCWEVGVSGSSA/GP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 258:

Met Gly Cys Leu Trp Gly Leu Ala Leu Pro Leu Phe Phe Phe Cys Trp  
   -25                  -20                  -15                  -10

Glu Val Gly Val Ser Gly Ser Ser Ala Gly Pro Ser Thr Arg Arg Ala  
                   -5                  1                  5

Asp Thr Ala Met Thr Thr Asp Asp  
                   10                  15

## (2) INFORMATION FOR SEQ ID NO: 259:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 38 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -20..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.3  
seq YLCHISLLDVTQQ/FP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 259:

```

Met Lys Gln Asn Thr Asp Pro Tyr Leu Cys His Ile Ser Leu Leu Asp
-20 -15 -10 -5
Val Thr Gln Gln Phe Pro Asn Pro Leu Pro Gly Arg Thr Ile Phe Pro
 1 5 10
Gly Ser Ser Thr Pro Arg
 15

```

## (2) INFORMATION FOR SEQ ID NO: 260:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 51 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (D) DEVELOPMENTAL STAGE: Fetal
- (F) TISSUE TYPE: liver

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -35..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.3  
seq LISLLSSPNTPSA/SI

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 260:

```

Met Val Thr Tyr Phe Asn Phe Thr Phe Lys Pro Phe Cys Ile Leu Ala
-35 -30 -25 -20
Ser Ile Ile Val Pro Thr Leu Ile Ser Leu Leu Ser Ser Pro Asn Thr
 -15 -10 -5
Pro Ser Ala Ser Ile Tyr Tyr Ser Pro Lys Cys Leu Cys Pro Leu Ala
 1 5 10
Thr Pro Arg
 15

```

## (2) INFORMATION FOR SEQ ID NO: 261:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 28 amino acids  
(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Colon

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -23..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 4.3  
seq QXILLGTTSVVTA/AL

(xi) SEQUENCE DESCRIPTION: SEO ID NO: 261:

Met Glu Ser Gly Gly Arg Pro Ser Leu Cys Gln Xaa Ile Leu Leu Gly  
-20 -15 -10

Thr Thr Ser Val Val Thr Ala Ala Leu Tyr Ser Val  
-5 1 5

(2) INFORMATION FOR SEQ ID NO: 262:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 91 amino acids  
(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Pancreas

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -43..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 4.2  
seq HMMAAAVADGTRA/AT

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 262:

Met Glu Ala Gln Gln Ala Gln Lys Ser Ala Glu Gln Pro Glu Gln Lys  
-40 -35 -30

Ala Ala Thr Glu Val Ser Xaa Glu Leu Ser Glu Ser Gln Val His Met  
-25 -20 -15

Met Ala Ala Ala Val Ala Asp Gly Thr Arg Ala Ala Thr Ile Ile Glu  
-10 -5 1 5

Ala Ala Thr Glu Val Ser Xaa Glu Leu Ser Glu Ser Gln Val His Met  
-25 -20 -15

Met Ala Ala Ala Val Ala Asp Gly Thr Arg Ala Ala Thr Ile Ile Glu  
-10 -5 1 5

215

Glu Arg Ser Pro Ser Trp Ile Ser Ala Ser Val Thr Glu Pro Leu Glu  
                  10                  15                  20  
Gln Val Glu Ala Glu Ala Ala Leu Leu Thr Glu Glu Val Leu Glu Arg  
                  25                  30                  35  
Glu Val Ile Ala Glu Glu Glu Pro Pro Thr Met  
                  40                  45

## (2) INFORMATION FOR SEQ ID NO: 263:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -17..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.2  
seq SVIWFGSVXPCIS/XV

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 263:

Met Pro Leu Asn Ser Val Ile Trp Phe Gly Ser Val Xaa Pro Cys Ile  
          -15                  -10                  -5  
Ser Xaa Val Glu Leu  
          1

## (2) INFORMATION FOR SEQ ID NO: 264:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 37 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -30..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.2

216

seq FLDFANLADLTALA/ES

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 264:

Met Leu Gln Gln Leu Asp Ser Ile Ser Leu Arg Arg Arg Glu Thr Ala  
 -30 -25 -20 -15

Asn Phe Leu Asp Phe Ala Asn Leu Ala Asp Leu Thr Leu Ala Glu Ser  
 -10 -5 1

Glu Val Phe Arg Leu  
 5

(2) INFORMATION FOR SEQ ID NO: 265:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 56 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -48..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.1  
seq FTTLNLSLPSQT/KD

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 265:

Met Cys Tyr Leu Ala Glu Leu Ser Leu Thr Thr Phe Xaa Xaa Gly Tyr  
 -45 -40 -35

Ile Val Thr Ser Arg Ala Thr Thr Thr Thr Thr Leu Ala Ile Gln Pro  
 -30 -25 -20

Gly Leu Pro Phe Thr Thr Leu Ser Asn Leu Ser Leu Pro Ser Gln Thr  
 -15 -10 -5

Lys Asp Glu Leu His Pro Pro Trp  
 1 5

(2) INFORMATION FOR SEQ ID NO: 266:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN



## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Pancreas

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -17..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 4.1  
seq LSSLILLPIWINM/AQ

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 266:

Met Ser Ile Ser Leu Ser Ser Leu Ile Leu Leu Pro Ile Trp Ile Asn  
-15 -10 -5

Met Ala Gln Ile Gln Arg Gly Gly  
1 5

## (2) INFORMATION FOR SEQ ID NO: 267:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 125 amino acids  
(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Lung

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -86..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 4  
seq LLFALSWKSDAPA/TS

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 267:

Met Asp Arg Asp Leu Leu Arg Gln Ser Leu Asn Cys His Gly Ser Ser  
-85 -80 -75

Leu Leu Ser Leu Leu Arg Ser Glu Gln Gln Asp Asn Pro His Phe Arg  
-70 -65 -60 -55

Ser Leu Leu Gly Ser Ala Ala Glu Pro Ala Arg Gly Pro Pro Pro Gln  
-50 -45 -40

His Pro Leu Gln Gly Arg Lys Glu Lys Arg Val Asp Asn Ile Glu Ile  
-35 -30 -25

Gln Lys Phe Ile Ser Lys Lys Ala Asp Leu Leu Phe Ala Leu Ser Trp  
-20 -15 -10

Lys Ser Asp Ala Pro Ala Thr Ser Glu Ile Asn Glu Asp Ser Glu Asp  
-5 1 5 10  
His Tyr Ala Ile Met Pro Pro Leu Glu Gln Phe Met Glu Ile Pro Ser  
15 20 25  
Met. Asp Arg Arg Glu Leu Phe Phe Arg Asp Ile Glu Arg  
30 35

(A) LENGTH: 25 amino acids  
(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Large intestine

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -17..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 4  
seq TLVTXXNASCSFA/SV

Met Val Leu Ala Thr Leu Val Thr Xaa Xaa Asn Ala Ser Cys Ser Phe  
-15 -10 -5

Ala Ser Val His Leu Ala Gln Gly Gly  
1 5

(A) LENGTH: 39 amino acids  
(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Lung (cells)

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -20..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 4  
seq IILKVLNQTCTQ/VQ

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 269:

Met Met Ile Trp Lys Arg Leu Ile Ile Leu Lys Val Leu Leu Asn Gln  
 -20 -15 -10 -5

Thr Cys Gln Thr Val Gln Thr Val Thr Pro Thr Ser Trp Val Phe Ser  
 1 5 10

Asn Gln Ala Gly Met Thr Arg  
 15

## (2) INFORMATION FOR SEQ ID NO: 270:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 100 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (D) DEVELOPMENTAL STAGE: Fetal
- (F) TISSUE TYPE: liver

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -61..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4  
seq AALVKCLPVLCLA/GF

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 270:

Met Asp Ala Gly Lys Ala Gly Gln Thr Leu Lys Thr His Cys Ser Ala  
 -60 -55 -50

Gln Arg Pro Asp Val Cys Arg Trp Leu Ser Pro Phe Ile Leu Ser Cys  
 -45 -40 -35 -30

Cys Val Tyr Phe Cys Leu Trp Ile Pro Glu Asp Gln Leu Ser Trp Phe  
 -25 -20 -15

Ala Ala Leu Val Lys Cys Leu Pro Val Leu Cys Leu Ala Gly Phe Leu  
 -10 -5 1

Trp Val Met Ser Pro Ser Gly Gly Tyr Thr Gln Leu Leu Gln Gly Ala  
 5 10 15

Leu Val Cys Ser Ala Val Gly Asp Ala Cys Leu Ile Trp Pro Ala Ala  
 20 25 30 35

Phe Val Pro Gly

220

## (2) INFORMATION FOR SEQ ID NO: 271:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 70 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -28..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4  
seq PLLGVLFFQGVYI/VF

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 271:

Met Gln Gln Arg Gly Ala Ala Gly Ser Arg Gly Cys Ala Leu Phe Pro  
                  -25                  -20                  -15

Leu Leu Gly Val Leu Phe Phe Gln Gly Val Tyr Ile Val Phe Ser Leu  
          -10                  -5                          1

Glu Ile Arg Ala Asp Ala His Val Arg Gly Tyr Val Gly Glu Lys Ile  
  5                          10                          15                  20

Lys Leu Lys Cys Thr Phe Lys Ser Thr Ser Asp Val Thr Asp Lys Leu  
                  25                          30                          35

Thr Ile Asp Trp Thr Gln  
                  40

## (2) INFORMATION FOR SEQ ID NO: 272:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 51 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Colon

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -32..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4  
seq LIYWYVLLILSFP/FI

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 272:

Met Leu Gly Thr His Ile Tyr Val Ser Leu Trp Ile Ile Leu Phe Ser  
           -30                              -25                              -20

Ser Pro His Leu Ile Tyr Trp Tyr Val Leu Leu Ile Leu Ser Phe Pro  
       -15                              -10                              -5

Phe Ile Ile Lys Phe Ser Met Asn Thr Leu Ser Arg Pro Pro Pro Asp  
   1                              5                              10                              15

Thr Pro Gln

## (2) INFORMATION FOR SEQ ID NO: 273:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Pancreas

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -19..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 3.9  
seq FLNLHGFLGHLLS/GE

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 273:

Met Ser Ile Tyr Asn Leu Phe Leu Asn Leu His Gly Phe Leu Gly His  
                   -15                              -10                              -5

Leu Leu Ser Gly Glu  
                   1

## (2) INFORMATION FOR SEQ ID NO: 274:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide

222

(B) LOCATION: -25..-1  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 3.9  
 seq PACVCMCTXSCYS/CQ

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 274:

Met Cys Met Gln Val Asp Leu Ala Phe Ser Phe Pro Pro Ala Cys Val  
 -25 -20 -15 -10

Cys Met Cys Thr Xaa Ser Cys Tyr Ser Cys Gln Cys Glu  
 -5 1

(2) INFORMATION FOR SEQ ID NO: 275:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 70 amino acids  
 (B) TYPE: AMINO ACID  
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
 (F) TISSUE TYPE: Pancreas

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: -32..-1  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 3.8  
 seq IRTATLVISLARG/WQ

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 275:

Met Ala Pro Gly Glu Lys Glu Ser Gly Glu Gly Pro Ala Lys Ser Ala  
 -30 -25 -20

Leu Arg Lys Ile Arg Thr Ala Thr Leu Val Ile Ser Leu Ala Arg Gly  
 -15 -10 -5

Trp Gln Gln Trp Ala Asn Glu Asn Ser Ile Arg Gln Ala Gln Glu Pro  
 1 5 10 15

Thr Gly Trp Leu Pro Gly Gly Thr Gln Asp Ser Pro Gln Ala Pro Lys  
 20 25 30

Pro Ile Thr Pro Arg Gly  
 35

(2) INFORMATION FOR SEQ ID NO: 276:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 52 amino acids  
 (B) TYPE: AMINO ACID

223

(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(D) DEVELOPMENTAL STAGE: Fetal  
(F) TISSUE TYPE: liver

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -42..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 3.7  
seq PLLHLFYQHLCFP/VP

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 276:

Met Glu Pro Lys Arg Gly Arg Met Trp Xaa Phe Glu Ile Glu Asp Ser  
-40 -35 -30  
Cys Ile Tyr Gln Asp Ile Pro Ser Phe Val Leu Leu Tyr Pro Leu Leu  
-25 -20 -15  
His Leu Phe Tyr Gln His Leu Cys Phe Pro Val Pro Cys Thr Arg Asn  
-10 -5 1 5  
Pro Gly Pro Gly  
10

(2) INFORMATION FOR SEQ ID NO: 277:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 amino acids  
(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Lung (cells)

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -17..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 3.6  
seq SVLQRCLFSFVTS/VE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 277:

Met Glu Phe Cys Ser Val Leu Gln Arg Cys Leu Phe Ser Phe Val Thr  
-15 -10 -5  
Ser Val Phe His Met Leu Phe Pro Leu Pro Gly  
1 5 10

## (2) INFORMATION FOR SEQ ID NO: 278:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 23 amino acids
  - (B) TYPE: AMINO ACID
  - (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: PROTEIN
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Homo Sapiens
  - (D) DEVELOPMENTAL STAGE: Fetal
  - (F) TISSUE TYPE: liver
- (ix) FEATURE:
  - (A) NAME/KEY: sig\_peptide
  - (B) LOCATION: -18..-1
  - (C) IDENTIFICATION METHOD: Von Heijne matrix
  - (D) OTHER INFORMATION: score 3.6  
seq IYVLLFFLLMKFS/FD
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 278:

Met Ala Glu Ser Gln Ile Tyr Val Leu Leu Phe Phe Leu Leu Met Lys  
                  -15                  -10                  -5  
  
Phe Ser Phe Asp Thr Arg Gly  
          1                  5

## (2) INFORMATION FOR SEQ ID NO: 279:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 27 amino acids
  - (B) TYPE: AMINO ACID
  - (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: PROTEIN
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Homo Sapiens
  - (F) TISSUE TYPE: Liver
- (ix) FEATURE:
  - (A) NAME/KEY: sig\_peptide
  - (B) LOCATION: -18..-1
  - (C) IDENTIFICATION METHOD: Von Heijne matrix
  - (D) OTHER INFORMATION: score 3.6  
seq ACSLSGGPLQINA/LP
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 279:

Met Gln Thr Asn Asn Ala Cys Ser Leu Ser Ser Gly Pro Leu Gln Ile  
                  -15                  -10                  -5



225

Asn Ala Leu Pro Asp Leu Pro Cys His Pro Gly  
1 5

## (2) INFORMATION FOR SEQ ID NO: 280:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Large intestine

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -26..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 3.6  
seq KVLMLLCNQTA/KR

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 280:

Met Gly Gln Asn Asn Ala Ser Phe His Cys Pro Cys Leu Lys Val Leu  
-25 -20 -15

Met Gly Leu Leu Cys Asn Gln Thr Ala Ala Lys Arg Pro  
-10 -5 1

## (2) INFORMATION FOR SEQ ID NO: 281:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Liver

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -14..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 3.6  
seq LPLLSVMWSPIAP/LT

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 281:

Met Leu Pro Leu Leu Ser Val Met Trp Ser Pro Ile Ala Pro Leu Thr  
-10 -5 1

Val Gly Ser Lys Asp Pro Cys His Phe Ile Pro Val His Asp Glu Met  
5 10 15

## (2) INFORMATION FOR SEQ ID NO: 282:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Thyroid

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -23..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 3.6  
seq WITCPPTFHGCRA/LF

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 282:

Met Trp Leu Asn Cys Gly Gly Leu Gln Arg Trp Ile Thr Cys Pro Pro  
-20 -15 -10  
Thr Phe His Gly Cys Arg Ala Leu Phe Pro Val Leu Asp Ala Gly  
-5 1 5

## (2) INFORMATION FOR SEQ ID NO: 283:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 40 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -32..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 3.6  
seq LGVLTFILQRTTC/LN

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 283:

Met Trp Gln Gly Cys Asn Cys Ser Gln Leu Ser Glu Thr Ala Val Asp

227

-30                      -25                      -20  
 Gln Glu Gln Leu Gly Val Leu Thr Phe Ile Leu Gln Arg Thr Thr Cys  
 -15                      -10                      -5  
 Leu Asn Val Ser Ala Gly Lys Arg  
 1                      5

## (2) INFORMATION FOR SEQ ID NO: 284:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -37..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 3.6  
seq LVTLLASKSPSCP/LH

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 284:

Met Cys Leu Pro His Pro Gln Val Val Ser Ser Asn Phe His Ile Leu  
 -35                      -30                      -25  
 Ile Phe Leu Leu Pro Thr Lys Met Leu Val Thr Leu Leu Ala Ser Lys  
 -20                      -15                      -10  
 Ser Pro Ser Cys Pro Leu His Pro Leu Arg  
 -5                      1                      5

## (2) INFORMATION FOR SEQ ID NO: 285:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 111 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Pancreas

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -74..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix

228

(D) OTHER INFORMATION: score 3.5  
seq ECLNLLLSSGADL/RR

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 285:

```

Met His Leu Ala Val Leu Phe Xaa Phe Ser Asp Cys Cys Arg Lys Xaa
 -70 -65 -60

Leu Ser Ser Gly Gln Leu Tyr Ser Ile Val Ser Ser Leu Ser Asn Glu
 -55 -50 -45

His Val Leu Ser Ala Gly Phe Asp Ile Asn Thr Pro Asp Asn Leu Gly
 -40 -35 -30

Arg Thr Cys Leu His Ala Ala Ala Ser Gly Gly Asn Val Glu Cys Leu
 -25 -20 -15

Asn Leu Leu Leu Ser Ser Gly Ala Asp Leu Arg Arg Arg Asp Lys Phe
 -10 -5 1 5

Gly Arg Thr Pro Leu Xaa Tyr Ala Ala Ala Asn Gly Ser Xaa Gln Cys
 10 15 20

Ala Val Thr Leu Val Thr Ala Gly Ala Gly Val Asn Glu Gly Xaa
 25 30 35

```

(2) INFORMATION FOR SEQ ID NO: 286:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Thyroid

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -24...-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 3.5  
seq LHDCFLSVFQVLS/SI

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 286:

```

Met Ser Phe Gln Trp Cys Gly Trp Gln Trp Gly Leu His Asp Cys Phe
 -20 -15 -10

Leu Ser Val Phe Gln Val Leu Ser Ser Ile Gly Leu Val Ser Phe Leu
 -5 1 5

Phe

```

## (2) INFORMATION FOR SEQ ID NO: 287:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 57 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Thyroid

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -20..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 3.5  
seq KFCLICLLTFIFH/HC

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 287:

Met Lys Val His Met His Thr Lys Phe Cys Leu Ile Cys Leu Leu Thr  
-20                               -15                               -10                               -5  
  
Phe Ile Phe His His Cys Asn His Cys His Glu Glu His Asp His Gly  
                                  1                               5                               10  
  
Pro Glu Ala Leu His Arg Xaa His Arg Gly Met Thr Glu Leu Glu Pro  
          15                               20                               25  
  
Ser Lys Phe Ser Lys Gln Ala Arg Gly  
          30                               35

## (2) INFORMATION FOR SEQ ID NO: 288:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 77 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -25..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 3.5  
seq IFLGKSLFSLLEA/MI

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 288:

230

```

Met Ser Phe Asn Leu Gln Ser Ser Lys Lys Leu Phe Ile Phe Leu Gly
-25 -20 -15 -10

Lys Ser Leu Phe Ser Leu Leu Glu Ala Met Ile Phe Ala Leu Leu Pro
 -5 1 5

Lys Pro Arg Lys Asn Val Ala Gly Glu Ile Val Leu Ile Thr Gly Ala
 10 15 20

Gly Ser Gly Leu Gly Arg Leu Leu Ala Leu Gln Phe Ala Arg Leu Gly
 25 30 35

Ser Val Leu Val Leu Trp Asp Ile Asn Lys Glu Gly Arg
 40 45 50

```

## (2) INFORMATION FOR SEQ ID NO: 289:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 126 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Large intestine

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -26..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 7.6  
seq FLLLVAAPRWVS/EM

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 289:

```

Met Asp Leu Met Cys Arg Lys Val Lys His Leu Leu Phe Phe Leu Leu
-25 -20 -15

Leu Val Ala Ala Pro Arg Trp Val Val Ser Glu Met Gln Ile Glu Glu
-10 -5 1 5

Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Thr Leu Thr Cys
 10 15 20

Asn Val Phe Gly Gly Ala Ile Asn Thr Asn Ala Tyr Tyr Trp Ala Trp
 25 30 35

Val Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Val Tyr
 40 45 50

Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr
 55 60 65 70

Met Ser Met Ala Thr Ser Arg Asn Gln Phe Ser Leu Gln Met Ser Ser
 75 80 85

```

Val Met Ala Thr Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gln  
                   90                                  95                                  100

## (2) INFORMATION FOR SEQ ID NO: 290:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 63 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -52..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 6.6  
seq FFAVLFFLWRSFX/SV

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 290:

Met Glu Leu Lys Ser Pro Glu Glu Glu Val Val Ala Ala Leu Pro Glu  
                   -50                                  -45                                  -40

Gly Met Arg Pro Asp Ser Asn Leu Tyr Gly Phe Pro Trp Glu Leu Val  
                   -35                                  -30                                  -25

Ile Cys Ala Ala Val Val Gly Phe Phe Ala Val Leu Phe Phe Leu Trp  
                   -20                                  -15                                  -10                                  -5

Arg Ser Phe Xaa Ser Val Arg Ser Arg Leu Tyr Val Gly Arg Gly  
                                   1                                  5                                  10

## (2) INFORMATION FOR SEQ ID NO: 291:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 77 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Thyroid

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -39..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 6.6  
seq LALVLAWLSTYVA/DS

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Glu | Leu | Ser | Asp | Val | Thr | Leu | Ile | Glu | Gly | Val | Gly | Asn | Glu | Val |
|     |     |     |     | -35 |     |     |     |     | -30 |     |     |     |     | -25 |     |
| Met | Val | Val | Ala | Gly | Val | Val | Val | Leu | Ile | Leu | Ala | Leu | Val | Leu | Ala |
|     |     |     | -20 |     |     |     |     | -15 |     |     |     |     | -10 |     |     |
| Trp | Leu | Ser | Thr | Tyr | Val | Ala | Asp | Ser | Gly | Ser | Asn | Gln | Leu | Leu | Gly |
|     |     | -5  |     |     |     |     | 1   |     |     |     | 5   |     |     |     |     |
| Ala | Ile | Val | Ser | Ala | Gly | Asp | Thr | Ser | Val | Leu | Xaa | Leu | Gly | His | Val |
| 10  |     |     |     |     | 15  |     |     |     |     | 20  |     |     |     |     | 25  |
| Asp | His | Leu | Val | Ala | Gly | Gln | Gly | Asn | Pro | Glu | Arg | Arg |     |     |     |
|     |     |     |     | 30  |     |     |     |     | 35  |     |     |     |     |     |     |

(2) INFORMATION FOR SEQ ID NO: 292:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 67 amino acids  
(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Pancreas

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide  
(B) LOCATION: -41..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 5.4  
seq RLLYIGFLGYCSG/LI

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 292:

```

Met Ile Ala Arg Arg Asn Pro Glu Pro Leu Arg Phe Leu Pro Asp Glu
 -40 -35 -30

Ala Arg Ser Leu Pro Pro Pro Lys Leu Thr Asp Pro Arg Leu Leu Tyr
-25 -20 -15 -10

Ile Gly Phe Leu Gly Tyr Cys Ser Gly Leu Ile Asp Asn Leu Ile Arg
 -5 1 5

Arg Arg Pro Ile Ala Thr Ala Gly Leu His Arg Gln Leu Leu Tyr Ile
 10 15 20

Xaa Ala Gly
 25

```



## (2) INFORMATION FOR SEQ ID NO: 293:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 48 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Thyroid

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -24..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5.2  
seq VGGLILWLSVGSS/GD

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 293:

Met Pro Pro Gly Pro Trp Glu Ser Cys Phe Trp Val Gly Gly Leu Ile  
                  -20                  -15                  -10

Leu Trp Leu Ser Val Gly Ser Ser Gly Asp Ala Pro Pro Thr Pro Gln  
                  -5                          1                          5

Pro Lys Cys Ala Asp Phe Gln Ser Ala Asn Leu Phe Glu Gly Thr Arg  
          10                          15                          20

## (2) INFORMATION FOR SEQ ID NO: 294:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -14..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5  
seq CARALLLACSSRG/RH

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 294:

Met Cys Ala Arg Ala Leu Leu Leu Ala Cys Ser Ser Arg Gly Arg His  
                  -10                          -5                          1

Arg Leu Ala Cys Gln Cys Ser Thr Ser Ala Thr Pro Ser Trp Ala Ala

234

5 10 15  
 Ala Ser Trp Gly  
 20

## (2) INFORMATION FOR SEQ ID NO: 295:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 108 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -46..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.7  
seq IICCVFLLLAIVG/YV

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 295:

Met Gly Asp Glu Arg Pro His Tyr Tyr Gly Lys His Gly Thr Pro Gln  
 -45 -40 -35

Lys Tyr Asp Pro Thr Phe Lys Gly Pro Ile Tyr Asn Arg Gly Cys Thr  
 -30 -25 -20 -15

Asp Ile Ile Cys Cys Val Phe Leu Leu Leu Ala Ile Val Gly Tyr Val  
 -10 -5 1

Ala Val Gly Ile Ile Ala Trp Thr His Gly Asp Pro Arg Lys Val Ile  
 5 10 15

Tyr Pro Thr Asp Ser Arg Gly Glu Phe Cys Gly Gln Lys Gly Thr Lys  
 20 25 30

Asn Glu Asn Lys Pro Tyr Leu Phe Tyr Phe Asn Ile Val Lys Cys Ala  
 35 40 45 50

Ser Pro Leu Val Leu Leu Glu Phe Gln Cys Pro Thr  
 55 60

## (2) INFORMATION FOR SEQ ID NO: 296:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 81 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -16..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 4.5  
seq RLLLRFLASVIS/RK

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 296:

Met Ala Gln Arg Leu Leu Leu Arg Arg Phe Leu Ala Ser Val Ile Ser  
-15 -10 -5  
Arg Lys Pro Ser Gln Gly Gln Trp Pro Pro Leu Thr Ser Arg Ala Leu  
1 5 10 15  
Gln Thr Pro Gln Cys Ser Pro Gly Gly Leu Thr Val Thr Pro Asn Pro  
20 25 30  
Ala Arg Thr Ile Tyr Thr Thr Arg Ile Ser Leu Thr Thr Phe Asn Ile  
35 40 45  
Gln Asp Gly Pro Asp Phe Gln Asp Arg Val Val Asn Ser Glu Thr Pro  
50 55 60  
Ala  
65

## (2) INFORMATION FOR SEQ ID NO: 297:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 90 amino acids  
(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -23..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 4.4  
seq QFILLGTTSVVTA/AL

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 297:

Met Glu Ser Gly Gly Arg Pro Ser Leu Cys Gln Phe Ile Leu Leu Gly  
-20 -15 -10

236

Thr Thr Ser Val Val Thr Ala Ala Leu Tyr Ser Val Tyr Arg Gln Lys  
           -5                          1                          5

Ala Arg Val Ser Gln Glu Leu Lys Gly Ala Lys Lys Val His Leu Gly  
   10                          15                          20                          25

Glu Asp Leu Lys Ser Ile Leu Ser Glu Ala Pro Gly Lys Cys Val Pro  
                           30                          35                          40

Xaa Ala Val Ile Glu Gly Ala Val Arg Ser Val Lys Glu Thr Leu Asn  
                           45                          50                          55

Ser Gln Phe Val Glu Asn Cys Lys Gly Xaa  
           60                          65

## (2) INFORMATION FOR SEQ ID NO: 298:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 73 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Liver

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -24...-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 16.4  
seq LLLLLLLASLTSG/SV

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 298:

Met Ala Leu Ser Ser Gln Ile Trp Ala Ala Cys Leu Leu Leu Leu Leu  
                           -20                          -15                          -10

Leu Leu Ala Ser Leu Thr Ser Gly Ser Val Phe Pro Gln Gln Thr Gly  
                           -5                          1                          5

Gln Leu Ala Glu Leu Gln Pro Gln Asp Arg Ala Gly Ala Arg Ala Ser  
   10                          15                          20

Trp Met Pro Met Phe Gln Arg Arg Arg Arg Arg Asp Thr His Phe Pro  
   25                          30                          35                          40

Ile Cys Ile Phe Cys Cys Gly Pro Gly  
                           45

## (2) INFORMATION FOR SEQ ID NO: 299:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 79 amino acids

237

(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Large intestine

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -23..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 14.4  
seq LGLLLFLLPGSLG/AE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 299:

```

Met Gly Val Pro Arg Pro Gln Pro Trp Ala Leu Gly Leu Leu Leu Phe
 -20 -15 -10
Leu Leu Pro Gly Ser Leu Gly Ala Glu Ser His Leu Ser Leu Leu Tyr
 -5 1 5
His Leu Thr Ala Val Ser Ser Pro Ala Pro Gly Thr Pro Ala Phe Trp
 10 15 20 25
Val Ser Gly Trp Leu Gly Pro Gln Gln Tyr Leu Ser Tyr Asn Ser Leu
 30 35 40
Arg Gly Glu Ala Xaa Xaa Val Glu Leu Gly Ser Gly Lys Thr Arg
 45 50 55

```

(2) INFORMATION FOR SEQ ID NO: 300:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 51 amino acids  
(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Liver

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -18..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 10.3  
seq SLLLSVLLAQVWL/VP

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 300:

```

Met Lys Val Val Pro Ser Leu Leu Leu Ser Val Leu Leu Ala Gln Val
 -15 -10 -5

```

Trp Leu Val Pro Gly Leu Ala Pro Ser Pro Gln Ser Pro Glu Thr Pro  
 1 5 10  
 Ala Pro Gln Asn Gln Thr Ser Arg Val Val Gln Ala Pro Arg Glu Glu  
 15 20 25 30  
 Glu Glu Trp

## (2) INFORMATION FOR SEQ ID NO: 301:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 195 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Pancreas

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -16..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 9.5  
seq ITVLAALLACASS/CG

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 301:

Met Leu Ser Ile Thr Val Leu Ala Ala Leu Leu Ala Cys Ala Ser Ser  
 -15 -10 -5  
 Cys Gly Val Pro Ser Phe Pro Pro Asn Leu Ser Ala Arg Xaa Val Gly  
 1 5 10 15  
 Gly Glu Asp Ala Arg Pro His Ser Trp Pro Trp Gln Ile Ser Leu Gln  
 20 25 30  
 Tyr Leu Lys Asn Asp Thr Trp Arg His Thr Cys Gly Gly Thr Leu Ile  
 35 40 45  
 Ala Ser Asn Phe Xaa Leu Thr Ala Ala His Cys Ile Ser Asn Thr Arg  
 50 55 60  
 Thr Tyr Arg Val Ala Val Gly Lys Asn Asn Leu Glu Val Glu Asp Glu  
 65 70 75 80  
 Glu Gly Ser Leu Phe Val Gly Val Asp Thr Ile His Val His Lys Xaa  
 85 90 95  
 Xaa Asn Ala Xaa Leu Leu Arg Asn Asp Ile Ala Leu Ile Lys Leu Ala  
 100 105 110  
 Glu His Val Glu Leu Ser Asp Thr Ile Gln Val Ala Cys Xaa Pro Glu  
 115 120 125

239

Lys Asp Ser Leu Leu Pro Lys Asp Tyr Pro Cys Tyr Val Ser Arg Leu  
 130 135 140

Xaa Pro Pro Xaa Gly Gly Xaa Ser Gly Gly Xaa Leu Asn Cys Gln Leu  
 145 150 155 160

Glu Asn Gly Ser Trp Glu Val Phe Gly Xaa Val Ser Phe Gly Ser Arg  
 165 170 175

Arg Gly Cys

## (2) INFORMATION FOR SEQ ID NO: 302:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 123 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Pancreas

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -16..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 9.5  
seq ITVLAALLACASS/CG

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 302:

Met Leu Gly Ile Thr Val Leu Ala Ala Leu Leu Ala Cys Ala Ser Ser  
 -15 -10 -5

Cys Gly Val Pro Ser Phe Pro Pro Asn Leu Ser Ala Arg Val Val Gly  
 1 5 10 15

Gly Glu Asp Ala Arg Pro His Xaa Trp Pro Trp Gln Ile Ser Leu Gln  
 20 25 30

Tyr Leu Lys Asn Asp Thr Trp Arg His Thr Cys Gly Gly Thr Leu Ile  
 35 40 45

Ala Ser Asn Phe Val Leu Thr Ala Ala His Cys Ile Ser Xaa Thr Arg  
 50 55 60

Thr Tyr Arg Val Ala Val Gly Lys Asn Asn Leu Glu Val Glu Asp Glu  
 65 70 75 80

Glu Gly Ser Leu Xaa Val Gly Val Asp Thr Ile His Val His Arg Arg  
 85 90 95

Trp Asn Ala Leu Leu Leu Arg Asn Asp Ile Ala  
 100 105

## (2) INFORMATION FOR SEQ ID NO: 303:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 52 amino acids
  - (B) TYPE: AMINO ACID
  - (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: PROTEIN
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Homo Sapiens
  - (F) TISSUE TYPE: Colon
- (ix) FEATURE:
  - (A) NAME/KEY: sig\_peptide
  - (B) LOCATION: -38..-1
  - (C) IDENTIFICATION METHOD: Von Heijne matrix
  - (D) OTHER INFORMATION: score 8.8  
seq LLLPLLSLPVTTP/WT
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 303:

```

Met Ala Gly Asn Gly Glu Ser Glu Pro Asp Arg Leu His Leu Leu Thr
 -35 -30 -25

Gly His Arg Val Lys Gly Glu Phe Gln Leu Leu Leu Pro Leu Leu Ser
 -20 -15 -10

Leu Pro Val Thr Thr Pro Trp Thr Asn Pro Glu Glu Gly Thr Phe Ser
 -5 1 5 10

Arg Ser His Gly

```

## (2) INFORMATION FOR SEQ ID NO: 304:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 90 amino acids
  - (B) TYPE: AMINO ACID
  - (D) TOPOLOGY: LINEAR
- (ii) MOLECULE TYPE: PROTEIN
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Homo Sapiens
  - (F) TISSUE TYPE: Large intestine
- (ix) FEATURE:
  - (A) NAME/KEY: sig\_peptide
  - (B) LOCATION: -14..-1
  - (C) IDENTIFICATION METHOD: Von Heijne matrix
  - (D) OTHER INFORMATION: score 8.7  
seq LWLVLLLLPTLK/SV
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 304:

```

Met Leu Trp Trp Leu Val Leu Leu Leu Leu Pro Thr Leu Lys Ser Val

```



241

-10                      -5                      1

Phe Cys Ser Leu Val Thr Ser Leu Tyr Leu Pro Asn Thr Glu Asp Leu  
                     5                      10                      15

Ser Leu Trp Leu Trp Pro Lys Pro Asp Leu His Ser Gly Thr Arg Thr  
                     20                      25                      30

Glu Val Ser Thr His Thr Val Pro Ser Lys Pro Gly Thr Ala Ser Pro  
                     35                      40                      45                      50

Cys Trp Pro Leu Ala Gly Ala Val Pro Ser Pro Thr Val Ser Arg Leu  
                     55                      60                      65

Glu Ala Leu Thr Arg Ala Val Gln Val Ala  
                     70                      75

## (2) INFORMATION FOR SEQ ID NO: 305:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 53 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Liver

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -29..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 8.5  
seq LLGLLMAACFTFC/LS

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 305:

Met Ala Pro Gln Ser Leu Pro Ser Ser Arg Met Ala Pro Leu Gly Met  
                     -25                      -20                      -15

Leu Leu Gly Leu Leu Met Ala Ala Cys Phe Thr Phe Cys Leu Ser His  
                     -10                      -5                      1

Gln Asn Leu Lys Glu Tyr Ala Leu Thr Asn Pro Xaa Lys Xaa Ser Thr  
                     5                      10                      15

Lys Glu Thr Glu Gly  
                     20

## (2) INFORMATION FOR SEQ ID NO: 306:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 70 amino acids
- (B) TYPE: AMINO ACID

242

(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens

(F) TISSUE TYPE: Lung

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide

(B) LOCATION: -23..-1

(C) IDENTIFICATION METHOD: Von Heijne matrix

(D) OTHER INFORMATION: score 8.1  
seq LLLVTVSSNLAIA/IK

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 306:

```

Met Met Leu His Ser Ala Leu Gly Leu Cys Leu Leu Val Thr Val
 -20 -15 -10

Ser Ser Asn Leu Ala Ile Ala Ile Lys Lys Glu Lys Arg Pro Pro Gln
 -5 1 5

Thr Leu Ser Arg Gly Trp Gly Asp Asp Ile Thr Trp Val Gln Thr Tyr
 10 15 20 25

Glu Glu Gly Leu Phe Tyr Ala Gln Lys Ser Lys Lys Pro Leu Met Val
 30 35 40

Ile His His Leu Asp Gly
 45

```

(2) INFORMATION FOR SEQ ID NO: 307:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 86 amino acids

(B) TYPE: AMINO ACID

(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens

(F) TISSUE TYPE: Liver

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide

(B) LOCATION: -26..-1

(C) IDENTIFICATION METHOD: Von Heijne matrix

(D) OTHER INFORMATION: score 7.6  
seq LITLCLVCIVANA/LL

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 307:

```

Met Cys Thr Gly Lys Cys Ala Arg Cys Val Gly Leu Ser Leu Ile Thr
-25 -20 -15

```

243

Leu Cys Leu Val Cys Ile Val Ala Asn Ala Leu Leu Val Pro Asn  
 -10                               -5                               1                               5  
 Gly Glu Thr Ser Trp Thr Asn Thr Asn His Leu Ser Leu Gln Val Trp  
                               10                               15                               20  
 Leu Met Gly Gly Phe Ile Gly Gly Gly Leu Met Val Leu Cys Pro Gly  
                               25                               30                               35  
 Ile Ala Ala Val Arg Ala Gly Gly Lys Xaa Cys Cys Gly Ala Gly Cys  
                               40                               45                               50  
 Cys Gly Asn Arg Leu Arg  
                               55                               60

## (2) INFORMATION FOR SEQ ID NO: 308:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -23..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 7.5  
seq LVLLLTLPPLHMA/LL

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 308:

Met Asp Ile Leu Val Pro Leu Leu Gln Leu Leu Val Leu Leu Leu Thr  
                               -20                               -15                               -10  
 Leu Pro Leu His Leu Met Ala Leu Leu Gly Cys Trp Gln Pro Leu Cys  
                               -5                               1                               5  
 Lys Ser Phe Gly  
                               10

## (2) INFORMATION FOR SEQ ID NO: 309:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

244

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Liver

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -15..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 7.5  
seq FLVLFSFFNIALC/AP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 309:

Met Pro Phe Leu Val Leu Phe Ser Phe Phe Asn Ile Ala Leu Cys Ala  
-15 -10 -5 1

Pro Arg Lys Phe Ala Arg Lys  
5

## (2) INFORMATION FOR SEQ ID NO: 310:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 108 amino acids  
(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Pancreas

## (ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -19..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 6.8  
seq AIVALAVCAALHA/SE

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 310:

Met Gln Gln Arg Gly Leu Ala Ile Val Ala Leu Ala Val Cys Ala Ala  
-15 -10 -5

Leu His Ala Ser Glu Ala Ile Leu Pro Ile Ala Ser Ser Cys Cys Thr  
1 5 10

Glu Val Ser His His Ile Ser Arg Arg Leu Leu Glu Arg Val Asn Met  
15 20 25

Cys Arg Ile Gln Arg Ala Asp Gly Asp Cys Asp Leu Ala Ala Val Ile  
30 35 40 45

Leu His Val Lys Arg Arg Arg Ile Cys Val Ser Pro His Asn His Thr  
50 55 60

Val Lys Gln Trp Met Lys Val Gln Ala Ala Lys Lys Asn Gly Lys Gly  
65 70 75

Asn Val Cys His Arg Lys Lys His His Gly Lys Arg  
 80 85

## (2) INFORMATION FOR SEQ ID NO: 311:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 108 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -20..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 6.8  
seq GLLWMLFVSELRA/AT

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 311:

Met Arg Lys Thr Arg Leu Trp Gly Leu Leu Trp Met Leu Phe Val Ser  
 -20 -15 -10 -5  
 Glu Leu Arg Ala Ala Thr Lys Leu Thr Glu Glu Lys Tyr Glu Leu Lys  
 1 5 10  
 Glu Gly Gln Thr Leu Asp Val Lys Cys Asp Tyr Thr Leu Glu Lys Phe  
 15 20 25  
 Ala Ser Ser Gln Lys Ala Trp Gln Ile Ile Arg Asp Gly Glu Met Pro  
 30 35 40  
 Lys Thr Leu Ala Cys Thr Glu Arg Pro Ser Lys Asn Ser His Pro Val  
 45 50 55 60  
 Gln Val Gly Arg Ile Ile Leu Glu Asp Tyr His Asp His Gly Leu Leu  
 65 70 75  
 Arg Val Arg Met Val Asn Leu Gln Val Xaa Asp Ser  
 80 85

## (2) INFORMATION FOR SEQ ID NO: 312:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 64 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

246

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Thyroid

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide  
(B) LOCATION: -22..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 6.8  
seq VSLVLLMPGPCDG/LF

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 312:

```

Met Val Gly Ala Met Trp Lys Val Ile Val Ser Leu Val Leu Leu Met
 -20 -15 -10

Pro Gly Pro Cys Asp Gly Leu Phe Arg Ser Leu Tyr Arg Ser Val Xaa
 -5 1 5 10

Met Pro Pro Lys Gly Asp Ser Gly Gln Pro Leu Phe Leu Thr Pro Tyr
 15 20 25

Ile Glu Ala Gly Lys Ile Gln Lys Gly Arg Glu Xaa Xaa Leu Val Gly
 30 35 40

```

## (2) INFORMATION FOR SEQ ID NO: 313:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 61 amino acids  
(B) TYPE: AMINO ACID  
(D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens  
(F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide  
(B) LOCATION: -40..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 6.1  
seq ICIGILVLPFIRC/CC

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 313:

```

Met Ile His Leu Arg Ile Ile Gln Arg Cys Tyr Met Ala Gly Leu Glu
-40 -35 -30 -25

Asn Lys Lys Asn Val Val Phe Glu Ala Lys Gln Ile Cys Ile Gly Ile
 -20 -15 -10

Leu Val Leu Pro Phe Ile Arg Cys Cys Cys Leu Val Gln Ile Thr Phe
 -5 1 5

Ser Leu Ser Leu His Phe Leu Ile Tyr Asn Met Arg Arg

```

10

15

20

## (2) INFORMATION FOR SEQ ID NO: 314:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 98 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -22..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5.9  
seq LIYILWQLTGSAA/SG

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 314:

```

Met Ala Gly Ser Pro Thr Cys Leu Thr Leu Ile Tyr Ile Leu Trp Gln
 -20 -15 -10

Leu Thr Gly Ser Ala Ala Ser Gly Pro Val Lys Glu Leu Val Gly Ser
 -5 1 5 10

Val Gly Gly Ala Val Thr Phe Pro Leu Lys Ser Lys Val Lys Gln Val
 15 20 25

Asp Ser Ile Val Trp Thr Phe Asn Thr Thr Pro Leu Val Thr Ile Gln
 30 35 40

Pro Glu Gly Gly Thr Ile Ile Val Thr Gln Asn Arg Asn Arg Glu Arg
 45 50 55

Val Asp Phe Pro Asp Gly Gly Tyr Ser Leu Lys Leu Ser Lys Leu Lys
 60 65 70

Lys Gly
 75

```

## (2) INFORMATION FOR SEQ ID NO: 315:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 113 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens

(F) TISSUE TYPE: Thyroid

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: -59..-1  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 5.7  
 seq ALLDLCAAPXGWL/QV

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 315:

```

Met Gly Lys Lys Gly Lys Val Gly Lys Ser Arg Arg Asp Lys Phe Tyr
 -55 -50 -45

His Leu Ala Lys Glu Thr Gly Tyr Arg Ser Arg Ser Ala Phe Lys Leu
 -40 -35 -30

Ile Gln Leu Asn Arg Arg Phe Gln Phe Leu Gln Lys Ala Arg Ala Leu
 -25 -20 -15

Leu Asp Leu Cys Ala Ala Pro Xaa Gly Trp Leu Gln Val Ala Ala Lys
 -10 -5 1 5

Phe Met Pro Val Ser Ser Leu Ile Val Gly Val Asp Leu Val Pro Ile
 10 15 20

Lys Pro Leu Pro Asn Val Val Thr Leu Gln Glu Asp Ile Thr Thr Glu
 25 30 35

Arg Cys Xaa Gln Arg His Trp Thr Ser Ala Ser Ala Leu Glu Arg Lys
 40 45 50

Met

```

(2) INFORMATION FOR SEQ ID NO: 316:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 75 amino acids  
 (B) TYPE: AMINO ACID  
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens  
 (D) DEVELOPMENTAL STAGE: Fetal  
 (F) TISSUE TYPE: liver

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide  
 (B) LOCATION: -32..-1  
 (C) IDENTIFICATION METHOD: Von Heijne matrix  
 (D) OTHER INFORMATION: score 5.7  
 seq FGLVXVGTALALA/RK

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 316:



249

```

Met Pro Leu Ser Asp Phe Ile Leu Ala Leu Lys Asp Asn Pro Tyr Phe
 -30 -25 -20

Gly Ala Gly Phe Gly Leu Val Xaa Val Gly Thr Ala Leu Ala Leu Ala
 -15 * -10 -5

Arg Lys Gly Val Gln Leu Gly Leu Val Ala Phe Arg Arg His Tyr Met
 1 5 10 15

Ile Thr Leu Glu Val Pro Ala Arg Asp Arg Ser Tyr Xaa Trp Leu Leu
 20 25 30

Ser Trp Leu Thr Arg His Ser Thr Arg Thr Gly
 35 40

```

## (2) INFORMATION FOR SEQ ID NO: 317:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 93 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Large intestine

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -19...-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 5.6  
seq WVFLVAIIKGVQC/QA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 317:

```

Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Ile Ile Lys Gly
 -15 -10 -5

Val Gln Cys Gln Ala Gln Leu Glu Glu Ser Gly Gly Gly Leu Val Gln
 1 5 10

Pro Gly Gly Ser Leu Arg Leu Ser Cys Arg Gly Ser Gly Phe Thr Leu
 15 20 25

Ser Asp His Tyr Met Ser Trp Ile Arg Gln Ser Pro Gly Lys Gly Xaa
 30 35 40 45

Xaa Trp Val Ala Tyr Ile Ser Tyr Ser Gly Ser Thr Ile Tyr Tyr Gly
 50 55 60

Asp Ser Val Asp Gly Arg Phe Thr Ile Ser Arg Asp Asn
 65 70

```

## (2) INFORMATION FOR SEQ ID NO: 318:

(ii) MOLECULE TYPE: PROTEIN

(A) NAME/KEY: sig\_peptide  
(B) LOCATION: -21..-1  
(C) IDENTIFICATION METHOD: Von Heijne matrix  
(D) OTHER INFORMATION: score 5.3  
seq SLFSSSLPIFLTWA/HI

Leu His Thr Ala His Asn Gly His Pro His Tyr Gly  
15 20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 319:

Glu Gly Ala Ile Tyr Leu Phe Asn Met Cys Leu Gln Gln Arg  
1 5 10

- ```

Met Glu Ala Val Val Phe Val Phe Ser Leu Leu Asp Cys Cys Ala Leu
-15              -10              -5              1

Ile Phe Leu Ser Val Tyr Phe Ile Ile Thr Leu Ser Asp Leu Glu Cys
      5              10              15

Asp Tyr Ile Asn Ala Arg Ser
      20

```

(2) INFORMATION FOR SEQ ID NO: 321:

- ```
(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 62 amino acids
 (B) TYPE: AMINO ACID
 (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: Homo Sapiens
 (F) TISSUE TYPE: Pancreas

(ix) FEATURE:
 (A) NAME/KEY: sig_peptide
 (B) LOCATION: -56..-1
 (C) IDENTIFICATION METHOD: Von Heijne matrix
 (D) OTHER INFORMATION: score 4.7
 seq FACVPGASXTTLA/FP

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 321:
```

Met Thr Gly Phe Leu Leu Pro Pro Ala Ser Arg Gly Thr Arg Arg Ser

252

-55                      -50                      -45  
 Cys Ser Arg Ser Arg Lys Arg Gln Thr Arg Arg Arg Arg Asn Pro Ser  
 -40                      -35                      -30                      -25  
 Ser Phe Val Ala Ser Cys Pro Thr Leu Leu Pro Phe Ala Cys Val Pro  
                          -20                      -15                      -10  
 Gly Ala Ser Xaa Thr Thr Leu Ala Phe Pro Pro Val Val Leu  
                          -5                      1                      5

## (2) INFORMATION FOR SEQ ID NO: 322:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 60 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Colon

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -19..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.5  
seq SVPLLTDAA TVSG/AE

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 322:

Met Cys Gly Asn Thr Met Ser Val Pro Leu Leu Thr Asp Ala Ala Thr  
                          -15                      -10                      -5  
 Val Ser Gly Ala Glu Arg Glu Thr Ala Ala Val Ile Phe Leu His Gly  
                          1                      5                      10  
 Leu Gly Asp Thr Gly His Ser Trp Ala Asp Ala Leu Ser Thr Ile Arg  
                          15                      20                      25  
 Leu Pro His Val Lys Tyr Ile Cys Pro His Ala Arg  
                          30                      35                      40

## (2) INFORMATION FOR SEQ ID NO: 323:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 61 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens

253

(F) TISSUE TYPE: Large intestine

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -43..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 4.3  
seq SLWRLQWLKDASC/DP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 323:

Met Xaa Xaa Xaa Xaa Glu Arg Arg Thr Ser Pro His Val Met Ala Asp  
          -40                    -35                    -30

Gln Ser Ser Thr Arg Asn Glu Asp Phe Leu Lys Lys Thr Trp Ser Leu  
          -25                    -20                    -15

Trp Arg Leu Gln Trp Leu Lys Asp Ala Ser Cys Asp Pro Tyr Pro Ala  
          -10                    -5                    1                    5

Leu Pro Xaa Phe Trp Xaa Thr Glu Ala Lys Cys Glu Ser  
                    10                    15

## (2) INFORMATION FOR SEQ ID NO: 324:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Pancreas

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -14..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 3.8  
seq FLLNCIVAVSQN/MG

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 324:

Met Phe Leu Leu Leu Asn Cys Ile Val Ala Val Ser Gln Asn Met Gly  
          -10                    -5                    1

Ile Gly Lys Asn Gly Asp Leu Pro Xaa Pro Gln  
          5                    10

## (2) INFORMATION FOR SEQ ID NO: 325:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 60 amino acids

254

- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -14..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 3.8  
seq LLVSAAPLGFGQG/VW

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 325:

Met Leu Leu Val Ser Ala Ala Pro Leu Gly Phe Gly Gln Gly Val Trp  
                  -10                  -5                  1  
Asn Arg Ala Ser Gln Leu Gln Gln Gly Xaa Asp Pro Leu Gly Ala Gly  
          5                          10                          15  
Arg Ser Trp Arg Gly Leu Cys Lys Leu Ser Gln Ala Leu Gly Ala Gly  
      20                          25                          30  
Thr Gly Ser Gly Phe His Thr His Thr Arg Ala Pro  
      35                          40                          45

(2) INFORMATION FOR SEQ ID NO: 326:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 36 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (D) DEVELOPMENTAL STAGE: Fetal
- (F) TISSUE TYPE: liver

(ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -16..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 3.7  
seq IALTLIPMSLSRA/AG

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 326:

Met Leu Arg Ile Ala Leu Thr Leu Ile Pro Ser Met Leu Ser Arg Ala  
      -15                          -10                          -5  
Ala Gly Trp Cys Trp Tyr Lys Glu Pro Thr Gln Gln Phe Ser Tyr Leu

255  
1 5 10 15  
Cys Leu Pro Gly  
20

## (2) INFORMATION FOR SEQ ID NO: 327:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 41 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -19..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 3.7  
seq LPGLRCSVPGVAA/RL

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 327:

Met Thr Leu Gly Gly Arg Leu Pro Gly Leu Arg Cys Ser Val Pro Gly  
-15 -10 -5  
Val Ala Ala Arg Leu Ser Thr Pro Pro Gln Val Arg Gln His Val Phe  
1 5 10  
Trp Ala Ala Ser Val Cys Xaa Xaa Thr  
15 20

## (2) INFORMATION FOR SEQ ID NO: 328:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 67 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Liver

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -14..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 3.6  
seq AFTLXSLQALL/CV

256

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 328:

```

Met Ala Phe Thr Leu Xaa Ser Leu Leu Gln Ala Ala Leu Leu Cys Val
 -10 -5 1
Asn Ala Ile Ala Val Leu His Glu Glu Arg Phe Leu Lys Asn Ile Gly
 5 10 15
Trp Gly Thr Asp Gln Gly Ile Gly Gly Phe Gly Glu Glu Pro Gly Ile
 20 25 30
Lys Ser Xaa Xaa Met Xaa Leu Ile Arg Ser Val Arg Thr Val Met Arg
 35 40 45 50
Val Pro Leu

```

(2) INFORMATION FOR SEQ ID NO: 329:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 92 amino acids

(B) TYPE: AMINO ACID

(D) TOPOLOGY: LINEAR

(ii) MOLECULE TYPE: PROTEIN

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo Sapiens

(F) TISSUE TYPE: Pancreas

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide

(B) LOCATION: -21..-1

(C) IDENTIFICATION METHOD: Von Heijne matrix

(D) OTHER INFORMATION: score 3.5  
seq LKVVFMVFASLXA/WY

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 329:

```

Met Arg Pro Leu Ala Gly Gly Leu Leu Lys Val Val Phe Met Val Phe
 -20 -15 -10
Ala Ser Leu Xaa Ala Trp Tyr Ser Gly Tyr Leu Leu Ala Xaa Xaa Ile
 -5 1 5 10
Pro Asp Ala Pro Leu Ser Ser Ala Ala Tyr Ser Ile Arg Ser Ile Gly
 15 20 25
Glu Arg Pro Val Leu Lys Ala Pro Val Pro Lys Arg Gln Lys Cys Asp
 30 35 40
His Trp Thr Pro Cys Pro Ser Xaa Xaa Tyr Ala Tyr Arg Leu Leu Ser
 45 50 55
Gly Gly Gly Arg Ser Lys Tyr Ala Lys Ile Cys Phe
 60 65 70

```



## (2) INFORMATION FOR SEQ ID NO: 330:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 58 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Colon

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -22..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 3.5  
seq AAPVAAGLGPVIS/RP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 330:

Met Phe Glu Glu Pro Glu Trp Ala Glu Ala Ala Pro Val Ala Ala Gly  
-20 -15 -10

Leu Gly Pro Val Ile Ser Arg Pro Pro Pro Ala Ala Ser Ser Gln Asn  
-5 1 5 10

Lys Gly Ser Lys Arg Arg Gln Leu Leu Ala Thr Leu Arg Ala Leu Glu  
15 20 25

Ala Ala Ser Leu Ser Gln His Pro Pro Met  
30 35

## (2) INFORMATION FOR SEQ ID NO: 331:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 amino acids
- (B) TYPE: AMINO ACID
- (D) TOPOLOGY: LINEAR

## (ii) MOLECULE TYPE: PROTEIN

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo Sapiens
- (F) TISSUE TYPE: Lung (cells)

## (ix) FEATURE:

- (A) NAME/KEY: sig\_peptide
- (B) LOCATION: -23..-1
- (C) IDENTIFICATION METHOD: Von Heijne matrix
- (D) OTHER INFORMATION: score 3.5  
seq ALYNIIYVCGIQG/IT

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 331:

258

Met His Ile Tyr Thr Gly Ile Lys Tyr Ile Ala Leu Tyr Asn Ile Ile  
-20 -15 -10

Tyr Val Cys Gly Ile Gln Gly Ile Thr Phe Met Arg Ala Arg  
-5 1 5

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |                                          |    |                                              |    |                          |
|----|--------------------------|----|------------------------------------------|----|----------------------------------------------|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   | ML | Mali                                         | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | MN | Mongolia                                     | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MR | Mauritania                                   | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MW | Malawi                                       | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MX | Mexico                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | NE | Niger                                        | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NL | Netherlands                                  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NO | Norway                                       | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NZ | New Zealand                                  | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | PL | Poland                                       |    |                          |
| CM | Cameroon                 | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CN | China                    | KZ | Kazakhstan                               | R  | Romania                                      |    |                          |
| CU | Cuba                     | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| CZ | Czech Republic           | LI | Liechtenstein                            | SD | Sudan                                        |    |                          |
| DE | Germany                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| DK | Denmark                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |
| EE | Estonia                  |    |                                          |    |                                              |    |                          |

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>(51) International Patent Classification</b> <sup>6</sup> :<br>C12N 15/12, C07K 14/47, C12N 15/10, 15/66, C12Q 1/68,<br>G01N 33/50, C07K 16/18, G01N 33/53, C12N 15/11,<br>A61K 48/00, A61K 38/17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | <b>A3</b> | <b>(11) International Publication Number:</b> <b>WO 99/06439</b><br><br><b>(43) International Publication Date:</b> 11 February 1999 (11.02.99)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| <b>(21) International Application Number:</b> PCT/IB98/01233<br><br><b>(22) International Filing Date:</b> 31 July 1998 (31.07.98)<br><br><b>(30) Priority Data:</b><br>08/904,468 1 August 1997 (01.08.97) US<br><br><b>(71) Applicant (for all designated States except US):</b> GENSET<br>[FR/FR]; 24, rue Royale, F-75008 Paris (FR).<br><br><b>(72) Inventors; and</b><br><b>(75) Inventors/Applicants (for US only):</b> DUMAS MILNE ED-<br>WARDS, Jean-Baptiste [FR/FR]; 8, rue Grégoire de Tours,<br>F-75006 Paris (FR). DUCLERT, Aymeric [FR/FR]; 6 ter,<br>rue Victorine, F-94100 Saint-Maur (FR). LACROIX, Bruno<br>[FR/FR]; 93, route de Vourles, F-69230 Saint-Genis Laval<br>(FR).<br><br><b>(74) Agents:</b> MARTIN, Jean-Jacques et al.; Cabinet Regimbeau,<br>26, avenue Kléber, F-75116 Paris (FR). |           | <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR,<br>BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE,<br>GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ,<br>LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,<br>MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,<br>TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO<br>patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian<br>patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European<br>patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,<br>IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF,<br>CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).<br><br><b>Published</b><br><i>With international search report.</i><br><br><b>(88) Date of publication of the international search report:</b><br>8 April 1999 (08.04.99) |
| <b>(54) Title:</b> 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN ENDODERM<br><br><b>(57) Abstract</b><br><br>The sequences of 5' ESTs derived from mRNAs encoding secreted proteins are disclosed. The 5' ESTs may be to obtain cDNAs and genomic DNAs corresponding to the 5' ESTs. The 5' ESTs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. Upstream regulatory sequences may also be obtained using the 5' ESTs. The 5' ESTs may also be used to design expression vectors and secretion vectors.                                                                                                                                                                                                                                                                       |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/IB 98/01233

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/47 C12N15/10 C12N15/66 C12Q1/68  
G01N33/50 C07K16/18 G01N33/53 C12N15/11 A61K48/00  
A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K C12Q G01N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Relevant to claim No. |
|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| E          | <p>WO 98 42738 A (HUMAN GENOME SCIENCES INC. (US); YOUNG PAUL ET AL.) 1 October 1998<br/>see page 40, line 34 - page 41, line 35<br/>Gene No.46<br/>see page 79<br/>see page 100, line 23-25<br/>Seq.ID:56 is 97% identical to Seq.ID:38<br/>see page 209 - page 210<br/>Seq.ID:110 is 98% identical to Seq.ID:38<br/>see page 259 - page 260<br/>Seq.ID:170 is 98% identical to Seq.ID:185<br/>see page 297 - page 298<br/>Seq.ID:224 is 98% identical to Seq.ID:185<br/>see page 331 - page 332<br/>see page 381 - page 384; claims</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p> | 1-28,<br>34-37        |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*A\* document member of the same patent family

Date of the actual completion of the international search

22 October 1998

Date of mailing of the international search report

29.01.99

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3018

Authorized officer

Macchia, G

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 98/01233

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                                                                                                                                     | Relevant to claim No. |
|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| X          | <p>ASAKURA K. ET AL.: "A monoclonal autoantibody which promotes central nervous system remyelination is highly polyreactive to multiple known and novel antigens"</p> <p>JOURNAL OF NEUROIMMUNOLOGY, vol. 65, no. 1, March 1996, pages 11-19, XP002081171</p> <p>see page 15; figure 5</p> <p>see page 17, right-hand column, paragraph 1</p>                          | 1-9,<br>15-37         |
| X          | <p>---</p> <p>Database EMBL Emest7, Entry HS1150166</p> <p>Accession number AA232452</p> <p>6 March 1997</p> <p>94% identity with Seq.ID:38 nt.39-352</p> <p>XP002080975</p> <p>see the whole document</p>                                                                                                                                                             | 1-9,<br>15-37         |
| X          | <p>---</p> <p>Database EMBL Emest15, Entry MMA28649</p> <p>Accession number AA028649</p> <p>17 August 1996</p> <p>83% identity with Seq.ID:38 nt.26-352</p> <p>XP002080976</p> <p>see the whole document</p>                                                                                                                                                           | 1-9,<br>15-37         |
| X          | <p>---</p> <p>Database EMBL Emest15, Entry MM70733</p> <p>Accession number W70707</p> <p>19 June 1996</p> <p>82% identity with Seq.ID:38 nt.36-352</p> <p>XP002080977</p> <p>see the whole document</p>                                                                                                                                                                | 1-9,<br>15-37         |
| X          | <p>---</p> <p>Database EMBL Emest15, Entry MM68132</p> <p>Accession number W70681</p> <p>19 June 1996</p> <p>81% identity with Seq.ID:38 nt.11-352</p> <p>XP002080978</p> <p>see the whole document</p>                                                                                                                                                                | 1-9,<br>15-37         |
| A          | <p>---</p> <p>OZAWA M.: "Cloning of a human homologue of mouse reticulocalbin reveals conservation of structural domains in the novel endoplasmic reticulum resident Ca<sup>2+</sup>-binding protein with multiple EF-hand motifs"</p> <p>JOURNAL OF BIOCHEMISTRY, vol. 117, 1995, pages 1113-1119, XP002070128</p> <p>---</p> <p style="text-align: center;">-/--</p> |                       |

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/IB 98/01233

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-37 all partially (subject 1. on continuation-sheet)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-37 all partially

Nucleic acid comprising the sequence as in Seq.ID:38, complementary sequence, fragments, hybridizing sequences. Polypeptide comprising a signal peptide encoded by said nucleotide sequence. Vector encoding a fusion protein comprising said signal peptide. A method of directing the extracellular secretion of a polypeptide by means of said vector. Method of importing a polypeptide into a cell by means of said signal peptide. A method for making a cDNA encoding a secretory protein, partially encoded by said nucleotide sequence, corresponding cDNA. Polypeptide encoded by said nucleotide sequence, comprising a sequence as in Seq.ID:185, method of making said polypeptide. Method of obtaining a promoter located upstream of said nucleotide sequence, promoter thereof.

2. Claims: 1-37 all partially

Inventions 2-147: Idem as subject 1 but limited to each of the DNA sequences as in Seq.ID:39-184, and corresponding polypeptides, where invention 2 is limited to Seq.ID:39 and 186, invention 3 is limited to Seq.ID:40 and 187,....., invention 147 is limited to Seq.ID:184 and 331).

For the sake of conciseness, the first subject matter is explicitly defined, the other subject matters are defined by analogy thereto.



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 98/01233

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s)                                                                                                   | Publication<br>date                                                                                          |
|-------------------------------------------|---------------------|------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|
| WO 9842738 A                              | 01-10-1998          | AU 6564698 A<br>AU 6562798 A                                                                                                 | 12-10-1998<br>20-10-1998                                                                                     |
| WO 9634981 A                              | 07-11-1996          | FR 2733765 A<br>FR 2733762 A<br>AU 5982996 A<br>CA 2220045 A<br>EP 0824598 A                                                 | 08-11-1996<br>08-11-1996<br>21-11-1996<br>07-11-1996<br>25-02-1996                                           |
| EP 0625572 A                              | 23-11-1994          | JP 6153953 A<br>WO 9408001 A<br>US 5597713 A                                                                                 | 03-06-1994<br>14-04-1994<br>28-01-1997                                                                       |
| WO 9707198 A                              | 27-02-1997          | US 5707829 A<br>AU 6712396 A<br>AU 6768596 A<br>CA 2227220 A<br>CA 2229208 A<br>EP 0839196 A<br>EP 0851875 A<br>WO 9704097 A | 13-01-1998<br>18-02-1997<br>12-03-1997<br>06-02-1997<br>27-02-1997<br>06-05-1998<br>08-07-1998<br>06-02-1997 |